Patent Grant
10524703
The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.
Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which can cause an array of physiological derangements associated with the deterioration of small blood vessels, for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye. A hypoglycemic reaction (low blood sugar) can be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
Conventionally, a person with diabetes carries a self-monitoring blood glucose (SMBG) monitor, which typically requires uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a person with diabetes normally only measures his or her glucose levels two to four times per day. Unfortunately, such time intervals are so far spread apart that the person with diabetes likely finds out too late of a hyperglycemic or hypoglycemic condition, sometimes incurring dangerous side effects. It is not only unlikely that a person with diabetes will take a timely SMBG value, it is also likely that he or she will not know if his or her blood glucose value is going up (higher) or down (lower) based on conventional method. This inhibits the ability to make educated insulin therapy decisions.
In a first aspect, a transcutaneous system for measuring an analyte concentration in a host is provided, the system comprising: a sensor adapted for transcutaneous placement through a skin of a host; and a mounting unit adapted for placement adjacent to the skin of the host, wherein the mounting unit comprises an electronics unit configured to process sensor data, and wherein the sensor is configured to extend from the mounting unit into the host.
In an embodiment of the first aspect, the sensor is configured to extend a fixed distance from the mounting unit.
In an embodiment of the first aspect, the sensor is configured to extend an adjustable distance from the mounting unit.
In an embodiment of the first aspect, the system further comprises an adhesive pad disposed on a back surface of the mounting unit, wherein the adhesive pad is configured to adhere the mounting unit to the skin of the host.
In an embodiment of the first aspect, the adhesive pad is waterproof.
In an embodiment of the first aspect, the adhesive pad comprises fibers selected from the group consisting of open-celled foam, closed-cell foam, non-woven fibers, woven fibers, and spun-laced fibers.
In an embodiment of the first aspect, the adhesive pad substantially covers the back surface of the mounting unit.
In an embodiment of the first aspect, the adhesive pad is configured to cover a surface area larger than a surface area of the back surface of the mounting unit.
In an embodiment of the first aspect, the adhesive pad is configured to cover a surface area greater than or equal to two times the surface area of the back surface of the mounting unit.
In an embodiment of the first aspect, the sensor is configured to exit the mounting unit at a position closer to a center of the mounting unit than to an edge of the mounting unit.
In an embodiment of the first aspect, the adhesive pad comprises an extensible adhesive pad disposed on a back surface of the mounting unit, wherein the extensible adhesive pad is configured to adhere the mounting unit onto the skin of the host, and wherein the extensible adhesive pad is configured to be released by stretching.
In a second aspect, a transcutaneous analyte sensor assembly for measuring an analyte in a host is provided, the assembly comprising: a housing configured for mounting on a skin of a host; a sensor comprising a distal portion and a proximal portion, wherein the distal portion is adapted to be inserted through the skin of a host, and wherein the proximal portion is operably connected to the housing; and electronics configured for measuring an analyte in the host, wherein the electronics are associated with the housing, wherein the electronics are connected to the sensor via at least one electrical contact, and wherein the electrical contact is substantially sealed from moisture in an external environment.
In an embodiment of the second aspect, the electrical contact is substantially sealed from moisture in an external environment by at least one sealing member that substantially surrounds at least a portion of the electrical contact.
In an embodiment of the second aspect, the electronics comprise an electronics unit detachably connectable to the housing, and wherein a sealing member substantially seals the electrical connection when the electronics unit is detachably connected to the housing.
In an embodiment of the second aspect, the assembly further comprises a sealant disposed adjacent to the sealing member when the electronics unit is detachable connected to the housing.
In an embodiment of the second aspect, the sealing member comprises at least one material selected from the group consisting of a flexible material, a malleable material, and an elastomer.
In an embodiment of the second aspect, the sealing member comprises a silicone material.
In an embodiment of the second aspect, the assembly further comprises a sealant disposed around the proximal portion of the sensor.
In an embodiment of the second aspect, the sensor extends from the housing adjacent to the electrical contact or extends from the housing from within the electrical contact, and wherein the sealant comprises a viscous material configured to conform to an open space between the sensor and the electrical contact.
In an embodiment of the second aspect, the sealant comprises an oil, a grease, or a gel.
In an embodiment of the second aspect, the sealant comprises a petroleum jelly.
In a third aspect, a transcutaneous analyte sensor assembly is provided, the assembly including: a mounting unit adapted for mounting on the skin of a host; and a sensor configured to measure a level of an analyte in the host, wherein the sensor extends from the mounting unit and is adapted to be inserted through the skin of the host, and wherein the mounting unit includes base and upper portions configured to pivot relative to each other between open and closed positions.
In an embodiment of the third aspect, the mounting unit is configured to guide insertion of the sensor into the host when the mounting unit is in the open position. In this embodiment, the mounting unit is configured to open to an angle adapted for insertion of the sensor into the host and the sensor measures the level of the analyte in the host when the mounting unit is in its closed position. The sensor further includes a mechanical joint for securing the base and upper portions in the closed position.
In a fourth aspect, a transcutaneous analyte sensor assembly is provided, the assembly including: a mounting unit adapted for mounting on the skin of a host; an electronics unit detachably connectable to the mounting unit; and a sensor configured to measure a level of an analyte in the host, wherein the sensor is operably connected to the electronics unit when the electronics unit is detachably connected to the mounting unit.
In an embodiment of the fourth aspect, the mounting unit includes a cavity for receiving the electronics unit. In an aspect of the second embodiment, the cavity is configured to releasably hold the electronics unit. In an aspect of the second embodiment, the mounting unit and electronics unit include mutually engaging electrical contacts that provide operable connection between the sensor and the electronics unit when connected thereto.
In a fifth aspect, a transcutaneous analyte sensor is provided, the sensor including: an in vivo portion adapted for at least partial insertion through the skin of a host, wherein the in vivo portion includes an anchoring mechanism adapted for maintaining a stable position of the in vivo portion of the sensor within the host.
In an embodiment of the fifth aspect, the anchoring mechanism includes at least one wire including a helical configuration.
In an embodiment of the fifth aspect, the anchoring mechanism includes at least one of prongs, bulbous portion, S-bend, spines, barbs, wings, and hooks extending from the in vivo portion of the sensor.
In an embodiment of the fifth aspect, the anchoring mechanism includes a rough surface topography formed on the in vivo portion of the sensor.
In an embodiment of the fifth aspect, the anchoring mechanism includes a gradually changing diameter on the in vivo portion of the sensor.
In an embodiment of the fifth aspect, the anchoring mechanism includes a porous material disposed on the in vivo portion of the sensor. The porous material can be configured to modify the host's tissue response to the sensor and the porous material can include a bioactive agent incorporated therein.
In an embodiment of the fifth aspect, the in vivo portion further includes a bioactive agent incorporated therein.
In a sixth aspect, a transcutaneous analyte sensor is provided, the sensor including a distal portion and a proximal portion, wherein the distal portion is adapted to be inserted through the skin of a host and wherein the proximal portion is adapted to remain substantially external to the host when the distal portion is inserted into the host, and wherein the sensor is configured to absorb movement of the in vivo or ex vivo portion of the sensor. In an embodiment of the sixth aspect, the sensor includes an S-bend configured to absorb movement of the in vivo or ex vivo portion of the sensor. In an embodiment of the sixth aspect, the sensor includes an expanding and contracting member configured to absorb movement of the in vivo or ex vivo portion of the sensor. In an embodiment of the sixth aspect, the expanding and contracting member is selected from the group consisting of a spring, accordion, telescoping, and bellows-type device. In an embodiment of the sixth aspect, the sensor further includes a mounting unit adapted for mounting on the skin of a host, wherein the mounting unit includes a flexible base.
In a seventh aspect, a transcutaneous analyte sensor assembly is provided, the assembly including: a mounting unit including a flexible base adapted for mounting on the skin of a host; and a sensor configured to measure a level of an analyte in the host, wherein the sensor extends from the mounting unit and is adapted to be inserted through the skin of the host.
In an embodiment of the seventh aspect, the flexible base is formed from an elastomer.
In an embodiment of the seventh aspect, the elastomer includes silicone or urethane.
In an embodiment of the seventh aspect, the flexible base includes a plurality of articulating pieces.
In an embodiment of the seventh aspect, the mounting unit further includes an upper portion attached to the base, and wherein the upper portion is formed from a material that is less flexible than the base. In an embodiment of the seventh aspect, the upper portion is pivotally mounted to the base for relative pivoting motion between first and second positions. In an aspect of the fifth embodiment, the upper portion includes an electronics unit. In an embodiment of the seventh aspect, the electronics unit is removably attached to the upper portion.
In an eight aspect, a transcutaneous analyte sensor assembly is provided for measuring a level of an analyte in a host, the assembly including: a housing for mounting on the skin; a sensor adapted to extend from the housing through the skin; and a sealing material on the housing, located to be interposed between the housing and the skin, wherein the sensor is adapted to extend through the sealing material.
In an embodiment of the eighth aspect, the sealing material is flexible material that substantially seals around the sensor. In an embodiment of the eighth aspect, the wherein the flexible material includes at least one of a malleable material, an elastomer, and a gel. In an aspect of the sixth embodiment, the flexible material includes an elastomer. In an embodiment of the eighth aspect, the elastomer includes silicone. In an embodiment of the eighth aspect, the sealing material includes a bioactive agent. In an embodiment of the eighth aspect, the bioactive agent includes at least one of anti-inflammatory, antimicrobial, antibiotics. In an aspect of the sixth embodiment, the sealing material includes a septum.
In a ninth aspect, a transcutaneous analyte sensor assembly is provided for measuring a level of an analyte in a host, the assembly including: a mounting unit including a base adapted for mounting on the skin of a host; a sensor including an in vivo portion for insertion through the skin of a host and an ex vivo portion connected to the mounting unit; and an extensible adhesive disposed on the base of the mounting unit for adhering the mounting unit onto the skin of the host, and wherein the extensible adhesive is configured to be released by stretching.
In an embodiment of the ninth aspect, the adhesive includes a non-extensible backing adhesive layer and an extensible adhesive layer, wherein the extensible adhesive layer is adapted to contact the host's skin such that the adhesive is release by pulling on the backing adhesive in a direction substantially parallel to the host's skin. In an embodiment of the ninth aspect, the adhesive is formed from an extensible material and further includes a pull-tab adapted to be grasped and pull substantially parallel to the host's skin to release the adhesive from the skin. In an embodiment of the ninth aspect, the adhesive includes first and second extensible adhesive layers with a non-extensible layer located therebetween, and wherein the adhesive is adapted to be released by pulling the non-extensible layer in a direction substantially parallel to the host's skin.
In tenth aspect, an analyte measuring system is provided, the system including: a mounting unit adapted for mounting on the skin of a host; an electronics unit detachably connectable to the mounting unit; a sensor for measuring a level of the analyte including an in vivo portion for insertion through the skin of a host and an ex vivo portion connected to the mounting unit, wherein the sensor is operably connected to the electronics unit when the electronics unit is detachably connected to the mounting unit; and a communication station for receiving and processing analyte measurements received from the electronics unit, wherein the communication station further includes a docking station for receiving the electronics unit when detached from the mounting unit.
In an embodiment of the tenth aspect, the communication station includes a hand-held receiver. In an aspect of the eighth embodiment, the communication station includes programming to search for transmissions from the electronics unit, and wherein the programming is further designed to stop searching for transmissions from the electronics unit when the electronics unit is docked on the communication station. In an embodiment of the tenth aspect, the communication station includes programming with a plurality of modes, and wherein the programming is configured to switch between the modes when the electronics unit docked on the communication station. In an embodiment of the tenth aspect, the communication station includes programming to calibrate the sensor, and wherein the programming is further configured to reset the calibration when the electronics unit is docked on the communication station. In an embodiment of the tenth aspect, the communication station is configured to recharge a battery in the electronics unit when the electronics unit is docked on the communication station. In an embodiment of the tenth aspect, the communication station is configured to measure battery voltage in the electronics unit and includes programming to disable the electronics unit if the voltage is below a predetermined threshold. In an aspect of the eighth embodiment, the communication station includes programming to initialize an electronics unit associated with the communication station. In an embodiment of the tenth aspect, the communication station includes programming to test operation of the electronics unit by stepping the electrodes through different current draws, and wherein the programming is further configured to disable usage of the electronics unit if a failure is detected. In an embodiment of the tenth aspect, the communication station includes programming to start or stop transmissions between the communication station and electronics unit when the electronics unit docked on the communication station.
The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
Definitions
In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
The term “analyte” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotimidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenyloin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
The term “host” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to mammals, particularly humans.
The term “exit-site” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to the area where a medical device (for example, a sensor and/or needle) exits from the host's body.
The phrase “continuous (or continual) analyte sensing” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to the period in which monitoring of analyte concentration is continuously, continually, and or intermittently (regularly or irregularly) performed, for example, about every 5 to 10 minutes.
The term “electrochemically reactive surface” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to the surface of an electrode where an electrochemical reaction takes place. For example, a working electrode measures hydrogen peroxide produced by the enzyme-catalyzed reaction of the analyte detected, which reacts to create an electric current. Glucose analyte can be detected utilizing glucose oxidase, which produces H2O2 as a byproduct. H2O2 reacts with the surface of the working electrode, producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2), which produces the electronic current being detected.
The term “electronic connection” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to any electronic connection known to those in the art that can be utilized to interface the sensing region electrodes with the electronic circuitry of a device, such as mechanical (for example, pin and socket) or soldered electronic connections.
The term “interferant” and “interferants,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, to refer to species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In one example of an electrochemical sensor, interferants are compounds with oxidation potentials that overlap with the analyte to be measured.
The term “sensing region” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to the region of a monitoring device responsible for the detection of a particular analyte. The sensing region generally comprises a non-conductive body, a working electrode (anode), a reference electrode (optional), and/or a counter electrode (cathode) passing through and secured within the body forming electrochemically reactive surfaces on the body and an electronic connective means at another location on the body, and a multi-domain membrane affixed to the body and covering the electrochemically reactive surface.
The term “high oxygen solubility domain” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a domain composed of a material that has higher oxygen solubility than aqueous media such that it concentrates oxygen from the biological fluid surrounding the membrane system. The domain can act as an oxygen reservoir during times of minimal oxygen need and has the capacity to provide, on demand, a higher oxygen gradient to facilitate oxygen transport across the membrane. Thus, the ability of the high oxygen solubility domain to supply a higher flux of oxygen to critical domains when needed can improve overall sensor function.
The term “domain” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a region of the membrane system that can be a layer, a uniform or non-uniform gradient (for example, an anisotropic region of a membrane), or a portion of a membrane.
The phrase “distal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. In general, the term indicates an element is located relatively far from the reference point than another element.
The term “proximal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. In general, the term indicates an element is located relatively near to the reference point than another element.
The terms “in vivo portion” and “distal portion” as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to the portion of the device (for example, a sensor) adapted for insertion into and/or existence within a living body of a host.
The terms “ex vivo portion” and “proximal portion” as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to the portion of the device (for example, a sensor) adapted to remain and/or exist outside of a living body of a host.
The terms “raw data stream” and “data stream,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, to refer to an analog or digital signal from the analyte sensor directly related to the measured analyte. For example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of an analyte concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, each of which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
The term “count,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to a unit of measurement of a digital signal. For example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode.
The term “physiologically feasible,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to one or more physiological parameters obtained from continuous studies of glucose data in humans and/or animals. For example, a maximal sustained rate of change of glucose in humans of about 4 to 6 mg/dL/min and a maximum acceleration of the rate of change of about 0.1 to 0.2 mg/dL/min/min are deemed physiologically feasible limits. Values outside of these limits are considered non-physiological and are likely a result of, e.g., signal error.
The term “ischemia,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, a sensor). Ischemia can be caused, for example, by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply.
The term “matched data pairs”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to reference data (for example, one or more reference analyte data points) matched with substantially time corresponding sensor data (for example, one or more sensor data points).
The term “Clarke Error Grid”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to an error grid analysis, for example, an error grid analysis used to evaluate the clinical significance of the difference between a reference glucose value and a sensor generated glucose value, taking into account 1) the value of the reference glucose measurement, 2) the value of the sensor glucose measurement, 3) the relative difference between the two values, and 4) the clinical significance of this difference. See Clarke et al., “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose”, Diabetes Care, Volume 10, Number 5, September-October 1987, the contents of which are hereby incorporated by reference herein in their entirety and are hereby made a part of this specification.
The term “Consensus Error Grid,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to an error grid analysis that assigns a specific level of clinical risk to any possible error between two time corresponding measurements, e.g., glucose measurements. The Consensus Error Grid is divided into zones signifying the degree of risk posed by the deviation. See Parkes et al., “A New Consensus Error Grid to Evaluate the Clinical Significance of Inaccuracies in the Measurement of Blood Glucose”, Diabetes Care, Volume 23, Number 8, August 2000, the contents of which are hereby incorporated by reference herein in their entirety and are hereby made a part of this specification.
The term “clinical acceptability”, as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to determination of the risk of an inaccuracy to a patient. Clinical acceptability considers a deviation between time corresponding analyte measurements (for example, data from a glucose sensor and data from a reference glucose monitor) and the risk (for example, to the decision making of a person with diabetes) associated with that deviation based on the analyte value indicated by the sensor and/or reference data. An example of clinical acceptability can be 85% of a given set of measured analyte values within the “A” and “B” region of a standard Clarke Error Grid when the sensor measurements are compared to a standard reference measurement.
The term “sensor” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to the component or region of a device by which an analyte can be quantified.
The term “needle,” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a slender hollow instrument for introducing material into or removing material from the body.
The terms “operably connected” and “operably linked” as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to one or more components linked to one or more other components. The terms can refer to a mechanical connection, an electrical connection, or a connection that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and to convert that information into a signal; the signal can then be transmitted to a circuit. In such an example, the electrode is “operably linked” to the electronic circuitry.
The term “baseline” as used herein is a broad term and is used in its ordinary sense, including, without limitation, is the component of an analyte sensor signal that is not related to the analyte concentration. In one example of a glucose sensor, the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide). In some embodiments wherein a calibration is defined by solving for the equation y=mx+b, the value of b represents the baseline of the signal.
The terms “sensitivity” and “slope,” as used herein are broad terms and are used in their ordinary sense, including, without limitation, to refer to an amount of electrical current produced by a predetermined amount (unit) of the measured analyte. For example, in one preferred embodiment, a sensor has a sensitivity (or slope) of about 3.5 to about 7.5 picoAmps of current for every 1 mg/dL of glucose analyte.
The term “membrane system,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to a permeable or semi-permeable membrane that can be comprised of two or more domains and is typically constructed of materials of a few microns thickness or more, which is permeable to oxygen and is optionally permeable to, e.g., glucose or another analyte. In one example, the membrane system comprises an immobilized glucose oxidase enzyme, which enables a reaction to occur between glucose and oxygen whereby a concentration of glucose can be measured.
The terms “processor module” and “microprocessor,” as used herein, are broad terms and are used in their ordinary sense, without limitation, to refer to a computer system, state machine, processor, or the like designed to perform arithmetic or logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer.
The terms “smoothing” and “filtering,” as used herein, are broad terms and are used in their ordinary sense, without limitation, to refer to modification of a set of data to make it smoother and more continuous or to remove or diminish outlying points, for example, by performing a moving average of the raw data stream.
The term “algorithm,” as used herein, is a broad term and is used in its ordinary sense, without limitation, to refer to a computational process (for example, programs) involved in transforming information from one state to another, for example, by using computer processing.
The term “regression,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to finding a line for which a set of data has a minimal measurement (for example, deviation) from that line. Regression can be linear, non-linear, first order, second order, or the like. One example of regression is least squares regression.
The term “calibration,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to the process of determining the relationship between the sensor data and the corresponding reference data, which can be used to convert sensor data into meaningful values substantially equivalent to the reference data. In some embodiments, namely, in continuous analyte sensors, calibration can be updated or recalibrated over time as changes in the relationship between the sensor data and reference data occur, for example, due to changes in sensitivity, baseline, transport, metabolism, or the like.
The terms “interferants” and “interfering species,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, to refer to effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte concentration. In one example of an electrochemical sensor, interfering species are compounds with an oxidation potential that overlap that of the analyte to be measured, thereby producing a false positive signal.
Sensor System
A transcutaneous analyte sensor system is provided that includes an applicator for inserting the transdermal analyte sensor under a host's skin. The sensor system includes a sensor for sensing the analyte, wherein the sensor is associated with a mounting unit adapted for mounting on the skin of the host. The mounting unit houses the electronics unit associated with the sensor and is adapted for fastening to the host's skin. In certain embodiments, the system further includes a receiver for receiving and/or processing sensor data.
The mounting unit 14 includes a base 24 adapted for mounting on the skin of a host, a sensor adapted for transdermal insertion through the skin of a host (see
In one embodiment, an applicator 12 is provided for inserting the sensor 32 through the host's skin at the appropriate insertion angle with the aid of a needle (see
The electronics unit 16 includes hardware, firmware, and/or software that enable measurement of levels of the analyte via the sensor. For example, the electronics unit 16 can comprise a potentiostat, a power source for providing power to the sensor, other components useful for signal processing, and preferably an RF module for transmitting data from the electronics unit 16 to a receiver (see
After insertion of the sensor using the applicator 12, and subsequent release of the applicator 12 from the mounting unit 14 (see
Mounting Unit
In preferred embodiments, the mounting unit 14, also referred to as a housing, comprises a base 24 adapted for fastening to a host's skin. The base can be formed from a variety of hard or soft materials, and preferably comprises a low profile for minimizing protrusion of the device from the host during use. In some embodiments, the base 24 is formed at least partially from a flexible material, which is believed to provide numerous advantages over conventional transcutaneous sensors, which, unfortunately, can suffer from motion-related artifacts associated with the host's movement when the host is using the device. For example, when a transcutaneous analyte sensor is inserted into the host, various movements of the sensor (for example, relative movement between the in vivo portion and the ex vivo portion, movement of the skin, and/or movement within the host (dermis or subcutaneous)) create stresses on the device and can produce noise in the sensor signal. It is believed that even small movements of the skin can translate to discomfort and/or motion-related artifact, which can be reduced or obviated by a flexible or articulated base. Thus, by providing flexibility and/or articulation of the device against the host's skin, better conformity of the sensor system 10 to the regular use and movements of the host can be achieved. Flexibility or articulation is believed to increase adhesion (with the use of an adhesive pad) of the mounting unit 14 onto the skin, thereby decreasing motion-related artifact that can otherwise translate from the host's movements and reduced sensor performance.
In certain embodiments, the mounting unit 14 is provided with an adhesive pad 8, preferably disposed on the mounting unit's back surface and preferably including a releasable backing layer 9. Thus, removing the backing layer 9 and pressing the base portion 24 of the mounting unit onto the host's skin adheres the mounting unit 14 to the host's skin. Additionally or alternatively, an adhesive pad can be placed over some or all of the sensor system after sensor insertion is complete to ensure adhesion, and optionally to ensure an airtight seal or watertight seal around the wound exit-site (or sensor insertion site) (not shown). Appropriate adhesive pads can be chosen and designed to stretch, elongate, conform to, and/or aerate the region (e.g., host's skin).
In preferred embodiments, the adhesive pad 8 is formed from spun-laced, open- or closed-cell foam, and/or non-woven fibers, and includes an adhesive disposed thereon, however a variety of adhesive pads appropriate for adhesion to the host's skin can be used, as is appreciated by one skilled in the art of medical adhesive pads. In some embodiments, a double-sided adhesive pad is used to adhere the mounting unit to the host's skin. In other embodiments, the adhesive pad includes a foam layer, for example, a layer wherein the foam is disposed between the adhesive pad's side edges and acts as a shock absorber.
In some embodiments, the surface area of the adhesive pad 8 is greater than the surface area of the mounting unit's back surface. Alternatively, the adhesive pad can be sized with substantially the same surface area as the back surface of the base portion. Preferably, the adhesive pad has a surface area on the side to be mounted on the host's skin that is greater than about 1, 1.25, 1.5, 1.75, 2, 2.25, or 2.5, times the surface area of the back surface 25 of the mounting unit base 24. Such a greater surface area can increase adhesion between the mounting unit and the host's skin, minimize movement between the mounting unit and the host's skin, and/or protect the wound exit-site (sensor insertion site) from environmental and/or biological contamination. In some alternative embodiments, however, the adhesive pad can be smaller in surface area than the back surface assuming a sufficient adhesion can be accomplished.
In some embodiments, the adhesive pad 8 is substantially the same shape as the back surface 25 of the base 24, although other shapes can also be advantageously employed, for example, butterfly-shaped, round, square, or rectangular. The adhesive pad backing can be designed for two-step release, for example, a primary release wherein only a portion of the adhesive pad is initially exposed to allow adjustable positioning of the device, and a secondary release wherein the remaining adhesive pad is later exposed to firmly and securely adhere the device to the host's skin once appropriately positioned. The adhesive pad is preferably waterproof. Preferably, a stretch-release adhesive pad is provided on the back surface of the base portion to enable easy release from the host's skin at the end of the useable life of the sensor, as is described in more detail with reference to
In some circumstances, it has been found that a conventional bond between the adhesive pad and the mounting unit may not be sufficient, for example, due to humidity that can cause release of the adhesive pad from the mounting unit. Accordingly, in some embodiments, the adhesive pad can be bonded using a bonding agent activated by or accelerated by an ultraviolet, acoustic, radio frequency, or humidity cure. In some embodiments, a eutectic bond of first and second composite materials can form a strong adhesion. In some embodiments, the surface of the mounting unit can be pretreated utilizing ozone, plasma, chemicals, or the like, in order to enhance the bondability of the surface.
A bioactive agent is preferably applied locally at the insertion site prior to or during sensor insertion. Suitable bioactive agents include those which are known to discourage or prevent bacterial growth and infection, for example, anti-inflammatory agents, antimicrobials, antibiotics, or the like. It is believed that the diffusion or presence of a bioactive agent can aid in prevention or elimination of bacteria adjacent to the exit-site. Additionally or alternatively, the bioactive agent can be integral with or coated on the adhesive pad, or no bioactive agent at all is employed
In the illustrated embodiment, the sealing member 36 is formed with a raised portion 37 surrounding the contacts 28. The raised portion 37 enhances the interference fit surrounding the contacts 28 when the electronics unit 16 is mated to the mounting unit 14. Namely, the raised portion surrounds each contact and presses against the electronics unit 16 to form a tight seal around the electronics unit.
Contacts 28 fit within the seal 36 and provide for electrical connection between the sensor 32 and the electronics unit 16. In general, the contacts are designed to ensure a stable mechanical and electrical connection of the electrodes that form the sensor 32 (see
In preferred embodiments, the contacts 28 are formed from a conductive elastomeric material, such as a carbon black elastomer, through which the sensor 32 extends (see
In an alternative embodiment, a conductive, stiff plastic forms the contacts, which are shaped to comply upon application of pressure (for example, a leaf-spring shape). Contacts of such a configuration can be used instead of a metallic spring, for example, and advantageously avoid the need for crimping or soldering through compliant materials; additionally, a wiping action can be incorporated into the design to remove contaminants from the surfaces during connection. Non-metallic contacts can be advantageous because of their seamless manufacturability, robustness to thermal compression, non-corrosive surfaces, and native resistance to electrostatic discharge (ESD) damage due to their higher-than-metal resistance.
Sensor
Preferably, the sensor 32 includes a distal portion 42, also referred to as the in vivo portion, adapted to extend out of the mounting unit for insertion under the host's skin, and a proximal portion 40, also referred to as an ex vivo portion, adapted to remain above the host's skin after sensor insertion and to operably connect to the electronics unit 16 via contacts 28. Preferably, the sensor 32 includes two or more electrodes: a working electrode 44 and at least one additional electrode, which can function as a counter electrode and/or reference electrode, hereinafter referred to as the reference electrode 46. A membrane system is preferably deposited over the electrodes, such as described in more detail with reference to
In alternative embodiments, the contacts 28 are formed into a variety of alternative shapes and/or sizes. For example, the contacts 28 can be discs, spheres, cuboids, and the like. Furthermore, the contacts 28 can be designed to extend from the mounting unit in a manner that causes an interference fit within a mating cavity or groove of the electronics unit, forming a stable mechanical and electrical connection therewith.
In preferred embodiments, each electrode is formed from a fine wire with a diameter of from about 0.001 or less to about 0.010 inches or more, for example, and is formed from, e.g., a plated insulator, a plated wire, or bulk electrically conductive material. Although the illustrated electrode configuration and associated text describe one preferred method of forming a transcutaneous sensor, a variety of known transcutaneous sensor configurations can be employed with the transcutaneous analyte sensor system of the preferred embodiments, such as are described in U.S. Pat. No. 6,695,860 to Ward et al., U.S. Pat. No. 6,565,509 to Say et al., U.S. Pat. No. 6,248,067 to Causey III, et al., and U.S. Pat. No. 6,514,718 to Heller et al.
In preferred embodiments, the working electrode comprises a wire formed from a conductive material, such as platinum, platinum-iridium, palladium, graphite, gold, carbon, conductive polymer, alloys, or the like. Although the electrodes can by formed by a variety of manufacturing techniques (bulk metal processing, deposition of metal onto a substrate, or the like), it can be advantageous to form the electrodes from plated wire (e.g., platinum on steel wire) or bulk metal (e.g., platinum wire). It is believed that electrodes formed from bulk metal wire provide superior performance (e.g., in contrast to deposited electrodes), including increased stability of assay, simplified manufacturability, resistance to contamination (e.g., which can be introduced in deposition processes), and improved surface reaction (e.g., due to purity of material) without peeling or delamination.
The working electrode 44 is configured to measure the concentration of an analyte. In an enzymatic electrochemical sensor for detecting glucose, for example, the working electrode measures the hydrogen peroxide produced by an enzyme catalyzed reaction of the analyte being detected and creates a measurable electronic current For example, in the detection of glucose wherein glucose oxidase produces hydrogen peroxide as a byproduct, hydrogen peroxide reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2), which produces the electronic current being detected.
In preferred embodiments, the working electrode 44 is covered with an insulating material 45, for example, a non-conductive polymer. Dip-coating, spray-coating, vapor-deposition, or other coating or deposition techniques can be used to deposit the insulating material on the working electrode. In one embodiment, the insulating material comprises parylene, which can be an advantageous polymer coating for its strength, lubricity, and electrical insulation properties. Generally, parylene is produced by vapor deposition and polymerization of para-xylylene (or its substituted derivatives). However, any suitable insulating material can be used, for example, fluorinated polymers, polyethyleneterephthalate, polyurethane, polyimide, other nonconducting polymers, or the like. Glass or ceramic materials can also be employed. Other materials suitable for use include surface energy modified coating systems such as are marketed under the trade names AMC18, AMC148, AMC141, and AMC321 by Advanced Materials Components Express of Bellafonte, Pa. In some alternative embodiments, however, the working electrode may not require a coating of insulator.
The reference electrode 46, which can function as a reference electrode alone, or as a dual reference and counter electrode, is formed from silver, silver/silver chloride, or the like. Preferably, the reference electrode 46 is juxtapositioned and/or twisted with or around the working electrode 44; however other configurations are also possible. In the illustrated embodiments, the reference electrode 46 is helically wound around the working electrode 44. The assembly of wires is then optionally coated or adhered together with an insulating material, similar to that described above, so as to provide an insulating attachment.
In embodiments wherein an outer insulator is disposed, a portion of the coated assembly structure can be stripped or otherwise removed, for example, by hand, excimer lasing, chemical etching, laser ablation, grit-blasting (e.g., with sodium bicarbonate or other suitable grit), or the like, to expose the electroactive surfaces. Alternatively, a portion of the electrode can be masked prior to depositing the insulator in order to maintain an exposed electroactive surface area. In one exemplary embodiment, grit blasting is implemented to expose the electroactive surfaces, preferably utilizing a grit material that is sufficiently hard to ablate the polymer material, while being sufficiently soft so as to minimize or avoid damage to the underlying metal electrode (e.g., a platinum electrode). Although a variety of “grit” materials can be used (e.g., sand, talc, walnut shell, ground plastic, sea salt, and the like), in some preferred embodiments, sodium bicarbonate is an advantageous grit-material because it is sufficiently hard to ablate, e.g., a parylene coating without damaging, e.g., an underlying platinum conductor. One additional advantage of sodium bicarbonate blasting includes its polishing action on the metal as it strips the polymer layer, thereby eliminating a cleaning step that might otherwise be necessary.
In the embodiment illustrated in
In some applications, cellular attack or migration of cells to the sensor can cause reduced sensitivity and/or function of the device, particularly after the first day of implantation. However, when the exposed electroactive surface is distributed circumferentially about the sensor (e.g., as in a radial window), the available surface area for reaction can be sufficiently distributed so as to minimize the effect of local cellular invasion of the sensor on the sensor signal. Alternatively, a tangential exposed electroactive window can be formed, for example, by stripping only one side of the coated assembly structure. In other alternative embodiments, the window can be provided at the tip of the coated assembly structure such that the electroactive surfaces are exposed at the tip of the sensor. Other methods and configurations for exposing electroactive surfaces can also be employed.
In some embodiments, the working electrode has a diameter of from about 0.001 inches or less to about 0.010 inches or more, preferably from about 0.002 inches to about 0.008 inches, and more preferably from about 0.004 inches to about 0.005 inches. The length of the window can be from about 0.1 mm (about 0.004 inches) or less to about 2 mm (about 0.078 inches) or more, and preferably from about 0.5 mm (about 0.02 inches) to about 0.75 mm (0.03 inches). In such embodiments, the exposed surface area of the working electrode is preferably from about 0.000013 in2 (0.0000839 cm2) or less to about 0.0025 in2 (0.016129 cm2) or more (assuming a diameter of from about 0.001 inches to about 0.010 inches and a length of from about 0.004 inches to about 0.078 inches). The preferred exposed surface area of the working electrode is selected to produce an analyte signal with a current in the picoAmp range, such as is described in more detail elsewhere herein. However, a current in the picoAmp range can be dependent upon a variety of factors, for example the electronic circuitry design (e.g., sample rate, current draw, A/D converter bit resolution, etc.), the membrane system (e.g., permeability of the analyte through the membrane system), and the exposed surface area of the working electrode. Accordingly, the exposed electroactive working electrode surface area can be selected to have a value greater than or less than the above-described ranges taking into consideration alterations in the membrane system and/or electronic circuitry. In preferred embodiments of a glucose sensor, it can be advantageous to minimize the surface area of the working electrode while maximizing the diffusivity of glucose in order to optimize the signal-to-noise ratio while maintaining sensor performance in both high and low glucose concentration ranges.
In some alternative embodiments, the exposed surface area of the working (and/or other) electrode can be increased by altering the cross-section of the electrode itself. For example, in some embodiments the cross-section of the working electrode can be defined by a cross, star, cloverleaf, ribbed, dimpled, ridged, irregular, or other non-circular configuration; thus, for any predetermined length of electrode, a specific increased surface area can be achieved (as compared to the area achieved by a circular cross-section). Increasing the surface area of the working electrode can be advantageous in providing an increased signal responsive to the analyte concentration, which in turn can be helpful in improving the signal-to-noise ratio, for example.
In some alternative embodiments, additional electrodes can be included within the assembly, for example, a three-electrode system (working, reference, and counter electrodes) and/or an additional working electrode (e.g., an electrode which can be used to generate oxygen, which is configured as a baseline subtracting electrode, or which is configured for measuring additional analytes). Co-pending U.S. patent application Ser. No. 11/007,635, filed Dec. 7, 2004 and entitled “SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYTE SENSORS” and U.S. patent application Ser. No. 11/004,561, filed Dec. 3, 2004 and entitled “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR” describe some systems and methods for implementing and using additional working, counter, and/or reference electrodes. In one implementation wherein the sensor comprises two working electrodes, the two working electrodes are juxtapositioned (e.g., extend parallel to each other), around which the reference electrode is disposed (e.g., helically wound). In some embodiments wherein two or more working electrodes are provided, the working electrodes can be formed in a double-, triple-, quad-, etc. helix configuration along the length of the sensor (for example, surrounding a reference electrode, insulated rod, or other support structure.) The resulting electrode system can be configured with an appropriate membrane system, wherein the first working electrode is configured to measure a first signal comprising glucose and baseline and the additional working electrode is configured to measure a baseline signal consisting of baseline only (e.g., configured to be substantially similar to the first working electrode without an enzyme disposed thereon.) In this way, the baseline signal can be subtracted from the first signal to produce a glucose-only signal that is substantially not subject to fluctuations in the baseline and/or interfering species on the signal.
Although the preferred embodiments illustrate one electrode configuration including one bulk metal wire helically wound around another bulk metal wire, other electrode configurations are also contemplated. In an alternative embodiment, the working electrode comprises a tube with a reference electrode disposed or coiled inside, including an insulator there between. Alternatively, the reference electrode comprises a tube with a working electrode disposed or coiled inside, including an insulator there between. In another alternative embodiment, a polymer (e.g., insulating) rod is provided, wherein the electrodes are deposited (e.g., electro-plated) thereon. In yet another alternative embodiment, a metallic (e.g., steel) rod is provided, coated with an insulating material, onto which the working and reference electrodes are deposited. In yet another alternative embodiment, one or more working electrodes are helically wound around a reference electrode.
Preferably, the electrodes and membrane systems of the preferred embodiments are coaxially formed, namely, the electrodes and/or membrane system all share the same central axis. While not wishing to be bound by theory, it is believed that a coaxial design of the sensor enables a symmetrical design without a preferred bend radius. Namely, in contrast to prior art sensors comprising a substantially planar configuration that can suffer from regular bending about the plane of the sensor, the coaxial design of the preferred embodiments do not have a preferred bend radius and therefore are not subject to regular bending about a particular plane (which can cause fatigue failures and the like). However, non-coaxial sensors can be implemented with the sensor system of the preferred embodiments.
In addition to the above-described advantages, the coaxial sensor design of the preferred embodiments enables the diameter of the connecting end of the sensor (proximal portion) to be substantially the same as that of the sensing end (distal portion) such that the needle is able to insert the sensor into the host and subsequently slide back over the sensor and release the sensor from the needle, without slots or other complex multi-component designs.
In one such alternative embodiment, the two wires of the sensor are held apart and configured for insertion into the host in proximal but separate locations. The separation of the working and reference electrodes in such an embodiment can provide additional electrochemical stability with simplified manufacture and electrical connectivity. It is appreciated by one skilled in the art that a variety of electrode configurations can be implemented with the preferred embodiments.
Anchoring Mechanism
It is preferred that the sensor remains substantially stationary within the tissue of the host, such that migration or motion of the sensor with respect to the surrounding tissue is minimized. Migration or motion is believed to cause inflammation at the sensor implant site due to irritation, and can also cause noise on the sensor signal due to motion-related artifact, for example. Therefore, it can be advantageous to provide an anchoring mechanism that provides support for the sensor's in vivo portion to avoid the above-mentioned problems. Combining advantageous sensor geometry with an advantageous anchoring minimizes additional parts and allows for an optimally small or low profile design of the sensor. In one embodiment the sensor includes a surface topography, such as the helical surface topography provided by the reference electrode surrounding the working electrode. In alternative embodiments, a surface topography could be provided by a roughened surface, porous surface (e.g. porous parylene), ridged surface, or the like. Additionally (or alternatively), the anchoring can be provided by prongs, spines, barbs, wings, hooks, a bulbous portion (for example, at the distal end), an S-bend along the sensor, a rough surface topography, a gradually changing diameter, combinations thereof, or the like, which can be used alone or in combination with the helical surface topography to stabilize the sensor within the subcutaneous tissue.
Variable Stiffness
As described above, conventional transcutaneous devices are believed to suffer from motion artifact associated with host movement when the host is using the device. For example, when a transcutaneous analyte sensor is inserted into the host, various movements on the sensor (for example, relative movement within and between the subcutaneous space, dermis, skin, and external portions of the sensor) create stresses on the device, which is known to produce artifacts on the sensor signal. Accordingly, there are different design considerations (for example, stress considerations) on various sections of the sensor. For example, the distal portion 42 of the sensor can benefit in general from greater flexibility as it encounters greater mechanical stresses caused by movement of the tissue within the patient and relative movement between the in vivo and ex vivo portions of the sensor. On the other hand, the proximal portion 40 of the sensor can benefit in general from a stiffer, more robust design to ensure structural integrity and/or reliable electrical connections. Additionally, in some embodiments wherein a needle is retracted over the proximal portion 40 of the device (see
The preferred embodiments provide a distal portion 42 of the sensor 32 designed to be more flexible than a proximal portion 40 of the sensor. The variable stiffness of the preferred embodiments can be provided by variable pitch of any one or more helically wound wires of the device, variable cross-section of any one or more wires of the device, and/or variable hardening and/or softening of any one or more wires of the device, such as is described in more detail with reference to U.S. patent application Ser. No. 11/077,759, now U.S. Pat. No. 7,783,333 described above and entitled “TRANSCUTANEOUS MEDICAL DEVICE WITH VARIABLE STIFFNESS.”
Membrane System
In general, the membrane system includes a plurality of domains, for example, an electrode domain 47, an interference domain 48, an enzyme domain 49 (for example, including glucose oxidase), and a resistance domain 50, and can include a high oxygen solubility domain, and/or a bioprotective domain (not shown), such as is described in more detail in U.S. patent application Ser. No. 10/838,912, and such as is described in more detail below. The membrane system can be deposited on the exposed electroactive surfaces using known thin film techniques (for example, spraying, electro-depositing, dipping, or the like). In one embodiment, one or more domains are deposited by dipping the sensor into a solution and drawing out the sensor at a speed that provides the appropriate domain thickness. However, the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method as will be appreciated by one skilled in the art.
Electrode Domain
In some embodiments, the membrane system comprises an optional electrode domain 47. The electrode domain 47 is provided to ensure that an electrochemical reaction occurs between the electroactive surfaces of the working electrode and the reference electrode, and thus the electrode domain 47 is preferably situated more proximal to the electroactive surfaces than the enzyme domain. Preferably, the electrode domain 47 includes a semipermeable coating that maintains a layer of water at the electrochemically reactive surfaces of the sensor, for example, a humectant in a binder material can be employed as an electrode domain; this allows for the full transport of ions in the aqueous environment. The electrode domain can also assist in stabilizing the operation of the sensor by overcoming electrode start-up and drifting problems caused by inadequate electrolyte. The material that forms the electrode domain can also protect against pH-mediated damage that can result from the formation of a large pH gradient due to the electrochemical activity of the electrodes.
In one embodiment, the electrode domain 47 includes a flexible, water-swellable, hydrogel film having a “dry film” thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation by standard coating techniques.
In certain embodiments, the electrode domain 47 is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. Particularly preferred coatings are formed of a polyurethane polymer having carboxylate functional groups and non-ionic hydrophilic polyether segments, wherein the polyurethane polymer is crosslinked with a water soluble carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC))) in the presence of polyvinylpyrrolidone and cured at a moderate temperature of about 50° C.
Preferably, the electrode domain 47 is deposited by spray or dip-coating the electroactive surfaces of the sensor 32. More preferably, the electrode domain is formed by dip-coating the electroactive surfaces in an electrode solution and curing the domain for a time of from about 15 to about 30 minutes at a temperature of from about 40 to about 55° C. (and can be accomplished under vacuum (e.g., 20 to 30 mmHg)). In embodiments wherein dip-coating is used to deposit the electrode domain, a preferred insertion rate of from about 1 to about 3 inches per minute, with a preferred dwell time of from about 0.5 to about 2 minutes, and a preferred withdrawal rate of from about 0.25 to about 2 inches per minute provide a functional coating. However, values outside of those set forth above can be acceptable or even desirable in certain embodiments, for example, dependent upon viscosity and surface tension as is appreciated by one skilled in the art. In one embodiment, the electroactive surfaces of the electrode system are dip-coated one time (one layer) and cured at 50° C. under vacuum for 20 minutes.
Although an independent electrode domain is described herein, in some embodiments, sufficient hydrophilicity can be provided in the interference domain and/or enzyme domain (the domain adjacent to the electroactive surfaces) so as to provide for the full transport of ions in the aqueous environment (e.g. without a distinct electrode domain).
Interference Domain
In some embodiments, an optional interference domain 48 is provided, which generally includes a polymer domain that restricts the flow of one or more interferants. In some embodiments, the interference domain 48 functions as a molecular sieve that allows analytes and other substances that are to be measured by the electrodes to pass through, while preventing passage of other substances, including interferants such as ascorbate and urea (see U.S. Pat. No. 6,001,067 to Shults). Some known interferants for a glucose-oxidase based electrochemical sensor include acetaminophen, ascorbic acid, bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyldopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid.
Several polymer types that can be utilized as a base material for the interference domain 48 include polyurethanes, polymers having pendant ionic groups, and polymers having controlled pore size, for example. In one embodiment, the interference domain includes a thin, hydrophobic membrane that is non-swellable and restricts diffusion of low molecular weight species. The interference domain 48 is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but restricts the passage of higher molecular weight substances, including glucose and ascorbic acid. Other systems and methods for reducing or eliminating interference species that can be applied to the membrane system of the preferred embodiments are described in co-pending U.S. patent application Ser. No. 10/896,312 filed Jul. 21, 2004 and entitled “ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS,” Ser. No. 10/991,353, filed Nov. 16, 2004 and entitled, “AFFINITY DOMAIN FOR AN ANALYTE SENSOR,” Ser. No. 11/007,635, filed Dec. 7, 2004 and entitled “SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYTE SENSORS” and Ser. No. 11/004,561, filed Dec. 3, 2004 and entitled, “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR.” In some alternative embodiments, a distinct interference domain is not included.
In preferred embodiments, the interference domain 48 is deposited onto the electrode domain (or directly onto the electroactive surfaces when a distinct electrode domain is not included) for a domain thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. Thicker membranes can also be useful, but thinner membranes are generally preferred because they have a lower impact on the rate of diffusion of hydrogen peroxide from the enzyme membrane to the electrodes. Unfortunately, the thin thickness of the interference domains conventionally used can introduce variability in the membrane system processing. For example, if too much or too little interference domain is incorporated within a membrane system, the performance of the membrane can be adversely affected.
Enzyme Domain
In preferred embodiments, the membrane system further includes an enzyme domain 49 disposed more distally situated from the electroactive surfaces than the interference domain 48 (or electrode domain 47 when a distinct interference is not included). In some embodiments, the enzyme domain is directly deposited onto the electroactive surfaces (when neither an electrode or interference domain is included). In the preferred embodiments, the enzyme domain 49 provides an enzyme to catalyze the reaction of the analyte and its co-reactant, as described in more detail below. Preferably, the enzyme domain includes glucose oxidase, however other oxidases, for example, galactose oxidase or uricase oxidase, can also be used.
For an enzyme-based electrochemical glucose sensor to perform well, the sensor's response is preferably limited by neither enzyme activity nor co-reactant concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of time even in ambient conditions, this behavior is compensated for in forming the enzyme domain. Preferably, the enzyme domain 49 is constructed of aqueous dispersions of colloidal polyurethane polymers including the enzyme. However, in alternative embodiments the enzyme domain is constructed from an oxygen enhancing material, for example, silicone or fluorocarbon, in order to provide a supply of excess oxygen during transient ischemia. Preferably, the enzyme is immobilized within the domain. See U.S. patent application Ser. No. 10/896,639 filed on Jul. 21, 2004 and entitled “Oxygen Enhancing Membrane Systems for Implantable Device.”
In preferred embodiments, the enzyme domain 49 is deposited onto the interference domain for a domain thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. However in some embodiments, the enzyme domain is deposited onto the electrode domain or directly onto the electroactive surfaces. Preferably, the enzyme domain 49 is deposited by spray or dip coating. More preferably, the enzyme domain is formed by dip-coating the electrode domain into an enzyme domain solution and curing the domain for from about 15 to about 30 minutes at a temperature of from about 40 to about 55° C. (and can be accomplished under vacuum (e.g., 20 to 30 mmHg)). In embodiments wherein dip-coating is used to deposit the enzyme domain at room temperature, a preferred insertion rate of from about 1 inch per minute to about 3 inches per minute, with a preferred dwell time of from about 0.5 minutes to about 2 minutes, and a preferred withdrawal rate of from about 0.25 inch per minute to about 2 inches per minute provide a functional coating. However, values outside of those set forth above can be acceptable or even desirable in certain embodiments, for example, dependent upon viscosity and surface tension as is appreciated by one skilled in the art. In one embodiment, the enzyme domain 49 is formed by dip coating two times (namely, forming two layers) in a coating solution and curing at 50° C. under vacuum for 20 minutes. However, in some embodiments, the enzyme domain can be formed by dip-coating and/or spray-coating one or more layers at a predetermined concentration of the coating solution, insertion rate, dwell time, withdrawal rate, and/or desired thickness.
Resistance Domain
In preferred embodiments, the membrane system includes a resistance domain 50 disposed more distal from the electroactive surfaces than the enzyme domain 49. Although the following description is directed to a resistance domain for a glucose sensor, the resistance domain can be modified for other analytes and co-reactants as well.
There exists a molar excess of glucose relative to the amount of oxygen in blood; that is, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see Updike et al., Diabetes Care 5:207-21 (1982)). However, an immobilized enzyme-based glucose sensor employing oxygen as co-reactant is preferably supplied with oxygen in non-rate-limiting excess in order for the sensor to respond linearly to changes in glucose concentration, while not responding to changes in oxygen concentration. Specifically, when a glucose-monitoring reaction is oxygen limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels can be obtained only for glucose concentrations of up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 400 mg/dL.
The resistance domain 50 includes a semi permeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain 49, preferably rendering oxygen in a non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the resistance domain. In one embodiment, the resistance domain 50 exhibits an oxygen to glucose permeability ratio of from about 50:1 or less to about 400:1 or more, preferably about 200:1. As a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)).
In alternative embodiments, a lower ratio of oxygen-to-glucose can be sufficient to provide excess oxygen by using a high oxygen solubility domain (for example, a silicone or fluorocarbon-based material or domain) to enhance the supply/transport of oxygen to the enzyme domain 49. If more oxygen is supplied to the enzyme, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess. In alternative embodiments, the resistance domain is formed from a silicone composition, such as is described in co-pending U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and entitled, “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE.”
In a preferred embodiment, the resistance domain 50 includes a polyurethane membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to an analyte sensor, the membrane being fabricated easily and reproducibly from commercially available materials. A suitable hydrophobic polymer component is a polyurethane, or polyetherurethaneurea. Polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Preferred diisocyanates include aliphatic diisocyanates containing from about 4 to about 8 methylene units. Diisocyanates containing cycloaliphatic moieties can also be useful in the preparation of the polymer and copolymer components of the membranes of preferred embodiments. The material that forms the basis of the hydrophobic matrix of the resistance domain can be any of those known in the art as appropriate for use as membranes in sensor devices and as having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes. Examples of materials which can be used to make non-polyurethane type membranes include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials, and mixtures or combinations thereof.
In a preferred embodiment, the hydrophilic polymer component is polyethylene oxide. For example, one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethylene oxide. The polyethylene oxide portions of the copolymer are thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic polymer component. The 20% polyethylene oxide-based soft segment portion of the copolymer used to form the final blend affects the water pick-up and subsequent glucose permeability of the membrane.
In preferred embodiments, the resistance domain 50 is deposited onto the enzyme domain 49 to yield a domain thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. Preferably, the resistance domain is deposited onto the enzyme domain by spray coating or dip coating. In certain embodiments, spray coating is the preferred deposition technique. The spraying process atomizes and mists the solution, and therefore most or all of the solvent is evaporated prior to the coating material settling on the underlying domain, thereby minimizing contact of the solvent with the enzyme. One additional advantage of spray-coating the resistance domain as described in the preferred embodiments includes formation of a membrane system that substantially blocks or resists ascorbate (a known electrochemical interferant in hydrogen peroxide-measuring glucose sensors). While not wishing to be bound by theory, it is believed that during the process of depositing the resistance domain as described in the preferred embodiments, a structural morphology is formed, characterized in that ascorbate does not substantially permeate there through.
In preferred embodiments, the resistance domain 50 is deposited on the enzyme domain 49 by spray-coating a solution of from about 1 wt. % to about 5 wt. % polymer and from about 95 wt. % to about 99 wt. % solvent. In spraying a solution of resistance domain material, including a solvent, onto the enzyme domain, it is desirable to mitigate or substantially reduce any contact with enzyme of any solvent in the spray solution that can deactivate the underlying enzyme of the enzyme domain 49. Tetrahydrofuran (THF) is one solvent that minimally or negligibly affects the enzyme of the enzyme domain upon spraying. Other solvents can also be suitable for use, as is appreciated by one skilled in the art.
Although a variety of spraying or deposition techniques can be used, spraying the resistance domain material and rotating the sensor at least one time by 180° can provide adequate coverage by the resistance domain. Spraying the resistance domain material and rotating the sensor at least two times by 120 degrees provides even greater coverage (one layer of 360° coverage), thereby ensuring resistivity to glucose, such as is described in more detail above.
In preferred embodiments, the resistance domain 50 is spray-coated and subsequently cured for a time of from about 15 to about 90 minutes at a temperature of from about 40 to about 60° C. (and can be accomplished under vacuum (e.g., 20 to 30 mmHg)). A cure time of up to about 90 minutes or more can be advantageous to ensure complete drying of the resistance domain. While not wishing to be bound by theory, it is believed that complete drying of the resistance domain aids in stabilizing the sensitivity of the glucose sensor signal. It reduces drifting of the signal sensitivity over time, and complete drying is believed to stabilize performance of the glucose sensor signal in lower oxygen environments.
In one embodiment, the resistance domain 50 is formed by spray-coating at least six layers (namely, rotating the sensor seventeen times by 120° for at least six layers of 360° coverage) and curing at 50° C. under vacuum for 60 minutes. However, the resistance domain can be formed by dip-coating or spray-coating any layer or plurality of layers, depending upon the concentration of the solution, insertion rate, dwell time, withdrawal rate, and/or the desired thickness of the resulting film.
Advantageously, sensors with the membrane system of the preferred embodiments, including an electrode domain 47 and/or interference domain 48, an enzyme domain 49, and a resistance domain 50, provide stable signal response to increasing glucose levels of from about 40 to about 400 mg/dL, and sustained function (at least 90% signal strength) even at low oxygen levels (for example, at about 0.6 mg/L O2). While not wishing to be bound by theory, it is believed that the resistance domain provides sufficient resistivity, or the enzyme domain provides sufficient enzyme, such that oxygen limitations are seen at a much lower concentration of oxygen as compared to prior art sensors.
In preferred embodiments, a sensor signal with a current in the picoAmp range is preferred, which is described in more detail elsewhere herein. However, the ability to produce a signal with a current in the picoAmp range can be dependent upon a combination of factors, including the electronic circuitry design (e.g., A/D converter, bit resolution, and the like), the membrane system (e.g., permeability of the analyte through the resistance domain, enzyme concentration, and/or electrolyte availability to the electrochemical reaction at the electrodes), and the exposed surface area of the working electrode. For example, the resistance domain can be designed to be more or less restrictive to the analyte depending upon to the design of the electronic circuitry, membrane system, and/or exposed electroactive surface area of the working electrode.
Accordingly, in preferred embodiments, the membrane system is designed with a sensitivity of from about 1 pA/mg/dL to about 100 pA/mg/dL, preferably from about 5 pA/mg/dL to 25 pA/mg/dL, and more preferably from about 4 to about 7 pA/mg/dL. While not wishing to be bound by any particular theory, it is believed that membrane systems designed with a sensitivity in the preferred ranges permit measurement of the analyte signal in low analyte and/or low oxygen situations. Namely, conventional analyte sensors have shown reduced measurement accuracy in low analyte ranges due to lower availability of the analyte to the sensor and/or have shown increased signal noise in high analyte ranges due to insufficient oxygen necessary to react with the amount of analyte being measured. While not wishing to be bound by theory, it is believed that the membrane systems of the preferred embodiments, in combination with the electronic circuitry design and exposed electrochemical reactive surface area design, support measurement of the analyte in the picoAmp range, which enables an improved level of resolution and accuracy in both low and high analyte ranges not seen in the prior art.
Mutarotase Enzyme
In some embodiments, mutarotase, an enzyme that converts α D-glucose to β D-glucose, is incorporated into the membrane system. Mutarotase can be incorporated into the enzyme domain and/or can be incorporated into another domain of the membrane system. In general, glucose exists in two distinct isomers, α and β, which are in equilibrium with one another in solution and in the blood or interstitial fluid. At equilibrium, α is present at a relative concentration of about 35.5% and β is present in the relative concentration of about 64.5% (see Okuda et. al., Anal Biochem. 1971 September; 43(1):312-5). Glucose oxidase, which is a conventional enzyme used to react with glucose in glucose sensors, reacts with β D-glucose and not with α D-glucose. Since only the β D-glucose isomer reacts with the glucose oxidase, errant readings may occur in a glucose sensor responsive to a shift of the equilibrium between the α D-glucose and the β D-glucose. Many compounds, such as calcium, can affect equilibrium shifts of α D-glucose and β D-glucose. For example, as disclosed in U.S. Pat. No. 3,964,974 to Banaugh et al., compounds that exert a mutarotation accelerating effect on α D-glucose include histidine, aspartic acid, imidazole, glutamic acid, a hydroxyl pyridine, and phosphate.
Accordingly, a shift in α D-glucose and β D-glucose equilibrium can cause a glucose sensor based on glucose oxidase to err high or low. To overcome the risks associated with errantly high or low sensor readings due to equilibrium shifts, the sensor of the preferred embodiments can be configured to measure total glucose in the host, including α D-glucose and β D-glucose by the incorporation of the mutarotase enzyme, which converts α D-glucose to β D-glucose.
Although sensors of some embodiments described herein include an optional interference domain in order to block or reduce one or more interferants, sensors with the membrane system of the preferred embodiments, including an electrode domain 47, an enzyme domain 48, and a resistance domain 49, have been shown to inhibit ascorbate without an additional interference domain. Namely, the membrane system of the preferred embodiments, including an electrode domain 47, an enzyme domain 48, and a resistance domain 49, has been shown to be substantially non-responsive to ascorbate in physiologically acceptable ranges. While not wishing to be bound by theory, it is believed that the processing process of spraying the depositing the resistance domain by spray coating, as described herein, forms results in a structural morphology that is substantially resistance resistant to ascorbate.
Interference-free Membrane Systems
In general, it is believed that appropriate solvents and/or deposition methods can be chosen for one or more of the domains of the membrane system that form one or more transitional domains such that interferants do not substantially permeate there through. Thus, sensors can be built without distinct or deposited interference domains, which are non-responsive to interferants. While not wishing to be bound by theory, it is believed that a simplified multilayer membrane system, more robust multilayer manufacturing process, and reduced variability caused by the thickness and associated oxygen and glucose sensitivity of the deposited micron-thin interference domain can be provided. Additionally, the optional polymer-based interference domain, which usually inhibits hydrogen peroxide diffusion, is eliminated, thereby enhancing the amount of hydrogen peroxide that passes through the membrane system.
Oxygen Conduit
As described above, certain sensors depend upon an enzyme within the membrane system through which the host's bodily fluid passes and in which the analyte (for example, glucose) within the bodily fluid reacts in the presence of a co-reactant (for example, oxygen) to generate a product. The product is then measured using electrochemical methods, and thus the output of an electrode system functions as a measure of the analyte. For example, when the sensor is a glucose oxidase based glucose sensor, the species measured at the working electrode is H2O2. An enzyme, glucose oxidase, catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction:
Glucose+O2→Gluconate+H2O2
Because for each glucose molecule reacted there is a proportional change in the product, H2O2, one can monitor the change in H2O2 to determine glucose concentration. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2 and other reducible species at a counter electrode, for example. See Fraser, D. M., “An Introduction to In Vivo Biosensing: Progress and Problems.” In “Biosensors and the Body,” D. M. Fraser, ed., 1997, pp. 1-56 John Wiley and Sons, New York))
In vivo, glucose concentration is generally about one hundred times or more that of the oxygen concentration. Consequently, oxygen is a limiting reactant in the electrochemical reaction, and when insufficient oxygen is provided to the sensor, the sensor is unable to accurately measure glucose concentration. Thus, depressed sensor function or inaccuracy is believed to be a result of problems in availability of oxygen to the enzyme and/or electroactive surface(s).
Accordingly, in an alternative embodiment, an oxygen conduit (for example, a high oxygen solubility domain formed from silicone or fluorochemicals) is provided that extends from the ex vivo portion of the sensor to the in vivo portion of the sensor to increase oxygen availability to the enzyme. The oxygen conduit can be formed as a part of the coating (insulating) material or can be a separate conduit associated with the assembly of wires that forms the sensor.
Porous Biointerface Materials
In alternative embodiments, the distal portion 42 includes a porous material disposed over some portion thereof, which modifies the host's tissue response to the sensor. In some embodiments, the porous material surrounding the sensor advantageously enhances and extends sensor performance and lifetime in the short term by slowing or reducing cellular migration to the sensor and associated degradation that would otherwise be caused by cellular invasion if the sensor were directly exposed to the in vivo environment. Alternatively, the porous material can provide stabilization of the sensor via tissue ingrowth into the porous material in the long term. Suitable porous materials include silicone, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polyvinyl alcohol (PVA), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyamides, polyurethanes, cellulosic polymers, polysulfones and block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers, as well as metals, ceramics, cellulose, hydrogel polymers, poly (2-hydroxyethyl methacrylate, pHEMA), hydroxyethyl methacrylate, (HEMA), polyacrylonitrile-polyvinyl chloride (PAN-PVC), high density polyethylene, acrylic copolymers, nylon, polyvinyl difluoride, polyanhydrides, poly(1-lysine), poly (L-lactic acid), hydroxyethylmetharcrylate, hydroxyapeptite, alumina, zirconia, carbon fiber, aluminum, calcium phosphate, titanium, titanium alloy, nintinol, stainless steel, and CoCr alloy, or the like, such as are described in co-pending U.S. patent application Ser. No. 10/842,716, filed May 10, 2004 and entitled, “BIOINTERFACE MEMBRANES INCORPORATING BIOACTIVE AGENTS” and U.S. patent application Ser. No. 10/647,065 filed Aug. 22, 2003 and entitled “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES.”
In some embodiments, the porous material surrounding the sensor provides unique advantages in the short term (e.g., one to 14 days) that can be used to enhance and extend sensor performance and lifetime. However, such materials can also provide advantages in the long term too (e.g., greater than 14 days). Particularly, the in vivo portion of the sensor (the portion of the sensor that is implanted into the host's tissue) is encased (partially or fully) in a porous material. The porous material can be wrapped around the sensor (for example, by wrapping the porous material around the sensor or by inserting the sensor into a section of porous material sized to receive the sensor). Alternately, the porous material can be deposited on the sensor (for example, by electrospinning of a polymer directly thereon). In yet other alternative embodiments, the sensor is inserted into a selected section of porous biomaterial. Other methods for surrounding the in vivo portion of the sensor with a porous material can also be used as is appreciated by one skilled in the art.
The porous material surrounding the sensor advantageously slows or reduces cellular migration to the sensor and associated degradation that would otherwise be caused by cellular invasion if the sensor were directly exposed to the in vivo environment. Namely, the porous material provides a barrier that makes the migration of cells towards the sensor more tortuous and therefore slower (providing short term advantages). It is believed that this reduces or slows the sensitivity loss normally observed in a short-term sensor over time.
In an embodiment wherein the porous material is a high oxygen solubility material, such as porous silicone, the high oxygen solubility porous material surrounds some of or the entire in vivo portion 42 of the sensor. High oxygen solubility materials are materials that dynamically retain a high availability of oxygen that can be used to compensate for the local oxygen deficit during times of transient ischemia (e.g., silicone and fluorocarbons). It is believed that some signal noise normally seen by a conventional sensor can be attributed to an oxygen deficit. In one exemplary embodiment, porous silicone surrounds the sensor and thereby effectively increases the concentration of oxygen local (proximal) to the sensor. Thus, an increase in oxygen availability proximal to the sensor as achieved by this embodiment ensures that an excess of oxygen over glucose is provided to the sensor; thereby reducing the likelihood of oxygen limited reactions therein. Accordingly, by providing a high oxygen solubility material (e.g., porous silicone) surrounding the in vivo portion of the sensor, it is believed that increased oxygen availability, reduced signal noise, longevity, and ultimately enhanced sensor performance can be achieved.
Bioactive Agents
In some alternative embodiments, a bioactive agent is incorporated into the above described porous material and/or membrane system, such as is described in co-pending U.S. patent application Ser. No. 10/842,716, which diffuses out into the environment adjacent to the sensing region. Additionally or alternately, a bioactive agent can be administered locally at the exit-site or implantation-site. Suitable bioactive agents are those that modify the host's tissue response to the sensor, for example anti-inflammatory agents, anti-infective agents, anesthetics, inflammatory agents, growth factors, immunosuppressive agents, antiplatelet agents, anti-coagulants, anti-proliferates, ACE inhibitors, cytotoxic agents, anti-barrier cell compounds, vascularization-inducing compounds, anti-sense molecules, or mixtures thereof, such as are described in more detail in co-pending U.S. patent application Ser. No. 10/842,716.
In embodiments wherein the porous material is designed to enhance short-term (e.g., between about 1 and 14 days) lifetime or performance of the sensor, a suitable bioactive agent can be chosen to ensure that tissue ingrowth does not substantially occur within the pores of the porous material. Namely, by providing a tissue modifying bioactive agent, such as an anti-inflammatory agent (for example, Dexamethasone), substantially tissue ingrowth can be inhibited, at least in the short term, in order to maintain sufficient glucose transport through the pores of the porous material to maintain a stable sensitivity.
In embodiments wherein the porous material is designed to enhance long-term (e.g., between about a day to a year or more) lifetime or performance of the sensor, a suitable bioactive agent, such as a vascularization-inducing compound or anti-barrier cell compound, can be chosen to encourage tissue ingrowth without barrier cell formation.
In some alternative embodiments, the in vivo portion of the sensor is designed with porosity there through, for example, a design wherein the sensor wires are configured in a mesh, loose helix configuration (namely, with spaces between the wires), or with micro-fabricated holes there through. Porosity within the sensor modifies the host's tissue response to the sensor, because tissue ingrowth into and/or through the in vivo portion of the sensor increases stability of the sensor and/or improves host acceptance of the sensor, thereby extending the lifetime of the sensor in vivo.
In some alternative embodiments, the sensor is manufactured partially or wholly using a continuous reel-to-reel process, wherein one or more manufacturing steps are automated. In such embodiments, a manufacturing process can be provided substantially without the need for manual mounting and fixturing steps and substantially without the need human interaction. A process can be utilized wherein a plurality of sensors of the preferred embodiments, including the electrodes, insulator, and membrane system, are continuously manufactured in a semi-automated or automated process.
In one embodiment, a plurality of twisted pairs are continuously formed into a coil, wherein a working electrode is coated with an insulator material around which a plurality of reference electrodes are wound. The plurality of twisted pairs are preferably indexed and subsequently moved from one station to the next whereby the membrane system is serially deposited according to the preferred embodiments. Preferably, the coil is continuous and remains as such during the entire sensor fabrication process, including winding of the electrodes, insulator application, and membrane coating processes. After drying of the membrane system, each individual sensor is cut from the continuous coil.
A continuous reel-to-reel process for manufacturing the sensor eliminates possible sensor damage due to handling by eliminating handling steps, and provides faster manufacturing due to faster trouble shooting by isolation when a product fails. Additionally, a process run can be facilitated because of elimination of steps that would otherwise be required (e.g., steps in a manual manufacturing process.) Finally, increased or improved product consistency due to consistent processes within a controlled environment can be achieved in a machine or robot driven operation.
In one alternative embodiment, a continuous manufacturing process is contemplated that utilizes physical vapor deposition in a vacuum to form the sensor. Physical vapor deposition can be used to coat one or more insulating layers onto the electrodes, and further can be used to deposit the membrane system thereon. While not wishing to be bound by theory, it is believed that by implementing physical vapor deposition to form some portions or the entire sensor of the preferred embodiments, simplified manufacturing, consistent deposition, and overall increased reproducibility can be achieved.
Applicator
The guide tube subassembly 20 includes a guide tube carrier 64 and a guide tube 66. In some embodiments, the guide tube is a cannula. The guide tube carrier 64 slides along the applicator body 18 and maintains the appropriate relative position of the guide tube 66 during insertion and subsequent retraction. For example, prior to and during insertion of the sensor, the guide tube 66 extends through the contact subassembly 26 to maintain an opening that enables easy insertion of the needle there through (see
A needle subassembly 68 is provided that includes a needle carrier 70 and needle 72. The needle carrier 70 cooperates with the other applicator components and carries the needle 72 between its extended and retracted positions. The needle can be of any appropriate size that can encompass the sensor 32 and aid in its insertion into the host. Preferred sizes include from about 32 gauge or less to about 18 gauge or more, more preferably from about 28 gauge to about 25 gauge, to provide a comfortable insertion for the host. Referring to the inner diameter of the needle, approximately 0.006 inches to approximately 0.023 inches is preferable, and 0.013 inches is most preferable. The needle carrier 70 is configured to engage with the guide tube carrier 64, while the needle 72 is configured to slidably nest within the guide tube 66, which allows for easy guided insertion (and retraction) of the needle through the contact subassembly 26.
A push rod subassembly 74 is provided that includes a push rod carrier 76 and a push rod 78. The push rod carrier 76 cooperates with other applicator components to ensure that the sensor is properly inserted into the host's skin, namely the push rod carrier 76 carries the push rod 78 between its extended and retracted positions. In this embodiment, the push rod 78 is configured to slidably nest within the needle 72, which allows for the sensor 32 to be pushed (released) from the needle 72 upon retraction of the needle, which is described in more detail with reference to
A plunger subassembly 22 is provided that includes a plunger 80 and plunger cap 82. The plunger subassembly 22 cooperates with other applicators components to ensure proper insertion and subsequent retraction of the applicator components. In this embodiment, the plunger 80 is configured to engage with the push rod to ensure the sensor remains extended (namely, in the host) during retraction, such as is described in more detail with reference to
Sensor Insertion
Referring to
Referring to
Referring to
Referring to
The preferred embodiments are generally designed with elastomeric contacts to ensure a retention force that retains the sensor 32 within the mounting unit 14 and to ensure stable electrical connection of the sensor 32 and its associated contacts 28. Although the illustrated embodiments and associated text describe the sensor 32 extending through the contacts 28 to form a friction fit therein, a variety of alternatives are contemplated. In one alternative embodiment, the sensor is configured to be disposed adjacent to the contacts (rather than between the contacts). The contacts can be constructed in a variety of known configurations, for example, metallic contacts, cantilevered fingers, pogo pins, or the like, which are configured to press against the sensor after needle retraction.
The illustrated embodiments are designed with coaxial contacts 28; namely, the contacts 28 are configured to contact the working and reference electrodes 44, 46 axially along the proximal portion 40 of the sensor 32 (see
The preferred embodiments advantageously provide a system and method for easy insertion of the sensor and subsequent retraction of the needle in a single push-pull motion. Because of the mechanical latching system of the applicator, the user provides a continuous force on the plunger cap 82 and guide tube carrier 64 that inserts and retracts the needle in a continuous motion. When a user grips the applicator, his or her fingers grasp the guide tube carrier 64 while his or her thumb (or another finger) is positioned on the plunger cap 82. The user squeezes his or her fingers and thumb together continuously, which causes the needle to insert (as the plunger slides forward) and subsequently retract (as the guide tube carrier slides backward) due to the system of latches located within the applicator (
In practice, the mounting unit is placed at an appropriate location on the host's skin, for example, the skin of the arm, thigh, or abdomen. Thus, removing the backing layer 9 from the adhesive pad 8 and pressing the base portion of the mounting unit on the skin adheres the mounting unit to the host's skin.
In one alternative embodiment, the mounting unit is configured to releasably mate with the applicator and electronics unit, such that when the applicator is releasably mated to the mounting unit (e.g., after sensor insertion), the electronics unit is configured to slide into the mounting unit, thereby triggering release of the applicator and simultaneous mating of the electronics unit to the mounting unit. Cooperating mechanical components, for example, sliding ball and detent type configurations, can be used to accomplish the simultaneous mating of electronics unit and release of the applicator.
In some embodiments, the sensor 32 exits the base of the mounting unit 14 at a location distant from an edge of the base. In some embodiments, the sensor 32 exits the base of the mounting unit 14 at a location substantially closer to the center than the edges thereof. While not wishing to be bound by theory, it is believed that by providing an exit port for the sensor 32 located away from the edges, the sensor 32 can be protected from motion between the body and the mounting unit, snagging of the sensor by an external source, and/or environmental contaminants that can migrate under the edges of the mounting unit. In some embodiments, the sensor exits the mounting unit away from an outer edge of the device. In some alternative embodiments, however, the sensor exits the mounting unit 14 at an edge or near an edge of the device. In some embodiments, the mounting unit is configured such that the exit port (location) of the sensor is adjustable; thus, in embodiments wherein the depth of the sensor insertion is adjustable, six-degrees of freedom can thereby be provided.
Extensible Adhesive Pad
In certain embodiments, an adhesive pad is used with the sensor system. A variety of design parameters are desirable when choosing an adhesive pad for the mounting unit. For example: 1) the adhesive pad can be strong enough to maintain full contact at all times and during all movements (devices that release even slightly from the skin have a greater risk of contamination and infection), 2) the adhesive pad can be waterproof or water permeable such that the host can wear the device even while heavily perspiring, showering, or even swimming in some cases, 3) the adhesive pad can be flexible enough to withstand linear and rotational forces due to host movements, 4) the adhesive pad can be comfortable for the host, 5) the adhesive pad can be easily releasable to minimize host pain, 6) and/or the adhesive pad can be easily releasable so as to protect the sensor during release. Unfortunately, these design parameters are difficult to simultaneously satisfy using known adhesive pads, for example, strong medical adhesive pads are available but are usually non-precise (for example, requiring significant “ripping” force during release) and can be painful during release due to the strength of their adhesion.
Therefore, the preferred embodiments provide an adhesive pad 8′ for mounting the mounting unit onto the host, including a sufficiently strong medical adhesive pad that satisfies one or more strength and flexibility requirements described above, and further provides a for easy, precise and pain-free release from the host's skin.
In one embodiment, the extensible adhesive pad includes a polymeric foam layer or is formed from adhesive pad foam. It is believed that the conformability and resiliency of foam aids in conformation to the skin and flexibility during movement of the skin. In another embodiment, a stretchable solid adhesive pad, such as a rubber-based or an acrylate-based solid adhesive pad can be used. In another embodiment, the adhesive pad comprises a film, which can aid in increasing load bearing strength and rupture strength of the adhesive pad
In one implementation, the mounting unit is bonded to the host's skin via a single layer of extensible adhesive pad 8′, which is illustrated in
In one alternative implementation, the adhesive pad 8′ includes two-sides, including the extensible adhesive pad and a backing adhesive pad (not shown). In this embodiment, the backing adhesive pad is bonded to the mounting unit's back surface 25 while the extensible adhesive pad 8′ is bonded to the host's skin. Both adhesive pads provide sufficient strength, flexibility, and waterproof or water permeable characteristics appropriate for their respective surface adhesion. In some embodiments, the backing and extensible adhesive pads are particularly designed with an optimized bond for their respective bonding surfaces (namely, the mounting unit and the skin).
In another alternative implementation, the adhesive pad 8′ includes a double-sided extensible adhesive pad surrounding a middle layer or backing layer (not shown). The backing layer can comprise a conventional backing film or can be formed from foam to enhance comfort, conformability, and flexibility. Preferably, each side of the double-sided adhesive pad is respectively designed for appropriate bonding surface (namely, the mounting unit and skin). A variety of alternative stretch-release configurations are possible. Controlled release of one or both sides of the adhesive pad can be facilitated by the relative lengths of each adhesive pad side, by incorporation of a non-adhesive pad zone, or the like.
Although the illustrated embodiments describe a fixed insertion angle designed into the applicator, alternative embodiments can design the insertion angle into other components of the system. For example, the insertion angle can be designed into the attachment of the applicator with the mounting unit, or the like. In some alternative embodiments, a variety of adjustable insertion angles can be designed into the system to provide for a variety of host dermis configurations.
The relative pivotal movement of the contact subassembly is advantageous, for example, for enabling the design of a low profile device while providing support for an appropriate needle insertion angle. In its insertion position, the sensor system is designed for easy sensor insertion while forming a stable electrical connection with the associated contacts 28. In its functional position, the sensor system maintains a low profile for convenience, comfort, and discreetness during use. Thus, the sensor systems of preferred embodiments are advantageously designed with a hinging configuration to provide an optimum guided insertion angle while maintaining a low profile device during sensor use.
In some embodiments, a shock-absorbing member or feature is incorporated into the design of the sensor and configured to absorb movement of the in vivo and/or ex vivo portion of the sensor. Conventional analyte sensors can suffer from motion-related artifact associated with host movement when the host is using the device. For example, when a transcutaneous analyte sensor is inserted into the host, various movements on the sensor (for example, relative movement between the in vivo portion and the ex vivo portion and/or movement within the host) create stresses on the device and can produce noise in the sensor signal. Accordingly in some embodiments, a shock-absorbing member is located on the sensor/mounting unit in a location that absorbs stresses associated with the above-described movement.
In the preferred embodiments, the sensor 32 bends from a substantially straight to substantially bent configuration upon pivoting of the contact subassembly from the insertion to functional position. The substantially straight sensor configuration during insertion advantageously provides ease of sensor insertion, while the substantial bend in the sensor in its functional position advantageously provides stability on the proximal end of the sensor with flexibility/mobility on the distal end of the sensor. Additionally, motion within the mounting unit (e.g., caused by external forces to the mounting unit, movement of the skin, and the like) does not substantially translate to the in vivo portion of the sensor. Namely, the bend formed within the sensor 32 functions to break column strength, causing flexion that effectively absorbs movements on the sensor during use. Additionally, the sensor can be designed with a length such that when the contact subassembly 26 is pivoted to its functional position (
In some alternative embodiments, the shock-absorbing member can be an expanding and contracting member, such as a spring, accordion, telescoping, or bellows-type device. In general, the shock absorbing member can be located such that relative movement between the sensor, the mounting unit, and the host is absorbed without (or minimally) affecting the connection of the sensor to the mounting unit and/or the sensor stability within the implantation site; for example, the shock-absorbing member can be formed as a part of or connected to the sensor 32.
Detachable connection between the mounting unit 14 and electronics unit 16 provides improved manufacturability, namely, the relatively inexpensive mounting unit 14 can be disposed of when replacing the sensor system after its usable life, while the relatively more expensive electronics unit 16 can be reusable with multiple sensor systems. In certain embodiments, the electronics unit 16 is configured with programming, for example, initialization, calibration reset, failure testing, or the like, each time it is initially inserted into the cavity and/or each time it initially communicates with the sensor 32. However, an integral (non-detachable) electronics unit can be configured as is appreciated by one skilled in the art.
Referring to the mechanical fit between the mounting unit 14 and the electronics unit 16 (and/or applicator 12), a variety of mechanical joints are contemplated, for example, snap fit, interference fit, or slide fit. In the illustrated embodiment of
In some circumstances, a drift of the sensor signal can cause inaccuracies in sensor performance and/or require re-calibration of the sensor. Accordingly, it can be advantageous to provide a sealant, whereby moisture (e.g., water and water vapor) cannot substantially penetrate to the sensor and its connection to the electrical contacts. The sealant described herein can be used alone or in combination with the sealing member 36 described in more detail above, to seal the sensor from moisture in the external environment.
Preferably, the sealant fills in holes, crevices, or other void spaces between the mounting unit 14 and electronics unit 16 and/or around the sensor 32 within the mounting unit 32. For example, the sealant can surround the sensor in the portion of the sensor 32 that extends through the contacts 28. Additionally, the sealant can be disposed within the additional void spaces, for example a hole 122 that extends through the sealing member 36.
Preferably, the sealant comprises a water impermeable material or compound, for example, oil, grease, or gel. In one exemplary embodiment, the sealant comprises petroleum jelly and is used to provide a moisture barrier surrounding the sensor 32. In one experiment, petroleum jelly was liquefied by heating, after which a sensor 32 was immersed into the liquefied petroleum jelly to coat the outer surfaces thereof. The sensor was then assembled into a housing and inserted into a host, during which deployment the sensor was inserted through the electrical contacts 28 and the petroleum jelly conforming there between. Sensors incorporating petroleum jelly, such as described above, when compared to sensors without the petroleum jelly moisture barrier exhibited less or no signal drift over time when studied in a humid or submersed environment. While not wishing to be bound by theory, it is believed that incorporation of a moisture barrier surrounding the sensor, especially between the sensor and its associated electrical contacts, reduces or eliminates the effects of humidity on the sensor signal. The viscosity of grease or oil-based moisture barriers allows penetration into and through even small cracks or crevices within the sensor and mounting unit, displacing moisture and thereby increasing the sealing properties thereof. U.S. Pat. Nos. 4,259,540 and 5,285,513 disclose materials suitable for use as a water impermeable material (sealant).
Referring to the electrical fit between the sensor 32 and the electronics unit 16, contacts 28 (through which the sensor extends) are configured to electrically connect with mutually engaging contacts on the electronics unit 16. A variety of configurations are contemplated; however, the mutually engaging contacts operatively connect upon detachable connection of the electronics unit 16 with the mounting unit 14, and are substantially sealed from external moisture by sealing member 36. Even with the sealing member, some circumstances may exist wherein moisture can penetrate into the area surrounding the sensor 32 and or contacts, for example, exposure to a humid or wet environment (e.g., caused by sweat, showering, or other environmental causes). It has been observed that exposure of the sensor to moisture can be a cause of baseline signal drift of the sensor over time. For example in a glucose sensor, the baseline is the component of a glucose sensor signal that is not related to glucose (the amount of signal if no glucose is present), which is ideally constant over time. However, some circumstances my exist wherein the baseline can fluctuate over time, also referred to as drift, which can be caused, for example, by changes in a host's metabolism, cellular migration surrounding the sensor, interfering species, humidity in the environment, and the like.
In some embodiments, the mounting unit is designed to provide ventilation (e.g., a vent hole 124) between the exit-site and the sensor. In certain embodiments, a filter (not shown) is provided in the vent hole 124 that allows the passage of air, while preventing contaminants from entering the vent hole 124 from the external environment. While not wishing to be bound by theory, it is believed that ventilation to the exit-site (or to the sensor 32) can reduce or eliminate trapped moisture or bacteria, which can otherwise increase the growth and/or lifetime of bacteria adjacent to the sensor.
In some alternative embodiments, a sealing material is provided, which seals the needle and/or sensor from contamination of the external environment during and after sensor insertion. For example, one problem encountered in conventional transcutaneous devices is infection of the exit-site of the wound. For example, bacteria or contaminants can migrate from ex vivo, for example, any ex vivo portion of the device or the ex vivo environment, through the exit-site of the needle/sensor, and into the subcutaneous tissue, causing contamination and infection. Bacteria and/or contaminants can originate from handling of the device, exposed skin areas, and/or leakage from the mounting unit (external to) on the host. In many conventional transcutaneous devices, there exists some path of migration for bacteria and contaminants to the exit-site, which can become contaminated during sensor insertion or subsequent handling or use of the device. Furthermore, in some embodiments of a transcutaneous analyte sensor, the insertion-aiding device (for example, needle) is an integral part of the mounting unit; namely, the device stores the insertion device after insertion of the sensor, which is isolated from the exit-site (namely, point-of-entry of the sensor) after insertion.
Accordingly, these alternative embodiments provide a sealing material on the mounting unit, interposed between the housing and the skin, wherein the needle and/or sensor are adapted to extend through, and be sealed by, the sealing material. The sealing material is preferably formed from a flexible material that substantially seals around the needle/sensor. Appropriate flexible materials include malleable materials, elastomers, gels, greases, or the like (e.g., see U.S. Pat. Nos. 4,259,540 and 5,285,513). However, not all embodiments include a sealing material, and in some embodiments a clearance hole or other space surrounding the needle and/or sensor is preferred.
In one embodiment, the base 24 of the mounting unit 14 is formed from a flexible material, for example silicone, which by its elastomeric properties seals the needle and/or sensor at the exit port 126, such as is illustrated in
During use, a host or caretaker positions the mounting unit at the appropriate location on or near the host's skin and prepares for sensor insertion. During insertion, the needle aids in sensor insertion, after which the needle is retracted into the mounting unit leaving the sensor in the subcutaneous tissue. In this embodiment, the exit-port 126 includes a layer of sealing material, such as a silicone membrane, that encloses the exit-port in a configuration that protects the exit-site from contamination that can migrate from the mounting unit or spacing external to the exit-site. Thus, when the sensor 32 and/or needle 72 extend through, for example, an aperture or a puncture in the sealing material, to provide communication between the mounting unit and subcutaneous space, a seal is formed there between. Elastomeric sealing materials can be advantageous in some embodiments because the elasticity provides a conforming seal between the needle/sensor and the mounting unit and/or because the elasticity provides shock-absorbing qualities allowing relative movement between the device and the various layers of the host's tissue, for example.
In some alternative embodiments, the sealing material includes a bioactive agent incorporated therein. Suitable bioactive agents include those which are known to discourage or prevent bacteria and infection, for example, anti-inflammatory, antimicrobials, antibiotics, or the like. It is believed that diffusion or presence of a bioactive agent can aid in prevention or elimination of bacteria adjacent to the exit-site.
In practice, after the sensor 32 has been inserted into the host's tissue, and an electrical connection formed by mating the electronics unit 16 to the mounting unit 14, the sensor measures an analyte concentration continuously or continually, for example, at an interval of from about fractions of a second to about 10 minutes or more.
Sensor Electronics
The following description of sensor electronics associated with the electronics unit is applicable to a variety of continuous analyte sensors, such as non-invasive, minimally invasive, and/or invasive (e.g., transcutaneous and wholly implantable) sensors. For example, the sensor electronics and data processing as well as the receiver electronics and data processing described below can be incorporated into the wholly implantable glucose sensor disclosed in co-pending U.S. patent application Ser. No. 10/838,912, filed May 3, 2004 and entitled “IMPLANTABLE ANALYTE SENSOR” and U.S. patent application Ser. No. 10/885,476 filed Jul. 6, 2004 and entitled, “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM”.
An A/D converter 136 digitizes the analog signal into a digital signal, also referred to as “counts” for processing. Accordingly, the resulting raw data stream in counts, also referred to as raw sensor data, is directly related to the current measured by the potentiostat 84.
A processor module 138 includes the central control unit that controls the processing of the sensor electronics 132. In some embodiments, the processor module includes a microprocessor, however a computer system other than a microprocessor can be used to process data as described herein, for example an ASIC can be used for some or all of the sensor's central processing. The processor typically provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, programming for data smoothing and/or replacement of signal artifacts such as is described in co-pending U.S. patent application Ser. No. 10/648,849, filed Aug. 22, 2003, and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”). The processor additionally can be used for the system's cache memory, for example for temporarily storing recent sensor data. In some embodiments, the processor module comprises memory storage components such as ROM, RAM, dynamic-RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, or the like.
In some embodiments, the processor module comprises a digital filter, for example, an IIR or FIR filter, configured to smooth the raw data stream from the A/D converter. Generally, digital filters are programmed to filter data sampled at a predetermined time interval (also referred to as a sample rate.) In some embodiments, wherein the potentiostat is configured to measure the analyte at discrete time intervals, these time intervals determine the sample rate of the digital filter. In some alternative embodiments, wherein the potentiostat is configured to continuously measure the analyte, for example, using a current-to-frequency converter as described above, the processor module can be programmed to request a digital value from the A/D converter at a predetermined time interval, also referred to as the acquisition time. In these alternative embodiments, the values obtained by the processor are advantageously averaged over the acquisition time due the continuity of the current measurement. Accordingly, the acquisition time determines the sample rate of the digital filter. In preferred embodiments, the processor module is configured with a programmable acquisition time, namely, the predetermined time interval for requesting the digital value from the A/D converter is programmable by a user within the digital circuitry of the processor module. An acquisition time of from about 2 seconds to about 512 seconds is preferred; however any acquisition time can be programmed into the processor module. A programmable acquisition time is advantageous in optimizing noise filtration, time lag, and processing/battery power.
Preferably, the processor module is configured to build the data packet for transmission to an outside source, for example, an RF transmission to a receiver as described in more detail below. Generally, the data packet comprises a plurality of bits that can include a sensor ID code, raw data, filtered data, and/or error detection or correction. The processor module can be configured to transmit any combination of raw and/or filtered data.
In some embodiments, the processor module further comprises a transmitter portion that determines the transmission interval of the sensor data to a receiver, or the like. In some embodiments, the transmitter portion, which determines the interval of transmission, is configured to be programmable. In one such embodiment, a coefficient can be chosen (e.g., a number of from about 1 to about 100, or more), wherein the coefficient is multiplied by the acquisition time (or sampling rate), such as described above, to define the transmission interval of the data packet. Thus, in some embodiments, the transmission interval is programmable between about 2 seconds and about 850 minutes, more preferably between about 30 second and 5 minutes; however, any transmission interval can be programmable or programmed into the processor module. However, a variety of alternative systems and methods for providing a programmable transmission interval can also be employed. By providing a programmable transmission interval, data transmission can be customized to meet a variety of design criteria (e.g., reduced battery consumption, timeliness of reporting sensor values, etc.)
Conventional glucose sensors measure current in the nanoAmp range. In contrast to conventional glucose sensors, the preferred embodiments are configured to measure the current flow in the picoAmp range, and in some embodiments, femtoAmps. Namely, for every unit (mg/dL) of glucose measured, at least one picoAmp of current is measured. Preferably, the analog portion of the A/D converter 136 is configured to continuously measure the current flowing at the working electrode and to convert the current measurement to digital values representative of the current. In one embodiment, the current flow is measured by a charge counting device (e.g., a capacitor). Thus, a signal is provided, whereby a high sensitivity maximizes the signal received by a minimal amount of measured hydrogen peroxide (e.g., minimal glucose requirements without sacrificing accuracy even in low glucose ranges), reducing the sensitivity to oxygen limitations in vivo (e.g., in oxygen-dependent glucose sensors).
A battery 144 is operably connected to the sensor electronics 132 and provides the power for the sensor. In one embodiment, the battery is a lithium manganese dioxide battery; however, any appropriately sized and powered battery can be used (for example, AAA, nickel-cadmium, zinc-carbon, alkaline, lithium, nickel-metal hydride, lithium-ion, zinc-air, zinc-mercury oxide, silver-zinc, and/or hermetically-sealed). In some embodiments, the battery is rechargeable, and/or a plurality of batteries can be used to power the system. The sensor can be transcutaneously powered via an inductive coupling, for example. In some embodiments, a quartz crystal 96 is operably connected to the processor 138 and maintains system time for the computer system as a whole, for example for the programmable acquisition time within the processor module.
Optional temperature probe 140 is shown, wherein the temperature probe is located on the electronics assembly or the glucose sensor itself. The temperature probe can be used to measure ambient temperature in the vicinity of the glucose sensor. This temperature measurement can be used to add temperature compensation to the calculated glucose value.
An RF module 148 is operably connected to the processor 138 and transmits the sensor data from the sensor to a receiver within a wireless transmission 150 via antenna 152. In some embodiments, a second quartz crystal 154 provides the time base for the RF carrier frequency used for data transmissions from the RF transceiver. In some alternative embodiments, however, other mechanisms, such as optical, infrared radiation (IR), ultrasonic, or the like, can be used to transmit and/or receive data.
In the RF telemetry module of the preferred embodiments, the hardware and software are designed for low power requirements to increase the longevity of the device (for example, to enable a life of from about 3 to about 24 months, or more) with maximum RF transmittance from the in vivo environment to the ex vivo environment for wholly implantable sensors (for example, a distance of from about one to ten meters or more). Preferably, a high frequency carrier signal of from about 402 MHz to about 433 MHz is employed in order to maintain lower power requirements. Additionally, in wholly implantable devices, the carrier frequency is adapted for physiological attenuation levels, which is accomplished by tuning the RF module in a simulated in vivo environment to ensure RF functionality after implantation; accordingly, the preferred glucose sensor can sustain sensor function for 3 months, 6 months, 12 months, or 24 months or more.
When a sensor is first implanted into host tissue, the sensor and receiver are initialized. This is referred to as start-up mode, and involves optionally resetting the sensor data and calibrating the sensor 32. In selected embodiments, mating the electronics unit 16 to the mounting unit triggers a start-up mode. In other embodiments, the start-up mode is triggered by the receiver, which is described in more detail with reference to
Preferably, the electronics unit 16 indicates to the receiver (
In some embodiments, the sensor electronics 132 are configured to detect a current drop to zero in the working electrode 44 associated with removal of a sensor 32 from the host (or the electronics unit 16 from the mounting unit 14), which can be configured to trigger an increment of the status code. If the incremented value reaches a maximum, it can be designed to roll over to 0. In some embodiments, the sensor electronics are configured to detect a voltage change cycle associated with removal and/or re-insertion of the sensor, which can be sensed in the counter electrode (e.g., of a three-electrode sensor), which can be configured to trigger an increment of the status code.
In some embodiments, the sensor electronics 132 can be configured to send a special value (for example, 0) that indicates that the electronics unit is not attached when removal of the sensor (or electronics unit) is detected. This special value can be used to trigger a variety of events, for example, to halt display of analyte values. Incrementing or decrementing routines can be used to skip this special value.
In some embodiments, the electronics unit 16 is configured to include additional contacts, which are designed to sense a specific resistance, or passive value, in the sensor system while the electronics unit is attached to the mounting unit. Preferably, these additional contacts are configured to detect information about a sensor, for example, whether the sensor is operatively connected to the mounting unit, the sensor's ID, a calibration code, or the like. For example, subsequent to sensing the passive value, the sensor electronics can be configured to change the sensor ID code by either mapping the value to a specific code, or internally detecting that the code is different and adjusting the sensor ID code in a predictable manner. As another example, the passive value can include information on parameters specific to a sensor (such as in vitro sensitivity information as described elsewhere herein).
In some embodiments, the electronics unit 16 includes additional contacts configured to communicate with a chip disposed in the mounting unit 14. In this embodiment, the chip is designed with a unique or near-unique signature that can be detected by the electronics unit 16 and noted as different, and/or transmitted to the receiver 158 as the sensor ID code.
In some embodiments, the electronics unit 16 is inductively coupled to an RFID or similar chip in the mounting unit 14. In this embodiment, the RFID tag uniquely identifies the sensor 32 and allows the transmitter to adjust the sensor ID code accordingly and/or to transmit the unique identifier to the receiver 158.
In some situations, it can be desirable to wait an amount of time after insertion of the sensor to allow the sensor to equilibrate in vivo, also referred to as “break-in”. Accordingly, the sensor electronics can be configured to aid in decreasing the break-in time of the sensor by applying different voltage settings (for example, starting with a higher voltage setting and then reducing the voltage setting) to speed the equilibration process.
In some situations, the sensor may not properly deploy, connect to, or otherwise operate as intended. Accordingly, the sensor electronics can be configured such that if the current obtained from the working electrode, or the subsequent conversion of the current into digital counts, for example, is outside of an acceptable threshold, then the sensor is marked with an error flag, or the like. The error flag can be transmitted to the receiver to instruct the user to reinsert a new sensor, or to implement some other error correction.
The above-described detection and transmission methods can be advantageously employed to minimize or eliminate human interaction with the sensor, thereby minimizing human error and/or inconvenience. Additionally, the sensors of preferred embodiments do not require that the receiver be in proximity to the transmitter during sensor insertion. Any one or more of the above described methods of detecting and transmitting insertion of a sensor and/or electronics unit can be combined or modified, as is appreciated by one skilled in the art.
Receiver
Receiver Electronics
Referring again to
The processor 176 is the central control unit that performs the processing, such as storing data, analyzing data streams, calibrating analyte sensor data, estimating analyte values, comparing estimated analyte values with time corresponding measured analyte values, analyzing a variation of estimated analyte values, downloading data, and controlling the user interface by providing analyte values, prompts, messages, warnings, alarms, or the like. The processor includes hardware and software that performs the processing described herein, for example flash memory provides permanent or semi-permanent storage of data, storing data such as sensor ID, receiver ID, and programming to process data streams (for example, programming for performing estimation and other algorithms described elsewhere herein) and random access memory (RAM) stores the system's cache memory and is helpful in data processing.
Preferably, the input module 174 or processor module 176 performs a Cyclic Redundancy Check (CRC) to verify data integrity, with or without a method of recovering the data if there is an error. In some embodiments, error correction techniques such as those that use Hamming codes or Reed-Solomon encoding/decoding methods are employed to correct for errors in the data stream. In one alternative embodiment, an iterative decoding technique is employed, wherein the decoding is processed iteratively (e.g., in a closed loop) to determine the most likely decoded signal. This type of decoding can allow for recovery of a signal that is as low as 0.5 dB above the noise floor, which is in contrast to conventional non-iterative decoding techniques (such as Reed-Solomon), which requires approximately 3 dB or about twice the signal power to recover the same signal (e.g., a turbo code).
An output module 178, which is integral with and/or operatively connected with the processor 176, includes programming for generating output based on the data stream received from the sensor system 10 and its processing incurred in the processor 176. In some embodiments, output is generated via a user interface 160.
The user interface 160 comprises a keyboard 162, speaker 164, vibrator 166, backlight 168, liquid crystal display (LCD) screen 170, and one or more buttons 172. The components that comprise the user interface 160 include controls to allow interaction of the user with the receiver. The keyboard 162 can allow, for example, input of user information about himself/herself, such as mealtime, exercise, insulin administration, customized therapy recommendations, and reference analyte values. The speaker 164 can produce, for example, audible signals or alerts for conditions such as present and/or estimated hyperglycemic or hypoglycemic conditions in a person with diabetes. The vibrator 166 can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. The backlight 168 can be provided, for example, to aid the user in reading the LCD 170 in low light conditions. The LCD 170 can be provided, for example, to provide the user with visual data output, such as is described in co-pending U.S. patent application Ser. No. 11/007,920 filed Dec. 8, 2004 and entitled “SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSORS.”
In some embodiments, prompts or messages can be displayed on the user interface to convey information to the user, such as reference outlier values, requests for reference analyte values, therapy recommendations, deviation of the measured analyte values from the estimated analyte values, or the like. Additionally, prompts can be displayed to guide the user through calibration or trouble-shooting of the calibration.
Additionally, data output from the output module 178 can provide wired or wireless, one- or two-way communication between the receiver 158 and an external device 180. The external device 180 can be any device that wherein interfaces or communicates with the receiver 158. In some embodiments, the external device 180 is a computer, and the receiver 158 is able to download historical data for retrospective analysis by the patient or physician, for example. In some embodiments, the external device 180 is a modem or other telecommunications station, and the receiver 158 is able to send alerts, warnings, emergency messages, or the like, via telecommunication lines to another party, such as a doctor or family member. In some embodiments, the external device 180 is an insulin pen, and the receiver 158 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pen. In some embodiments, the external device 180 is an insulin pump, and the receiver 158 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pump. The external device 180 can include other technology or medical devices, for example pacemakers, implanted analyte sensor patches, other infusion devices, telemetry devices, or the like.
The user interface 160, including keyboard 162, buttons 172, a microphone (not shown), and the external device 180, can be configured to allow input of data. Data input can be helpful in obtaining information about the patient (for example, meal time, exercise, or the like), receiving instructions from a physician (for example, customized therapy recommendations, targets, or the like), and downloading software updates, for example. Keyboard, buttons, touch-screen, and microphone are all examples of mechanisms by which a user can input data directly into the receiver. A server, personal computer, personal digital assistant, insulin pump, and insulin pen are examples of external devices that can provide useful information to the receiver. Other devices internal or external to the sensor that measure other aspects of a patient's body (for example, temperature sensor, accelerometer, heart rate monitor, oxygen monitor, or the like) can be used to provide input helpful in data processing. In one embodiment, the user interface can prompt the patient to select an activity most closely related to their present activity, which can be helpful in linking to an individual's physiological patterns, or other data processing. In another embodiment, a temperature sensor and/or heart rate monitor can provide information helpful in linking activity, metabolism, and glucose excursions of an individual. While a few examples of data input have been provided here, a variety of information can be input, which can be helpful in data processing.
Although a few exemplary screens are depicted herein, a variety of screens can be provided for illustrating any of the information described in the preferred embodiments, as well as additional information. A user can toggle between these screens (e.g., using buttons 172) and/or the screens can be automatically displayed responsive to programming within the receiver 158, and can be simultaneously accompanied by another type of alert (audible or tactile, for example).
Algorithms
Calibration of an analyte sensor comprises data processing that converts sensor data signal into an estimated analyte measurement that is meaningful to a user. Accordingly, a reference analyte value is used to calibrate the data signal from the analyte sensor.
At block 202, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from the sensor 32 via the receiver 158, which can be in wired or wireless communication with the sensor 32. The sensor data point(s) can be smoothed (filtered) in certain embodiments using a filter, for example, a finite impulse response (FIR) or infinite impulse response (IIR) filter. During the initialization of the sensor, prior to initial calibration, the receiver receives and stores the sensor data, however it can be configured to not display any data to the user until initial calibration and, optionally, stabilization of the sensor has been established. In some embodiments, the data stream can be evaluated to determine sensor break-in (equilibration of the sensor in vitro or in vivo).
At block 204, a reference data receiving module, also referred to as the reference input module, receives reference data from a reference analyte monitor, including one or more reference data points. In one embodiment, the reference analyte points can comprise results from a self-monitored blood analyte test (e.g., finger stick test). For example, the user can administer a self-monitored blood analyte test to obtain an analyte value (e.g., point) using any known analyte sensor, and then enter the numeric analyte value into the computer system. Alternatively, a self-monitored blood analyte test is transferred into the computer system through a wired or wireless connection to the receiver (e.g. computer system) so that the user simply initiates a connection between the two devices, and the reference analyte data is passed or downloaded between the self-monitored blood analyte test and the receiver. In yet another embodiment, the self-monitored analyte test (e.g., SMBG) is integral with the receiver so that the user simply provides a blood sample to the receiver, and the receiver runs the analyte test to determine a reference analyte value. Co-pending U.S. patent application Ser. No. 10/991,966, filed on Nov. 17, 2004 and entitled “INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR” describes some systems and methods for integrating a reference analyte monitor into a receiver for a continuous analyte sensor.
In some alternative embodiments, the reference data is based on sensor data from another substantially continuous analyte sensor, e.g., a transcutaneous analyte sensor described herein, or another type of suitable continuous analyte sensor. In an embodiment employing a series of two or more transcutaneous (or other continuous) sensors, the sensors can be employed so that they provide sensor data in discrete or overlapping periods. In such embodiments, the sensor data from one continuous sensor can be used to calibrate another continuous sensor, or be used to confirm the validity of a subsequently employed continuous sensor.
In some embodiments, reference data can be subjected to “outlier detection” wherein the accuracy of a received reference analyte data is evaluated as compared to time-corresponding sensor data. In one embodiment, the reference data is compared to the sensor data on a modified Clarke Error Grid (e.g., a test similar to the Clarke Error Grid except the boundaries between the different regions are modified slightly) to determine if the data falls within a predetermined threshold. If the data is not within the predetermined threshold, then the receiver can be configured to request additional reference analyte data. If the additional reference analyte data confirms (e.g., closely correlates to) the first reference analyte data, then the first and second reference values are assumed to be accurate and calibration of the sensor is adjusted or re-initialized. Alternatively, if the second reference analyte value falls within the predetermined threshold, then the first reference analyte value is assumed to be an outlier and the second reference analyte value is used by the algorithm(s) instead. In one alternative embodiments of outlier detection, projection is used to estimate an expected analyte value, which is compared with the actual value and a delta evaluated for substantial correspondence. However, other methods of outlier detection are possible.
Certain acceptability parameters can be set for reference values received from the user. For example, in one embodiment, the receiver can be configured to only accept reference analyte values of from about 40 mg/dL to about 400 mg/dL.
At block 206, a data matching module, also referred to as the processor module, matches reference data (e.g., one or more reference analyte data points) with substantially time corresponding sensor data (e.g., one or more sensor data points) to provide one or more matched data pairs. One reference data point can be matched to one time corresponding sensor data point to form a matched data pair. Alternatively, a plurality of reference data points can be averaged (e.g., equally or non-equally weighted average, mean-value, median, or the like) and matched to one time corresponding sensor data point to form a matched data pair, one reference data point can be matched to a plurality of time corresponding sensor data points averaged to form a matched data pair, or a plurality of reference data points can be averaged and matched to a plurality of time corresponding sensor data points averaged to form a matched data pair.
In one embodiment, time corresponding sensor data comprises one or more sensor data points that occur from about 0 minutes to about 20 minutes after the reference analyte data time stamp (e.g., the time that the reference analyte data is obtained). In one embodiment, a 5-minute time delay is chosen to compensate for a system time-lag (e.g., the time necessary for the analyte to diffusion through a membrane(s) of an analyte sensor). In alternative embodiments, the time corresponding sensor value can be greater than or less than that of the above-described embodiment, for example ±60 minutes. Variability in time correspondence of sensor and reference data can be attributed to, for example, a longer or shorter time delay introduced by the data smoothing filter, or if the configuration of the analyte sensor incurs a greater or lesser physiological time lag.
In some implementations of the sensor, the reference analyte data is obtained at a time that is different from the time that the data is input into the receiver. Accordingly, the “time stamp” of the reference analyte (e.g., the time at which the reference analyte value was obtained) is not the same as the time at which the receiver obtained the reference analyte data. Therefore, some embodiments include a time stamp requirement that ensures that the receiver stores the accurate time stamp for each reference analyte value, that is, the time at which the reference value was actually obtained from the user.
In certain embodiments, tests are used to evaluate the best-matched pair using a reference data point against individual sensor values over a predetermined time period (e.g., about 30 minutes). In one such embodiment, the reference data point is matched with sensor data points at 5-minute intervals and each matched pair is evaluated. The matched pair with the best correlation can be selected as the matched pair for data processing. In some alternative embodiments, matching a reference data point with an average of a plurality of sensor data points over a predetermined time period can be used to form a matched pair.
At block 208, a calibration set module, also referred to as the processor module, forms an initial calibration set from a set of one or more matched data pairs, which are used to determine the relationship between the reference analyte data and the sensor analyte data. The matched data pairs, which make up the initial calibration set, can be selected according to predetermined criteria. The criteria for the initial calibration set can be the same as, or different from, the criteria for the updated calibration sets. In certain embodiments, the number (n) of data pair(s) selected for the initial calibration set is one. In other embodiments, n data pairs are selected for the initial calibration set wherein n is a function of the frequency of the received reference data points. In various embodiments, two data pairs make up the initial calibration set or six data pairs make up the initial calibration set. In an embodiment wherein a substantially continuous analyte sensor provides reference data, numerous data points are used to provide reference data from more than 6 data pairs (e.g., dozens or even hundreds of data pairs). In one exemplary embodiment, a substantially continuous analyte sensor provides 288 reference data points per day (every five minutes for twenty-four hours), thereby providing an opportunity for a matched data pair 288 times per day, for example. While specific numbers of matched data pairs are referred to in the preferred embodiments, any suitable number of matched data pairs per a given time period can be employed.
In certain embodiments, the data pairs are selected only within a certain analyte value threshold, for example wherein the reference analyte value is from about 40 mg/dL to about 400 mg/dL. In certain embodiments, the data pairs that form the initial calibration set are selected according to their time stamp, for example, by waiting a predetermined “break-in” time period after implantation, the stability of the sensor data can be increased. In certain embodiments, the data pairs that form the initial calibration set are spread out over a predetermined time period, for example, a period of two hours or more. In certain embodiments, the data pairs that form the initial calibration set are spread out over a predetermined glucose range, for example, spread out over a range of at least 90 mg/dL or more.
At block 210, a conversion function module, also referred to as the processor module, uses the calibration set to create a conversion function. The conversion function substantially defines the relationship between the reference analyte data and the analyte sensor data.
A variety of known methods can be used with the preferred embodiments to create the conversion function from the calibration set. In one embodiment, wherein a plurality of matched data points form the calibration set, a linear least squares regression is used to calculate the conversion function; for example, this regression calculates a slope and an offset using the equation y=mx+b. A variety of regression or other conversion schemes can be implemented herein.
In some alternative embodiments, the sensor is calibrated with a single-point through the use of a dual-electrode system to simplify sensor calibration. In one such dual-electrode system, a first electrode functions as a hydrogen peroxide sensor including a membrane system containing glucose-oxidase disposed thereon, which operates as described herein. A second electrode is a hydrogen peroxide sensor that is configured similar to the first electrode, but with a modified membrane system (with the enzyme domain removed, for example). This second electrode provides a signal composed mostly of the baseline signal, b.
In some dual-electrode systems, the baseline signal is (electronically or digitally) subtracted from the glucose signal to obtain a glucose signal substantially without baseline. Accordingly, calibration of the resultant difference signal can be performed by solving the equation y=mx with a single paired measurement. Calibration of the implanted sensor in this alternative embodiment can be made less dependent on the values/range of the paired measurements, less sensitive to error in manual blood glucose measurements, and can facilitate the sensor's use as a primary source of glucose information for the user. Co-pending U.S. patent application Ser. No. 11/004,561 filed Dec. 3, 2004 and entitled, “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR” describes systems and methods for subtracting the baseline from a sensor signal.
In some alternative dual-electrode system embodiments, the analyte sensor is configured to transmit signals obtained from each electrode separately (e.g., without subtraction of the baseline signal). In this way, the receiver can process these signals to determine additional information about the sensor and/or analyte concentration. For example, by comparing the signals from the first and second electrodes, changes in baseline and/or sensitivity can be detected and/or measured and used to update calibration (e.g., without the use of a reference analyte value). In one such example, by monitoring the corresponding first and second signals over time, an amount of signal contributed by baseline can be measured. In another such example, by comparing fluctuations in the correlating signals over time, changes in sensitivity can be detected and/or measured.
In some alternative embodiments, a regression equation y=mx+b is used to calculate the conversion function; however, prior information can be provided for m and/or b, thereby enabling calibration to occur with fewer paired measurements. In one calibration technique, prior information (e.g., obtained from in vivo or in vitro tests) determines a sensitivity of the sensor and/or the baseline signal of the sensor by analyzing sensor data from measurements taken by the sensor (e.g., prior to inserting the sensor). For example, if there exists a predictive relationship between in vitro sensor parameters and in vivo parameters, then this information can be used by the calibration procedure. For example, if a predictive relationship exists between in vitro sensitivity and in vivo sensitivity, m≈f(min vitro), then the predicted m can be used, along with a single matched pair, to solve for b (b=y−mx). If, in addition, b can be assumed=0, for example with a dual-electrode configuration that enables subtraction of the baseline from the signal such as described above, then both m and b are known a priori, matched pairs are not needed for calibration, and the sensor can be completely calibrated e.g. without the need for reference analyte values (e.g. values obtained after implantation in vivo.)
In another alternative embodiment, prior information can be provided to guide or validate the baseline (b) and/or sensitivity (m) determined from the regression analysis. In this embodiment, boundaries can be set for the regression line that defines the conversion function such that working sensors are calibrated accurately and easily (with two points), and non-working sensors are prevented from being calibrated. If the boundaries are drawn too tightly, a working sensor may not enter into calibration. Likewise, if the boundaries are drawn too loosely, the scheme can result in inaccurate calibration or can permit non-working sensors to enter into calibration. For example, subsequent to performing regression, the resulting slope and/or baseline are tested to determine whether they fall within a predetermined acceptable threshold (boundaries). These predetermined acceptable boundaries can be obtained from in vivo or in vitro tests (e.g., by a retrospective analysis of sensor sensitivities and/or baselines collected from a set of sensors/patients, assuming that the set is representative of future data).
If the slope and/or baseline fall within the predetermined acceptable boundaries, then the regression is considered acceptable and processing continues to the next step (e.g., block 212). Alternatively, if the slope and/or baseline fall outside the predetermined acceptable boundaries, steps can be taken to either correct the regression or fail-safe such that a system will not process or display errant data. This can be useful in situations wherein regression results in errant slope or baseline values. For example, when points (matched pairs) used for regression are too close in value, the resulting regression statistically is less accurate than when the values are spread farther apart. As another example, a sensor that is not properly deployed or is damaged during deployment can yield a skewed or errant baseline signal.
A plurality of matched data pairs 217 represents data pairs in a calibration set obtained from a glucose sensor as described in the preferred embodiments. The matched data pairs are plotted according to their sensor data and time-corresponding reference glucose data. A regression line 218 represents the result of regressing the matched data pairs 217 using least squares regression. In this example, the regression line falls within the upper and lower boundaries 215, 216 indicating that the sensor calibration is acceptable.
However, if the slope and/or baseline had fallen outside the predetermined acceptable boundaries, which would be illustrated in this graph by a line that crosses the upper and/or lower boundaries 215, 216, then the system is configured to assume a baseline value and re-run the regression (or a modified version of the regression) with the assumed baseline, wherein the assumed baseline value is derived from in vivo or in vitro testing. Subsequently, the newly derived slope and baseline are again tested to determine whether they fall within the predetermined acceptable boundaries. Similarly, the processing continues in response to the results of the boundary test. In general, for a set of matched pairs (e.g., calibration set), regression lines with higher slope (sensitivity) have a lower baseline and regression lines with lower slope (sensitivity) have a higher baseline. Accordingly, the step of assuming a baseline and testing against boundaries can be repeated using a variety of different assumed baselines based on the baseline, sensitivity, in vitro testing, and/or in vivo testing. For example, if a boundary test fails due to high sensitivity, then a higher baseline is assumed and the regression re-run and boundary-tested. It is preferred that after about two iterations of assuming a baseline and/or sensitivity and running a modified regression, the system assumes an error has occurred (if the resulting regression lines fall outside the boundaries) and fail-safe. The term “fail-safe” includes modifying the system processing and/or display of data responsive to a detected error avoid reporting of inaccurate or clinically irrelevant analyte values.
In these various embodiments utilizing an additional electrode, prior information (e.g., in vitro or in vivo testing), signal processing, or other information for assisting in the calibration process can be used alone or in combination to reduce or eliminate the dependency of the calibration on reference analyte values obtained by the host.
At block 212, a sensor data transformation module uses the conversion function to transform sensor data into substantially real-time analyte value estimates, also referred to as calibrated data, or converted sensor data, as sensor data is continuously (or intermittently) received from the sensor. For example, the sensor data, which can be provided to the receiver in “counts”, is translated in to estimate analyte value(s) in mg/dL. In other words, the offset value at any given point in time can be subtracted from the raw value (e.g., in counts) and divided by the slope to obtain the estimate analyte value:
In some alternative embodiments, the sensor and/or reference analyte values are stored in a database for retrospective analysis.
At block 214, an output module provides output to the user via the user interface. The output is representative of the estimated analyte value, which is determined by converting the sensor data into a meaningful analyte value. User output can be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example. Other representations of the estimated analyte values are also possible, for example audio and tactile.
In some embodiments, annotations are provided on the graph; for example, bitmap images are displayed thereon, which represent events experienced by the host. For example, information about meals, insulin, exercise, sensor insertion, sleep, and the like, can be obtained by the receiver (by user input or receipt of a transmission from another device) and displayed on the graphical representation of the host's glucose over time. It is believed that illustrating a host's life events matched with a host's glucose concentration over time can be helpful in educating the host to his or her metabolic response to the various events.
In yet another alternative embodiment, the sensor utilizes one or more additional electrodes to measure an additional analyte. Such measurements can provide a baseline or sensitivity measurement for use in calibrating the sensor. Furthermore, baseline and/or sensitivity measurements can be used to trigger events such as digital filtering of data or suspending display of data, all of which are described in more detail in co-pending U.S. patent application Ser. No. 11/004,561, filed Dec. 3, 2004 and entitled, “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR.”
One cause for discrepancies in reference and sensor data is a sensitivity drift that can occur over time, when a sensor is inserted into a host and cellular invasion of the sensor begins to block transport of the analyte to the sensor, for example. Therefore, it can be advantageous to validate the acceptability of converted sensor data against reference analyte data, to determine if a drift of sensitivity has occurred and whether the calibration should be updated.
In one embodiment, the reference analyte data is evaluated with respect to substantially time corresponding converted sensor data to determine the acceptability of the matched pair. For example, clinical acceptability considers a deviation between time corresponding analyte measurements (for example, data from a glucose sensor and data from a reference glucose monitor) and the risk (for example, to the decision making of a person with diabetes) associated with that deviation based on the glucose value indicated by the sensor and/or reference data. Evaluating the clinical acceptability of reference and sensor analyte data, and controlling the user interface dependent thereon, can minimize clinical risk. Preferably, the receiver evaluates clinical acceptability each time reference data is obtained.
After initial calibration, such as is described in more detail with reference to
At block 222, the reference data receiving module, also referred to as the reference input module, receives reference analyte data from a reference analyte monitor. In one embodiment, the reference data comprises one analyte value obtained from a reference monitor. In some alternative embodiments however, the reference data includes a set of analyte values entered by a user into the interface and averaged by known methods, such as are described elsewhere herein. In some alternative embodiments, the reference data comprises a plurality of analyte values obtained from another continuous analyte sensor.
The reference data can be pre-screened according to environmental and physiological issues, such as time of day, oxygen concentration, postural effects, and patient-entered environmental data. In one exemplary embodiment, wherein the sensor comprises an implantable glucose sensor, an oxygen sensor within the glucose sensor is used to determine if sufficient oxygen is being provided to successfully complete the necessary enzyme and electrochemical reactions for accurate glucose sensing. In another exemplary embodiment, the patient is prompted to enter data into the user interface, such as meal times and/or amount of exercise, which can be used to determine likelihood of acceptable reference data. In yet another exemplary embodiment, the reference data is matched with time-corresponding sensor data, which is then evaluated on a modified clinical error grid to determine its clinical acceptability.
Some evaluation data, such as described in the paragraph above, can be used to evaluate an optimum time for reference analyte measurement. Correspondingly, the user interface can then prompt the user to provide a reference data point for calibration within a given time period. Consequently, because the receiver proactively prompts the user during optimum calibration times, the likelihood of error due to environmental and physiological limitations can decrease and consistency and acceptability of the calibration can increase.
At block 224, the evaluation module, also referred to as acceptability module, evaluates newly received reference data. In one embodiment, the evaluation module evaluates the clinical acceptability of newly received reference data and time corresponding converted sensor data (new matched data pair). In one embodiment, a clinical acceptability evaluation module 224 matches the reference data with a substantially time corresponding converted sensor value, and determines the Clarke Error Grid coordinates. In this embodiment, matched pairs that fall within the A and B regions of the Clarke Error Grid are considered clinically acceptable, while matched pairs that fall within the C, D, and E regions of the Clarke Error Grid are not considered clinically acceptable.
A variety of other known methods of evaluating clinical acceptability can be utilized. In one alternative embodiment, the Consensus Grid is used to evaluate the clinical acceptability of reference and sensor data. In another alternative embodiment, a mean absolute difference calculation can be used to evaluate the clinical acceptability of the reference data. In another alternative embodiment, the clinical acceptability can be evaluated using any relevant clinical acceptability test, such as a known grid (e.g., Clarke Error or Consensus), and additional parameters, such as time of day and/or the increase or decreasing trend of the analyte concentration. In another alternative embodiment, a rate of change calculation can be used to evaluate clinical acceptability. In yet another alternative embodiment, wherein the received reference data is in substantially real time, the conversion function could be used to predict an estimated glucose value at a time corresponding to the time stamp of the reference analyte value (this can be required due to a time lag of the sensor data such as described elsewhere herein). Accordingly, a threshold can be set for the predicted estimated glucose value and the reference analyte value disparity, if any. In some alternative embodiments, the reference data is evaluated for physiological and/or statistical acceptability as described in more detail elsewhere herein.
At decision block 226, results of the evaluation are assessed. If acceptability is determined, then processing continues to block 228 to re-calculate the conversion function using the new matched data pair in the calibration set.
At block 228, the conversion function module re-creates the conversion function using the new matched data pair associated with the newly received reference data. In one embodiment, the conversion function module adds the newly received reference data (e.g., including the matched sensor data) into the calibration set, and recalculates the conversion function accordingly. In alternative embodiments, the conversion function module displaces the oldest, and/or least concordant matched data pair from the calibration set, and recalculates the conversion function accordingly.
At block 230, the sensor data transformation module uses the new conversion function (from block 228) to continually (or intermittently) convert sensor data into estimated analyte values, also referred to as calibrated data, or converted sensor data, such as is described in more detail above.
At block 232, an output module provides output to the user via the user interface. The output is representative of the estimated analyte value, which is determined by converting the sensor data into a meaningful analyte value. User output can be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example. Other representations of the estimated analyte values are also possible, for example audio and tactile.
If, however, acceptability is determined at decision block 226 as negative (unacceptable), then the processing progresses to block 234 to adjust the calibration set. In one embodiment of a calibration set adjustment, the conversion function module removes one or more oldest matched data pair(s) and recalculates the conversion function accordingly. In an alternative embodiment, the conversion function module removes the least concordant matched data pair from the calibration set, and recalculates the conversion function accordingly.
At block 236, the conversion function module re-creates the conversion function using the adjusted calibration set. While not wishing to be bound by theory, it is believed that removing the least concordant and/or oldest matched data pair(s) from the calibration set can reduce or eliminate the effects of sensor sensitivity drift over time, adjusting the conversion function to better represent the current sensitivity of the sensor.
At block 224, the evaluation module re-evaluates the acceptability of newly received reference data with time corresponding converted sensor data that has been converted using the new conversion function (block 236). The flow continues to decision block 238 to assess the results of the evaluation, such as described with reference to decision block 226, above. If acceptability is determined, then processing continues to block 230 to convert sensor data using the new conversion function and continuously display calibrated sensor data on the user interface.
If, however, acceptability is determined at decision block 226 as negative, then the processing loops back to block 234 to adjust the calibration set once again. This process can continue until the calibration set is no longer sufficient for calibration, for example, when the calibration set includes only one or no matched data pairs with which to create a conversion function. In this situation, the system can return to the initial calibration or start-up mode, which is described in more detail with reference to
In alternative embodiments, the acceptability is determined by a quality evaluation, for example, calibration quality can be evaluated by determining the statistical association of data that forms the calibration set, which determines the confidence associated with the conversion function used in calibration and conversion of raw sensor data into estimated analyte values. See, e.g., co-pending U.S. patent application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA.”
Alternatively, each matched data pair can be evaluated based on clinical or statistical acceptability such as described above; however, when a matched data pair does not pass the evaluation criteria, the system can be configured to ask for another matched data pair from the user. In this way, a secondary check can be used to determine whether the error is more likely due to the reference glucose value or to the sensor value. If the second reference glucose value substantially correlates to the first reference glucose value, it can be presumed that the reference glucose value is more accurate and the sensor values are errant. Some reasons for errancy of the sensor values include a shift in the baseline of the signal or noise on the signal due to low oxygen, for example. In such cases, the system can be configured to re-initiate calibration using the secondary reference glucose value. If, however, the reference glucose values do not substantially correlate, it can be presumed that the sensor glucose values are more accurate and the reference glucose values eliminated from the algorithm.
One reason for anomalies in calibrated sensor data includes transient events, such as local ischemia at the implant site, which can temporarily cause erroneous readings caused by insufficient oxygen to react with the analyte. Accordingly, the flow chart 190 illustrates one self-diagnostic check that can be used to catch erroneous data before displaying it to the user.
At block 252, a sensor data receiving module, also referred to as the sensor data module, receives new sensor data from the sensor.
At block 24, the sensor data transformation module continuously (or intermittently) converts new sensor data into estimated analyte values, also referred to as calibrated data.
At block 256, a self-diagnostic module compares the new calibrated sensor data with previous calibrated sensor data, for example, the most recent calibrated sensor data value. In comparing the new and previous sensor data, a variety of parameters can be evaluated. In one embodiment, the rate of change and/or acceleration (or deceleration) of change of various analytes, which have known physiological limits within the body, and sensor data can be evaluated accordingly. For example, a limit can be set to determine if the new sensor data is within a physiologically feasible range, indicated by a rate of change from the previous data that is within known physiological (and/or statistical) limits. Similarly, any algorithm that predicts a future value of an analyte can be used to predict and then compare an actual value to a time corresponding predicted value to determine if the actual value falls within a statistically and/or clinically acceptable range based on the predictive algorithm, for example. In certain embodiments, identifying a disparity between predicted and measured analyte data can be used to identify a shift in signal baseline responsive to an evaluated difference between the predicted data and time-corresponding measured data. In some alternative embodiments, a shift in signal baseline and/or sensitivity can be determined by monitoring a change in the conversion function; namely, when a conversion function is re-calculated using the equation y=mx+b, a change in the values of m (sensitivity) or b (baseline) above a pre-selected “normal” threshold, can be used to trigger a fail-safe or further diagnostic evaluation.
Although the above-described self-diagnostics are generally employed with calibrated sensor data, some alternative embodiments are contemplated that check for aberrancy of consecutive sensor values prior to sensor calibration, for example, on the raw data stream and/or after filtering of the raw data stream. In certain embodiments, an intermittent or continuous signal-to-noise measurement can be evaluated to determine aberrancy of sensor data responsive to a signal-to-noise ratio above a set threshold. In certain embodiments, signal residuals (e.g., by comparing raw and filtered data) can be intermittently or continuously analyzed for noise above a set threshold. In certain embodiments, pattern recognition can be used to identify noise associated with physiological conditions, such as low oxygen (see, e.g., co-pending U.S. application Ser. No. 10/648,849 filed Aug. 22, 2003 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”), or other known signal aberrancies. Accordingly, in these embodiments, the system can be configured, in response to aberrancies in the data stream, to trigger signal estimation, adaptively filter the data stream according to the aberrancy, or the like, as described in more detail in the above cited co-pending U.S. application Ser. No. 10/648,849.
In another embodiment, reference analyte values are processed to determine a level of confidence, wherein reference analyte values are compared to their time-corresponding calibrated sensor values and evaluated for clinical or statistical accuracy. In yet another alternative embodiment, new and previous reference analyte data are compared in place of or in addition to sensor data. In general, there exist known patterns and limitations of analyte values that can be used to diagnose certain anomalies in raw or calibrated sensor and/or reference analyte data.
Block 193 describes additional systems and methods that can by utilized by the self-diagnostics module of the preferred embodiments.
At decision block 258, the system determines whether the comparison returned aberrant values. In one embodiment, the slope (rate of change) between the new and previous sensor data is evaluated, wherein values greater than +/−10, 15, 20, 25, or 30% or more change and/or +/−2, 3, 4, 5, 6 or more mg/dL/min, more preferably +/−4 mg/dL/min, rate of change are considered aberrant. In certain embodiments, other known physiological parameters can be used to determine aberrant values. However, a variety of comparisons and limitations can be set.
At block 260, if the values are not found to be aberrant, the sensor data transformation module continuously (or intermittently) converts received new sensor data into estimated analyte values, also referred to as calibrated data.
At block 262, if the values are found to be aberrant, the system goes into a suspended mode, also referred to as fail-safe mode in some embodiments, which is described in more detail below with reference to
In some alternative embodiments, in response to a positive determination of aberrant value(s), the system can be configured to estimate one or more glucose values for the time period during which aberrant values exist. Signal estimation generally refers to filtering, data smoothing, augmenting, projecting, and/or other methods for estimating glucose values based on historical data, for example. In one implementation of signal estimation, physiologically feasible values are calculated based on the most recent glucose data, and the aberrant values are replaced with the closest physiologically feasible glucose values. See also co-pending U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA,” U.S. application Ser. No. 10/648,849 filed Aug. 22, 2003 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM,” and U.S. Provisional Patent Application No. 60/528,382 filed Dec. 9, 2003 entitled, “SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSORS.”
At block 282, a sensor data receiving module, also referred to as the sensor data module, receives new sensor data from the sensor.
At block 284, the sensor data transformation module continuously (or intermittently) converts received new sensor data into estimated analyte values, also referred to as calibrated data.
At block 286, a self-diagnostics module, also referred to as a fail-safe module, performs one or more calculations to determine the accuracy, reliability, and/or clinical acceptability of the sensor data. Some examples of the self-diagnostics module are described above, with reference block 256. The self-diagnostics module can be further configured to run periodically (e.g., intermittently or in response to a trigger), for example, on raw data, filtered data, calibrated data, predicted data, and the like.
In certain embodiments, the self-diagnostics module evaluates an amount of time since sensor insertion into the host, wherein a threshold is set for the sensor's usable life, after which time period the sensor is considered to be unreliable. In certain embodiments, the self-diagnostics module counts the number of times a failure or reset is required (for example, how many times the system is forced into suspended or start-up mode), wherein a count threshold is set for a predetermined time period, above which the system is considered to be unreliable. In certain embodiments, the self-diagnostics module compares newly received calibrated sensor data with previously calibrated sensor data for aberrant values, such as is described in more detail with reference to
At block 288, a mode determination module, which can be a part of the sensor evaluation module 224, determines in which mode the sensor should be set (or remain). In some embodiments, the system is programmed with three modes: 1) start-up mode; 2) normal mode; and 3) suspended mode. Although three modes are described herein, the preferred embodiments are limited to the number or types of modes with which the system can be programmed. In some embodiments, the system is defined as “in-cal” (in calibration) in normal mode; otherwise, the system is defined as “out-of-cal” (out of calibration) in start-up and suspended mode. The terms as used herein are meant to describe the functionality and are not limiting in their definitions.
Preferably, a start-up mode is provided, wherein the start-up mode is set when the system determines that it can no longer remain in suspended or normal mode (for example, due to problems detected by the self-diagnostics module, such as described in more detail above) and/or wherein the system is notified that a new sensor has been inserted. Upon initialization of start-up mode, the system ensures that any old matched data pairs and/or calibration information is purged. In start-up mode, the system initializes the calibration set, such as described in more detail with reference to
Preferably, a normal mode is provided, wherein the normal mode is set when the system is accurately and reliably converting sensor data, for example, wherein clinical acceptability is positively determined, aberrant values are negatively determined, and/or the self-diagnostics modules confirms reliability of data. In normal mode, the system continuously (or intermittently) converts (calibrates) sensor data. Additionally, reference analyte values received by the system are matched with sensor data points and added to the calibration set.
In certain embodiments, the calibration set is limited to a predetermined number of matched data pairs, after which the systems purges old or less desirable matched data pairs when a new matched data pair is added to the calibration set. Less desirable matched data pairs can be determined by inclusion criteria, which include one or more criteria that define a set of matched data pairs that form a substantially optimal calibration set.
One inclusion criterion comprises ensuring the time stamp of the matched data pairs (that make up the calibration set) span at least a preselected time period (e.g., three hours). Another inclusion criterion comprises ensuring that the time stamps of the matched data pairs are not more than a preselected age (e.g., one week old). Another inclusion criterion ensures that the matched pairs of the calibration set have a substantially evenly distributed amount of high and low raw sensor data points, estimated sensor analyte values, and/or reference analyte values. Another criterion comprises ensuring all raw sensor data, estimated sensor analyte values, and/or reference analyte values are within a predetermined range (e.g., 40 mg/dL to 400 mg/dL for glucose values). Another criterion comprises evaluating the rate of change of the analyte concentration (e.g., from sensor data) during the time stamp of the matched pair(s). For example, sensor and reference data obtained during the time when the analyte concentration is undergoing a slow rate of change can be less susceptible to inaccuracies caused by time lag and other physiological and non-physiological effects. Another criterion comprises evaluating the congruence of respective sensor and reference data in each matched data pair; the matched pairs with the most congruence can be chosen. Another criterion comprises evaluating physiological changes (e.g., low oxygen due to a user's posture, position, or motion that can cause pressure on the sensor and effect the function of a subcutaneously implantable analyte sensor, or other effects such as described with reference to
Unfortunately, some circumstances can exist wherein a system in normal mode can be changed to start-up or suspended mode. In general, the system is programmed to change to suspended mode when a failure of clinical acceptability, aberrant value check and/or other self-diagnostic evaluation is determined, such as described in more detail above, and wherein the system requires further processing to determine whether a system re-start is required (e.g., start-up mode). In general, the system will change to start-up mode when the system is unable to resolve itself in suspended mode and/or when the system detects a new sensor has been inserted (e.g., via system trigger or user input).
Preferably, a suspended mode is provided wherein the suspended mode is set when a failure of clinical acceptability, aberrant value check, and/or other self-diagnostic evaluation determines unreliability of sensor data. In certain embodiments, the system enters suspended mode when a predetermined time period passes without receiving a reference analyte value. In suspended mode, the calibration set is not updated with new matched data pairs, and sensor data can optionally be converted, but not displayed on the user interface. The system can be changed to normal mode upon resolution of a problem (positive evaluation of sensor reliability from the self-diagnostics module, for example). The system can be changed to start-up mode when the system is unable to resolve itself in suspended mode and/or when the system detects a new sensor has been inserted (via system trigger or user input).
The systems of preferred embodiments, including a transcutaneous analyte sensor, mounting unit, electronics unit, applicator, and receiver for inserting the sensor, and measuring, processing, and displaying sensor data, provide improved convenience and accuracy because of their designed stability within the host's tissue with minimum invasive trauma, while providing a discreet and reliable data processing and display, thereby increasing overall host comfort, confidence, safety, and convenience. Namely, the geometric configuration, sizing, and material of the sensor of the preferred embodiments enable the manufacture and use of an atraumatic device for continuous measurement of analytes, in contrast to conventional continuous glucose sensors available to persons with diabetes, for example. Additionally, the sensor systems of preferred embodiments provide a comfortable and reliable system for inserting a sensor and measuring an analyte level for up to 7 days or more without surgery. The sensor systems of the preferred embodiments are designed for host comfort, with chemical and mechanical stability that provides measurement accuracy. Furthermore, the mounting unit is designed with a miniaturized and reusable electronics unit that maintains a low profile during use. The usable life of the sensor can be extended by incorporation of a bioactive agent into the sensor that provides local release of an anti-inflammatory, for example, in order to slow the subcutaneous foreign body response to the sensor.
After the usable life of the sensor (for example, due to a predetermined expiration, potential infection, or level of inflammation), the host can remove the sensor and mounting from the skin, and dispose of the sensor and mounting unit (preferably saving the electronics unit for reuse). Another sensor system can be inserted with the reusable electronics unit and thus provide continuous sensor output for long periods of time.
A transcutaneous glucose sensor was built according to the preferred embodiments and implanted in a human host where it remained over a period of time. The graph illustrates approximately 3 days of data obtained by the electronics unit operably connected to the sensor implanted in the human host. Finger-prick blood samples were taken periodically and glucose concentration measured by a blood glucose meter (SHBG). The graph shows the subcutaneous sensor data obtained by the transcutaneous glucose sensor tracking glucose concentration as it rises and falls over time. The time-corresponding blood glucose values show the correlation of the sensor data to the blood glucose data, indicating appropriate tracking of glucose concentration over time.
The signal has a current measurement in the picoAmp range. Namely, for every unit (mg/dL) of glucose, approximately 3.5 to 7.5 pA of current is measured. Generally, the approximately 3.5 to 7.5 pA/mg/dL sensitivity exhibited by the device can be attributed to a variety of design factors, including resistance of the membrane system to glucose, amount of enzyme in the membrane system, surface area of the working electrode, and electronic circuitry design. Accordingly, a current in the picoAmp range enables an analyte sensor that: 1) requires (or utilizes) less enzyme (e.g., because the membrane system is highly resistive and allows less glucose through for reaction in the enzyme domain); 2) requires less oxygen (e.g., because less reaction of glucose in the enzyme domain requires less oxygen as a co-reactant) and therefore performs better during transient ischemia of the subcutaneous tissue; and 3) accurately measures glucose even in hypoglycemic ranges (e.g., because the electronic circuitry is able to measure very small amounts of glucose (hydrogen peroxide at the working electrode)). Advantageously, the analyte sensors of the preferred embodiments exhibit improved performance over convention analyte sensors at least in part because a current in the picoAmp range enables less enzyme, less oxygen, better resolution, lower power usage, and therefore better performance in the hypoglycemic range wherein lower mg/dL values conventionally have yielded lower accuracy.
The base portion 240 is configured to lie adjacent to the host's skin during use of the sensor assembly 210. Accordingly, a first major side 214 of the base portion 240, also referred to as the backside, can include an adhesive disposed thereon for adhering to the host's skin during use.
A variety of adhesives appropriate for adhesion to the host's skin can be used, as is appreciated by one skilled in the art. In some embodiments, a double-sided adhesive is used to adhere the mounting unit to the host's skin. In some embodiments, the adhesive includes a foam layer, for example, wherein the foam is disposed between the adhesive sides and acts as a shock absorber. In some embodiments, the adhesive is sized with substantially the same surface area as the backside 314 of the base portion 340. In some embodiments, the adhesive is at least 1.5, 2, 2.5, or more times the surface area of the backside 314 of the base portion 340. In some embodiments, the adhesive is substantially the same shape as the backside 314 of the base portion 340, although other shapes can also be advantageous, for example butterfly-shaped. In some embodiments, the adhesive backing is designed for two-step release, for example a primary release, wherein only a portion of the adhesive is initially exposed to allow adjustable positioning of the device, and a secondary release, wherein the remaining adhesive is later exposed to firmly and securely adhere the device to the host's skin once appropriately positioned. In some embodiments, a stretch-release adhesive is provided on the backside of the base portion to enable easy release from the host's skin after the useable life of the sensor, which is described in more detail with reference to
The second major side of the base portion 340, also referred to as the front side 343 includes a mating, nesting, or a complementary surface designed to receive the upper portion 342, which minimizes the profile (for example, height) of the mounting unit 312 among other advantages. In some embodiments, the upper and base portions snap-fit, press-fit, or otherwise securely fit together to discourage separation during use. In some embodiments, a mechanical joint is provided to ensure secure closure of the upper and base portions. In some alternative embodiments, an adhesive is provided to aid in securing the upper and base portions together in their closed position. In some alternative embodiments, the upper and base portions lock together after sensor insertion, which will be described in more detail with reference to
The relative pivotal movement between the base and upper portions is advantageous, for example, by enabling the design of a low profile device while providing support for an appropriate needle insertion angle; however, not all implementations require the pivoting design. In some alternative embodiments, the mounting unit is formed from one unitary flexible piece of material (for example silicone or urethane rubber), wherein the material is sufficiently flexible to enable bending of the unit at a point from an angle appropriate for insertion to a flat functional (wearable) configuration. This unitary flexible unit can additionally provide a method of insertion of the electronics unit during flexion and maintenance of the electronics unit in mounting unit during wear (in its flat configuration). In some embodiments, a protective flap, or the like, can be provided to cover and protect the electronics unit from the environment. Other implementations of the pivotal design include two pieces connected via an adhesive hinge, or two substantially planar pieces that articulate relative to each other (see for example,
In this embodiment, the upper portion 342 further includes a cavity 344 configured to receive and releasably hold the electronics unit 318 therein. Mutually engaging electrical contacts (not shown) within the cavity 344 and on the electronics unit 318 allow for operable connection of the sensor 316 to the electronics unit 318 when connected to the mounting unit 312, however other methods of electrically connecting the electronics unit 318 to the sensor 316 are also possible as is appreciated by one skilled in the art (for example, a cable or other connector). Detachable connection between the mounting unit 312 and electronics unit 318 provides improved manufacturability, namely, the relatively inexpensive mounting unit 312 can be disposable when replacing the sensor assembly after its usable life, while the relatively more expensive electronics unit 318 can be reusable with multiple sensor assemblies. In some embodiments, the electronics unit 318 is configured with programming, for example initialization, calibration reset, failure testing, or the like, each time it is initially inserted into the cavity 344 and/or initially communicates with the sensor 316.
The base and upper portions 340, 342 can be formed from the same or different materials, for example plastics or ceramics. In some embodiments, the base portion is formed from a flexible material, such as silicone, urethane rubber, or other flexible or elastomeric material. In some alternative embodiments, the base portion is formed from a plurality of articulating components, for example one or more sections hinged or otherwise moveably (for example, linearly) or rotatably (for example, angularly) attached to each other. In some embodiments, the upper portion 342 is formed from a material or design that is less flexible than the base portion 340. In this way, the greater rigidity of the upper portion 342 provides for a more stable electrical connection to the electronics unit 318 while the greater flexibility of the base portion 340 (adjacent to the host's skin) enables the device to substantially mimic or move with the flexibility and/or motion of the host's skin. It is noted however that in some embodiments it is preferred that the upper portion is at least semi-rigid to enable easy removal of the electronics unit by a flexing motion of the upper portion.
A flexible base portion 340 is believed to provide numerous advantages over conventional transcutaneous sensors, which unfortunately can suffer from motion-related artifacts associated with the host's movement when the host is using the device. For example, when a transcutaneous analyte sensor is inserted into the host, various movements of the sensor (for example, relative movement between the in vivo portion and the ex vivo portion, movement of the skin, and/or movement within the host (dermis or subcutaneous)) create stresses on the device and can produce noise on the sensor signal. It is believed that even small movements of the skin will translate to discomfort and motion-related artifact, which can be reduced or obviated by a flexible or articulated design. For example, a conventional transcutaneous analyte sensor is formed from relatively rigid material and does not conform well to the skin, making it uncomfortable for the host, more likely to detach from the host during movement, and can induce motion-related artifact on the sensor (for example, noise on the signal). Thus, by providing flexibility and/or articulation of the device against the host's skin, better conformity of the sensor assembly 310 to the regular use and movements of the host is achieved, which is believed to increase adhesion of mounting unit 312 on the skin and decrease motion-related artifact that can otherwise translate from the host's movements to reduced sensor performance.
The electronics unit 318 includes hardware and software that enables measurement of levels of the analyte via the sensor 316. For example, the electronics unit 318 comprises a potentiostat, a power source for providing power to the sensor, other components useful for signal processing, and preferably an RF module for transmitting data from the electronics unit 318 to receiver (see
A needle 346 is slidably disposed within the mounting unit 312 for guided movement between inserted and retracted positions, which will be described in more detail with reference to
The sensor 316 preferably includes electrodes and a membrane system, such as described in more detail with reference to
In some embodiments, a shock-absorbing member is included in the design of the sensor and configured to absorb movement of the in vivo and/or ex vivo portion of the sensor. It is noted that conventional analyte sensors can suffer from motion-related artifact associated with host movement when the host is using the device. For example, when a transcutaneous analyte sensor is inserted into the host, various movements on the sensor (for example, relative movement between the in vivo portion and the ex vivo portion and/or movement within the host) create stresses on the device and can produce noise in the sensor signal. Accordingly in some embodiments, a shock-absorbing member is located on the sensor/mounting unit in a location that absorbs stresses associated with the above-described movement.
In some embodiments, the shock absorbing member is formed into the sensor, for example an S-bend formed within the in vivo and/or ex vivo portion of the sensor 316 that functions to break column strength, effectively absorbing movements on the sensor during use. In some alternative embodiments, the shock-absorbing member can be any expanding and contracting member, such as a spring, accordion, telescoping, or bellows-type device. The expanding and contracting member can be located such that relative movement between the sensor, the mounting unit, and the host is absorbed without (or minimally) affecting the connection of the sensor to the mounting unit and/or the sensor stability within the implantation site; for example, the expanding and contracting member can be formed as a part of or connected to the sensor 316.
In some embodiments, the sensor is configured with a variable stiffness along at least a portion of its length. As described above, conventional analyte sensors suffer from motion artifact associated with host movement when the host is using the device. Thus, in the preferred embodiments, the portion of the sensor that is implanted in a host (in vivo portion) is designed to be more flexible than the portion of the sensor that extends into the mounting unit (ex vivo portion), in order to decrease the mechanical stress and signal noise associated with host movement. Additionally, because the ex vivo portion is stiffer, greater stability is achieved providing more reliable electronic connections and less noise in the mounting unit. Variable stiffness can be provided by variable pitch of the one or more electrodes of the sensor, variable cross-section one or more electrodes, annealing of at least some portions of the sensor, or the like.
The retractor 348 includes a tab 349, or the like, which enable manual and/or automatic insertion and/or retraction of the needle within the mounting unit. The retractor can be attached to the needle using a variety of attachments and configurations that allow for insertion of the sensor, which is described in more detail with reference to
In one embodiment, the mounting unit is provided with an adhesive disposed on the mounting unit's backside 314 and including a releasable backing layer. Thus, removing the backing layer and pressing the base portion of the mounting unit on the skin accomplishes adhesion. Additionally or alternatively, an adhesive is placed over some or all of the sensor assembly after sensor insertion is complete (see
After inserting the needle 446 into the host, the side tabs 460a, 460b are pulled back to a rearward position, which causes the needle 446 to retract back into the mounting unit 412 while leaving the sensor 416 in the host's tissue. The upper portion of the mounting unit 462 is then closed into its functional position, including the tabs 460a and 460b locking into the base portion (molded foot) of the mounting unit 464. It is noted that locking the tabs 460a and 460b into the base portion of the mounting 464 unit in its closed position prohibits an accidental re-insertion of the needle 446, effectively ensuring only one insertion of the needle. In its functional position against the host's skin, the sensor assembly 310 holds the sensor 416 in the host's subcutaneous tissue and the sensor 416 is operably connected to the sensor electronics 418, which will is described in more detail with reference to
The upper portion of the mounting unit 462, which in this implementation includes the main PCB assembly 468, mini connector PCB 470, first upper base 472, needle holder 474, lower base 476, and sensor probe 416, are assembled together for pivotal movement relative to the base portion 464 (molded foot) about a pivot or hinge 478. The lower base 472 of the upper portion 476 is formed from an acetal resin and is configured to fit within the cavity of the base portion (molded foot) 464. The lower base portion 476 further includes a groove 480 configured to guide the needle holder 474 between the insertion (forward) position and retracted (backward) position. The lower base 476 is further configured to receive the sensor 416, which extends through a hole in the lower base 476, through the needle 446 held by the needle holder 474, and finally through an exit port on the base portion (molded foot) 464 into host tissue (not shown) as described in the preferred embodiments.
The sensor probe 416 includes electrodes and a membrane system as described with reference to the preferred embodiments, and can include a variable stiffness or other advantageous properties as described in more detail above. The sensor probe 416 is sized and arranged to extend from the lower base 476 and connect through a hole in the first upper base 472 to solder pads 480 on the mini connector PCB 470. In this implementation, the sensor probe 416 remains fixed in an extended position, namely extending through the exit port in the molded foot, however the assembly can be modified to allow relative movement of the sensor probe to include an initial retracted (or cocked) position in which the sensor probe does not extend from the molded foot prior to insertion.
The needle holder 474 is configured to slide within the groove 480 on the second upper section 476 between an insertion (forward) position (as illustrated in
The upper base 472 is formed from polyetherimide and includes a cavity 482 for receiving the PCB boards 468 and 470 and holes for receiving screws for attachment to the lower base 376. The upper base 472 further includes a hole (not shown) for receiving one end of the sensor probe 416. Mini connector PCB 470 is received within the cavity 482 and includes two solder pads on which the two electrodes (working and reference) of the sensor probe 416 are soldered for electrical connection thereto, which is described in more detail below. Another PCB, hereinafter referred as the main PCB 468, substantially includes the sensor electronics for processing sensor data, such as described in co-pending U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA,” which is incorporated herein by reference in its entirety. The main PCB 468 is received over and connected to the mini connector PCB 470. The main PCB 468 is operably connected to the mini connector PCT 470 in order to provide an operative link between the sensor 416 and the sensor electronics housed thereon, which is described in more detail below. Together, the components of the upper portion 362 are assembled and pivotally mounted to the molded foot 464 for relative pivotal motion therewith.
Referring to the electronics housed of the two PCBs 468 and 470, working and reference electrodes are soldered to solder pads and provide for electrical connection between the electrodes and the PCB. The solder pads are connected via a trace, or the like (not shown) to the three pin receptacles that connect the mini connector board 470 to the main PCB 468. The main PCB 468 includes three pins that are received by the three pin receptacles for operable connection between the two boards 468 and 470. The three pins are configured to provide separate connection for working, reference, and counter electrodes if desired. However, because this implementation is configured with a two electrode sensor, the reference and counter electrodes are linked as is appreciated by one skilled in the art (for example, via a resistor or the like). The three pins are then connected, via a trace or the like, to the sensor electronics (not shown), which include hardware and software configured to measure and process the glucose signal from the working electrode, for example. Accordingly, when the sensor 416 is inserted into the tissue of a host, the sensor assembly 310 measures a concentration of the glucose and can subsequently transmit that information to a communication station, such as described in more detail in the preferred embodiments.
After inserting the needle 546 into the host, retraction tab 560 is pulled back to its retracted position, which causes the needle 546 to retract back into the mounting unit 512 while leaving the sensor 516 in the host's tissue. The mounting unit 512 is configured to lock or retain the needle 546 therein by rotating the retractor 90 degrees, however a variety of locking or retraining mechanisms are contemplated as is appreciated by one skilled in the art. Once the needle 546 is retracted, retractor 574 is broken of at a perforated portion, for example, to further prohibit accidental re-insertion of the needle, effectively ensuring only one insertion of the needle 546.
The upper portion 562 of the mounting unit 512 includes a variety of components, including the carrier 592, upper adhesive 550b, retractor 574 (with retractor tab 560 and needle 546), electrodes 544, connector 594, and sensor electronics 518. The upper portion 562 of the mounting unit is pivotally connected to the base portion 564 at a hinge 578 for relative motion of the base and upper portions 564 and 562, respectively, between an open position and a closed position. The upper adhesive 550b is disposed on the backside of the carrier 592 for adhesion to the host's skin in the closed (functional) position. The carrier 592 is formed from plastic, or the like, and is dimensioned and arranged to support or receive functional components described herein. The carrier 592 includes a groove, into which the retractor 560 is received and can slide between the insertion and retraction positions.
The retractor 574 includes the retractor tab 560 and a needle 546 attached thereto and is designed to slide within the groove of the carrier 592 to enable to needle to move between insertion and retraction positions as illustrated in
The sensor 516 is formed from three electrodes 544 in this implementation, however a two, four, or other electrode system can be substituted. The electrodes 544 can be configured in a variety of manners and include a membrane system such as described with reference to the preferred embodiments. The sensor 516 is configured to remain in the insertion position during and after needle retraction such that the sensor is exposed to the host's tissue at its in vivo end after the needle 546 is retracted back into the mounting unit 512. The electrodes 544 that form the sensor 516 are exposed at their ex vivo end to a contact which can be held thereon by a connector 594, or the like, for operable connection with the sensor electronics 518. Namely, the working, reference, and counter electrodes are connected via the contact/connector 594 on the carrier 592 to a contact on the electronics unit 518.
The sensor electronics unit 518 is a detachable and reusable piece designed for multiple uses and includes hardware and software configured that enable the sensor 516 to measure glucose in the host's tissue. The sensor electronics 518 further include an RF transmitter that transmits glucose data to a communication station (not shown), such as described in the embodiments discussed herein. In general, the sensor electronics unit 518 is configured as described above, and can be modified in a variety of manners as is appreciated by one skilled in the art.
The sensor assembly 310 can be manually loaded into the inserter 600 by a host or caretaker or can come loaded from the manufacturer. Manual loading can be advantageous, however, in order to enable reuse of the inserter 600 for more than one sensor assembly 310. The sharp needle 546 is protected within the inserter 600 prior to host activation to minimize accidental pricking or contamination. The sensor assembly 310 can be cocked using a variety of mechanisms, however one preferred mechanism includes a detent mechanism on the inner bore of the inserter 600 designed to hold and subsequently release the sensor assembly 310 upon activation. A button 604 is provided for activation of the sensor assembly 310, for example, for application of force (for example, spring-loaded force) to insert the sensor assembly 310 into the host's tissue and/or for releasing the detent mechanism that holds the sensor assembly in the cocked position.
The spring-loaded inserter 600 provides the appropriate force to insert the needle 546 under the skin upon activation by the button 604. It is noted that adhesive, or the like, can be disposed on the sensor assembly to secure the lower portion of the holder adjacent to the skin during needle retraction and during use.
The transcutaneous analyte sensor assembly 310 measures a concentration of an analyte or a substance indicative of the concentration or presence of the analyte as described above. Although some of the examples, such as many of the embodiments discussed herein, are drawn to a glucose sensor, the analyte sensor 716 can be any sensor capable of determining the level of any analyte in the body, for example oxygen, lactase, insulin, hormones, cholesterol, medicaments, viruses, or the like. Once the electronics unit 718 is connected to the mounting unit 712, the sensor 716 is able to measure levels of the analyte in the host. Preferably the electronics unit 718 is wirelessly connected to a receiver 720 via one- or two-way RF transmissions 150 or the like, however a wired connection is also possible. The receiver 720 provides much of the processing and display of the sensor data, and can be selectively worn and/or removed at the host's convenience. Thus, the sensor assembly 310 can be discretely worn, and the receiver 720, which provides much of the processing and display of the sensor data, can be selectively worn and/or removed at the host's convenience. Particularly, the receiver 720 includes programming for retrospectively and/or prospectively initiating a calibration, converting sensor data, updating the calibration, evaluating received reference and sensor data, and evaluating the calibration for the analyte sensor, such as described in more detail with reference to co-pending U.S. patent application Ser. No. 10/633,367, filed Aug. 1, 2003 and entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA,” which is incorporated herein by reference in its entirety.
Accordingly, this embodiment provides a docking station 722 on the receiver 720 that enables storage, electrical connection, and/or battery recharge, for example, for the electronics unit 718 while not in use on a sensor assembly 310. Complementary contacts or pins can be provided on the electronics unit 718 and the docking station 722 that enable operable connection therebetween.
In some embodiments, the receiver 720 includes programming that stops searching for a transmission from the sensor assembly 310 (particularly, from electronics unit 718) when the electronics unit 718 is docked on the receiver 720, which is believed to minimize unnecessary use of power. In some embodiments, the receiver 720 includes programming to switch the receiver into an alternate mode (for example, a sleep mode wherein the receiver does not attempt to calibrate, or the like) when the electronics unit 718 is docked on the receiver 720. In some embodiments, the receiver 720 includes programming that resets calibration when the electronics unit 718 is docked on the receiver 720.
In some embodiments, the receiver 720 is configured to recharge a battery in the electronics unit 718 when docked on the receiver, thereby increasing the useable life of the electronics unit. In some embodiments, the receiver 720 is configured to measure battery voltage in the electronics unit 718 and to disable the electronics unit if the voltage is below a certain threshold (for example, less than 3 days of usable life left). In some embodiments, the receiver 720 is configured to reset states in the battery, such as initializing a new (unused) electronics unit 718 to work with the receiver when the electronics unit 718 is docked on the receiver 720.
In some embodiments, the receiver 720 is configured to test operation of the electronics unit 718 by stepping the electrodes through different current draws and disabling usage of the electronics unit if a failure is detected (see
Thus, the preferred embodiments provide an analyte sensor assembly that enables a comfortable and reliable system for measuring an analyte level for up to 7 days or more without surgery. The sensor of the preferred embodiments is designed for host comfort, with chemical and mechanical stability that provides accuracy of measurements. Additionally, the mounting unit is designed with a miniaturized and reusable electronics unit 718 that maintains a low profile during use. It is noted that the usable life of the sensor can be extended by incorporated a bioactive agent into the sensor that provides local release of an anti-inflammatory, for example, in order to slow the subcutaneous foreign body response to the sensor catheter.
After the usable life of the sensor (for example, due to a predetermined expiration, potential infection, or level of inflammation), the host can remove the sensor and mounting from the skin, dispose of the sensor and mounting unit (preferably saving the electronics unit for reuse). Another sensor assembly can be inserted with the reusable electronics unit and thus provide continuous sensor output for long periods of time.
Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; U.S. Pat. No. 4,757,022 issued February Jul. 12, 1988 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; U.S. Pat. No. 6,001,067 issued February Dec. 14, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 6,741,877 issued February May 25, 2004 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 6,702,857 issued February Mar. 9, 2004 and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; and U.S. Pat. No. 6,558,321 issued February May 6, 2003 and entitled “SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES.” Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in co-pending U.S. application Ser. No. 10/991,353 filed Nov. 16, 2004 and entitled “AFFINITY DOMAIN FOR ANALYTE SENSOR”; U.S. application Ser. No. 11/055,779 filed Feb. 9, 2005 and entitled “BIOINTERFACE WITH MACRO-AND-MICRO-ARCHITECTURE”; U.S. application Ser. No. 11/004,561 filed Dec. 3, 2004 and entitled “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR”; U.S. application Ser. No. 11/034,343 filed Jan. 11, 2005 and entitled “COMPOSITE MATERIAL FOR IMPLANTABLE DEVICE”; U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 11/021,046 filed Dec. 22, 2004 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 09/916,858 filed Jul. 27, 2001 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 11/039,269 filed Jan. 19, 2005 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/897,377 filed Jul. 21, 2004 and entitled “ELECTROCHEMICAL SENSORS INCLUDING ELECTRODE SYSTEMS WITH INCREASED OXYGEN GENERATION”; U.S. application Ser. No. 10/897,312 filed Jul. 21, 2004 and entitled “ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS”; U.S. application Ser. No. 10/838,912 filed May 3, 2004 and entitled “IMPLANTABLE ANALYTE SENSOR”; U.S. application Ser. No. 10/838,909 filed May 3, 2004 and entitled “IMPLANTABLE ANALYTE SENSOR”; U.S. application Ser. No. 10/838,658 filed May 3, 2004 and entitled “IMPLANTABLE ANALYTE SENSOR”; U.S. application Ser. No. 11/034,344 filed Jan. 11, 2005 and entitled “IMPLANTABLE DEVICE WITH IMPROVED RADIO FREQUENCY CAPABILITIES”; U.S. application Ser. No. 10/896,772 filed Jul. 21, 2004 and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE SYSTEM”; U.S. application Ser. No. 10/789,359 filed Feb. 26, 2004 and entitled “INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR”; U.S. application Ser. No. 10/991,966 filed Nov. 17, 2004 and entitled “INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR”; U.S. application Ser. No. 10/646,333 filed Aug. 22, 2003 and entitled “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/896,639 filed Jul. 21, 2004 and entitled “OXYGEN ENHANCING MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/647,065 filed Aug. 22, 2003 and entitled “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/896,637 filed Jul. 21, 2004 and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. application Ser. No. 09/916,711 filed Jul. 27, 2001 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICE”; U.S. application Ser. No. 11/021,162 filed Dec. 22, 2004 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 11/007,920 filed Dec. 8, 2004 and entitled “SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR”; U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and entitled “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE”; U.S. application Ser. No. 11/038,340 filed Jan. 18, 2005 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 11/007,635 filed Dec. 7, 2004 and entitled “SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYTE SENSORS”; U.S. application Ser. No. 10/885,476 filed Jul. 6, 2004 and entitled “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM”; U.S. application Ser. No. 10/648,849 filed Aug. 22, 2003 and entitled “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”; U.S. application Ser. No. 10/153,356 filed May 22, 2002 and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 10/846,150 filed May 14, 2004 and entitled “ANALYTE MEASURING DEVICE”; U.S. application Ser. No. 10/842,716 filed May 10, 2004 and entitled “BIOINTERFACE MEMBRANES INCORPORATING BIOACTIVE AGENTS”; U.S. application Ser. No. 10/657,843 filed Sep. 9, 2003 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/768,889 filed Jan. 29, 2004 and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 10/632,537 filed Aug. 1, 2003 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 10/633,404 filed Aug. 1, 2003 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 10/633,329 filed Aug. 1, 2003 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; and U.S. Application No. 60/660,743 filed on Mar. 10, 2005 and entitled “SYSTEMS AND METHODS FOR PROCESSING ANALYTE SENSOR DATA FOR SENSOR CALIBRATION.”
All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, and also including but not limited to the references listed in the Appendix, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.
Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. application Ser. No. 13/077,884 filed Mar. 31, 2011, which is a continuation of U.S. application Ser. No. 11/077,883 filed Mar. 10, 2005, now U.S. Pat. No. 7,946,984, which claims the benefit of U.S. Provisional Application No. 60/587,787 filed Jul. 13, 2004; U.S. Provisional Application No. 60/587,800 filed Jul. 13, 2004; U.S. Provisional Application No. 60/614,683 filed Sep. 30, 2004; and U.S. Provisional Application No. 60/614,764 filed Sep. 30, 2004; each of which is incorporated by reference herein in its entirety, and each of which is hereby made a part of this specification.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1498738 | Lahousse et al. | Jun 1924 | A |
| 1564641 | St. James | Dec 1925 | A |
| 1726766 | Rector et al. | Sep 1929 | A |
| 2057029 | Johnstone | Oct 1936 | A |
| 2402306 | Turkel | Jun 1946 | A |
| 2497894 | Clare et al. | Feb 1950 | A |
| 2719797 | Rosenblatt et al. | Oct 1955 | A |
| 2882696 | Herrmann et al. | Apr 1959 | A |
| 2910256 | Leidolf et al. | Oct 1959 | A |
| 3022639 | Brown et al. | Feb 1962 | A |
| 3210578 | Sherer | Oct 1965 | A |
| 3218819 | Crotser et al. | Nov 1965 | A |
| 3219533 | Mullins | Nov 1965 | A |
| 3381371 | Russell et al. | May 1968 | A |
| 3506032 | Eveleigh et al. | Apr 1970 | A |
| 3539455 | Clark, Jr. et al. | Nov 1970 | A |
| 3556950 | Dahms et al. | Jan 1971 | A |
| 3562352 | Nyilas | Feb 1971 | A |
| 3607329 | Manjikian | Sep 1971 | A |
| 3610226 | Albisser et al. | Oct 1971 | A |
| 3652475 | Wada et al. | Mar 1972 | A |
| 3728678 | Tong | Apr 1973 | A |
| 3775182 | Patton et al. | Nov 1973 | A |
| 3780727 | King | Dec 1973 | A |
| 3791871 | Rowley | Feb 1974 | A |
| 3826244 | Salcman et al. | Jul 1974 | A |
| 3837339 | Aisenberg et al. | Sep 1974 | A |
| 3838033 | Mindt et al. | Sep 1974 | A |
| 3838682 | Clark et al. | Oct 1974 | A |
| 3872455 | Fuller et al. | Mar 1975 | A |
| 3874850 | Sorensen et al. | Apr 1975 | A |
| 3882011 | Hines et al. | May 1975 | A |
| 3898984 | Mandel et al. | Aug 1975 | A |
| 3910256 | Clark et al. | Oct 1975 | A |
| 3926760 | Allen et al. | Dec 1975 | A |
| 3929971 | Roy et al. | Dec 1975 | A |
| 3930462 | Day et al. | Jan 1976 | A |
| 3933593 | Sternberg | Jan 1976 | A |
| 3943918 | Lewis | Mar 1976 | A |
| 3957613 | Macur | May 1976 | A |
| 3957651 | Kesting et al. | May 1976 | A |
| 3964974 | Banauch et al. | Jun 1976 | A |
| 3966580 | Janata et al. | Jun 1976 | A |
| 3978684 | Taylor et al. | Sep 1976 | A |
| 3979274 | Newman | Sep 1976 | A |
| 3982530 | Storch | Sep 1976 | A |
| 4003621 | Lamp | Jan 1977 | A |
| 4008717 | Kowarski et al. | Feb 1977 | A |
| 4016866 | Lawton et al. | Apr 1977 | A |
| 4024312 | Korpman et al. | May 1977 | A |
| 4036749 | Anderson | Jul 1977 | A |
| 4037563 | Pflueger et al. | Jul 1977 | A |
| 4040908 | Clark, Jr. | Aug 1977 | A |
| 4052754 | Homsy | Oct 1977 | A |
| 4055175 | Clemens et al. | Oct 1977 | A |
| 4067322 | Johnson | Jan 1978 | A |
| 4068660 | Beck | Jan 1978 | A |
| 4073713 | Newman | Feb 1978 | A |
| 4076656 | White et al. | Feb 1978 | A |
| 4101395 | Motani et al. | Jul 1978 | A |
| 4109505 | Clark et al. | Aug 1978 | A |
| 4110997 | Klotz et al. | Sep 1978 | A |
| 4116920 | Honma et al. | Sep 1978 | A |
| 4119406 | Clemens et al. | Oct 1978 | A |
| 4151845 | Clemens | May 1979 | A |
| 4172770 | Semersky et al. | Oct 1979 | A |
| 4176659 | Rolfe | Dec 1979 | A |
| 4187390 | Gore | Feb 1980 | A |
| 4197840 | Beck et al. | Apr 1980 | A |
| 4197852 | Schindler et al. | Apr 1980 | A |
| 4206755 | Klein | Jun 1980 | A |
| 4215703 | Willson | Aug 1980 | A |
| 4225410 | Pace et al. | Sep 1980 | A |
| 4230118 | Holman et al. | Oct 1980 | A |
| 4240438 | Shults et al. | Dec 1980 | A |
| 4240889 | Yoda et al. | Dec 1980 | A |
| 4245634 | Albisser et al. | Jan 1981 | A |
| 4253469 | Yoda et al. | Mar 1981 | A |
| 4255500 | Hooke | Mar 1981 | A |
| 4259540 | Sabia | Mar 1981 | A |
| 4260725 | Keogh et al. | Apr 1981 | A |
| 4260726 | Deubzer et al. | Apr 1981 | A |
| 4265249 | Schindler et al. | May 1981 | A |
| 4286039 | Landa et al. | Aug 1981 | A |
| 4319578 | Enger | Mar 1982 | A |
| 4324256 | Vesterager et al. | Apr 1982 | A |
| 4324257 | Albarda et al. | Apr 1982 | A |
| 4327725 | Cortese et al. | May 1982 | A |
| 4353368 | Slovak et al. | Oct 1982 | A |
| 4353888 | Sefton et al. | Oct 1982 | A |
| 4366040 | Marsoner et al. | Dec 1982 | A |
| 4369785 | Rehkopf et al. | Jan 1983 | A |
| 4374013 | Enfors | Feb 1983 | A |
| 4378016 | Loeb | Mar 1983 | A |
| 4388166 | Suzuki et al. | Jun 1983 | A |
| 4402694 | Ash et al. | Sep 1983 | A |
| 4403847 | Chrestensen | Sep 1983 | A |
| 4403984 | Ash et al. | Sep 1983 | A |
| 4415666 | D'Orazio et al. | Nov 1983 | A |
| 4418148 | Oberhardt | Nov 1983 | A |
| 4419535 | O'hara | Dec 1983 | A |
| 4431004 | Bessman et al. | Feb 1984 | A |
| 4431507 | Nankai et al. | Feb 1984 | A |
| 4432366 | Margules | Feb 1984 | A |
| 4436094 | Cerami | Mar 1984 | A |
| 4442841 | Uehara et al. | Apr 1984 | A |
| 4453537 | Spitzer | Jun 1984 | A |
| 4454295 | Wittmann et al. | Jun 1984 | A |
| 4457339 | Juan et al. | Jul 1984 | A |
| 4469110 | Slama | Sep 1984 | A |
| 4477314 | Richter et al. | Oct 1984 | A |
| 4478222 | Koning et al. | Oct 1984 | A |
| 4484987 | Gough | Nov 1984 | A |
| 4486290 | Cahalan et al. | Dec 1984 | A |
| 4492575 | Mabille | Jan 1985 | A |
| 4493714 | Ueda et al. | Jan 1985 | A |
| 4494950 | Fischell | Jan 1985 | A |
| 4506680 | Stokes | Mar 1985 | A |
| 4519973 | Cahalan et al. | May 1985 | A |
| RE31916 | Oswin et al. | Jun 1985 | E |
| 4526569 | Bernardi | Jul 1985 | A |
| 4527999 | Lee | Jul 1985 | A |
| 4534355 | Potter | Aug 1985 | A |
| 4534825 | Koning et al. | Aug 1985 | A |
| 4535786 | Kater | Aug 1985 | A |
| 4538616 | Rogoff | Sep 1985 | A |
| 4545382 | Higgins et al. | Oct 1985 | A |
| 4554927 | Fussell | Nov 1985 | A |
| 4561963 | Owen et al. | Dec 1985 | A |
| 4565665 | Fogt | Jan 1986 | A |
| 4565666 | Cahalan et al. | Jan 1986 | A |
| 4568444 | Nakamura et al. | Feb 1986 | A |
| 4571292 | Liu et al. | Feb 1986 | A |
| 4573968 | Parker | Mar 1986 | A |
| 4577642 | Stokes | Mar 1986 | A |
| 4578215 | Bradley | Mar 1986 | A |
| 4579120 | MacGregor | Apr 1986 | A |
| 4583976 | Ferguson | Apr 1986 | A |
| 4592824 | Smith et al. | Jun 1986 | A |
| 4600495 | Fogt | Jul 1986 | A |
| 4602922 | Cabasso et al. | Jul 1986 | A |
| 4603152 | Laurin et al. | Jul 1986 | A |
| 4614514 | Carr et al. | Sep 1986 | A |
| 4619793 | Lee | Oct 1986 | A |
| 4625730 | Fountain et al. | Dec 1986 | A |
| 4626104 | Pointon et al. | Dec 1986 | A |
| RE32361 | Duggan | Feb 1987 | E |
| 4647643 | Zdrahala et al. | Mar 1987 | A |
| 4650547 | Gough | Mar 1987 | A |
| 4655880 | Liu | Apr 1987 | A |
| 4663824 | Kenmochi | May 1987 | A |
| 4671288 | Gough | Jun 1987 | A |
| 4672970 | Uchida et al. | Jun 1987 | A |
| 4675346 | Lin et al. | Jun 1987 | A |
| 4680268 | Clark, Jr. | Jul 1987 | A |
| 4684538 | Klemarczyk | Aug 1987 | A |
| 4684558 | Keusch et al. | Aug 1987 | A |
| 4685463 | Williams | Aug 1987 | A |
| 4685903 | Cable et al. | Aug 1987 | A |
| 4686137 | Ward, Jr. et al. | Aug 1987 | A |
| 4689149 | Kanno et al. | Aug 1987 | A |
| 4689309 | Jones | Aug 1987 | A |
| 4694861 | Goodale et al. | Sep 1987 | A |
| 4703756 | Gough et al. | Nov 1987 | A |
| 4703989 | Price et al. | Nov 1987 | A |
| 4705503 | Dorman et al. | Nov 1987 | A |
| 4711245 | Higgins et al. | Dec 1987 | A |
| 4711251 | Stokes | Dec 1987 | A |
| 4721677 | Clark, Jr. | Jan 1988 | A |
| 4781680 | Redmond et al. | Jan 1988 | A |
| 4726381 | Jones | Feb 1988 | A |
| 4731726 | Allen, III | Mar 1988 | A |
| 4734092 | Millerd | Mar 1988 | A |
| 4736748 | Nakamura et al. | Apr 1988 | A |
| 4739380 | Lauks et al. | Apr 1988 | A |
| 4747822 | Peabody | May 1988 | A |
| 4750496 | Reinhart et al. | Jun 1988 | A |
| 4752935 | Beck | Jun 1988 | A |
| 4753652 | Langer et al. | Jun 1988 | A |
| 4755168 | Romanelli et al. | Jul 1988 | A |
| 4757022 | Shults et al. | Jul 1988 | A |
| 4759828 | Young et al. | Jul 1988 | A |
| 4761748 | Le Rat et al. | Aug 1988 | A |
| 4763648 | Wyatt | Aug 1988 | A |
| 4763658 | Jones | Aug 1988 | A |
| 4776343 | Hubbard et al. | Oct 1988 | A |
| 4777953 | Ash et al. | Oct 1988 | A |
| 4781798 | Gough | Nov 1988 | A |
| 4784157 | Halls et al. | Nov 1988 | A |
| 4786394 | Enzer et al. | Nov 1988 | A |
| 4787398 | Garcia et al. | Nov 1988 | A |
| 4789467 | Lindsay et al. | Dec 1988 | A |
| 4791932 | Margules | Dec 1988 | A |
| 4793555 | Lee et al. | Dec 1988 | A |
| 4795435 | Steer | Jan 1989 | A |
| 4795542 | Ross et al. | Jan 1989 | A |
| 4803243 | Fujimoto et al. | Feb 1989 | A |
| 4805624 | Yao et al. | Feb 1989 | A |
| 4805625 | Wyler | Feb 1989 | A |
| 4807632 | Liess et al. | Feb 1989 | A |
| 4808089 | Buchholtz et al. | Feb 1989 | A |
| 4808292 | Kessler et al. | Feb 1989 | A |
| 4809704 | Sogawa et al. | Mar 1989 | A |
| 4810243 | Howson | Mar 1989 | A |
| 4810470 | Burkhardt et al. | Mar 1989 | A |
| 4813424 | Wilkins | Mar 1989 | A |
| 4815471 | Stobie | Mar 1989 | A |
| 4820281 | Lawler, Jr. | Apr 1989 | A |
| 4822336 | Ditraglia | Apr 1989 | A |
| 4826706 | Hilker et al. | May 1989 | A |
| 4828544 | Lane et al. | May 1989 | A |
| 4830013 | Maxwell | May 1989 | A |
| 4831070 | McInally et al. | May 1989 | A |
| 4832005 | Takamiya et al. | May 1989 | A |
| 4832034 | Pizziconi et al. | May 1989 | A |
| 4834101 | Collison et al. | May 1989 | A |
| 4838281 | Rogers et al. | Jun 1989 | A |
| 4841974 | Gumbrecht et al. | Jun 1989 | A |
| 4849458 | Reed et al. | Jul 1989 | A |
| 4852573 | Kennedy | Aug 1989 | A |
| 4852604 | Wales et al. | Aug 1989 | A |
| 4854322 | Ash et al. | Aug 1989 | A |
| 4858615 | Meinema | Aug 1989 | A |
| 4861454 | Ushizawa et al. | Aug 1989 | A |
| 4867741 | Portnoy | Sep 1989 | A |
| 4871440 | Nagata et al. | Oct 1989 | A |
| 4874363 | Abell | Oct 1989 | A |
| 4883057 | Broderick | Nov 1989 | A |
| 4883467 | Franetzki et al. | Nov 1989 | A |
| 4886070 | Demarest | Dec 1989 | A |
| 4886562 | Pinson | Dec 1989 | A |
| 4889528 | Nadai et al. | Dec 1989 | A |
| 4889744 | Quaid | Dec 1989 | A |
| 4890620 | Gough | Jan 1990 | A |
| 4890621 | Hakky | Jan 1990 | A |
| 4894339 | Hanazato et al. | Jan 1990 | A |
| 4900305 | Smith et al. | Feb 1990 | A |
| 4902294 | Gosserez | Feb 1990 | A |
| 4907857 | Giuliani et al. | Mar 1990 | A |
| 4909786 | Gijselhart et al. | Mar 1990 | A |
| 4909908 | Ross et al. | Mar 1990 | A |
| 4919114 | Miyazaki | Apr 1990 | A |
| 4919141 | Zier et al. | Apr 1990 | A |
| 4919649 | Timothy et al. | Apr 1990 | A |
| 4921477 | Davis | May 1990 | A |
| 4921480 | Sealfon | May 1990 | A |
| 4925444 | Orkin et al. | May 1990 | A |
| 4927407 | Dorman | May 1990 | A |
| 4927516 | Yamaguchi et al. | May 1990 | A |
| 4928694 | Maxwell | May 1990 | A |
| 4934369 | Maxwell | Jun 1990 | A |
| 4934375 | Cole et al. | Jun 1990 | A |
| 4935345 | Guilbeau et al. | Jun 1990 | A |
| 4940065 | Tanagho et al. | Jul 1990 | A |
| 4944299 | Silvian | Jul 1990 | A |
| 4946439 | Eggers | Aug 1990 | A |
| 4951657 | Pfister et al. | Aug 1990 | A |
| 4951669 | Maxwell et al. | Aug 1990 | A |
| 4952618 | Olsen | Aug 1990 | A |
| 4953552 | DeMarzo | Sep 1990 | A |
| 4955861 | Enegren et al. | Sep 1990 | A |
| 4957483 | Gonser et al. | Sep 1990 | A |
| 4958148 | Olson | Sep 1990 | A |
| 4960594 | Honeycutt | Oct 1990 | A |
| 4961434 | Stypulkowski | Oct 1990 | A |
| 4963595 | Ward et al. | Oct 1990 | A |
| 4966579 | Polaschegg | Oct 1990 | A |
| 4967940 | Blette et al. | Nov 1990 | A |
| 4970145 | Bennetto et al. | Nov 1990 | A |
| 4974592 | Branco | Dec 1990 | A |
| 4974929 | Curry | Dec 1990 | A |
| 4975175 | Karube et al. | Dec 1990 | A |
| 4975636 | Desautels | Dec 1990 | A |
| 4976687 | Martin | Dec 1990 | A |
| 4979509 | Hakky | Dec 1990 | A |
| 4984929 | Rock et al. | Jan 1991 | A |
| 4986271 | Wilkins | Jan 1991 | A |
| 4986671 | Sun et al. | Jan 1991 | A |
| 4988341 | Columbus et al. | Jan 1991 | A |
| 4988758 | Fukuda | Jan 1991 | A |
| 4989607 | Keusch et al. | Feb 1991 | A |
| 4990231 | Stewart et al. | Feb 1991 | A |
| 4992794 | Brouwers | Feb 1991 | A |
| 4994026 | Fecondini | Feb 1991 | A |
| 4994167 | Shults et al. | Feb 1991 | A |
| 4997627 | Bergkuist et al. | Mar 1991 | A |
| 5000194 | Van Den Honert et al. | Mar 1991 | A |
| 5002055 | Merki et al. | Mar 1991 | A |
| 5002572 | Picha | Mar 1991 | A |
| 5002590 | Friesen et al. | Mar 1991 | A |
| 5006050 | Cooke et al. | Apr 1991 | A |
| 5006111 | Inokuchi et al. | Apr 1991 | A |
| 5007929 | Quaid | Apr 1991 | A |
| 5009251 | Pike et al. | Apr 1991 | A |
| 5019096 | Fox, Jr. et al. | May 1991 | A |
| 5026348 | Venegas | Jun 1991 | A |
| 5030199 | Barwick et al. | Jul 1991 | A |
| 5030310 | Wogoman | Jul 1991 | A |
| 5030333 | Clark, Jr. | Jul 1991 | A |
| 5034112 | Murase et al. | Jul 1991 | A |
| 5035711 | Aoki et al. | Jul 1991 | A |
| 5037497 | Stypulkowski | Aug 1991 | A |
| 5041092 | Barwick | Aug 1991 | A |
| 5045057 | Van Driessche et al. | Sep 1991 | A |
| 5045601 | Capelli et al. | Sep 1991 | A |
| 5046496 | Betts et al. | Sep 1991 | A |
| 5048525 | Maxwell | Sep 1991 | A |
| 5050612 | Matsumura | Sep 1991 | A |
| 5055171 | Peck | Oct 1991 | A |
| 5055198 | Shettigar | Oct 1991 | A |
| 5059654 | Hou et al. | Oct 1991 | A |
| 5063081 | Cozzette et al. | Nov 1991 | A |
| 5067491 | Taylor, II et al. | Nov 1991 | A |
| 5068536 | Rosenthal | Nov 1991 | A |
| 5077476 | Rosenthal | Dec 1991 | A |
| 5082550 | Rishpon et al. | Jan 1992 | A |
| 5088981 | Howson et al. | Feb 1992 | A |
| 5089112 | Skotheim et al. | Feb 1992 | A |
| 5089421 | Dieffenbach | Feb 1992 | A |
| 5096669 | Lauks et al. | Mar 1992 | A |
| 5097834 | Skrabal | Mar 1992 | A |
| 5098377 | Borsanyi et al. | Mar 1992 | A |
| 5101814 | Palti | Apr 1992 | A |
| 5108819 | Heller et al. | Apr 1992 | A |
| 5109850 | Blanco et al. | May 1992 | A |
| 5112301 | Fenton, Jr. et al. | May 1992 | A |
| 5116313 | McGregor | May 1992 | A |
| 5120813 | Ward, Jr. | Jun 1992 | A |
| 5127405 | Alcala, Jr. et al. | Jul 1992 | A |
| 5130009 | Marsoner et al. | Jul 1992 | A |
| 5130231 | Kennedy et al. | Jul 1992 | A |
| 5135297 | Valint, Jr. | Aug 1992 | A |
| 5137028 | Nishimura | Aug 1992 | A |
| 5140985 | Schroeder et al. | Aug 1992 | A |
| 5145565 | Kater et al. | Sep 1992 | A |
| 5147725 | Pinchuk | Sep 1992 | A |
| 5152746 | Atkinson et al. | Oct 1992 | A |
| 5160418 | Mullen | Nov 1992 | A |
| 5161532 | Joseph | Nov 1992 | A |
| 5162407 | Turner | Nov 1992 | A |
| 5165406 | Wong | Nov 1992 | A |
| 5165407 | Wilson et al. | Nov 1992 | A |
| 5171689 | Kawaguri et al. | Dec 1992 | A |
| 5174123 | Erickson | Dec 1992 | A |
| 5174291 | Schoonen et al. | Dec 1992 | A |
| 5176632 | Bernardi | Jan 1993 | A |
| 5176658 | Ranford | Jan 1993 | A |
| 5176662 | Bartholomew et al. | Jan 1993 | A |
| 5178142 | Harjunmaa et al. | Jan 1993 | A |
| 5178957 | Kolpe et al. | Jan 1993 | A |
| 5182004 | Kohno | Jan 1993 | A |
| 5183549 | Joseph et al. | Feb 1993 | A |
| 5188591 | Dorsey, III | Feb 1993 | A |
| 5190038 | Polson et al. | Mar 1993 | A |
| 5190041 | Palti | Mar 1993 | A |
| 5195963 | Yafuso et al. | Mar 1993 | A |
| 5198771 | Fidler et al. | Mar 1993 | A |
| 5200051 | Cozzette et al. | Apr 1993 | A |
| 5202261 | Musho et al. | Apr 1993 | A |
| 5207218 | Carpentier et al. | May 1993 | A |
| 5208147 | Kagenow et al. | May 1993 | A |
| 5208313 | Krishnan | May 1993 | A |
| 5212050 | Mier et al. | May 1993 | A |
| 5220917 | Cammilli et al. | Jun 1993 | A |
| 5220920 | Gharib | Jun 1993 | A |
| 5222980 | Gealow | Jun 1993 | A |
| 5224929 | Remiszewski | Jul 1993 | A |
| 5225063 | Gumbrecht et al. | Jul 1993 | A |
| 5232434 | Inagaki et al. | Aug 1993 | A |
| 5235003 | Ward et al. | Aug 1993 | A |
| 5243696 | Carr et al. | Sep 1993 | A |
| 5243982 | Mostl et al. | Sep 1993 | A |
| 5243983 | Tarr et al. | Sep 1993 | A |
| 5249576 | Goldberger et al. | Oct 1993 | A |
| 5250439 | Musho et al. | Oct 1993 | A |
| 5254102 | Ogawa | Oct 1993 | A |
| 5261892 | Bertaud et al. | Nov 1993 | A |
| 5262305 | Heller et al. | Nov 1993 | A |
| 5264104 | Gregg et al. | Nov 1993 | A |
| 5265594 | Olsson et al. | Nov 1993 | A |
| 5265999 | Wenschhof et al. | Nov 1993 | A |
| 5266179 | Nankai et al. | Nov 1993 | A |
| 5269891 | Colin | Dec 1993 | A |
| 5271736 | Picha | Dec 1993 | A |
| 5271815 | Wong | Dec 1993 | A |
| 5279294 | Anderson et al. | Jan 1994 | A |
| 5281319 | Kaneko et al. | Jan 1994 | A |
| 5282844 | Stokes et al. | Feb 1994 | A |
| 5282848 | Schmitt | Feb 1994 | A |
| 5284140 | Allen et al. | Feb 1994 | A |
| 5284570 | Savage et al. | Feb 1994 | A |
| 5285513 | Kaurman et al. | Feb 1994 | A |
| 5286364 | Yacynych et al. | Feb 1994 | A |
| 5287753 | Routh et al. | Feb 1994 | A |
| 5296144 | Sternina et al. | Mar 1994 | A |
| 5298022 | Bernardi | Mar 1994 | A |
| 5298144 | Spokane | Mar 1994 | A |
| 5299571 | Mastrototaro | Apr 1994 | A |
| 5302093 | Owens et al. | Apr 1994 | A |
| 5302440 | Davis | Apr 1994 | A |
| 5304468 | Phillips et al. | Apr 1994 | A |
| 5307263 | Brown | Apr 1994 | A |
| 5310469 | Cunningham et al. | May 1994 | A |
| 5311908 | Barone et al. | May 1994 | A |
| 5312361 | Zadini et al. | May 1994 | A |
| 5314471 | Brauker et al. | May 1994 | A |
| 5316008 | Suga et al. | May 1994 | A |
| 5316452 | Bogen et al. | May 1994 | A |
| 5318511 | Riquier et al. | Jun 1994 | A |
| 5322063 | Allen et al. | Jun 1994 | A |
| 5324322 | Grill, Jr. et al. | Jun 1994 | A |
| 5326356 | Della Valle et al. | Jul 1994 | A |
| 5326449 | Cunningham | Jul 1994 | A |
| 5328451 | Davis et al. | Jul 1994 | A |
| 5330521 | Cohen | Jul 1994 | A |
| 5330634 | Wong et al. | Jul 1994 | A |
| 5331555 | Hashimoto et al. | Jul 1994 | A |
| 5335658 | Bedingham | Aug 1994 | A |
| 5336102 | Cairns et al. | Aug 1994 | A |
| 5337747 | Neftel | Aug 1994 | A |
| 5340352 | Nakanishi et al. | Aug 1994 | A |
| 5342409 | Mullett | Aug 1994 | A |
| 5342789 | Chick et al. | Aug 1994 | A |
| 5343869 | Pross et al. | Sep 1994 | A |
| 5344451 | Dayton | Sep 1994 | A |
| 5344454 | Clarke et al. | Sep 1994 | A |
| 5345932 | Yafuso et al. | Sep 1994 | A |
| 5348788 | White | Sep 1994 | A |
| 5352348 | Young et al. | Oct 1994 | A |
| 5352351 | White et al. | Oct 1994 | A |
| 5354272 | Swendson et al. | Oct 1994 | A |
| 5354449 | Band et al. | Oct 1994 | A |
| 5356375 | Higley | Oct 1994 | A |
| 5356378 | Doan | Oct 1994 | A |
| 5356786 | Heller et al. | Oct 1994 | A |
| 5358409 | Obara | Oct 1994 | A |
| 5362761 | Uragami et al. | Nov 1994 | A |
| 5368028 | Palti | Nov 1994 | A |
| 5368224 | Richardson et al. | Nov 1994 | A |
| 5368562 | Blomquist et al. | Nov 1994 | A |
| 5372133 | Hogen Esch | Dec 1994 | A |
| 5372135 | Mendelson et al. | Dec 1994 | A |
| 5372709 | Hood | Dec 1994 | A |
| 5372719 | Afeyan et al. | Dec 1994 | A |
| 5376070 | Purvis et al. | Dec 1994 | A |
| 5378229 | Layer et al. | Jan 1995 | A |
| 5380268 | Wheeler | Jan 1995 | A |
| 5380422 | Negishi et al. | Jan 1995 | A |
| 5380491 | Carver, Jr. et al. | Jan 1995 | A |
| 5380536 | Hubbell et al. | Jan 1995 | A |
| 5380665 | Cusack et al. | Jan 1995 | A |
| 5382514 | Passaniti et al. | Jan 1995 | A |
| 5384028 | Ito | Jan 1995 | A |
| 5387327 | Khan | Feb 1995 | A |
| 5390671 | Lord et al. | Feb 1995 | A |
| 5391250 | Cheney, II et al. | Feb 1995 | A |
| 5393401 | Knoll | Feb 1995 | A |
| 5397848 | Yang et al. | Mar 1995 | A |
| 5400267 | Denen et al. | Mar 1995 | A |
| 5404877 | Nolan et al. | Apr 1995 | A |
| 5405510 | Betts et al. | Apr 1995 | A |
| 5411052 | Murray | May 1995 | A |
| 5411647 | Johnson et al. | May 1995 | A |
| 5411866 | Luong et al. | May 1995 | A |
| 5417115 | Burns | May 1995 | A |
| 5417206 | Kaneyoshi | May 1995 | A |
| 5417395 | Fowler et al. | May 1995 | A |
| 5421328 | Bedingham | Jun 1995 | A |
| 5421923 | Clarke et al. | Jun 1995 | A |
| 5423738 | Robinson et al. | Jun 1995 | A |
| 5423749 | Merte et al. | Jun 1995 | A |
| 5425717 | Mohiuddin | Jun 1995 | A |
| 5426032 | Phillips et al. | Jun 1995 | A |
| 5428123 | Ward et al. | Jun 1995 | A |
| 5429129 | Lovejoy et al. | Jul 1995 | A |
| 5429485 | Dodge | Jul 1995 | A |
| 5429602 | Hauser | Jul 1995 | A |
| 5429735 | Johnson et al. | Jul 1995 | A |
| 5431160 | Wilkins | Jul 1995 | A |
| 5431174 | Knute | Jul 1995 | A |
| 5431921 | Thombre | Jul 1995 | A |
| 5434412 | Sodickson et al. | Jul 1995 | A |
| 5437635 | Fields et al. | Aug 1995 | A |
| 5437999 | Diebold et al. | Aug 1995 | A |
| 5438984 | Schoendorfer | Aug 1995 | A |
| 5445610 | Evert | Aug 1995 | A |
| 5448992 | Kupershmidt | Sep 1995 | A |
| 5451260 | Versteeg et al. | Sep 1995 | A |
| 5453199 | Afeyan et al. | Sep 1995 | A |
| 5453278 | Chan et al. | Sep 1995 | A |
| 5458631 | Xavier | Oct 1995 | A |
| 5462051 | Oka et al. | Oct 1995 | A |
| 5462064 | D'Angelo et al. | Oct 1995 | A |
| 5462645 | Albery et al. | Oct 1995 | A |
| 5466356 | Schneider et al. | Nov 1995 | A |
| 5466575 | Cozzette et al. | Nov 1995 | A |
| 5469846 | Khan | Nov 1995 | A |
| 5474552 | Palti | Dec 1995 | A |
| 5476094 | Allen et al. | Dec 1995 | A |
| 5476776 | Wilkins | Dec 1995 | A |
| 5480711 | Ruefer | Jan 1996 | A |
| 5482008 | Stafford et al. | Jan 1996 | A |
| 5482446 | Williamson et al. | Jan 1996 | A |
| 5482473 | Lord et al. | Jan 1996 | A |
| 5484404 | Schulman et al. | Jan 1996 | A |
| 5486776 | Chiang | Jan 1996 | A |
| 5490323 | Thacker et al. | Feb 1996 | A |
| 5491474 | Suni et al. | Feb 1996 | A |
| 5494562 | Maley et al. | Feb 1996 | A |
| 5496453 | Uenoyama et al. | Mar 1996 | A |
| 5497772 | Schulman et al. | Mar 1996 | A |
| 5502396 | Desarzens et al. | Mar 1996 | A |
| 5505828 | Wong et al. | Apr 1996 | A |
| 5507288 | Bocker et al. | Apr 1996 | A |
| 5508203 | Fuller et al. | Apr 1996 | A |
| 5508509 | Yafuso et al. | Apr 1996 | A |
| 5509888 | Miller | Apr 1996 | A |
| 5512046 | Pusinelli et al. | Apr 1996 | A |
| 5512248 | Van | Apr 1996 | A |
| 5513636 | Palti | May 1996 | A |
| 5514253 | Davis et al. | May 1996 | A |
| 5515851 | Goldstein | May 1996 | A |
| 5516832 | Kennan et al. | May 1996 | A |
| 5518601 | Foos et al. | May 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5529066 | Palti | Jun 1996 | A |
| 5529676 | Maley et al. | Jun 1996 | A |
| 5531679 | Schulman et al. | Jul 1996 | A |
| 5531878 | Vadgama et al. | Jul 1996 | A |
| 5540828 | Yacynych | Jul 1996 | A |
| 5545200 | West et al. | Aug 1996 | A |
| 5545220 | Andrews et al. | Aug 1996 | A |
| 5545223 | Neuenfeldt et al. | Aug 1996 | A |
| 5549547 | Cohen et al. | Aug 1996 | A |
| 5549548 | Larsson | Aug 1996 | A |
| 5549569 | Lynn et al. | Aug 1996 | A |
| 5549651 | Lynn | Aug 1996 | A |
| 5549675 | Neuenfeldt et al. | Aug 1996 | A |
| 5551850 | Williamson et al. | Sep 1996 | A |
| 5552112 | Schiffmann et al. | Sep 1996 | A |
| 5553616 | Ham et al. | Sep 1996 | A |
| 5554339 | Cozzette et al. | Sep 1996 | A |
| 5558957 | Datta et al. | Sep 1996 | A |
| 5562614 | O'Donnell | Oct 1996 | A |
| 5562615 | Nassif | Oct 1996 | A |
| 5564439 | Picha | Oct 1996 | A |
| 5568806 | Cheney, II et al. | Oct 1996 | A |
| 5569186 | Lord et al. | Oct 1996 | A |
| 5569188 | MacKool | Oct 1996 | A |
| 5569219 | Hakki et al. | Oct 1996 | A |
| 5569462 | Martinson et al. | Oct 1996 | A |
| 5571395 | Park et al. | Nov 1996 | A |
| 5575293 | Miller et al. | Nov 1996 | A |
| 5575930 | Tietje-Girault et al. | Nov 1996 | A |
| 5577499 | Teves | Nov 1996 | A |
| 5582184 | Erickson et al. | Dec 1996 | A |
| 5582497 | Noguchi | Dec 1996 | A |
| 5582593 | Hultman | Dec 1996 | A |
| 5582697 | Ikeda et al. | Dec 1996 | A |
| 5584813 | Livingston et al. | Dec 1996 | A |
| 5584876 | Bruchman et al. | Dec 1996 | A |
| 5586553 | Halili et al. | Dec 1996 | A |
| 5587273 | Yan et al. | Dec 1996 | A |
| 5588560 | Benedict et al. | Dec 1996 | A |
| 5589133 | Suzuki | Dec 1996 | A |
| 5589563 | Ward et al. | Dec 1996 | A |
| 5590651 | Shaffer et al. | Jan 1997 | A |
| 5593440 | Brauker et al. | Jan 1997 | A |
| 5593852 | Heller et al. | Jan 1997 | A |
| 5607565 | Azarnia et al. | Mar 1997 | A |
| 5609572 | Lang | Mar 1997 | A |
| 5611900 | Vorden | Mar 1997 | A |
| 5624409 | Seale | Apr 1997 | A |
| 5624537 | Turner et al. | Apr 1997 | A |
| 5626561 | Butler et al. | May 1997 | A |
| 5626563 | Dodge et al. | May 1997 | A |
| 5628619 | Wilson | May 1997 | A |
| 5628890 | Carter et al. | May 1997 | A |
| 5630978 | Domb | May 1997 | A |
| 5637083 | Bertrand et al. | Jun 1997 | A |
| 5637135 | Ottenstein et al. | Jun 1997 | A |
| 5640470 | Iyer et al. | Jun 1997 | A |
| 5640954 | Pfeiffer et al. | Jun 1997 | A |
| 5643195 | Drevet et al. | Jul 1997 | A |
| 5651767 | Schulman et al. | Jul 1997 | A |
| 5653756 | Clarke et al. | Aug 1997 | A |
| 5653863 | Genshaw et al. | Aug 1997 | A |
| 5658247 | Henley | Aug 1997 | A |
| 5658250 | Blomquist et al. | Aug 1997 | A |
| 5658330 | Carlisle et al. | Aug 1997 | A |
| 5658802 | Hayes et al. | Aug 1997 | A |
| 5660163 | Schulman et al. | Aug 1997 | A |
| 5660177 | Faupel et al. | Aug 1997 | A |
| 5662616 | Bousguet | Sep 1997 | A |
| 5665061 | Antwiler | Sep 1997 | A |
| 5665065 | Colman et al. | Sep 1997 | A |
| 5665215 | Bussmann et al. | Sep 1997 | A |
| 5667504 | Baumann et al. | Sep 1997 | A |
| 5673694 | Rivers | Oct 1997 | A |
| 5676651 | Larson, Jr. et al. | Oct 1997 | A |
| 5676820 | Wang et al. | Oct 1997 | A |
| 5681572 | Seare, Jr. | Oct 1997 | A |
| 5682884 | Hill et al. | Nov 1997 | A |
| 5683562 | Schaffar et al. | Nov 1997 | A |
| 5686829 | Girault | Nov 1997 | A |
| 5688239 | Walker | Nov 1997 | A |
| 5688244 | Lang | Nov 1997 | A |
| 5690119 | Rytky et al. | Nov 1997 | A |
| 5695623 | Michel et al. | Dec 1997 | A |
| 5696314 | McCaffrey et al. | Dec 1997 | A |
| 5697366 | Kimball et al. | Dec 1997 | A |
| 5697899 | Hillman et al. | Dec 1997 | A |
| 5697976 | Chesterfield et al. | Dec 1997 | A |
| 5703359 | Wampler, III | Dec 1997 | A |
| 5704354 | Preidel et al. | Jan 1998 | A |
| 5706807 | Picha | Jan 1998 | A |
| 5707502 | McCaffrey et al. | Jan 1998 | A |
| 5711302 | Lampropoulos et al. | Jan 1998 | A |
| 5711685 | Wood | Jan 1998 | A |
| 5711861 | Ward et al. | Jan 1998 | A |
| 5713842 | Kay | Feb 1998 | A |
| 5713888 | Neuenfeldt et al. | Feb 1998 | A |
| 5714123 | Sohrab | Feb 1998 | A |
| 5714391 | Omura et al. | Feb 1998 | A |
| 5720293 | Quinn et al. | Feb 1998 | A |
| 5730654 | Brown | Mar 1998 | A |
| 5733336 | Neuenfeldt et al. | Mar 1998 | A |
| 5735273 | Kurnik et al. | Apr 1998 | A |
| 5741319 | Woloszko et al. | Apr 1998 | A |
| 5741330 | Brauker et al. | Apr 1998 | A |
| 5741634 | Nozoe et al. | Apr 1998 | A |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5746898 | Preidel | May 1998 | A |
| 5749832 | Vadgama et al. | May 1998 | A |
| 5749907 | Mann | May 1998 | A |
| 5755692 | Manicom | May 1998 | A |
| 5756632 | Ward et al. | May 1998 | A |
| 5758643 | Wong et al. | Jun 1998 | A |
| 5763760 | Gumbrecht et al. | Jun 1998 | A |
| 5763787 | Gravel et al. | Jun 1998 | A |
| 5766151 | Valley et al. | Jun 1998 | A |
| 5770028 | Maley et al. | Jun 1998 | A |
| 5771890 | Tamada | Jun 1998 | A |
| 5773270 | D'Orazio et al. | Jun 1998 | A |
| 5773286 | Dionne et al. | Jun 1998 | A |
| 5776324 | Usala | Jul 1998 | A |
| 5777060 | Van Antwerp | Jul 1998 | A |
| 5779665 | Mastrototaro et al. | Jul 1998 | A |
| 5781455 | Hyodo | Jul 1998 | A |
| 5782880 | Lahtinen et al. | Jul 1998 | A |
| 5782912 | Brauker et al. | Jul 1998 | A |
| 5783054 | Raguse et al. | Jul 1998 | A |
| 5786439 | Van Antwerp et al. | Jul 1998 | A |
| 5787900 | Butler et al. | Aug 1998 | A |
| 5791344 | Schulman et al. | Aug 1998 | A |
| 5791880 | Wilson | Aug 1998 | A |
| 5795453 | Gilmartin | Aug 1998 | A |
| 5795774 | Matsumoto et al. | Aug 1998 | A |
| 5798065 | Picha | Aug 1998 | A |
| 5798085 | Seaton et al. | Aug 1998 | A |
| 5800383 | Chandler et al. | Sep 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5800529 | Brauker et al. | Sep 1998 | A |
| 5804048 | Wong et al. | Sep 1998 | A |
| 5806517 | Gerhardt et al. | Sep 1998 | A |
| 5807274 | Henning et al. | Sep 1998 | A |
| 5807312 | Dzwonkiewicz | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5807406 | Brauker et al. | Sep 1998 | A |
| 5810736 | Pail | Sep 1998 | A |
| 5810770 | Chin et al. | Sep 1998 | A |
| 5811487 | Schulz, Jr. et al. | Sep 1998 | A |
| 5814599 | Mitragotri et al. | Sep 1998 | A |
| 5820570 | Erickson et al. | Oct 1998 | A |
| 5820589 | Torgerson et al. | Oct 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5822715 | Worthington et al. | Oct 1998 | A |
| 5823802 | Bartley | Oct 1998 | A |
| 5824651 | Nanci et al. | Oct 1998 | A |
| 5827183 | Kurnik et al. | Oct 1998 | A |
| 5833603 | Kovacs et al. | Nov 1998 | A |
| 5836886 | Itoigawa et al. | Nov 1998 | A |
| 5836887 | Oka et al. | Nov 1998 | A |
| 5836989 | Shelton | Nov 1998 | A |
| 5837454 | Cozzette et al. | Nov 1998 | A |
| 5837728 | Purcell | Nov 1998 | A |
| 5840026 | Uber, III et al. | Nov 1998 | A |
| 5840148 | Campbell et al. | Nov 1998 | A |
| 5840240 | Stenoien et al. | Nov 1998 | A |
| 5843069 | Butler et al. | Dec 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5857983 | Douglas et al. | Jan 1999 | A |
| 5858296 | Domb | Jan 1999 | A |
| 5858365 | Faller | Jan 1999 | A |
| 5858747 | Schinstine et al. | Jan 1999 | A |
| 5861019 | Sun et al. | Jan 1999 | A |
| 5863400 | Drummond et al. | Jan 1999 | A |
| 5863460 | Slovacek et al. | Jan 1999 | A |
| 5871499 | Hahn et al. | Feb 1999 | A |
| 5871514 | Wiklund et al. | Feb 1999 | A |
| 5872198 | Mosbach et al. | Feb 1999 | A |
| 5872499 | Poulsen | Feb 1999 | A |
| 5873862 | Lopez | Feb 1999 | A |
| 5874500 | Rhee et al. | Feb 1999 | A |
| 5879373 | Roper et al. | Mar 1999 | A |
| 5879713 | Roth et al. | Mar 1999 | A |
| 5879828 | Debe et al. | Mar 1999 | A |
| 5882354 | Brauker et al. | Mar 1999 | A |
| 5882494 | Van Antwerp | Mar 1999 | A |
| 5895235 | Droz | Apr 1999 | A |
| 5897525 | Dey et al. | Apr 1999 | A |
| 5897578 | Wiklund et al. | Apr 1999 | A |
| 5897955 | Drumheller | Apr 1999 | A |
| 5899855 | Brown | May 1999 | A |
| 5904666 | Dedecker et al. | May 1999 | A |
| 5904708 | Goedeke | May 1999 | A |
| 5910554 | Kempe et al. | Jun 1999 | A |
| 5911219 | Aylsworth et al. | Jun 1999 | A |
| 5913998 | Butler et al. | Jun 1999 | A |
| 5914026 | Blubaugh, Jr. et al. | Jun 1999 | A |
| 5914182 | Drumheller | Jun 1999 | A |
| 5916445 | Hjerten et al. | Jun 1999 | A |
| 5917346 | Gord | Jun 1999 | A |
| 5919215 | Wiklund et al. | Jul 1999 | A |
| 5921951 | Morris | Jul 1999 | A |
| 5928130 | Schmidt | Jul 1999 | A |
| 5928155 | Eggers et al. | Jul 1999 | A |
| 5928182 | Kraus et al. | Jul 1999 | A |
| 5928189 | Phillips et al. | Jul 1999 | A |
| 5928195 | Malamud et al. | Jul 1999 | A |
| 5931814 | Alex et al. | Aug 1999 | A |
| 5932175 | Knute et al. | Aug 1999 | A |
| 5933136 | Brown | Aug 1999 | A |
| 5935785 | Reber et al. | Aug 1999 | A |
| 5938636 | Kramer et al. | Aug 1999 | A |
| 5938679 | Freeman et al. | Aug 1999 | A |
| 5944661 | Swette et al. | Aug 1999 | A |
| 5945498 | Hoepken et al. | Aug 1999 | A |
| 5947911 | Wong et al. | Sep 1999 | A |
| 5951521 | Mastrototaro et al. | Sep 1999 | A |
| 5954643 | Van Antwerp et al. | Sep 1999 | A |
| 5954685 | Tierney | Sep 1999 | A |
| 5954954 | Houck et al. | Sep 1999 | A |
| 5957854 | Besson et al. | Sep 1999 | A |
| 5957903 | Mirzaee et al. | Sep 1999 | A |
| 5959050 | Mosbach et al. | Sep 1999 | A |
| 5961451 | Reber et al. | Oct 1999 | A |
| 5963132 | Yoakum | Oct 1999 | A |
| 5964261 | Neuenfeldt et al. | Oct 1999 | A |
| 5964745 | Lyles et al. | Oct 1999 | A |
| 5964804 | Brauker et al. | Oct 1999 | A |
| 5964993 | Blubaugh et al. | Oct 1999 | A |
| 5965125 | Mineau-Hanschke | Oct 1999 | A |
| 5965380 | Heller et al. | Oct 1999 | A |
| 5967986 | Cimochowski et al. | Oct 1999 | A |
| 5971922 | Arita et al. | Oct 1999 | A |
| 5972199 | Heller et al. | Oct 1999 | A |
| 5976085 | Kimball et al. | Nov 1999 | A |
| 5977241 | Koloski et al. | Nov 1999 | A |
| 5985129 | Gough et al. | Nov 1999 | A |
| 5985693 | Leedy | Nov 1999 | A |
| 5987352 | Klein et al. | Nov 1999 | A |
| 5989409 | Kurnik et al. | Nov 1999 | A |
| 5995208 | Sarge et al. | Nov 1999 | A |
| 5995860 | Sun et al. | Nov 1999 | A |
| 5997501 | Gross et al. | Dec 1999 | A |
| 5998247 | Wu | Dec 1999 | A |
| 5999848 | Gord et al. | Dec 1999 | A |
| 5999849 | Gord et al. | Dec 1999 | A |
| 6001067 | Shults et al. | Dec 1999 | A |
| 6001471 | Bries et al. | Dec 1999 | A |
| 6007845 | Domb et al. | Dec 1999 | A |
| 6011984 | Van Antwerp et al. | Jan 2000 | A |
| 6013113 | Mika | Jan 2000 | A |
| 6014577 | Henning et al. | Jan 2000 | A |
| 6015392 | Douglas et al. | Jan 2000 | A |
| 6015572 | Lin et al. | Jan 2000 | A |
| 6016448 | Busacker et al. | Jan 2000 | A |
| 6017435 | Hassard et al. | Jan 2000 | A |
| 6018033 | Chen et al. | Jan 2000 | A |
| 6023629 | Tamada | Feb 2000 | A |
| 6024720 | Chandler et al. | Feb 2000 | A |
| 6027445 | Von Bahr | Feb 2000 | A |
| 6027479 | Alei et al. | Feb 2000 | A |
| 6032059 | Henning et al. | Feb 2000 | A |
| 6032667 | Heinonen | Mar 2000 | A |
| 6036924 | Simons et al. | Mar 2000 | A |
| 6043328 | Domschke et al. | Mar 2000 | A |
| 6045671 | Wu et al. | Apr 2000 | A |
| 6048691 | Maracas | Apr 2000 | A |
| 6049727 | Crothall | Apr 2000 | A |
| 6051372 | Bayerl et al. | Apr 2000 | A |
| 6051389 | Ahi et al. | Apr 2000 | A |
| 6057377 | Sasaki et al. | May 2000 | A |
| 6059946 | Yukawa et al. | May 2000 | A |
| 6060640 | Pauley et al. | May 2000 | A |
| 6063637 | Arnold et al. | May 2000 | A |
| 6065154 | Hulings et al. | May 2000 | A |
| 6066083 | Slater et al. | May 2000 | A |
| 6066088 | Davis | May 2000 | A |
| 6066448 | Wohlstadter et al. | May 2000 | A |
| 6068668 | Mastroianni | May 2000 | A |
| 6071391 | Gotoh et al. | Jun 2000 | A |
| 6071406 | Tsou | Jun 2000 | A |
| 6074775 | Gartstein et al. | Jun 2000 | A |
| 6077299 | Adelberg et al. | Jun 2000 | A |
| 6080583 | Von Bahr | Jun 2000 | A |
| 6081735 | Diab et al. | Jun 2000 | A |
| 6081736 | Colvin et al. | Jun 2000 | A |
| 6083523 | Dionne et al. | Jul 2000 | A |
| 6083710 | Heller et al. | Jul 2000 | A |
| 6088608 | Schulman et al. | Jul 2000 | A |
| 6090087 | Tsukada et al. | Jul 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6093156 | Cunningham et al. | Jul 2000 | A |
| 6093172 | Funderburk et al. | Jul 2000 | A |
| 6099511 | Devos et al. | Aug 2000 | A |
| 6101404 | Yoon et al. | Aug 2000 | A |
| 6103033 | Say et al. | Aug 2000 | A |
| 6103533 | Hassard et al. | Aug 2000 | A |
| 6106486 | Tenerz et al. | Aug 2000 | A |
| 6107083 | Collins et al. | Aug 2000 | A |
| 6115622 | Minoz | Sep 2000 | A |
| 6115634 | Donders et al. | Sep 2000 | A |
| 6117290 | Say et al. | Sep 2000 | A |
| 6119028 | Schulman et al. | Sep 2000 | A |
| 6120676 | Heller et al. | Sep 2000 | A |
| 6121009 | Heller et al. | Sep 2000 | A |
| 6122536 | Sun et al. | Sep 2000 | A |
| 6123827 | Wong et al. | Sep 2000 | A |
| 6127154 | Mosbach et al. | Oct 2000 | A |
| 6128519 | Say | Oct 2000 | A |
| 6134461 | Say et al. | Oct 2000 | A |
| 6135978 | Houben et al. | Oct 2000 | A |
| 6139718 | Kurnik et al. | Oct 2000 | A |
| 6141573 | Kurnik et al. | Oct 2000 | A |
| 6142939 | Eppstein et al. | Nov 2000 | A |
| 6144869 | Berner et al. | Nov 2000 | A |
| 6144871 | Saito et al. | Nov 2000 | A |
| RE36991 | Yamamoto et al. | Dec 2000 | E |
| 6156051 | Schraga | Dec 2000 | A |
| 6157860 | Hauser et al. | Dec 2000 | A |
| 6159186 | Wickham et al. | Dec 2000 | A |
| 6159497 | LaPrade | Dec 2000 | A |
| 6162201 | Cohen et al. | Dec 2000 | A |
| 6162611 | Heller et al. | Dec 2000 | A |
| 6164921 | Moubayed et al. | Dec 2000 | A |
| 6165154 | Gray et al. | Dec 2000 | A |
| 6165156 | Cesarczyk | Dec 2000 | A |
| 6167614 | Tuttle et al. | Jan 2001 | B1 |
| 6168568 | Gavriely | Jan 2001 | B1 |
| 6169155 | Alvarez et al. | Jan 2001 | B1 |
| 6171276 | Lippe et al. | Jan 2001 | B1 |
| 6175752 | Say et al. | Jan 2001 | B1 |
| 6175767 | Doyle, Sr. | Jan 2001 | B1 |
| 6180221 | Crotzer et al. | Jan 2001 | B1 |
| 6180416 | Kurnik et al. | Jan 2001 | B1 |
| 6183437 | Walker | Feb 2001 | B1 |
| 6187062 | Oweis et al. | Feb 2001 | B1 |
| 6189536 | Martinez et al. | Feb 2001 | B1 |
| 6191860 | Klinger et al. | Feb 2001 | B1 |
| 6192891 | Gravel et al. | Feb 2001 | B1 |
| 6198969 | Kuzma | Mar 2001 | B1 |
| 6200772 | Vadgama et al. | Mar 2001 | B1 |
| 6201979 | Kurnik et al. | Mar 2001 | B1 |
| 6201980 | Darrow et al. | Mar 2001 | B1 |
| 6201993 | Kruse et al. | Mar 2001 | B1 |
| 6206856 | Mahurkar | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6212416 | Ward et al. | Apr 2001 | B1 |
| 6212424 | Robinson | Apr 2001 | B1 |
| 6213739 | Phallen et al. | Apr 2001 | B1 |
| 6214185 | Offenbacher et al. | Apr 2001 | B1 |
| 6214901 | Chudzik et al. | Apr 2001 | B1 |
| 6219574 | Cormier et al. | Apr 2001 | B1 |
| 6223080 | Thompson | Apr 2001 | B1 |
| 6223083 | Rosar | Apr 2001 | B1 |
| 6230059 | Duffin | May 2001 | B1 |
| 6231879 | Li et al. | May 2001 | B1 |
| 6232783 | Merrill | May 2001 | B1 |
| 6233080 | Brenner et al. | May 2001 | B1 |
| 6233471 | Berner et al. | May 2001 | B1 |
| 6241663 | Wu et al. | Jun 2001 | B1 |
| 6241863 | Monbouquette | Jun 2001 | B1 |
| 6248067 | Causey, III et al. | Jun 2001 | B1 |
| 6248077 | Elson et al. | Jun 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6251280 | Dai et al. | Jun 2001 | B1 |
| 6254586 | Mann et al. | Jul 2001 | B1 |
| 6255592 | Pennington et al. | Jul 2001 | B1 |
| 6256522 | Schultz | Jul 2001 | B1 |
| 6259937 | Schulman et al. | Jul 2001 | B1 |
| 6263222 | Diab et al. | Jul 2001 | B1 |
| 6264825 | Blackburn et al. | Jul 2001 | B1 |
| 6266551 | Osadchy et al. | Jul 2001 | B1 |
| 6268161 | Han et al. | Jul 2001 | B1 |
| 6270478 | Mernoee | Aug 2001 | B1 |
| 6271332 | Lohmann et al. | Aug 2001 | B1 |
| 6272364 | Kurnik | Aug 2001 | B1 |
| 6272382 | Faltys et al. | Aug 2001 | B1 |
| 6272480 | Tresp et al. | Aug 2001 | B1 |
| 6274285 | Gries et al. | Aug 2001 | B1 |
| 6274686 | Mosbach et al. | Aug 2001 | B1 |
| 6275717 | Gross et al. | Aug 2001 | B1 |
| 6280408 | Sipin | Aug 2001 | B1 |
| 6284126 | Kurnik et al. | Sep 2001 | B1 |
| 6284478 | Heller et al. | Sep 2001 | B1 |
| 6285897 | Kilcoyne et al. | Sep 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6294281 | Heller | Sep 2001 | B1 |
| 6295506 | Heinonen et al. | Sep 2001 | B1 |
| 6296615 | Brockway et al. | Oct 2001 | B1 |
| 6298254 | Tamada | Oct 2001 | B2 |
| 6298255 | Cordero et al. | Oct 2001 | B1 |
| 6299578 | Kurnik et al. | Oct 2001 | B1 |
| 6299583 | Eggers et al. | Oct 2001 | B1 |
| 6300002 | Webb et al. | Oct 2001 | B1 |
| 6300884 | Wilson | Oct 2001 | B1 |
| 6302855 | Lav et al. | Oct 2001 | B1 |
| 6306424 | Vyakarnam et al. | Oct 2001 | B1 |
| 6306594 | Cozzette et al. | Oct 2001 | B1 |
| 6308089 | Von Der Ruhr et al. | Oct 2001 | B1 |
| 6309351 | Kurnik et al. | Oct 2001 | B1 |
| 6309384 | Harrington et al. | Oct 2001 | B1 |
| 6309526 | Fujiwara et al. | Oct 2001 | B1 |
| 6309884 | Cooper et al. | Oct 2001 | B1 |
| 6310110 | Markowitz et al. | Oct 2001 | B1 |
| 6315738 | Nishikawa et al. | Nov 2001 | B1 |
| 6319566 | Polanyi et al. | Nov 2001 | B1 |
| 6325978 | Labuda et al. | Dec 2001 | B1 |
| 6325979 | Hahn et al. | Dec 2001 | B1 |
| 6326160 | Dunn et al. | Dec 2001 | B1 |
| 6329161 | Heller et al. | Dec 2001 | B1 |
| 6329488 | Terry et al. | Dec 2001 | B1 |
| 6329929 | Weijand et al. | Dec 2001 | B1 |
| 6330464 | Colvin, Jr. et al. | Dec 2001 | B1 |
| 6336269 | Eldridge et al. | Jan 2002 | B1 |
| 6341232 | Conn et al. | Jan 2002 | B1 |
| 6343225 | Clark, Jr. | Jan 2002 | B1 |
| 6344021 | Juster | Feb 2002 | B1 |
| 6346114 | Schraga | Feb 2002 | B1 |
| 6355000 | Ogura | Mar 2002 | B1 |
| 6356776 | Berner et al. | Mar 2002 | B1 |
| 6358225 | Butterfield | Mar 2002 | B1 |
| 6360888 | McIvor et al. | Mar 2002 | B1 |
| 6365670 | Ry | Apr 2002 | B1 |
| 6366794 | Moussy et al. | Apr 2002 | B1 |
| 6368141 | Van Antwerp et al. | Apr 2002 | B1 |
| 6368274 | Van Antwerp et al. | Apr 2002 | B1 |
| 6368658 | Schwarz et al. | Apr 2002 | B1 |
| 6370410 | Kurnik et al. | Apr 2002 | B2 |
| 6370941 | Nakamura et al. | Apr 2002 | B2 |
| 6371963 | Nishtala et al. | Apr 2002 | B1 |
| 6372244 | Antanavich et al. | Apr 2002 | B1 |
| 6379201 | Biggs et al. | Apr 2002 | B1 |
| 6379301 | Worthington et al. | Apr 2002 | B1 |
| 6379317 | Kintzig et al. | Apr 2002 | B1 |
| 6379883 | Davis et al. | Apr 2002 | B2 |
| 6387709 | Mason et al. | May 2002 | B1 |
| 6391019 | Ito | May 2002 | B1 |
| 6393318 | Conn et al. | May 2002 | B1 |
| 6398562 | Butler et al. | Jun 2002 | B1 |
| 6400974 | Lesho | Jun 2002 | B1 |
| 6402703 | Kensey et al. | Jun 2002 | B1 |
| 6403944 | MacKenzie et al. | Jun 2002 | B1 |
| 6405066 | Essenpreis et al. | Jun 2002 | B1 |
| 6406066 | Uegane | Jun 2002 | B1 |
| 6406426 | Reuss et al. | Jun 2002 | B1 |
| 6407195 | Sherman et al. | Jun 2002 | B2 |
| 6409674 | Brockway et al. | Jun 2002 | B1 |
| 6413393 | Van Antwerp et al. | Jul 2002 | B1 |
| 6416651 | Millar | Jul 2002 | B1 |
| 6418332 | Mastrototaro et al. | Jul 2002 | B1 |
| 6424847 | Mastrototaro et al. | Jul 2002 | B1 |
| 6427088 | Bowman, IV et al. | Jul 2002 | B1 |
| 6430437 | Marro | Aug 2002 | B1 |
| 6432050 | Porat et al. | Aug 2002 | B1 |
| 6438414 | Conn et al. | Aug 2002 | B1 |
| 6442413 | Silver | Aug 2002 | B1 |
| 6447448 | Ishikawa et al. | Sep 2002 | B1 |
| 6447542 | Weadock | Sep 2002 | B1 |
| 6454710 | Ballerstadt et al. | Sep 2002 | B1 |
| 6459917 | Gowda et al. | Oct 2002 | B1 |
| 6461496 | Feldman et al. | Oct 2002 | B1 |
| 6464849 | Say et al. | Oct 2002 | B1 |
| 6465066 | Rule et al. | Oct 2002 | B1 |
| 6466810 | Ward et al. | Oct 2002 | B1 |
| 6467480 | Meier et al. | Oct 2002 | B1 |
| 6468287 | Baugh | Oct 2002 | B1 |
| 6471689 | Joseph et al. | Oct 2002 | B1 |
| 6471993 | Shastri et al. | Oct 2002 | B1 |
| 6474360 | Ito | Nov 2002 | B1 |
| 6475372 | Ohara et al. | Nov 2002 | B1 |
| 6475750 | Han et al. | Nov 2002 | B1 |
| 6477392 | Honigs et al. | Nov 2002 | B1 |
| 6481440 | Gielen et al. | Nov 2002 | B2 |
| 6484045 | Holker et al. | Nov 2002 | B1 |
| 6484046 | Say et al. | Nov 2002 | B1 |
| 6484132 | Hively et al. | Nov 2002 | B1 |
| 6485449 | Ito | Nov 2002 | B2 |
| 6487429 | Hockersmith et al. | Nov 2002 | B2 |
| 6488652 | Weijand et al. | Dec 2002 | B1 |
| 6494830 | Wessel | Dec 2002 | B1 |
| 6494879 | Lennox et al. | Dec 2002 | B2 |
| 6497729 | Moussy et al. | Dec 2002 | B1 |
| 6498043 | Schulman et al. | Dec 2002 | B1 |
| 6498941 | Jackson | Dec 2002 | B1 |
| 6510239 | Wieres et al. | Jan 2003 | B1 |
| 6510329 | Heckel | Jan 2003 | B2 |
| 6512939 | Colvin, Jr. et al. | Jan 2003 | B1 |
| 6514718 | Heller et al. | Feb 2003 | B2 |
| 6517508 | Utterberg et al. | Feb 2003 | B1 |
| 6520326 | McIvor et al. | Feb 2003 | B2 |
| 6520477 | Trimmer | Feb 2003 | B2 |
| 6520937 | Hart et al. | Feb 2003 | B2 |
| 6520938 | Funderburk et al. | Feb 2003 | B1 |
| 6520997 | Pekkarinen et al. | Feb 2003 | B1 |
| 6522903 | Berman et al. | Feb 2003 | B1 |
| 6524861 | Anderson | Feb 2003 | B1 |
| 6526298 | Khalil et al. | Feb 2003 | B1 |
| 6527729 | Turcott | Mar 2003 | B1 |
| 6528584 | Kennedy et al. | Mar 2003 | B2 |
| 6529755 | Kurnik et al. | Mar 2003 | B2 |
| 6534711 | Pollack | Mar 2003 | B1 |
| 6536433 | Cewers | Mar 2003 | B1 |
| 6537318 | Ita et al. | Mar 2003 | B1 |
| 6541107 | Zhong et al. | Apr 2003 | B1 |
| 6541266 | Modzelewski et al. | Apr 2003 | B2 |
| 6542765 | Guy et al. | Apr 2003 | B1 |
| 6544212 | Galley et al. | Apr 2003 | B2 |
| 6545085 | Kilgour et al. | Apr 2003 | B2 |
| 6546268 | Ishikawa et al. | Apr 2003 | B1 |
| 6546269 | Kurnik | Apr 2003 | B1 |
| 6547839 | Zhang et al. | Apr 2003 | B2 |
| 6551494 | Heller et al. | Apr 2003 | B1 |
| 6551496 | Moles et al. | Apr 2003 | B1 |
| 6553241 | Mannheimer et al. | Apr 2003 | B2 |
| 6553244 | Lesho et al. | Apr 2003 | B2 |
| 6554805 | Hiejima | Apr 2003 | B2 |
| 6554822 | Holschneider et al. | Apr 2003 | B1 |
| 6558320 | Causey, III et al. | May 2003 | B1 |
| 6558321 | Burd et al. | May 2003 | B1 |
| 6558347 | Jhuboo et al. | May 2003 | B1 |
| 6558351 | Steil et al. | May 2003 | B1 |
| 6560471 | Heller et al. | May 2003 | B1 |
| 6561978 | Conn et al. | May 2003 | B1 |
| 6565509 | Say et al. | May 2003 | B1 |
| 6565535 | Zaias et al. | May 2003 | B2 |
| 6565807 | Patterson et al. | May 2003 | B1 |
| 6569309 | Otsuka et al. | May 2003 | B2 |
| 6569521 | Sheridan et al. | May 2003 | B1 |
| 6572545 | Knobbe et al. | Jun 2003 | B2 |
| 6572579 | Raghavan et al. | Jun 2003 | B1 |
| 6572745 | Rappin et al. | Jun 2003 | B2 |
| 6574490 | Abbink et al. | Jun 2003 | B2 |
| 6579257 | Elgas et al. | Jun 2003 | B1 |
| 6579498 | Eglise | Jun 2003 | B1 |
| 6579690 | Bonnecaze et al. | Jun 2003 | B1 |
| 6584335 | Haar et al. | Jun 2003 | B1 |
| 6585644 | Lebel et al. | Jul 2003 | B2 |
| 6585675 | O'Mahony et al. | Jul 2003 | B1 |
| 6585763 | Keilman et al. | Jul 2003 | B1 |
| 6587704 | Fine et al. | Jul 2003 | B1 |
| 6587705 | Kim et al. | Jul 2003 | B1 |
| 6589229 | Connelly et al. | Jul 2003 | B1 |
| 6591123 | Fein et al. | Jul 2003 | B2 |
| 6591125 | Buse et al. | Jul 2003 | B1 |
| 6592745 | Feldman et al. | Jul 2003 | B1 |
| 6594514 | Berner et al. | Jul 2003 | B2 |
| 6595756 | Gray et al. | Jul 2003 | B2 |
| 6602221 | Saravia et al. | Aug 2003 | B1 |
| 6603995 | Carter | Aug 2003 | B1 |
| 6605072 | Struys et al. | Aug 2003 | B2 |
| 6607509 | Bobroff et al. | Aug 2003 | B2 |
| 6607658 | Heller et al. | Aug 2003 | B1 |
| 6609071 | Shapiro et al. | Aug 2003 | B2 |
| 6612984 | Kerr, II | Sep 2003 | B1 |
| 6613379 | Ward et al. | Sep 2003 | B2 |
| 6615061 | Khalil et al. | Sep 2003 | B1 |
| 6615078 | Burson et al. | Sep 2003 | B1 |
| 6618603 | Varalli et al. | Sep 2003 | B2 |
| 6618934 | Feldman et al. | Sep 2003 | B1 |
| 6628975 | Fein et al. | Sep 2003 | B1 |
| 6633772 | Ford et al. | Oct 2003 | B2 |
| 6641533 | Causey, III et al. | Nov 2003 | B2 |
| 6642015 | Vachon et al. | Nov 2003 | B2 |
| 6645181 | Lavi et al. | Nov 2003 | B1 |
| 6645219 | Roe | Nov 2003 | B2 |
| 6648821 | Lebel et al. | Nov 2003 | B2 |
| 6653091 | Dunn et al. | Nov 2003 | B1 |
| 6654625 | Say et al. | Nov 2003 | B1 |
| 6656157 | Duchon et al. | Dec 2003 | B1 |
| 6663615 | Madou et al. | Dec 2003 | B1 |
| 6666821 | Keimel | Dec 2003 | B2 |
| 6673022 | Bobo et al. | Jan 2004 | B1 |
| 6673596 | Sayler et al. | Jan 2004 | B1 |
| 6679865 | Shekalim | Jan 2004 | B2 |
| 6683535 | Utke | Jan 2004 | B1 |
| 6684904 | Ito | Feb 2004 | B2 |
| 6685668 | Cho et al. | Feb 2004 | B1 |
| 6687522 | Tamada | Feb 2004 | B2 |
| 6689089 | Tiedtke et al. | Feb 2004 | B1 |
| 6689265 | Heller et al. | Feb 2004 | B2 |
| 6692456 | Eppstein et al. | Feb 2004 | B1 |
| 6694191 | Starkweather et al. | Feb 2004 | B2 |
| 6695860 | Ward et al. | Feb 2004 | B1 |
| 6699188 | Wessel | Mar 2004 | B2 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6699383 | Lemire et al. | Mar 2004 | B2 |
| 6702249 | Ito | Mar 2004 | B2 |
| 6702972 | Markle | Mar 2004 | B1 |
| 6711424 | Fine et al. | Mar 2004 | B1 |
| 6712796 | Fentis et al. | Mar 2004 | B2 |
| 6721586 | Kiser et al. | Apr 2004 | B2 |
| 6721587 | Gough | Apr 2004 | B2 |
| 6723077 | Pickup et al. | Apr 2004 | B2 |
| 6723086 | Bassuk et al. | Apr 2004 | B2 |
| 6730072 | Shawgo et al. | May 2004 | B2 |
| 6730200 | Stewart et al. | May 2004 | B1 |
| 6731976 | Penn et al. | May 2004 | B2 |
| 6733655 | Davies et al. | May 2004 | B1 |
| 6736777 | Kim et al. | May 2004 | B2 |
| 6736783 | Blake et al. | May 2004 | B2 |
| 6737158 | Thompson | May 2004 | B1 |
| 6740059 | Flaherty | May 2004 | B2 |
| 6740075 | Lebel et al. | May 2004 | B2 |
| 6741877 | Shults et al. | May 2004 | B1 |
| 6742635 | Hirshberg | Jun 2004 | B2 |
| 6743635 | Neel et al. | Jun 2004 | B2 |
| 6749587 | Flaherty | Jun 2004 | B2 |
| 6767632 | Axelgaard | Jul 2004 | B2 |
| 6770030 | Schaupp et al. | Aug 2004 | B1 |
| 6770067 | Lorenzen et al. | Aug 2004 | B2 |
| 6773565 | Kunimoto et al. | Aug 2004 | B2 |
| 6780297 | Matsumoto et al. | Aug 2004 | B2 |
| 6782343 | Hasper | Aug 2004 | B2 |
| 6784274 | Van Antwerp et al. | Aug 2004 | B2 |
| 6789634 | Denton | Sep 2004 | B1 |
| 6793632 | Sohrab | Sep 2004 | B2 |
| 6793802 | Lee et al. | Sep 2004 | B2 |
| 6801041 | Karinka et al. | Oct 2004 | B2 |
| 6802957 | Jung et al. | Oct 2004 | B2 |
| 6804002 | Fine et al. | Oct 2004 | B2 |
| 6804544 | Van Antwerp et al. | Oct 2004 | B2 |
| 6805693 | Gray et al. | Oct 2004 | B2 |
| 6809507 | Morgan et al. | Oct 2004 | B2 |
| 6809653 | Mann et al. | Oct 2004 | B1 |
| 6810290 | Lebel et al. | Oct 2004 | B2 |
| 6810736 | Ikezawa et al. | Nov 2004 | B2 |
| 6811548 | Jeffrey | Nov 2004 | B2 |
| 6813519 | Lebel et al. | Nov 2004 | B2 |
| 6814845 | Wilson et al. | Nov 2004 | B2 |
| 6815186 | Clark, Jr. | Nov 2004 | B2 |
| 6830551 | Uchigaki et al. | Dec 2004 | B1 |
| 6835553 | Han et al. | Dec 2004 | B2 |
| 6849052 | Uchigaki et al. | Feb 2005 | B2 |
| 6850790 | Berner et al. | Feb 2005 | B2 |
| 6858020 | Rusnak | Feb 2005 | B2 |
| 6862465 | Shults et al. | Mar 2005 | B2 |
| 6863800 | Karinka et al. | Mar 2005 | B2 |
| 6867262 | Angel et al. | Mar 2005 | B1 |
| 6869413 | Langley et al. | Mar 2005 | B2 |
| 6875386 | Ward et al. | Apr 2005 | B1 |
| 6882940 | Potts et al. | Apr 2005 | B2 |
| 6885883 | Parris et al. | Apr 2005 | B2 |
| 6887228 | McKay | May 2005 | B2 |
| 6892085 | McIvor et al. | May 2005 | B2 |
| 6893552 | Wang et al. | May 2005 | B1 |
| 6895263 | Shin et al. | May 2005 | B2 |
| 6895265 | Silver | May 2005 | B2 |
| 6902544 | Ludin et al. | Jun 2005 | B2 |
| 6908681 | Terry et al. | Jun 2005 | B2 |
| 6919566 | Cadell | Jul 2005 | B1 |
| 6923763 | Kovatchev et al. | Aug 2005 | B1 |
| 6925393 | Kalatz et al. | Aug 2005 | B1 |
| 6926691 | Miethke | Aug 2005 | B2 |
| 6931327 | Goode, Jr. et al. | Aug 2005 | B2 |
| 6932584 | Gray et al. | Aug 2005 | B2 |
| 6932894 | Mao et al. | Aug 2005 | B2 |
| 6936006 | Sabra | Aug 2005 | B2 |
| 6945965 | Whiting | Sep 2005 | B2 |
| 6948492 | Wermeling et al. | Sep 2005 | B2 |
| 6952604 | Denuzzio et al. | Oct 2005 | B2 |
| 6954662 | Freger et al. | Oct 2005 | B2 |
| 6960192 | Flaherty et al. | Nov 2005 | B1 |
| 6965791 | Hitchcock et al. | Nov 2005 | B1 |
| 6966325 | Erickson | Nov 2005 | B2 |
| 6972080 | Tomioka et al. | Dec 2005 | B1 |
| 6973706 | Say et al. | Dec 2005 | B2 |
| 6975893 | Say et al. | Dec 2005 | B2 |
| 6979315 | Rogers et al. | Dec 2005 | B2 |
| 6989891 | Braig et al. | Jan 2006 | B2 |
| 6990366 | Say et al. | Jan 2006 | B2 |
| 6991643 | Saadat | Jan 2006 | B2 |
| 6997921 | Gray et al. | Feb 2006 | B2 |
| 6998247 | Monfre et al. | Feb 2006 | B2 |
| 7003336 | Holker et al. | Feb 2006 | B2 |
| 7003341 | Say et al. | Feb 2006 | B2 |
| 7008979 | Schottman et al. | Mar 2006 | B2 |
| 7011630 | Desai et al. | Mar 2006 | B2 |
| 7016713 | Gardner et al. | Mar 2006 | B2 |
| 7022072 | Fox et al. | Apr 2006 | B2 |
| 7022219 | Mansouri et al. | Apr 2006 | B2 |
| 7025425 | Kovatchev et al. | Apr 2006 | B2 |
| 7025727 | Brockway et al. | Apr 2006 | B2 |
| 7025743 | Mann et al. | Apr 2006 | B2 |
| 7027848 | Robinson et al. | Apr 2006 | B2 |
| 7029444 | Shin et al. | Apr 2006 | B2 |
| 7039446 | Ruchti et al. | May 2006 | B2 |
| 7048687 | Reuss et al. | May 2006 | B1 |
| 7048727 | Moss | May 2006 | B1 |
| 7058437 | Buse et al. | Jun 2006 | B2 |
| 7060059 | Keith et al. | Jun 2006 | B2 |
| 7061593 | Braig et al. | Jun 2006 | B2 |
| 7063086 | Shahbazpour et al. | Jun 2006 | B2 |
| 7066884 | Custer et al. | Jun 2006 | B2 |
| 7070577 | Haller et al. | Jul 2006 | B1 |
| 7070580 | Nielsen | Jul 2006 | B2 |
| 7074307 | Simpson et al. | Jul 2006 | B2 |
| 7078582 | Stebbings et al. | Jul 2006 | B2 |
| 7081195 | Simpson et al. | Jul 2006 | B2 |
| 7097775 | Greenberg et al. | Aug 2006 | B2 |
| 7098803 | Mann et al. | Aug 2006 | B2 |
| 7100628 | Izenson et al. | Sep 2006 | B1 |
| 7108778 | Simpson et al. | Sep 2006 | B2 |
| 7110803 | Shults et al. | Sep 2006 | B2 |
| 7114502 | Schulman et al. | Oct 2006 | B2 |
| 7115884 | Walt et al. | Oct 2006 | B1 |
| 7120483 | Russell et al. | Oct 2006 | B2 |
| 7131967 | Gray et al. | Nov 2006 | B2 |
| 7134999 | Brauker et al. | Nov 2006 | B2 |
| 7136689 | Shults et al. | Nov 2006 | B2 |
| 7141034 | Eppstein et al. | Nov 2006 | B2 |
| 7144496 | Meserol et al. | Dec 2006 | B2 |
| 7146202 | Ward et al. | Dec 2006 | B2 |
| 7150741 | Erickson et al. | Dec 2006 | B2 |
| 7153265 | Vachon | Dec 2006 | B2 |
| 7162290 | Levin | Jan 2007 | B1 |
| 7163511 | Conn et al. | Jan 2007 | B2 |
| 7166074 | Reghabi et al. | Jan 2007 | B2 |
| 7168597 | Jones et al. | Jan 2007 | B1 |
| 7169289 | Schuelein et al. | Jan 2007 | B2 |
| 7172075 | Ji | Feb 2007 | B1 |
| 7183102 | Monfre et al. | Feb 2007 | B2 |
| 7184810 | Caduff et al. | Feb 2007 | B2 |
| 7190988 | Say et al. | Mar 2007 | B2 |
| 7192450 | Brauker et al. | Mar 2007 | B2 |
| 7207968 | Harcinske | Apr 2007 | B1 |
| 7207974 | Safabash et al. | Apr 2007 | B2 |
| 7211074 | Sansoucy | May 2007 | B2 |
| 7221970 | Parker | May 2007 | B2 |
| 7223253 | Hogendijk | May 2007 | B2 |
| 7225535 | Feldman et al. | Jun 2007 | B2 |
| 7226978 | Tapsak et al. | Jun 2007 | B2 |
| 7228162 | Ward et al. | Jun 2007 | B2 |
| 7229288 | Stuart et al. | Jun 2007 | B2 |
| 7238165 | Vincent et al. | Jul 2007 | B2 |
| 7241586 | Gulati et al. | Jul 2007 | B2 |
| 7247138 | Reghabi et al. | Jul 2007 | B2 |
| 7248906 | Dirac et al. | Jul 2007 | B2 |
| 7254450 | Christopherson et al. | Aug 2007 | B2 |
| 7255690 | Gray et al. | Aug 2007 | B2 |
| 7258681 | Houde | Aug 2007 | B2 |
| 7261690 | Teller et al. | Aug 2007 | B2 |
| 7266400 | Fine et al. | Sep 2007 | B2 |
| 7267665 | Steil et al. | Sep 2007 | B2 |
| 7276029 | Goode, Jr. et al. | Oct 2007 | B2 |
| 7278983 | Ireland et al. | Oct 2007 | B2 |
| 7288085 | Olsen | Oct 2007 | B2 |
| 7295867 | Berner et al. | Nov 2007 | B2 |
| 7299082 | Feldman et al. | Nov 2007 | B2 |
| 7310544 | Brister et al. | Dec 2007 | B2 |
| 7311690 | Burnett | Dec 2007 | B2 |
| 7313425 | Finarov et al. | Dec 2007 | B2 |
| 7314452 | Madonia | Jan 2008 | B2 |
| 7315767 | Caduff et al. | Jan 2008 | B2 |
| 7316662 | Delnevo et al. | Jan 2008 | B2 |
| 7317939 | Fine et al. | Jan 2008 | B2 |
| 7318814 | Levine et al. | Jan 2008 | B2 |
| 7324012 | Mann et al. | Jan 2008 | B2 |
| 7327273 | Hung et al. | Feb 2008 | B2 |
| 7329234 | Sansoucy | Feb 2008 | B2 |
| 7329239 | Safabash et al. | Feb 2008 | B2 |
| 7334594 | Ludin | Feb 2008 | B2 |
| 7335179 | Burnett | Feb 2008 | B2 |
| 7335195 | Mehier | Feb 2008 | B2 |
| 7335286 | Abel et al. | Feb 2008 | B2 |
| 7338464 | Blischak et al. | Mar 2008 | B2 |
| 7344499 | Prausnitz et al. | Mar 2008 | B1 |
| 7354420 | Steil et al. | Apr 2008 | B2 |
| 7359723 | Jones | Apr 2008 | B2 |
| 7361155 | Sage, Jr. et al. | Apr 2008 | B2 |
| 7364562 | Braig et al. | Apr 2008 | B2 |
| 7364592 | Carr-Brendel et al. | Apr 2008 | B2 |
| 7366556 | Brister et al. | Apr 2008 | B2 |
| 7366566 | Henry et al. | Apr 2008 | B2 |
| 7367942 | Grage et al. | May 2008 | B2 |
| 7381184 | Funderburk | Jun 2008 | B2 |
| 7392080 | Eppstein et al. | Jun 2008 | B2 |
| 7395158 | Monfre et al. | Jul 2008 | B2 |
| 7396353 | Lorenzen et al. | Jul 2008 | B2 |
| 7399277 | Saidara et al. | Jul 2008 | B2 |
| 7402153 | Steil et al. | Jul 2008 | B2 |
| 7404819 | Darios et al. | Jul 2008 | B1 |
| 7405055 | Dunn et al. | Jul 2008 | B2 |
| 7417164 | Suri | Aug 2008 | B2 |
| 7424318 | Brister et al. | Sep 2008 | B2 |
| 7426408 | Denuzzio et al. | Sep 2008 | B2 |
| 7433727 | Ward et al. | Oct 2008 | B2 |
| 7460898 | Brister et al. | Dec 2008 | B2 |
| 7467003 | Brister et al. | Dec 2008 | B2 |
| 7471972 | Rhodes et al. | Dec 2008 | B2 |
| 7494465 | Brister et al. | Feb 2009 | B2 |
| 7497827 | Brister et al. | Mar 2009 | B2 |
| 7519408 | Rasdal et al. | Apr 2009 | B2 |
| 7519478 | Bartkowiak et al. | Apr 2009 | B2 |
| 7523004 | Bartkowiak et al. | Apr 2009 | B2 |
| 7525298 | Morgan et al. | Apr 2009 | B2 |
| 7582059 | Funderburk et al. | Sep 2009 | B2 |
| 7583990 | Goode, Jr. et al. | Sep 2009 | B2 |
| 7587287 | Connolly et al. | Sep 2009 | B2 |
| 7599726 | Goode, Jr. et al. | Oct 2009 | B2 |
| 7604593 | Parris et al. | Oct 2009 | B2 |
| 7615007 | Shults et al. | Nov 2009 | B2 |
| 7618368 | Brown | Nov 2009 | B2 |
| 7618369 | Hayter et al. | Nov 2009 | B2 |
| 7624028 | Brown | Nov 2009 | B1 |
| 7632228 | Brauker et al. | Dec 2009 | B2 |
| 7636602 | Baru Fassio et al. | Dec 2009 | B2 |
| 7637868 | Saint et al. | Dec 2009 | B2 |
| 7640032 | Jones | Dec 2009 | B2 |
| 7640048 | Dobbles et al. | Dec 2009 | B2 |
| 7647237 | Dobbles et al. | Dec 2009 | C1 |
| 7647237 | Malave et al. | Jan 2010 | B2 |
| 7654956 | Brister et al. | Feb 2010 | B2 |
| 7687586 | Ward et al. | Mar 2010 | B2 |
| 7695434 | Malecha | Apr 2010 | B2 |
| 7697967 | Stafford | Apr 2010 | B2 |
| 7699775 | Desai et al. | Apr 2010 | B2 |
| 7711493 | Bartkowiak et al. | May 2010 | B2 |
| 7713574 | Brister et al. | May 2010 | B2 |
| 7731659 | Malecha | Jun 2010 | B2 |
| 7761126 | Gardner et al. | Jul 2010 | B2 |
| 7766830 | Fox et al. | Aug 2010 | B2 |
| 7771352 | Shults et al. | Aug 2010 | B2 |
| 7792562 | Shults et al. | Sep 2010 | B2 |
| 7826981 | Goode, Jr. et al. | Nov 2010 | B2 |
| 7862622 | Dunlap et al. | Jan 2011 | B2 |
| 7874985 | Kovatchev et al. | Jan 2011 | B2 |
| 7879010 | Hunn et al. | Feb 2011 | B2 |
| 7881763 | Brauker et al. | Feb 2011 | B2 |
| 7885698 | Feldman | Feb 2011 | B2 |
| 7890295 | Shin et al. | Feb 2011 | B2 |
| 7917186 | Kamath et al. | Mar 2011 | B2 |
| 7310544 | Brister et al. | Apr 2011 | C1 |
| 7920906 | Goode, Jr. et al. | Apr 2011 | B2 |
| 7925321 | Goode, Jr. et al. | Apr 2011 | B2 |
| 7927274 | Rasdal et al. | Apr 2011 | B2 |
| 7935499 | Dunn et al. | May 2011 | B2 |
| 7946984 | Brister et al. | May 2011 | B2 |
| 7946985 | Mastrototaro et al. | May 2011 | B2 |
| 7949381 | Brister et al. | May 2011 | B2 |
| 7986986 | Goode et al. | Jul 2011 | B2 |
| 7998071 | Goode, Jr. et al. | Aug 2011 | B2 |
| 8000901 | Brauker et al. | Aug 2011 | B2 |
| 8005524 | Brauker et al. | Aug 2011 | B2 |
| 8005525 | Goode, Jr. et al. | Aug 2011 | B2 |
| 8019421 | Darvish et al. | Sep 2011 | B2 |
| 7497827 | Brister et al. | Oct 2011 | C1 |
| 7905833 | Brister et al. | Nov 2011 | C1 |
| 8060173 | Goode, Jr. et al. | Nov 2011 | B2 |
| RE43039 | Brister et al. | Dec 2011 | E |
| 8073520 | Kamath et al. | Dec 2011 | B2 |
| 8118877 | Brauker et al. | Feb 2012 | B2 |
| 7774145 | Brauker | Mar 2012 | C1 |
| 8152789 | Starkweather et al. | Apr 2012 | B2 |
| 8160669 | Brauker et al. | Apr 2012 | B2 |
| 8160671 | Kamath et al. | Apr 2012 | B2 |
| 8167801 | Goode, Jr. et al. | May 2012 | B2 |
| 7713574 | Brister et al. | Jun 2012 | C1 |
| 8216139 | Brauker et al. | Jul 2012 | B2 |
| 8229534 | Brister et al. | Jul 2012 | B2 |
| 8233958 | Brauker et al. | Jul 2012 | B2 |
| 8251906 | Brauker et al. | Aug 2012 | B2 |
| 8257259 | Brauker et al. | Sep 2012 | B2 |
| 8265725 | Brauker et al. | Sep 2012 | B2 |
| 8275438 | Simpson et al. | Sep 2012 | B2 |
| 8280475 | Brister et al. | Oct 2012 | B2 |
| 8282549 | Brauker et al. | Oct 2012 | B2 |
| 8290559 | Shariati et al. | Oct 2012 | B2 |
| 8290560 | Kamath et al. | Oct 2012 | B2 |
| 8290561 | Brauker et al. | Oct 2012 | B2 |
| 8298142 | Simpson et al. | Oct 2012 | B2 |
| 7310544 | Brister et al. | Nov 2012 | C2 |
| 8311749 | Brauker et al. | Nov 2012 | B2 |
| 8313434 | Brister et al. | Nov 2012 | B2 |
| 8321149 | Brauker et al. | Nov 2012 | B2 |
| 8353881 | Jennewine | Jan 2013 | B2 |
| 8355753 | Bochenko et al. | Jan 2013 | B2 |
| 8374667 | Brauker et al. | Feb 2013 | B2 |
| 8463350 | Kamath et al. | Jun 2013 | B2 |
| 8469886 | Brauker et al. | Jun 2013 | B2 |
| 8506482 | Feldman | Aug 2013 | B2 |
| 8515516 | Kamath et al. | Aug 2013 | B2 |
| 8515519 | Brister et al. | Aug 2013 | B2 |
| 8548551 | Kamath et al. | Oct 2013 | B2 |
| 8560037 | Goode, Jr. et al. | Oct 2013 | B2 |
| 8565848 | Brister et al. | Oct 2013 | B2 |
| 8565849 | Kamath et al. | Oct 2013 | B2 |
| 8571625 | Kamath et al. | Oct 2013 | B2 |
| 8579816 | Kamath et al. | Nov 2013 | B2 |
| 8611978 | Kamath et al. | Dec 2013 | B2 |
| 7713574 | Brister et al. | Mar 2014 | C2 |
| 8663109 | Brister et al. | Mar 2014 | B2 |
| 8788007 | Brauker et al. | Jul 2014 | B2 |
| 8792953 | Brister et al. | Jul 2014 | B2 |
| 8792954 | Brister et al. | Jul 2014 | B2 |
| 8825127 | Kamath et al. | Sep 2014 | B2 |
| 8858434 | Kamath et al. | Oct 2014 | B2 |
| 8915849 | Brauker et al. | Dec 2014 | B2 |
| 8968198 | Brauker et al. | Mar 2015 | B2 |
| 8986209 | Brauker et al. | Mar 2015 | B2 |
| 8989833 | Brauker et al. | Mar 2015 | B2 |
| 9055901 | Brister et al. | Jun 2015 | B2 |
| 9060742 | Brister et al. | Jun 2015 | B2 |
| 9078608 | Kamath et al. | Jul 2015 | B2 |
| 9078626 | Brister et al. | Jul 2015 | B2 |
| 9155496 | Shults et al. | Oct 2015 | B2 |
| 9220449 | Pryor et al. | Dec 2015 | B2 |
| 9247900 | Brister et al. | Feb 2016 | B2 |
| 9314196 | Pryor et al. | Apr 2016 | B2 |
| 9603557 | Brister et al. | Mar 2017 | B2 |
| 9610031 | Brister et al. | Apr 2017 | B2 |
| 9668677 | Brister et al. | Jun 2017 | B2 |
| 9669156 | Jennewine | Jun 2017 | B2 |
| 9724028 | Brauker et al. | Aug 2017 | B2 |
| 9775543 | Brister et al. | Oct 2017 | B2 |
| 9801572 | Brister et al. | Oct 2017 | B2 |
| 9814414 | Brister et al. | Nov 2017 | B2 |
| 9918668 | Pryor et al. | Mar 2018 | B2 |
| 10314525 | Simpson et al. | Jun 2019 | B2 |
| 20010008187 | Hanssen et al. | Jul 2001 | A1 |
| 20010016682 | Berner et al. | Aug 2001 | A1 |
| 20010020546 | Eldridge et al. | Sep 2001 | A1 |
| 20010021817 | Brugger et al. | Sep 2001 | A1 |
| 20010027327 | Schraga | Oct 2001 | A1 |
| 20010039053 | Liseo et al. | Nov 2001 | A1 |
| 20010039387 | Rutynowski et al. | Nov 2001 | A1 |
| 20010044413 | Pierce et al. | Nov 2001 | A1 |
| 20010044588 | Mault | Nov 2001 | A1 |
| 20010051766 | Gazdzinski | Dec 2001 | A1 |
| 20010051768 | Schulman et al. | Dec 2001 | A1 |
| 20010053933 | Phaneuf et al. | Dec 2001 | A1 |
| 20020009810 | O'Connor et al. | Jan 2002 | A1 |
| 20020016535 | Martin et al. | Feb 2002 | A1 |
| 20020019330 | Murray et al. | Feb 2002 | A1 |
| 20020022883 | Burg | Feb 2002 | A1 |
| 20020023852 | McIvor et al. | Feb 2002 | A1 |
| 20020026111 | Ackerman | Feb 2002 | A1 |
| 20020032531 | Mansky et al. | Mar 2002 | A1 |
| 20020042561 | Schulman et al. | Apr 2002 | A1 |
| 20020043471 | Ikeda et al. | Apr 2002 | A1 |
| 20020043651 | Darrow et al. | Apr 2002 | A1 |
| 20020055673 | Van Antwerp et al. | May 2002 | A1 |
| 20020071776 | Bandis et al. | Jun 2002 | A1 |
| 20020077599 | Wojcik | Jun 2002 | A1 |
| 20020084196 | Liamos et al. | Jul 2002 | A1 |
| 20020099282 | Knobbe et al. | Jul 2002 | A1 |
| 20020099997 | Pi ret | Jul 2002 | A1 |
| 20020100474 | Kellner et al. | Aug 2002 | A1 |
| 20020100725 | Lee et al. | Aug 2002 | A1 |
| 20020119711 | Van Antwerp et al. | Aug 2002 | A1 |
| 20020123048 | Gau, Jr. | Sep 2002 | A1 |
| 20020128546 | Silver | Sep 2002 | A1 |
| 20020132279 | Hockersmith | Sep 2002 | A1 |
| 20020133224 | Bajgar et al. | Sep 2002 | A1 |
| 20020137991 | Scarantino et al. | Sep 2002 | A1 |
| 20020151796 | Koulik | Oct 2002 | A1 |
| 20020151816 | Rich et al. | Oct 2002 | A1 |
| 20020155615 | Novikov et al. | Oct 2002 | A1 |
| 20020160722 | Terranova et al. | Oct 2002 | A1 |
| 20020161288 | Shin et al. | Oct 2002 | A1 |
| 20020169369 | Ward et al. | Nov 2002 | A1 |
| 20020169405 | Roberts | Nov 2002 | A1 |
| 20020177763 | Burns et al. | Nov 2002 | A1 |
| 20020177764 | Sohrab | Nov 2002 | A1 |
| 20020182241 | Borenstein et al. | Dec 2002 | A1 |
| 20020185384 | Leong et al. | Dec 2002 | A1 |
| 20020186185 | Ide et al. | Dec 2002 | A1 |
| 20020188185 | Sohrab | Dec 2002 | A1 |
| 20020188216 | Kayyali et al. | Dec 2002 | A1 |
| 20020188252 | Bardy | Dec 2002 | A1 |
| 20020193885 | Legeay et al. | Dec 2002 | A1 |
| 20030003524 | Taniike et al. | Jan 2003 | A1 |
| 20030004432 | Assenheimer | Jan 2003 | A1 |
| 20030004457 | Andersson | Jan 2003 | A1 |
| 20030006669 | Pei et al. | Jan 2003 | A1 |
| 20030021729 | Moller et al. | Jan 2003 | A1 |
| 20030023171 | Sato et al. | Jan 2003 | A1 |
| 20030023317 | Brauker et al. | Jan 2003 | A1 |
| 20030024811 | Davies et al. | Feb 2003 | A1 |
| 20030032874 | Rhodes et al. | Feb 2003 | A1 |
| 20030036773 | Whitehurst et al. | Feb 2003 | A1 |
| 20030049166 | Pendo et al. | Mar 2003 | A1 |
| 20030059631 | Al-Lamee | Mar 2003 | A1 |
| 20030060765 | Campbell et al. | Mar 2003 | A1 |
| 20030065254 | Schulman et al. | Apr 2003 | A1 |
| 20030070548 | Clausen | Apr 2003 | A1 |
| 20030072741 | Berglund et al. | Apr 2003 | A1 |
| 20030078560 | Miller et al. | Apr 2003 | A1 |
| 20030088166 | Say et al. | May 2003 | A1 |
| 20030091433 | Tam et al. | May 2003 | A1 |
| 20030096424 | Mao et al. | May 2003 | A1 |
| 20030097082 | Purdy et al. | May 2003 | A1 |
| 20030099682 | Moussy et al. | May 2003 | A1 |
| 20030100040 | Bonnecaze et al. | May 2003 | A1 |
| 20030100821 | Heller et al. | May 2003 | A1 |
| 20030114735 | Silver et al. | Jun 2003 | A1 |
| 20030117296 | Seely | Jun 2003 | A1 |
| 20030119208 | Yoon et al. | Jun 2003 | A1 |
| 20030120152 | Omiya | Jun 2003 | A1 |
| 20030125613 | Enegren et al. | Jul 2003 | A1 |
| 20030130616 | Steil et al. | Jul 2003 | A1 |
| 20030132227 | Geisler et al. | Jul 2003 | A1 |
| 20030134100 | Mao et al. | Jul 2003 | A1 |
| 20030134347 | Heller et al. | Jul 2003 | A1 |
| 20030138674 | Zeikus et al. | Jul 2003 | A1 |
| 20030143746 | Sage, Jr. | Jul 2003 | A1 |
| 20030153821 | Berner et al. | Aug 2003 | A1 |
| 20030157409 | Huang | Aug 2003 | A1 |
| 20030176183 | Drucker et al. | Sep 2003 | A1 |
| 20030181794 | Rini et al. | Sep 2003 | A1 |
| 20030186457 | Iwaki et al. | Oct 2003 | A1 |
| 20030187338 | Say et al. | Oct 2003 | A1 |
| 20030190383 | Kim | Oct 2003 | A1 |
| 20030199745 | Burson et al. | Oct 2003 | A1 |
| 20030199878 | Pohjonen | Oct 2003 | A1 |
| 20030200040 | Trygg et al. | Oct 2003 | A1 |
| 20030203498 | Neel et al. | Oct 2003 | A1 |
| 20030208113 | Mault et al. | Nov 2003 | A1 |
| 20030211625 | Cohan | Nov 2003 | A1 |
| 20030212346 | Yuzhakov et al. | Nov 2003 | A1 |
| 20030212347 | Sohrab | Nov 2003 | A1 |
| 20030225324 | Anderson et al. | Dec 2003 | A1 |
| 20030225361 | Sabra | Dec 2003 | A1 |
| 20030225437 | Ferguson | Dec 2003 | A1 |
| 20030228681 | Ritts et al. | Dec 2003 | A1 |
| 20030231550 | MacFarlane | Dec 2003 | A1 |
| 20030235817 | Bartkowiak et al. | Dec 2003 | A1 |
| 20040002682 | Kovelman et al. | Jan 2004 | A1 |
| 20040006263 | Anderson et al. | Jan 2004 | A1 |
| 20040008761 | Kelliher et al. | Jan 2004 | A1 |
| 20040010207 | Flaherty et al. | Jan 2004 | A1 |
| 20040015134 | Lavi et al. | Jan 2004 | A1 |
| 20040023253 | Kunwar et al. | Feb 2004 | A1 |
| 20040023317 | Motamedi et al. | Feb 2004 | A1 |
| 20040024327 | Brodnick | Feb 2004 | A1 |
| 20040030285 | Lavi et al. | Feb 2004 | A1 |
| 20040030294 | Mahurkar | Feb 2004 | A1 |
| 20040039298 | Abreu | Feb 2004 | A1 |
| 20040039342 | Eppstein et al. | Feb 2004 | A1 |
| 20040039406 | Jessen | Feb 2004 | A1 |
| 20040040840 | Mao et al. | Mar 2004 | A1 |
| 20040052689 | Yao | Mar 2004 | A1 |
| 20040054352 | Adams et al. | Mar 2004 | A1 |
| 20040064156 | Shah et al. | Apr 2004 | A1 |
| 20040068230 | Estes et al. | Apr 2004 | A1 |
| 20040074785 | Holker | Apr 2004 | A1 |
| 20040078219 | Kaylor | Apr 2004 | A1 |
| 20040087671 | Tamada et al. | May 2004 | A1 |
| 20040088023 | Imran et al. | May 2004 | A1 |
| 20040106741 | Kriesel et al. | Jun 2004 | A1 |
| 20040106857 | Gough | Jun 2004 | A1 |
| 20040106858 | Say et al. | Jun 2004 | A1 |
| 20040106859 | Say et al. | Jun 2004 | A1 |
| 20040113164 | Corbet | Jun 2004 | A1 |
| 20040120848 | Teodorczyk | Jun 2004 | A1 |
| 20040127818 | Roe et al. | Jul 2004 | A1 |
| 20040133131 | Kuhn et al. | Jul 2004 | A1 |
| 20040133164 | Funderburk et al. | Jul 2004 | A1 |
| 20040146909 | Duong et al. | Jul 2004 | A1 |
| 20040147872 | Thompson | Jul 2004 | A1 |
| 20040152187 | Haight et al. | Aug 2004 | A1 |
| 20040158138 | Kilcoyne et al. | Aug 2004 | A1 |
| 20040158207 | Hunn et al. | Aug 2004 | A1 |
| 20040167801 | Say et al. | Aug 2004 | A1 |
| 20040173472 | Jung et al. | Sep 2004 | A1 |
| 20040176672 | Silver et al. | Sep 2004 | A1 |
| 20040180391 | Gratzl et al. | Sep 2004 | A1 |
| 20040186365 | Jin et al. | Sep 2004 | A1 |
| 20040197846 | Hockersmith et al. | Oct 2004 | A1 |
| 20040204687 | Mogensen | Oct 2004 | A1 |
| 20040204744 | Penner et al. | Oct 2004 | A1 |
| 20040219664 | Heller et al. | Nov 2004 | A1 |
| 20040225199 | Evanyk et al. | Nov 2004 | A1 |
| 20040228902 | Benz | Nov 2004 | A1 |
| 20040234575 | Horres et al. | Nov 2004 | A1 |
| 20040236200 | Say et al. | Nov 2004 | A1 |
| 20040236251 | Roe et al. | Nov 2004 | A1 |
| 20040242982 | Sakata et al. | Dec 2004 | A1 |
| 20040244151 | Sakata et al. | Dec 2004 | A1 |
| 20040249421 | Harel et al. | Dec 2004 | A1 |
| 20040253365 | Warren et al. | Dec 2004 | A1 |
| 20040254433 | Bandis | Dec 2004 | A1 |
| 20040260234 | Srinivasan et al. | Dec 2004 | A1 |
| 20040265940 | Slater et al. | Dec 2004 | A1 |
| 20050000829 | Morita et al. | Jan 2005 | A1 |
| 20050003399 | Blackburn et al. | Jan 2005 | A1 |
| 20050006122 | Burnette | Jan 2005 | A1 |
| 20050008671 | Van Antwerp | Jan 2005 | A1 |
| 20050010265 | Baru Fassio et al. | Jan 2005 | A1 |
| 20050013842 | Qiu et al. | Jan 2005 | A1 |
| 20050016325 | Enokido | Jan 2005 | A1 |
| 20050026689 | Marks | Feb 2005 | A1 |
| 20050027182 | Siddiqui et al. | Feb 2005 | A1 |
| 20050027463 | Goode et al. | Feb 2005 | A1 |
| 20050031689 | Shults et al. | Feb 2005 | A1 |
| 20050033132 | Shults et al. | Feb 2005 | A1 |
| 20050038332 | Saidara et al. | Feb 2005 | A1 |
| 20050043598 | Goode et al. | Feb 2005 | A1 |
| 20050049472 | Manda et al. | Mar 2005 | A1 |
| 20050051427 | Brauker et al. | Mar 2005 | A1 |
| 20050054909 | Petisce et al. | Mar 2005 | A1 |
| 20050056551 | White et al. | Mar 2005 | A1 |
| 20050056552 | Simpson et al. | Mar 2005 | A1 |
| 20050059871 | Gough et al. | Mar 2005 | A1 |
| 20050065464 | Talbot et al. | Mar 2005 | A1 |
| 20050077584 | Uhland et al. | Apr 2005 | A1 |
| 20050079200 | Rathenow et al. | Apr 2005 | A1 |
| 20050080345 | Finburgh et al. | Apr 2005 | A1 |
| 20050085839 | Allen et al. | Apr 2005 | A1 |
| 20050090607 | Tapsak et al. | Apr 2005 | A1 |
| 20050096512 | Fox et al. | May 2005 | A1 |
| 20050101847 | Routt et al. | May 2005 | A1 |
| 20050103625 | Rhodes et al. | May 2005 | A1 |
| 20050106713 | Phan et al. | May 2005 | A1 |
| 20050115832 | Simpson et al. | Jun 2005 | A1 |
| 20050118344 | Pacetti | Jun 2005 | A1 |
| 20050119720 | Gale et al. | Jun 2005 | A1 |
| 20050121322 | Say et al. | Jun 2005 | A1 |
| 20050131305 | Danielson et al. | Jun 2005 | A1 |
| 20050133368 | Davies et al. | Jun 2005 | A1 |
| 20050139489 | Davies et al. | Jun 2005 | A1 |
| 20050143635 | Kamath et al. | Jun 2005 | A1 |
| 20050143636 | Zhang et al. | Jun 2005 | A1 |
| 20050143675 | Neel et al. | Jun 2005 | A1 |
| 20050154264 | Lecompte et al. | Jul 2005 | A1 |
| 20050154272 | Dirac et al. | Jul 2005 | A1 |
| 20050173245 | Feldman et al. | Aug 2005 | A1 |
| 20050176136 | Burd et al. | Aug 2005 | A1 |
| 20050176678 | Horres et al. | Aug 2005 | A1 |
| 20050177036 | Shults et al. | Aug 2005 | A1 |
| 20050177398 | Watanabe et al. | Aug 2005 | A1 |
| 20050181012 | Saint et al. | Aug 2005 | A1 |
| 20050182451 | Griffin et al. | Aug 2005 | A1 |
| 20050183954 | Hitchcock et al. | Aug 2005 | A1 |
| 20050192557 | Brauker et al. | Sep 2005 | A1 |
| 20050195930 | Spital et al. | Sep 2005 | A1 |
| 20050196747 | Stiene | Sep 2005 | A1 |
| 20050197554 | Polcha | Sep 2005 | A1 |
| 20050209665 | Hunter et al. | Sep 2005 | A1 |
| 20050215871 | Feldman et al. | Sep 2005 | A1 |
| 20050215872 | Berner et al. | Sep 2005 | A1 |
| 20050215979 | Kornerup et al. | Sep 2005 | A1 |
| 20050225361 | Rhee | Oct 2005 | A1 |
| 20050228238 | Monitzer | Oct 2005 | A1 |
| 20050233407 | Pamidi et al. | Oct 2005 | A1 |
| 20050242479 | Petisce et al. | Nov 2005 | A1 |
| 20050245795 | Goode et al. | Nov 2005 | A1 |
| 20050245799 | Brauker et al. | Nov 2005 | A1 |
| 20050258037 | Hajizadeh et al. | Nov 2005 | A1 |
| 20050261563 | Zhou et al. | Nov 2005 | A1 |
| 20050267325 | Bouchier et al. | Dec 2005 | A1 |
| 20050267440 | Herman et al. | Dec 2005 | A1 |
| 20050271546 | Gerber et al. | Dec 2005 | A1 |
| 20050272989 | Shah et al. | Dec 2005 | A1 |
| 20050282997 | Ward et al. | Dec 2005 | A1 |
| 20050288596 | Eigler et al. | Dec 2005 | A1 |
| 20060001550 | Mann et al. | Jan 2006 | A1 |
| 20060003398 | Heller et al. | Jan 2006 | A1 |
| 20060008370 | Massaro et al. | Jan 2006 | A1 |
| 20060015020 | Neale et al. | Jan 2006 | A1 |
| 20060015024 | Brister et al. | Jan 2006 | A1 |
| 20060016700 | Brister et al. | Jan 2006 | A1 |
| 20060020186 | Brister et al. | Jan 2006 | A1 |
| 20060020187 | Brister et al. | Jan 2006 | A1 |
| 20060020189 | Brister et al. | Jan 2006 | A1 |
| 20060020191 | Brister et al. | Jan 2006 | A1 |
| 20060020192 | Brister et al. | Jan 2006 | A1 |
| 20060025663 | Talbot et al. | Feb 2006 | A1 |
| 20060036139 | Brister et al. | Feb 2006 | A1 |
| 20060036141 | Kamath et al. | Feb 2006 | A1 |
| 20060036142 | Brister et al. | Feb 2006 | A1 |
| 20060036143 | Brister et al. | Feb 2006 | A1 |
| 20060036144 | Brister et al. | Feb 2006 | A1 |
| 20060036145 | Brister et al. | Feb 2006 | A1 |
| 20060040402 | Brauker et al. | Feb 2006 | A1 |
| 20060047215 | Newman et al. | Mar 2006 | A1 |
| 20060052745 | Van Antwerp et al. | Mar 2006 | A1 |
| 20060065527 | Samproni | Mar 2006 | A1 |
| 20060068208 | Tapsak et al. | Mar 2006 | A1 |
| 20060079740 | Silver et al. | Apr 2006 | A1 |
| 20060079809 | Goldberger et al. | Apr 2006 | A1 |
| 20060086624 | Tapsak et al. | Apr 2006 | A1 |
| 20060094946 | Kellogg et al. | May 2006 | A1 |
| 20060100588 | Brunnberg et al. | May 2006 | A1 |
| 20060118415 | Say et al. | Jun 2006 | A1 |
| 20060142651 | Brister et al. | Jun 2006 | A1 |
| 20060155180 | Brister et al. | Jul 2006 | A1 |
| 20060159718 | Rathenow et al. | Jul 2006 | A1 |
| 20060159981 | Heller | Jul 2006 | A1 |
| 20060171980 | Helmus et al. | Aug 2006 | A1 |
| 20060173444 | Choy et al. | Aug 2006 | A1 |
| 20060183984 | Dobbles et al. | Aug 2006 | A1 |
| 20060183985 | Brister et al. | Aug 2006 | A1 |
| 20060189856 | Petisce | Aug 2006 | A1 |
| 20060189863 | Peyser et al. | Aug 2006 | A1 |
| 20060195029 | Shults et al. | Aug 2006 | A1 |
| 20060198864 | Shults et al. | Sep 2006 | A1 |
| 20060200019 | Petisce et al. | Sep 2006 | A1 |
| 20060200020 | Brister et al. | Sep 2006 | A1 |
| 20060200022 | Brauker et al. | Sep 2006 | A1 |
| 20060200970 | Brister et al. | Sep 2006 | A1 |
| 20060204536 | Shults et al. | Sep 2006 | A1 |
| 20060222566 | Brauker et al. | Oct 2006 | A1 |
| 20060224108 | Brauker et al. | Oct 2006 | A1 |
| 20060224141 | Rush et al. | Oct 2006 | A1 |
| 20060229512 | Petisce et al. | Oct 2006 | A1 |
| 20060235285 | Brister et al. | Oct 2006 | A1 |
| 20060253085 | Geismar et al. | Nov 2006 | A1 |
| 20060257995 | Simpson et al. | Nov 2006 | A1 |
| 20060257996 | Simpson et al. | Nov 2006 | A1 |
| 20060258761 | Boock et al. | Nov 2006 | A1 |
| 20060263673 | Kim et al. | Nov 2006 | A1 |
| 20060263763 | Simpson et al. | Nov 2006 | A1 |
| 20060263839 | Ward et al. | Nov 2006 | A1 |
| 20060270922 | Brauker et al. | Nov 2006 | A1 |
| 20060270923 | Brauker et al. | Nov 2006 | A1 |
| 20060275859 | Kjaer | Dec 2006 | A1 |
| 20060281985 | Ward et al. | Dec 2006 | A1 |
| 20060289307 | Yu et al. | Dec 2006 | A1 |
| 20060293576 | Van Antwerp et al. | Dec 2006 | A1 |
| 20070003588 | Chinn et al. | Jan 2007 | A1 |
| 20070007133 | Mang et al. | Jan 2007 | A1 |
| 20070016381 | Kamath et al. | Jan 2007 | A1 |
| 20070017805 | Hodges et al. | Jan 2007 | A1 |
| 20070027370 | Brauker et al. | Feb 2007 | A1 |
| 20070027381 | Stafford | Feb 2007 | A1 |
| 20070027384 | Brister et al. | Feb 2007 | A1 |
| 20070027385 | Brister et al. | Feb 2007 | A1 |
| 20070032706 | Kamath et al. | Feb 2007 | A1 |
| 20070032717 | Brister et al. | Feb 2007 | A1 |
| 20070032718 | Shults et al. | Feb 2007 | A1 |
| 20070038044 | Dobbles et al. | Feb 2007 | A1 |
| 20070045902 | Brauker et al. | Mar 2007 | A1 |
| 20070049865 | Radmer | Mar 2007 | A1 |
| 20070049873 | Hansen et al. | Mar 2007 | A1 |
| 20070059196 | Brister et al. | Mar 2007 | A1 |
| 20070066873 | Kamath et al. | Mar 2007 | A1 |
| 20070073129 | Shah et al. | Mar 2007 | A1 |
| 20070085995 | Pesach et al. | Apr 2007 | A1 |
| 20070093704 | Brister et al. | Apr 2007 | A1 |
| 20070116600 | Kochar et al. | May 2007 | A1 |
| 20070129524 | Sunkara | Jun 2007 | A1 |
| 20070129619 | Ward et al. | Jun 2007 | A1 |
| 20070129621 | Kellogg et al. | Jun 2007 | A1 |
| 20070135698 | Shah et al. | Jun 2007 | A1 |
| 20070135699 | Ward et al. | Jun 2007 | A1 |
| 20070142584 | Schorzman et al. | Jun 2007 | A1 |
| 20070151869 | Heller et al. | Jul 2007 | A1 |
| 20070173706 | Neinast et al. | Jul 2007 | A1 |
| 20070173709 | Petisce et al. | Jul 2007 | A1 |
| 20070173710 | Petisce et al. | Jul 2007 | A1 |
| 20070173711 | Shah et al. | Jul 2007 | A1 |
| 20070179436 | Braig et al. | Aug 2007 | A1 |
| 20070197889 | Brister et al. | Aug 2007 | A1 |
| 20070197890 | Boock et al. | Aug 2007 | A1 |
| 20070200254 | Curry | Aug 2007 | A1 |
| 20070200267 | Tsai | Aug 2007 | A1 |
| 20070202562 | Curry | Aug 2007 | A1 |
| 20070202672 | Curry | Aug 2007 | A1 |
| 20070203407 | Hoss et al. | Aug 2007 | A1 |
| 20070203410 | Say et al. | Aug 2007 | A1 |
| 20070203966 | Brauker et al. | Aug 2007 | A1 |
| 20070206193 | Pesach | Sep 2007 | A1 |
| 20070208245 | Brauker et al. | Sep 2007 | A1 |
| 20070208246 | Brauker et al. | Sep 2007 | A1 |
| 20070213610 | Say et al. | Sep 2007 | A1 |
| 20070213611 | Simpson et al. | Sep 2007 | A1 |
| 20070215491 | Heller et al. | Sep 2007 | A1 |
| 20070218097 | Heller et al. | Sep 2007 | A1 |
| 20070219441 | Carlin et al. | Sep 2007 | A1 |
| 20070225579 | Lucassen et al. | Sep 2007 | A1 |
| 20070225675 | Robinson et al. | Sep 2007 | A1 |
| 20070227907 | Shah et al. | Oct 2007 | A1 |
| 20070232876 | Otto et al. | Oct 2007 | A1 |
| 20070232879 | Brister et al. | Oct 2007 | A1 |
| 20070233013 | Schoenberg | Oct 2007 | A1 |
| 20070235331 | Simpson et al. | Oct 2007 | A1 |
| 20070240497 | Robinson et al. | Oct 2007 | A1 |
| 20070244381 | Robinson et al. | Oct 2007 | A1 |
| 20070244382 | Robinson et al. | Oct 2007 | A1 |
| 20070249916 | Pesach et al. | Oct 2007 | A1 |
| 20070255114 | Ackermann et al. | Nov 2007 | A1 |
| 20070255126 | Moberg et al. | Nov 2007 | A1 |
| 20070259217 | Logan | Nov 2007 | A1 |
| 20070275193 | Desimone et al. | Nov 2007 | A1 |
| 20070276211 | Mir et al. | Nov 2007 | A1 |
| 20070282180 | Caduff et al. | Dec 2007 | A1 |
| 20070299385 | Santini, Jr. et al. | Dec 2007 | A1 |
| 20070299409 | Whitbourne et al. | Dec 2007 | A1 |
| 20080001318 | Schorzman et al. | Jan 2008 | A1 |
| 20080021666 | Goode et al. | Jan 2008 | A1 |
| 20080029390 | Roche et al. | Feb 2008 | A1 |
| 20080029391 | Mao et al. | Feb 2008 | A1 |
| 20080033254 | Kamath et al. | Feb 2008 | A1 |
| 20080033268 | Stafford | Feb 2008 | A1 |
| 20080033269 | Zhang | Feb 2008 | A1 |
| 20080034972 | Gough et al. | Feb 2008 | A1 |
| 20080045824 | Tapsak et al. | Feb 2008 | A1 |
| 20080064944 | Van Antwerp et al. | Mar 2008 | A1 |
| 20080071157 | McGarraugh et al. | Mar 2008 | A1 |
| 20080071158 | McGarraugh et al. | Mar 2008 | A1 |
| 20080072663 | Keenan et al. | Mar 2008 | A1 |
| 20080081969 | Feldman et al. | Apr 2008 | A1 |
| 20080086040 | Heller et al. | Apr 2008 | A1 |
| 20080086041 | Heller et al. | Apr 2008 | A1 |
| 20080086042 | Brister et al. | Apr 2008 | A1 |
| 20080086043 | Heller et al. | Apr 2008 | A1 |
| 20080086044 | Brister et al. | Apr 2008 | A1 |
| 20080091094 | Heller et al. | Apr 2008 | A1 |
| 20080091095 | Heller et al. | Apr 2008 | A1 |
| 20080108942 | Brister et al. | May 2008 | A1 |
| 20080119703 | Brister et al. | May 2008 | A1 |
| 20080119704 | Brister et al. | May 2008 | A1 |
| 20080119706 | Brister et al. | May 2008 | A1 |
| 20080119707 | Stafford | May 2008 | A1 |
| 20080125751 | Fjield et al. | May 2008 | A1 |
| 20080139910 | Mastrototaro et al. | Jun 2008 | A1 |
| 20080154101 | Jain et al. | Jun 2008 | A1 |
| 20080161666 | Feldman et al. | Jul 2008 | A1 |
| 20080183061 | Goode et al. | Jul 2008 | A1 |
| 20080183399 | Goode et al. | Jul 2008 | A1 |
| 20080187655 | Markle et al. | Aug 2008 | A1 |
| 20080188722 | Markle et al. | Aug 2008 | A1 |
| 20080188725 | Markle et al. | Aug 2008 | A1 |
| 20080188731 | Brister et al. | Aug 2008 | A1 |
| 20080189051 | Goode et al. | Aug 2008 | A1 |
| 20080193936 | Squirrell | Aug 2008 | A1 |
| 20080194837 | Kim et al. | Aug 2008 | A1 |
| 20080194935 | Brister et al. | Aug 2008 | A1 |
| 20080194936 | Goode et al. | Aug 2008 | A1 |
| 20080194938 | Brister et al. | Aug 2008 | A1 |
| 20080197024 | Simpson et al. | Aug 2008 | A1 |
| 20080200788 | Brister et al. | Aug 2008 | A1 |
| 20080200789 | Brister et al. | Aug 2008 | A1 |
| 20080200791 | Simpson et al. | Aug 2008 | A1 |
| 20080208025 | Shults et al. | Aug 2008 | A1 |
| 20080210557 | Heller et al. | Sep 2008 | A1 |
| 20080214915 | Brister et al. | Sep 2008 | A1 |
| 20080214918 | Brister et al. | Sep 2008 | A1 |
| 20080228051 | Shults et al. | Sep 2008 | A1 |
| 20080228054 | Shults et al. | Sep 2008 | A1 |
| 20080242961 | Brister et al. | Oct 2008 | A1 |
| 20080262469 | Brister et al. | Oct 2008 | A1 |
| 20080275313 | Brister et al. | Nov 2008 | A1 |
| 20080275326 | Kasielke et al. | Nov 2008 | A1 |
| 20080287764 | Rasdal et al. | Nov 2008 | A1 |
| 20080287765 | Rasdal et al. | Nov 2008 | A1 |
| 20080296155 | Shults et al. | Dec 2008 | A1 |
| 20080305009 | Gamsey et al. | Dec 2008 | A1 |
| 20080305506 | Suri | Dec 2008 | A1 |
| 20080306368 | Goode, Jr. et al. | Dec 2008 | A1 |
| 20080306433 | Cesaroni | Dec 2008 | A1 |
| 20080306434 | Dobbles et al. | Dec 2008 | A1 |
| 20080306435 | Kamath et al. | Dec 2008 | A1 |
| 20080306444 | Brister et al. | Dec 2008 | A1 |
| 20080312397 | Lai et al. | Dec 2008 | A1 |
| 20080312859 | Skyggebjerg et al. | Dec 2008 | A1 |
| 20080313896 | Shah et al. | Dec 2008 | A1 |
| 20090005666 | Shin et al. | Jan 2009 | A1 |
| 20090012379 | Goode, Jr. et al. | Jan 2009 | A1 |
| 20090018418 | Markle et al. | Jan 2009 | A1 |
| 20090018424 | Kamath et al. | Jan 2009 | A1 |
| 20090018426 | Markle et al. | Jan 2009 | A1 |
| 20090030294 | Petisce et al. | Jan 2009 | A1 |
| 20090036758 | Brauker et al. | Feb 2009 | A1 |
| 20090036763 | Brauker et al. | Feb 2009 | A1 |
| 20090043181 | Brauker et al. | Feb 2009 | A1 |
| 20090043182 | Brauker et al. | Feb 2009 | A1 |
| 20090043525 | Brauker et al. | Feb 2009 | A1 |
| 20090045055 | Rhodes et al. | Feb 2009 | A1 |
| 20090054812 | Mace | Feb 2009 | A1 |
| 20090061528 | Suri | Mar 2009 | A1 |
| 20090062633 | Brauker et al. | Mar 2009 | A1 |
| 20090062635 | Brauker et al. | Mar 2009 | A1 |
| 20090062645 | Fehre et al. | Mar 2009 | A1 |
| 20090076356 | Simpson | Mar 2009 | A1 |
| 20090076360 | Brister et al. | Mar 2009 | A1 |
| 20090081803 | Gamsey et al. | Mar 2009 | A1 |
| 20090099434 | Liu et al. | Apr 2009 | A1 |
| 20090099436 | Brister et al. | Apr 2009 | A1 |
| 20090124877 | Goode, Jr. et al. | May 2009 | A1 |
| 20090124878 | Goode, Jr. et al. | May 2009 | A1 |
| 20090124879 | Brister et al. | May 2009 | A1 |
| 20090124964 | Leach et al. | May 2009 | A1 |
| 20090131769 | Leach et al. | May 2009 | A1 |
| 20090131777 | Simpson et al. | May 2009 | A1 |
| 20090137886 | Shariati et al. | May 2009 | A1 |
| 20090137887 | Shariati et al. | May 2009 | A1 |
| 20090143659 | Li et al. | Jun 2009 | A1 |
| 20090143660 | Brister et al. | Jun 2009 | A1 |
| 20090163790 | Brister et al. | Jun 2009 | A1 |
| 20090177059 | Say et al. | Jul 2009 | A1 |
| 20090177060 | Say et al. | Jul 2009 | A1 |
| 20090177143 | Markle et al. | Jul 2009 | A1 |
| 20090178459 | Li et al. | Jul 2009 | A1 |
| 20090182217 | Li et al. | Jul 2009 | A1 |
| 20090187090 | Say et al. | Jul 2009 | A1 |
| 20090187091 | Say et al. | Jul 2009 | A1 |
| 20090192366 | Mensinger et al. | Jul 2009 | A1 |
| 20090192380 | Shariati et al. | Jul 2009 | A1 |
| 20090192722 | Shariati et al. | Jul 2009 | A1 |
| 20090192745 | Kamath et al. | Jul 2009 | A1 |
| 20090192751 | Kamath et al. | Jul 2009 | A1 |
| 20090203981 | Brauker et al. | Aug 2009 | A1 |
| 20090204340 | Feldman et al. | Aug 2009 | A1 |
| 20090240120 | Mensinger et al. | Sep 2009 | A1 |
| 20090240128 | Mensinger et al. | Sep 2009 | A1 |
| 20090240193 | Mensinger et al. | Sep 2009 | A1 |
| 20090242399 | Kamath et al. | Oct 2009 | A1 |
| 20090242425 | Kamath et al. | Oct 2009 | A1 |
| 20090247857 | Harper et al. | Oct 2009 | A1 |
| 20090264719 | Markle et al. | Oct 2009 | A1 |
| 20090264856 | Lebel et al. | Oct 2009 | A1 |
| 20090287074 | Shults et al. | Nov 2009 | A1 |
| 20090299155 | Yang et al. | Dec 2009 | A1 |
| 20090299156 | Simpson et al. | Dec 2009 | A1 |
| 20090299162 | Brauker et al. | Dec 2009 | A1 |
| 20090299276 | Brauker et al. | Dec 2009 | A1 |
| 20100010330 | Rankers et al. | Jan 2010 | A1 |
| 20100010332 | Brauker et al. | Jan 2010 | A1 |
| 20100016687 | Brauker et al. | Jan 2010 | A1 |
| 20100030053 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100030484 | Brauker et al. | Feb 2010 | A1 |
| 20100036215 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100036216 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100036224 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100036225 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100041971 | Goode, Jr. et al. | Feb 2010 | A1 |
| 20100045465 | Brauker et al. | Feb 2010 | A1 |
| 20100049024 | Saint et al. | Feb 2010 | A1 |
| 20100069728 | Funderburk et al. | Mar 2010 | A1 |
| 20100076283 | Simpson et al. | Mar 2010 | A1 |
| 20100081908 | Dobbles et al. | Apr 2010 | A1 |
| 20100081910 | Brister et al. | Apr 2010 | A1 |
| 20100087721 | Stafford | Apr 2010 | A1 |
| 20100087724 | Brauker et al. | Apr 2010 | A1 |
| 20100113897 | Brenneman et al. | May 2010 | A1 |
| 20100161269 | Kamath et al. | Jun 2010 | A1 |
| 20100168543 | Kamath et al. | Jul 2010 | A1 |
| 20100174157 | Brister et al. | Jul 2010 | A1 |
| 20100174158 | Kamath et al. | Jul 2010 | A1 |
| 20100174163 | Brister et al. | Jul 2010 | A1 |
| 20100174167 | Kamath et al. | Jul 2010 | A1 |
| 20100174168 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100179399 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100179401 | Rasdal et al. | Jul 2010 | A1 |
| 20100179404 | Kamath et al. | Jul 2010 | A1 |
| 20100179408 | Kamath et al. | Jul 2010 | A1 |
| 20100179409 | Kamath et al. | Jul 2010 | A1 |
| 20100185065 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100185070 | Brister et al. | Jul 2010 | A1 |
| 20100185071 | Simpson et al. | Jul 2010 | A1 |
| 20100185072 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100185073 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100185074 | Goode, Jr. et al. | Jul 2010 | A1 |
| 20100191082 | Brister et al. | Jul 2010 | A1 |
| 20100198035 | Kamath et al. | Aug 2010 | A1 |
| 20100204555 | Shults et al. | Aug 2010 | A1 |
| 20100212583 | Brister et al. | Aug 2010 | A1 |
| 20100214104 | Goode, Jr. et al. | Aug 2010 | A1 |
| 20100217106 | Goode, Jr. et al. | Aug 2010 | A1 |
| 20100217555 | Kamath et al. | Aug 2010 | A1 |
| 20100234707 | Goode, Jr. et al. | Sep 2010 | A1 |
| 20100234796 | Kamath et al. | Sep 2010 | A1 |
| 20100240975 | Goode, Jr. et al. | Sep 2010 | A1 |
| 20100240976 | Goode, Jr. et al. | Sep 2010 | A1 |
| 20100286496 | Simpson et al. | Nov 2010 | A1 |
| 20100331648 | Kamath et al. | Dec 2010 | A1 |
| 20100331656 | Mensinger et al. | Dec 2010 | A1 |
| 20100331657 | Mensinger et al. | Dec 2010 | A1 |
| 20110009727 | Mensinger et al. | Jan 2011 | A1 |
| 20110027127 | Simpson et al. | Feb 2011 | A1 |
| 20110028815 | Simpson et al. | Feb 2011 | A1 |
| 20110028816 | Simpson et al. | Feb 2011 | A1 |
| 20110046467 | Simpson et al. | Feb 2011 | A1 |
| 20110087196 | Hunn et al. | Apr 2011 | A1 |
| 20110118579 | Goode, Jr. et al. | May 2011 | A1 |
| 20110124992 | Brauker et al. | May 2011 | A1 |
| 20110124997 | Goode, Jr. et al. | May 2011 | A1 |
| 20110128052 | Fujibe et al. | Jun 2011 | A1 |
| 20110130970 | Goode, Jr. et al. | Jun 2011 | A1 |
| 20110136249 | Stiene | Jun 2011 | A1 |
| 20110137601 | Goode, Jr. et al. | Jun 2011 | A1 |
| 20110178378 | Brister et al. | Jul 2011 | A1 |
| 20110190614 | Brister et al. | Aug 2011 | A1 |
| 20110201910 | Rasdal et al. | Aug 2011 | A1 |
| 20110218414 | Kamath et al. | Sep 2011 | A1 |
| 20110231140 | Goode, Jr. et al. | Sep 2011 | A1 |
| 20110231141 | Goode, Jr. et al. | Sep 2011 | A1 |
| 20110231142 | Goode, Jr. et al. | Sep 2011 | A1 |
| 20110253533 | Shults et al. | Oct 2011 | A1 |
| 20110263958 | Brauker et al. | Oct 2011 | A1 |
| 20110270158 | Brauker et al. | Nov 2011 | A1 |
| 20110290645 | Brister et al. | Dec 2011 | A1 |
| 20110313543 | Brauker et al. | Dec 2011 | A1 |
| 20110319739 | Kamath et al. | Dec 2011 | A1 |
| 20120265042 | Neinast et al. | Oct 2012 | A1 |
| 20120277562 | Brister et al. | Nov 2012 | A1 |
| 20130131478 | Simpson et al. | May 2013 | A1 |
| 20130267808 | Brister et al. | Oct 2013 | A1 |
| 20130281931 | Hunn et al. | Oct 2013 | A1 |
| 20140128704 | Simpson et al. | May 2014 | A1 |
| 20140257065 | Brister et al. | Sep 2014 | A1 |
| 20140288402 | Brister et al. | Sep 2014 | A1 |
| 20160008029 | Brister et al. | Jan 2016 | A1 |
| 20160051173 | Brister et al. | Feb 2016 | A1 |
| 20160310051 | Brister et al. | Oct 2016 | A1 |
| 20170196491 | Brister et al. | Jul 2017 | A1 |
| 20170367627 | Brister et al. | Dec 2017 | A1 |
| 20180014762 | Brister et al. | Jan 2018 | A1 |
| 20180049682 | Brister et al. | Feb 2018 | A1 |
| 20180055423 | Pryor et al. | Mar 2018 | A1 |
| 20180140236 | Brister et al. | May 2018 | A1 |
| 20180160949 | Brister et al. | Jun 2018 | A1 |
| 20180242894 | Brauker et al. | Aug 2018 | A1 |
| 20180303394 | Brauker et al. | Oct 2018 | A1 |
| 20190015020 | Brister et al. | Jan 2019 | A1 |
| 20190069817 | Brister et al. | Mar 2019 | A1 |
| 20190076071 | Brister et al. | Mar 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2127172 | Jul 1998 | CA |
| 2658734 | Jun 1978 | DE |
| 3144459 | Oct 1982 | DE |
| 4105222 | Aug 1992 | DE |
| 3933373 | Sep 1992 | DE |
| 20110059 | Aug 2002 | DE |
| 10117285 | Nov 2002 | DE |
| 0 098 592 | Jan 1984 | EP |
| 0107634 | May 1984 | EP |
| 0 127 958 | Dec 1984 | EP |
| 0 284 518 | Sep 1988 | EP |
| 0282349 | Sep 1988 | EP |
| 0286039 | Oct 1988 | EP |
| 0288793 | Nov 1988 | EP |
| 0143517 | Apr 1989 | EP |
| 0314027 | May 1989 | EP |
| 0 320 109 | Jun 1989 | EP |
| 0351892 | Jan 1990 | EP |
| 0352138 | Jan 1990 | EP |
| 0352610 | Jan 1990 | EP |
| 0352631 | Jan 1990 | EP |
| 0352708 | Jan 1990 | EP |
| 0 353 328 | Feb 1990 | EP |
| 0 390 390 | Oct 1990 | EP |
| 0396788 | Nov 1990 | EP |
| 0406473 | Jan 1991 | EP |
| 0420021 | Apr 1991 | EP |
| 0440044 | Aug 1991 | EP |
| 0441252 | Aug 1991 | EP |
| 0441394 | Aug 1991 | EP |
| 0457292 | Nov 1991 | EP |
| 0467078 | Jan 1992 | EP |
| 0471391 | Feb 1992 | EP |
| 0 476 980 | Mar 1992 | EP |
| 0473065 | Mar 1992 | EP |
| 0275139 | Apr 1992 | EP |
| 0477501 | Apr 1992 | EP |
| 0494704 | Sep 1992 | EP |
| 0494705 | Sep 1992 | EP |
| 0508388 | Oct 1992 | EP |
| 0512122 | Nov 1992 | EP |
| 0520430 | Dec 1992 | EP |
| 0520443 | Dec 1992 | EP |
| 0262328 | Jan 1993 | EP |
| 0319277 | Mar 1993 | EP |
| 0535898 | Apr 1993 | EP |
| 0539625 | May 1993 | EP |
| 0264036 | Jun 1993 | EP |
| 0351891 | Sep 1993 | EP |
| 0 563 795 | Oct 1993 | EP |
| 0567725 | Nov 1993 | EP |
| 0323605 | Jan 1994 | EP |
| 0279069 | Jul 1994 | EP |
| 0595474 | Jul 1994 | EP |
| 0561966 | Oct 1994 | EP |
| 0286118 | Jan 1995 | EP |
| 0478550 | Jan 1995 | EP |
| 0647849 | Apr 1995 | EP |
| 0424634 | Jun 1995 | EP |
| 0677743 | Oct 1995 | EP |
| 0191640 | Nov 1995 | EP |
| 0424633 | Jan 1996 | EP |
| 0690134 | Jan 1996 | EP |
| 0534074 | Mar 1996 | EP |
| 0709677 | May 1996 | EP |
| 0532187 | Oct 1996 | EP |
| 0470652 | Dec 1996 | EP |
| 0476715 | Dec 1996 | EP |
| 0747069 | Dec 1996 | EP |
| 0776628 | Jun 1997 | EP |
| 0387696 | Aug 1997 | EP |
| 0593096 | Dec 1997 | EP |
| 0838230 | Apr 1998 | EP |
| 0880936 | Dec 1998 | EP |
| 0885932 | Dec 1998 | EP |
| 0587008 | Feb 1999 | EP |
| 0967788 | Dec 1999 | EP |
| 0 995 805 | Apr 2000 | EP |
| 0678308 | May 2000 | EP |
| 1077634 | Feb 2001 | EP |
| 1078258 | Feb 2001 | EP |
| 1028320 | Mar 2001 | EP |
| 1111378 | Jun 2001 | EP |
| 1112717 | Jul 2001 | EP |
| 1112718 | Jul 2001 | EP |
| 1120084 | Aug 2001 | EP |
| 1120085 | Aug 2001 | EP |
| 1120650 | Aug 2001 | EP |
| 1130386 | Sep 2001 | EP |
| 1153571 | Nov 2001 | EP |
| 0817809 | Jul 2002 | EP |
| 1251137 | Oct 2002 | EP |
| 0958495 | Nov 2002 | EP |
| 1258728 | Nov 2002 | EP |
| 1266607 | Dec 2002 | EP |
| 1281351 | Feb 2003 | EP |
| 0824900 | Apr 2003 | EP |
| 1340980 | Sep 2003 | EP |
| 1340981 | Sep 2003 | EP |
| 1 077 636 | Jan 2004 | EP |
| 0674176 | Feb 2004 | EP |
| 1391728 | Feb 2004 | EP |
| 0846776 | Mar 2004 | EP |
| 0777122 | Apr 2004 | EP |
| 1413245 | Apr 2004 | EP |
| 1498067 | Jan 2005 | EP |
| 1498428 | Jan 2005 | EP |
| 1614464 | Jan 2006 | EP |
| 0922959 | Oct 2006 | EP |
| 1717924 | Nov 2006 | EP |
| 0877252 | Jan 2007 | EP |
| 1234053 | Apr 2007 | EP |
| 1798542 | Jun 2007 | EP |
| 1286164 | Jul 2007 | EP |
| 1804650 | Jul 2007 | EP |
| 1612560 | Oct 2007 | EP |
| 1905514 | Apr 2008 | EP |
| 1582874 | Jul 2008 | EP |
| 1977829 | Oct 2008 | EP |
| 1982644 | Oct 2008 | EP |
| 1457913 | Dec 2008 | EP |
| 2223710 | Sep 2010 | EP |
| 2226086 | Sep 2010 | EP |
| 2228642 | Sep 2010 | EP |
| 2236077 | Oct 2010 | EP |
| 2327362 | Jun 2011 | EP |
| 2329770 | Sep 2014 | EP |
| 2407094 | Oct 2014 | EP |
| 2335584 | May 2015 | EP |
| 2656423 | Jun 1991 | FR |
| 2760962 | Sep 1998 | FR |
| 1442303 | Jul 1976 | GB |
| 1556969 | Dec 1979 | GB |
| 2149918 | Jun 1985 | GB |
| S5441190 | Apr 1979 | JP |
| S57156004 | Sep 1982 | JP |
| S58124912 | Jul 1983 | JP |
| S59211459 | Nov 1984 | JP |
| S61271418 | Dec 1986 | JP |
| 62083849 | Apr 1987 | JP |
| S6283649 | Apr 1987 | JP |
| 02002913 | Jan 1990 | JP |
| 3-293556 | Dec 1991 | JP |
| H06288853 | Oct 1994 | JP |
| H06307898 | Nov 1994 | JP |
| H0783871 | Mar 1995 | JP |
| H11258381 | Sep 1999 | JP |
| 2000060826 | Feb 2000 | JP |
| 2000149072 | May 2000 | JP |
| 2002513602 | May 2002 | JP |
| 2002189015 | Jul 2002 | JP |
| 2003108679 | Apr 2003 | JP |
| 2003297163 | Oct 2003 | JP |
| WO 1981-003614 | Dec 1981 | WO |
| WO-8706342 | Oct 1987 | WO |
| WO-8706706 | Nov 1987 | WO |
| WO-8808137 | Oct 1988 | WO |
| WO 1989-02720 | Apr 1989 | WO |
| WO-8904302 | May 1989 | WO |
| WO-8907263 | Aug 1989 | WO |
| WO-9000738 | Jan 1990 | WO |
| WO-9002938 | Mar 1990 | WO |
| WO-9005296 | May 1990 | WO |
| WO-9005301 | May 1990 | WO |
| WO-9005302 | May 1990 | WO |
| WO-9005910 | May 1990 | WO |
| WO-9007525 | Jul 1990 | WO |
| WO-9007575 | Jul 1990 | WO |
| WO-9010716 | Sep 1990 | WO |
| WO-9010861 | Sep 1990 | WO |
| WO-9013021 | Nov 1990 | WO |
| WO 1991-09302 | Jun 1991 | WO |
| WO-9115993 | Oct 1991 | WO |
| WO-9116416 | Oct 1991 | WO |
| WO-9117259 | Nov 1991 | WO |
| WO-9201315 | Jan 1992 | WO |
| WO-9201928 | Feb 1992 | WO |
| WO-9207525 | May 1992 | WO |
| WO-9208985 | May 1992 | WO |
| WO-9210584 | Jun 1992 | WO |
| WO-9212255 | Jul 1992 | WO |
| WO 1992-13271 | Aug 1992 | WO |
| WO-9214138 | Aug 1992 | WO |
| WO-9214139 | Aug 1992 | WO |
| WO-9218887 | Oct 1992 | WO |
| WO-9221772 | Dec 1992 | WO |
| WO-9301308 | Jan 1993 | WO |
| WO-9302703 | Feb 1993 | WO |
| WO-9303362 | Feb 1993 | WO |
| WO-9305701 | Apr 1993 | WO |
| WO-9312256 | Jun 1993 | WO |
| WO-9313048 | Jul 1993 | WO |
| WO-9313408 | Jul 1993 | WO |
| WO-9314185 | Jul 1993 | WO |
| WO 1993-14693 | Aug 1993 | WO |
| WO-9319370 | Sep 1993 | WO |
| WO-9319701 | Oct 1993 | WO |
| WO-9320240 | Oct 1993 | WO |
| WO-9320440 | Oct 1993 | WO |
| WO-9320441 | Oct 1993 | WO |
| WO-9320443 | Oct 1993 | WO |
| WO-9320444 | Oct 1993 | WO |
| WO-9320450 | Oct 1993 | WO |
| WO 1993-23744 | Nov 1993 | WO |
| WO-9406011 | Mar 1994 | WO |
| WO-9406012 | Mar 1994 | WO |
| WO-9408236 | Apr 1994 | WO |
| WO-9409506 | Apr 1994 | WO |
| WO-9409507 | Apr 1994 | WO |
| WO-9419695 | Sep 1994 | WO |
| WO-9421642 | Sep 1994 | WO |
| WO-9421643 | Sep 1994 | WO |
| WO-9421644 | Sep 1994 | WO |
| WO-9422367 | Oct 1994 | WO |
| WO-9426414 | Nov 1994 | WO |
| WO 1995-02357 | Jan 1995 | WO |
| WO 1995-07109 | Mar 1995 | WO |
| WO-9508774 | Mar 1995 | WO |
| WO-9510044 | Apr 1995 | WO |
| WO-9511454 | Apr 1995 | WO |
| WO-9513838 | May 1995 | WO |
| WO-9517966 | Jul 1995 | WO |
| WO-9522597 | Aug 1995 | WO |
| WO 1997-019344 | Nov 1995 | WO |
| WO-9528878 | Nov 1995 | WO |
| WO-9534814 | Dec 1995 | WO |
| WO-9601611 | Jan 1996 | WO |
| WO-9603117 | Feb 1996 | WO |
| WO-9605501 | Feb 1996 | WO |
| WO-9606947 | Mar 1996 | WO |
| WO-9614026 | May 1996 | WO |
| WO 199625088 | Aug 1996 | WO |
| WO 1996-25089 | Aug 1996 | WO |
| WO-9622991 | Aug 1996 | WO |
| WO-9622992 | Aug 1996 | WO |
| WO-9624690 | Aug 1996 | WO |
| WO-9630431 | Oct 1996 | WO |
| WO-9632076 | Oct 1996 | WO |
| WO-9636296 | Nov 1996 | WO |
| WO-9636870 | Nov 1996 | WO |
| WO-9641179 | Dec 1996 | WO |
| WO 1997-01986 | Jan 1997 | WO |
| WO-9702811 | Jan 1997 | WO |
| WO 1997-06727 | Feb 1997 | WO |
| WO-9711080 | Mar 1997 | WO |
| WO-9713874 | Apr 1997 | WO |
| WO 1997-17884 | May 1997 | WO |
| WO-9719188 | May 1997 | WO |
| WO-9728737 | Aug 1997 | WO |
| WO-9730628 | Aug 1997 | WO |
| WO-9733176 | Sep 1997 | WO |
| WO-9738625 | Oct 1997 | WO |
| WO-9743633 | Nov 1997 | WO |
| WO-9801071 | Jan 1998 | WO |
| WO-9806423 | Feb 1998 | WO |
| WO 1998-19159 | May 1998 | WO |
| WO 1998-24358 | Jun 1998 | WO |
| WO-9824366 | Jun 1998 | WO |
| WO 199833549 | Aug 1998 | WO |
| WO-9834541 | Aug 1998 | WO |
| WO 1998-38906 | Sep 1998 | WO |
| WO-9838904 | Sep 1998 | WO |
| WO-9841854 | Sep 1998 | WO |
| WO 199842249 | Oct 1998 | WO |
| WO-9844347 | Oct 1998 | WO |
| WO-9844348 | Oct 1998 | WO |
| WO-9845331 | Oct 1998 | WO |
| WO-9845427 | Oct 1998 | WO |
| WO-9852043 | Nov 1998 | WO |
| WO 1998-56293 | Dec 1998 | WO |
| WO 1998-058250 | Dec 1998 | WO |
| WO-9856923 | Dec 1998 | WO |
| WO-9904043 | Jan 1999 | WO |
| WO 1999-012607 | Mar 1999 | WO |
| WO-9913101 | Mar 1999 | WO |
| WO-9913574 | Mar 1999 | WO |
| WO 1999-56613 | Apr 1999 | WO |
| WO 1999-029230 | Jun 1999 | WO |
| WO-9927848 | Jun 1999 | WO |
| WO-9927852 | Jun 1999 | WO |
| WO-9929429 | Jun 1999 | WO |
| WO-9929892 | Jun 1999 | WO |
| WO 199933504 | Jul 1999 | WO |
| WO-9940848 | Aug 1999 | WO |
| WO-9948419 | Sep 1999 | WO |
| WO-9949856 | Oct 1999 | WO |
| WO-9958051 | Nov 1999 | WO |
| WO-9958709 | Nov 1999 | WO |
| WO-9958973 | Nov 1999 | WO |
| WO-9959657 | Nov 1999 | WO |
| WO-9964620 | Dec 1999 | WO |
| WO-0007013 | Feb 2000 | WO |
| WO-0012720 | Mar 2000 | WO |
| WO-0013002 | Mar 2000 | WO |
| WO-0013003 | Mar 2000 | WO |
| WO 2000-019887 | Apr 2000 | WO |
| WO-0018449 | Apr 2000 | WO |
| WO-0020626 | Apr 2000 | WO |
| WO 2000-032098 | Jun 2000 | WO |
| WO 2000-033065 | Jun 2000 | WO |
| WO-0030530 | Jun 2000 | WO |
| WO-0035530 | Jun 2000 | WO |
| WO 2000-049940 | Aug 2000 | WO |
| WO 2000049941 | Aug 2000 | WO |
| WO 2000049942 | Aug 2000 | WO |
| WO-0045696 | Aug 2000 | WO |
| WO 2000-059373 | Oct 2000 | WO |
| WO 2000-074753 | Dec 2000 | WO |
| WO-0078210 | Dec 2000 | WO |
| WO-0078992 | Dec 2000 | WO |
| WO-0079258 | Dec 2000 | WO |
| WO-0100865 | Jan 2001 | WO |
| WO 2001-012158 | Feb 2001 | WO |
| WO-0109096 | Feb 2001 | WO |
| WO 2001-020019 | Mar 2001 | WO |
| WO-0116579 | Mar 2001 | WO |
| WO-0120334 | Mar 2001 | WO |
| WO-0121827 | Mar 2001 | WO |
| WO-0134243 | May 2001 | WO |
| WO-0136666 | May 2001 | WO |
| WO-0143660 | Jun 2001 | WO |
| WO 2001052935 | Jul 2001 | WO |
| WO-0152727 | Jul 2001 | WO |
| WO 2001-058348 | Aug 2001 | WO |
| WO-0154753 | Aug 2001 | WO |
| WO-0158347 | Aug 2001 | WO |
| WO-01594254 | Aug 2001 | WO |
| WO 2001064105 | Sep 2001 | WO |
| WO-0168901 | Sep 2001 | WO |
| WO-0169222 | Sep 2001 | WO |
| WO 2001-073109 | Oct 2001 | WO |
| WO-0188524 | Nov 2001 | WO |
| WO-0188534 | Nov 2001 | WO |
| WO-0191634 | Dec 2001 | WO |
| WO 2002-007617 | Jan 2002 | WO |
| WO-0202755 | Jan 2002 | WO |
| WO-0205702 | Jan 2002 | WO |
| WO-0207596 | Jan 2002 | WO |
| WO-0216535 | Feb 2002 | WO |
| WO-0217780 | Mar 2002 | WO |
| WO-0224065 | Mar 2002 | WO |
| WO-0233407 | Apr 2002 | WO |
| WO 2002-043585 | Jun 2002 | WO |
| WO-02056751 | Jul 2002 | WO |
| WO 2002-058537 | Aug 2002 | WO |
| WO-02062210 | Aug 2002 | WO |
| WO-02066509 | Aug 2002 | WO |
| WO-02066986 | Aug 2002 | WO |
| WO-02074161 | Sep 2002 | WO |
| WO-02082989 | Oct 2002 | WO |
| WO-02087681 | Nov 2002 | WO |
| WO-02089666 | Nov 2002 | WO |
| WO 2002-100457 | Dec 2002 | WO |
| WO-02097414 | Dec 2002 | WO |
| WO-02099097 | Dec 2002 | WO |
| WO-02099428 | Dec 2002 | WO |
| WO-02100266 | Dec 2002 | WO |
| WO-02100474 | Dec 2002 | WO |
| WO-03000127 | Jan 2003 | WO |
| WO-03008013 | Jan 2003 | WO |
| WO-03008014 | Jan 2003 | WO |
| WO-03009207 | Jan 2003 | WO |
| WO-03009208 | Jan 2003 | WO |
| WO-03011131 | Feb 2003 | WO |
| WO-03012422 | Feb 2003 | WO |
| WO-03022327 | Mar 2003 | WO |
| WO 2003-028797 | Apr 2003 | WO |
| WO-03032411 | Apr 2003 | WO |
| WO-03033726 | Apr 2003 | WO |
| WO-03035117 | May 2003 | WO |
| WO-03036310 | May 2003 | WO |
| WO-03044511 | May 2003 | WO |
| WO-03053498 | Jul 2003 | WO |
| WO-03057028 | Jul 2003 | WO |
| WO-03063700 | Aug 2003 | WO |
| WO 2003-072164 | Sep 2003 | WO |
| WO 2003-082091 | Sep 2003 | WO |
| WO-03072269 | Sep 2003 | WO |
| WO-03076937 | Sep 2003 | WO |
| WO-03088832 | Oct 2003 | WO |
| WO 2003094714 | Nov 2003 | WO |
| WO 2003097866 | Nov 2003 | WO |
| WO 2005-065542 | Dec 2003 | WO |
| WO-03101862 | Dec 2003 | WO |
| WO-03106031 | Dec 2003 | WO |
| WO-03106966 | Dec 2003 | WO |
| WO-2004004905 | Jan 2004 | WO |
| WO 2004-010844 | Feb 2004 | WO |
| WO-2004030726 | Apr 2004 | WO |
| WO-2004036183 | Apr 2004 | WO |
| WO-2004039265 | May 2004 | WO |
| WO 2004052190 | Jun 2004 | WO |
| WO 2004060455 | Jul 2004 | WO |
| WO-2004061420 | Jul 2004 | WO |
| WO-2004063718 | Jul 2004 | WO |
| WO-2004071291 | Aug 2004 | WO |
| WO-2004073138 | Aug 2004 | WO |
| WO-2004086970 | Oct 2004 | WO |
| WO 2004-098685 | Nov 2004 | WO |
| WO-2004105641 | Dec 2004 | WO |
| WO-2004110256 | Dec 2004 | WO |
| WO-2004113901 | Dec 2004 | WO |
| WO 2005-011489 | Feb 2005 | WO |
| WO 2005-012873 | Feb 2005 | WO |
| WO-2005013824 | Feb 2005 | WO |
| WO 2005026689 | Mar 2005 | WO |
| WO-2005018443 | Mar 2005 | WO |
| WO-2005026178 | Mar 2005 | WO |
| WO-2005026690 | Mar 2005 | WO |
| WO-2005032362 | Apr 2005 | WO |
| WO-2005032400 | Apr 2005 | WO |
| WO-2005041766 | May 2005 | WO |
| WO-2005048834 | Jun 2005 | WO |
| WO-2005051440 | Jun 2005 | WO |
| WO-2005057168 | Jun 2005 | WO |
| WO-2005057173 | Jun 2005 | WO |
| WO-2005057175 | Jun 2005 | WO |
| WO-2005063115 | Jul 2005 | WO |
| WO-2005067797 | Jul 2005 | WO |
| WO-2005070287 | Aug 2005 | WO |
| WO-2005074811 | Aug 2005 | WO |
| WO-2005078424 | Aug 2005 | WO |
| WO-2005084530 | Sep 2005 | WO |
| WO-2005084545 | Sep 2005 | WO |
| WO-2005084546 | Sep 2005 | WO |
| WO-2005089103 | Sep 2005 | WO |
| WO-2005094714 | Oct 2005 | WO |
| WO-2005098431 | Oct 2005 | WO |
| WO-2005107594 | Nov 2005 | WO |
| WO-2005114218 | Dec 2005 | WO |
| WO-2005121355 | Dec 2005 | WO |
| WO-2005121785 | Dec 2005 | WO |
| WO-2005122296 | Dec 2005 | WO |
| WO-2006001929 | Jan 2006 | WO |
| WO-2006001973 | Jan 2006 | WO |
| WO-2006002960 | Jan 2006 | WO |
| WO-2006005503 | Jan 2006 | WO |
| WO 2006-017358 | Feb 2006 | WO |
| WO-2006010533 | Feb 2006 | WO |
| WO-2006018425 | Feb 2006 | WO |
| WO-2006019665 | Feb 2006 | WO |
| WO-2006021430 | Mar 2006 | WO |
| WO-2006024671 | Mar 2006 | WO |
| WO-2006029293 | Mar 2006 | WO |
| WO-2006050405 | May 2006 | WO |
| WO-2006050843 | May 2006 | WO |
| WO-2006060806 | Jun 2006 | WO |
| WO-2006071770 | Jul 2006 | WO |
| WO-2006072089 | Jul 2006 | WO |
| WO-2006076412 | Jul 2006 | WO |
| WO-2006088576 | Aug 2006 | WO |
| WO-2006098887 | Sep 2006 | WO |
| WO-2006099151 | Sep 2006 | WO |
| WO-2006102359 | Sep 2006 | WO |
| WO-2006102412 | Sep 2006 | WO |
| WO 2006-105146 | Oct 2006 | WO |
| WO-2006104843 | Oct 2006 | WO |
| WO-2006108811 | Oct 2006 | WO |
| WO-2006118713 | Nov 2006 | WO |
| WO-2006122048 | Nov 2006 | WO |
| WO-2006122553 | Nov 2006 | WO |
| WO-2006124759 | Nov 2006 | WO |
| WO 2008-088490 | Dec 2006 | WO |
| WO-2006130268 | Dec 2006 | WO |
| WO-2006131288 | Dec 2006 | WO |
| WO-2006132884 | Dec 2006 | WO |
| WO-2006133171 | Dec 2006 | WO |
| WO-2007002209 | Jan 2007 | WO |
| WO-2007002579 | Jan 2007 | WO |
| WO-2007005170 | Jan 2007 | WO |
| WO-2007006454 | Jan 2007 | WO |
| WO-2007009911 | Jan 2007 | WO |
| WO-2007011587 | Jan 2007 | WO |
| WO-2007016399 | Feb 2007 | WO |
| WO-2007021892 | Feb 2007 | WO |
| WO-2007021894 | Feb 2007 | WO |
| WO-2007025088 | Mar 2007 | WO |
| WO-2007028138 | Mar 2007 | WO |
| WO-2007028271 | Mar 2007 | WO |
| WO-2007033010 | Mar 2007 | WO |
| WO-2007037970 | Apr 2007 | WO |
| WO-2007037989 | Apr 2007 | WO |
| WO-2007040559 | Apr 2007 | WO |
| WO-2007041070 | Apr 2007 | WO |
| WO-2007041072 | Apr 2007 | WO |
| WO-2007041248 | Apr 2007 | WO |
| WO-2007053832 | May 2007 | WO |
| WO-2007056638 | May 2007 | WO |
| WO-2007058921 | May 2007 | WO |
| WO-2007059476 | May 2007 | WO |
| WO-2007059478 | May 2007 | WO |
| WO-2007061992 | May 2007 | WO |
| WO-2007065285 | Jun 2007 | WO |
| WO-2007070486 | Jun 2007 | WO |
| WO-2007076303 | Jul 2007 | WO |
| WO-2007079015 | Jul 2007 | WO |
| WO-2007079025 | Jul 2007 | WO |
| WO-2007081811 | Jul 2007 | WO |
| WO-2007090037 | Aug 2007 | WO |
| WO-2007097754 | Aug 2007 | WO |
| WO-2007101223 | Sep 2007 | WO |
| WO-2007101260 | Sep 2007 | WO |
| WO-2007109372 | Sep 2007 | WO |
| WO-2007111885 | Oct 2007 | WO |
| WO-2007112006 | Oct 2007 | WO |
| WO-2007114943 | Oct 2007 | WO |
| WO-2007115094 | Oct 2007 | WO |
| WO-2007120363 | Oct 2007 | WO |
| WO-2007127606 | Nov 2007 | WO |
| WO-2007127622 | Nov 2007 | WO |
| WO-2007127879 | Nov 2007 | WO |
| WO-2007127880 | Nov 2007 | WO |
| WO-2007130239 | Nov 2007 | WO |
| WO-2007137286 | Nov 2007 | WO |
| WO-2007143225 | Dec 2007 | WO |
| WO-2008001091 | Jan 2008 | WO |
| WO-2008003003 | Jan 2008 | WO |
| WO-2008005780 | Jan 2008 | WO |
| WO-2008013849 | Jan 2008 | WO |
| WO-2008016486 | Feb 2008 | WO |
| WO-2008021913 | Feb 2008 | WO |
| WO-2008022021 | Feb 2008 | WO |
| WO 2008028644 | Mar 2008 | WO |
| WO-2008031106 | Mar 2008 | WO |
| WO-2008031110 | Mar 2008 | WO |
| WO-2008037485 | Apr 2008 | WO |
| WO-2008039944 | Apr 2008 | WO |
| WO-2008039946 | Apr 2008 | WO |
| WO-2008039949 | Apr 2008 | WO |
| WO-2008042760 | Apr 2008 | WO |
| WO-2008048709 | Apr 2008 | WO |
| WO-2008051407 | May 2008 | WO |
| WO-2008051924 | May 2008 | WO |
| WO-2008052199 | May 2008 | WO |
| WO-2008055037 | May 2008 | WO |
| WO-2008055128 | May 2008 | WO |
| WO-2008055199 | May 2008 | WO |
| WO 2008069931 | Jun 2008 | WO |
| WO 2008101217 | Jun 2008 | WO |
| WO-2008067314 | Jun 2008 | WO |
| WO-2008069932 | Jun 2008 | WO |
| WO-2008073813 | Jun 2008 | WO |
| WO-2008076868 | Jun 2008 | WO |
| WO 2008079616 | Jul 2008 | WO |
| WO-2008080591 | Jul 2008 | WO |
| WO-2008083379 | Jul 2008 | WO |
| WO-2008094249 | Aug 2008 | WO |
| WO-2008101211 | Aug 2008 | WO |
| WO-2008103620 | Aug 2008 | WO |
| WO-2006023241 | Oct 2008 | WO |
| WO-2008116329 | Oct 2008 | WO |
| WO-2008118257 | Oct 2008 | WO |
| WO-2008119470 | Oct 2008 | WO |
| WO-2008124597 | Oct 2008 | WO |
| WO 2008138006 | Nov 2008 | WO |
| WO-2008134441 | Nov 2008 | WO |
| WO-2008135453 | Nov 2008 | WO |
| WO-2008137405 | Nov 2008 | WO |
| WO-2008150280 | Dec 2008 | WO |
| WO-2008150917 | Dec 2008 | WO |
| WO-2008150946 | Dec 2008 | WO |
| WO-2008150949 | Dec 2008 | WO |
| WO-2009006139 | Jan 2009 | WO |
| WO-2009105709 | Aug 2009 | WO |
| WO 2006-017358 | Feb 2016 | WO |
| Entry |
|---|
| US 7,530,950 B2, 05/2009, Brister et al. (withdrawn) |
| Bergveld et al., 1993. Fabrication and Mass Production. Advances in Biosensors, Supplement 1 (1993) Chapter 6; 165-186. |
| Kusano, H. 1989. Glucose enzyme electrode with percutaneous interface which operates independently of dissolved oxygen. Clin Phys Physiol Meas. 10(1):1-9. |
| Reach et at, 1993. Clinical Needs for In Vivo Monitoring. Advances in Biosensors, Supplement 1 Chapter 1; 7-28. |
| Shichin et al., 1988. In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers. Implantable Glucose Sensors—The State of the Art, Hormone and Metabolic Research Supplement Series vol. No. 20 (1988) 17-20. |
| EP App. No. 10195496.4, filed Dec. 16, 2010: European Office Action dated Dec. 15, 2011. |
| EP App. No. 10195496.4, filed Dec. 16, 2010: Response to Office Action filed Jun. 22, 2012. |
| EP App. No. 10195520.1, filed Dec. 16, 2010: European Extended Search Report dated Aug. 3, 2011 |
| EP App. No. 10195520.1, filed Dec. 16, 2010: European Office Action dated Jul. 19, 2012 for Application No. EP 10195520.1, filed Jul. 13, 2005; 4 pages. |
| EP App. No. 10195520.1, filed Dec. 16, 2010: Response to Office Action filed Jan. 16, 2013. |
| EP App. No. 1986543. Granted Dec. 14, 2011: Notice of Opposition dated Jul. 25, 2012. |
| JP App. No. 2011-121598, filed May 31, 2011: Office Action dated May 22, 2012. |
| U.S. Control No. 90/012558, filed Sep. 13, 2012: Request for Ex Parte Reexamination of U.S. Pat. No. 7,310,544. |
| U.S. Control No. 95/002333, filed Sep. 14, 2012: Request for Inter Partes Reexamination of U.S. Pat. No. 7,713,574. |
| U.S. Appl. No. 12/359,207, filed Jan. 23, 2009: Office Action dated Jan. 20, 2012. |
| Aalders et al. 1991, Development of a wearable glucose sensor; studies in healthy volunteers and in diabetic patients. The International Journal of Artificial Organs 14(2): 102-108. |
| Abe et al. 1992. Characterization of glucose microsensors for intracellular measurements. Anal. Chem. 64(18):2160-2163. |
| Abel et al. 1984. Experience with an implantable glucose sensor as a prerequisite of an artificial beta cell, Biomedica Biochimica Acta 43(51:577-584. |
| Abel et al. 2002. Biosensors for in vivo glucose measurement: can we cross the experimental stage. Biosensors & Bioelectronics 17:1059-1070. |
| Alcock & Turner. 1994. Continuous Analyte Monitoring to Aid Clinical Practice. IEEE Engineering in Medicine & Biology 13:319-325. |
| American Heritage Dictionary, 4th Edition. 2000. Houghton Mifflin Company, p. 82. |
| Amin et al. 2003. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: Use of continuous glucose monitoring system. Diabetes Care 26(3):662-667. |
| Answers.com. “xenogenic.” The American Heritage Stedman's Medical Dictionary. Houghton Mifflin Company, 2002. Answers.com Nov. 7, 2006 http:--www. Answers.com-topic-xenogenic. |
| Armour et al. Dec. 1990. Application of Chronic lntravascular Blood Glucose Sensor in Dogs. Diabetes 39:1519-1526. |
| Atanasov et al. 1994. Biosensor for continuous glucose monitoring. Biotechnology & Bioengineering 43:262-266. |
| Atanasov et al. 1997. Implantation of a refillable glucose monitoring-telemetry device. Biosensors & Bioelectronics 12:669-680. |
| Aussedat et al. 1997. A user-friendly method for calibrating a subcutaneous glucose sensor-based hypoglycaemic alarm. Biosensors & Bioelectronics 12( 11): 1061-1071. |
| Bailey et al. 2007. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technology & Therapeutics 9(3):203-210. |
| Beach et al. 1999. Subminiature implantable potentiostat and modified commercial telemetry device for remote glucose monitoring. IEEE Transactions on Instrumentation and Measurement 48(6):1239-1245. |
| Bellucci et al. Jan. 1986. Electrochemical behaviour of graphite-epoxy composite materials (GECM) in aqueous salt solutions, Journal of Applied Electrochemistry, 16( 1): 15-22. |
| Bessman et al., Progress toward a glucose sensor for the artificial pancreas, Proceedings of a Workshop on Ion-Selective Microelectrodes, Jun. 4-5, 1973; Boston, MA, 189-197. |
| Biermann et al. 2008. How would patients behave if they were continually informed of their blood glucose levels? A simulation study using a “virtual” patient. Diabetes Technology & Therapeutics 10:178-187. |
| Bindra et al. 1991. Design and In Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring. Analytical Chemistry 63:1692-96. |
| Bisenberger et al. 1995, A triple-step potential waveform at enzyme multisensors with thick-film gold electrodes for detection of glucose and sucrose. Sensors & Actuators, B 28:181-189. |
| Bland et al. 1990. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput. Biol. Med. 20(5):337-340. |
| Bobbioni-Harsch et al. 1993. Lifespan of subcutaneous glucose sensors and their performances during dynamic glycaemia changes in rats. J. Biomedical Engineering 15:457-463. |
| Bode et al. 1999. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study. Diabetes Research and Clinical Practice 46:183-190. |
| Bode et al. 2000. Using the continuous glucose monitoring system to improve the management of type 1 diabetes. Diabetes Technology & Therapeutics, 2(Suppl 1):S43-48. |
| Bode, B. W. 2000. Clinical utility of the continuous glucose monitoring system. Diabetes Technology & Therapeutics 2(Suppl 1):S35-41. |
| Boedeker Plastics, Inc. 2009. Polyethylene Specifications Data Sheet, http:--www.boedeker.com-polve_p.htm [Aug. 19, 2009 3:36:33 PM]. |
| Boland et al. 2001, Limitations of conventional methods of self-monitoring of blood glucose. Diabetes Care 24(11): 1858-1862. |
| Bowman et al. 1986. The packaging of implantable integrated sensors. IEEE Transactions on Biomedical Engineering BME33(2):248-255. |
| Brauker et al. Jun. 27, 1996. Local Inflammatory Response Around Diffusion Chambers Containing Xenografts. Transplantation 61(12):1671-1677. |
| Braunwald, 2008. Biomarkers in heart failure. N. Engl. J. Med., 358: 2148-2159. |
| Bremer et al. 2001. Benchmark data from the literature for evaluation of new glucose sensing technologies. Diabetes Technology & Therapeutics 3(3):409-418. |
| Brooks et al., 1987-88. Development of an on-line glucose sensor for fermentation monitoring. Biosensors 3:45-56 (1987-88). |
| Bruckel et al. 1989. In vivo measurement of subcutaneous glucose concentrations with an enzymatic glucose sensor and a wick method. Klin Wochenschr 67:491-495. |
| Cai et al. 2004. A wireless, remote query glucose biosensor based on a pH-sensitive polymer, Analytical Chemistry 76(4):4038-4043. |
| Campanella et al. 1993. Biosensor for direct determination of glucose and lactate in undiluted biological fluids. Biosensors & Bioelectronics 8:307-314. |
| Candas et al. 1994. An adaptive plasma glucose controller based on a nonlinear insulin-glucose model . IEEE Transactions on Biomedical Engineering, 41(2): 116-124. |
| Cass et al. 1984. “Ferrocene-mediated enzyme electrodes for amperometric determination of glucose,” Analytical Chemistry 36:667-71. |
| Cassidy et al., Apr. 1993. Novel electrochemical device for the detection of cholesterol or glucose. Analyst 118:415-418. |
| Chase et al. 2001. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 107:222-226. |
| Ciba® Irgacure® 2959 Photoinitiator, Product Description. Apr. 2, 1998, Ciba Specialty Chemicals Inc., Basel, Switzerland. 3 pages. |
| Claremont et al. 1986, Subcutaneous implantation of a ferrocene-mediated glucose sensor in pigs. Diabetologia 29:817-821. |
| Claremont et al. Jul. 1986. Potentially-implantable, ferrocene-mediated glucose sensor. J. Biomedical Engineering 8:272-274. |
| Clark et al. 1981. One-minute electrochemical enzymic assay for cholesterol in biological materials, Clinical Chemistry 27(12): 1978-1982. |
| Clark et al. 1987. Configurational cyclic voltammetry: increasing the specificity and reliability of implanted electrodes; IEEE-Ninth Annual Conference of the Engineering in Medicine and Biology Society, pp. 0782-0783. |
| Clark et al. 1988. Long-term stability of electroenzymatic glucose sensors implanted in mice. Trans Am Soc Artif Intern Organs 34:259-265. |
| CLSI. 2008. Performance metrics for continuous interstitial glucose monitoring; approved guideline, CLSI document POCT05-A. Wayne, PA: Clinical and Laboratory Standards Institute. 28(33), 72 pp. |
| Colangelo et al. 1967. Corrosion rate measurements in vivo. Journal of Biomedical Materials Research 1:405-414. |
| Colowick et al. 1976. Methods in Enzymology, vol. XLIV, Immobilized Enzymes. New York: Academic Press. 11 pages. |
| Cox et al. 1985. Accuracy of perceiving blood glucose in IDDM. Diabetes Care 8(6):529-536. |
| Csoregi et al., 1994. Design, characterization, and one-point in vivo calibration of a subcutaneously implanted glucose electrode. Analytical Chemistry 66(19):3131-3138. |
| Danielsson et al. 1988, Enzyme thermistors, Methods in Enzymology, 137:181-197. |
| Dessau et al. 2009. In silico evaluation platform for artificial pancreatic (3-cell development-a dynamic simulator for closed loop control with hardware-in-the-loop. Diabetes Technology & Therapeutics 11(3):1-8. |
| Davies, et al. 1992. Polymer membranes in clinical sensor applications. I. An overview of membrane function. Biomaterials 13(14):971-978. |
| Davis et al. 1983. Bioelectrochemical fuel cell and sensor based on a quinoprotein, alcohol dehydrogenase. Enzyme Microb. Technol. vol. 5, September, 383-388. |
| Direct 30-30® Blood Glucose Sensor, (Markwell Medical) Catalog, © 1990, ELCO Diagnostics Company. 1 page. |
| Dixon et al. 2002. Characterization in vitro and in vivo of the oxygen dependence of an enzyme-polymer biosensor for monitoring brain glucose. Journal of Neuroscience Methods 119:135-142. |
| DuPont Dimension AR®. 1998. The chemistry analyzer that makes the most of your time, money and effort. Catalog. Dade International, Chemistry Systems. Newark, DE. 18 pages. |
| Durliat et al. 1976. Spectrophotometric and electrochemical determinatians of L(+)-lactate in blood by use of lactate dehydrogenase from yeast. Clinical Chemistry 22(11):1802-1805. |
| Edwards Lifesciences. 2002. Accuracy for you and your patients. Marketing materials, 4 pages. |
| El Degheidy et al. 1986. Optimization of an implantable coated wire glucose sensor. J. Biomedical Engineering. 8: 21-129. |
| El-Khatib et al. 2007. Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine. Journal of Diabetes Science and Technology, 1(2):181-192. |
| El-Sa'ad et al. 1990. Moisture Absorption by Epoxy Resins: the Reverse Thermal Effect. Journal of Materials Science 25:3577-3582. |
| Ernst et al. 2002. Reliable glucose monitoring through the use of microsystem technology. Analytical and Bioanalytical Chemistry 373:758-761. |
| Fahy et al. Mar. 2008. An analysis: hyperglycemic intensive care patients need continuous glucose monitoring—easier said than done. Journal of Diabetes Science and Technology, 2(2):201-204. |
| Fare et al. 1998. Functional characterization of a conducting polymer-based immunoassay system. Biosensors& Bioelectronics 13(3-4):459-470. |
| Feldman et al. 2003. A continuous glucose sensor based on wired enzyme technology—results from a 3-day trial in patients with type 1 diabetes. Diabetes Technology & Therapeutics 5(5):769-779. |
| Fischer et al. 1987. Assessment of subcutaneous glucose concentration: validation of the wick technique as a reference for implanted electrochemical sensors in normal and diabetic dogs. Diabetologia 30:940-945. |
| Fischer et al. 1989. Oxygen Tension at the Subcutaneous Implantation Site of Glucose Sensors. Biomed. Biochem 11-12:965-972. |
| Fischer et al. 1995. Abstract: Hypoglycaemia-warning by means of subcutaneous electrochemical glucose sensors: an animal study. Norm. Metab. Res. 27:53. |
| Freedman et al. 1991. Statistics, Second Edition, W.W. Norton & Company; p. 74. |
| Frohnauer et al. 2001. Graphical human insulin time-activity profiles using standardized definitions. Diabetes Technology & Therapeutics 3(3):419-429. |
| Frost et al. 2002. Implantable chemical sensors for real-time clinical monitoring: Progress and challenges. Current Opinion in Chemical Biology 6:633-641. |
| Gabbay et al. 2008. Optical coherence tomography-based continuous noninvasive glucose monitoring in patients with diabetes. Diab. Technology & Therapeutics 10:188-193. |
| Ganesan et al., 2005. Gold layer-based dual crosslinking procedure of glucose oxidase with ferrocene monocarboxylic acid provides a stable biosensor. Analytical Biochemistry 343:188-191. |
| Ganesh et al. Mar. 2008. Evaluation of the VIA® blood chemistry monitor for glucose in healthy and diabetic volunteers. Journal of Diabetes Science and Technology, 2(2): 182-193. |
| Garg et al. 2004 . Improved Glucose Excursions Using an Implantable Real-Time continuous Glucose Sensor in Adults with Type I Diabetes. Diabetes Care 27:734-738. |
| Gerritsen et al. 1999. Performance of subcutaneously implanted glucose sensors for continuous monitoring. The Netherlands Journal of Medicine 54:167-179. |
| Gerritsen, M. 2000. Problems associated with subcutaneously implanted glucose sensors. Diabetes Care 23(2): 143-145. |
| Gilligan et al. 1994: Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care 17(8):882-887. |
| Gilligan et al. 2004. Feasibility of continuous long-term glucose monitoring from a subcutaneous glucose sensor in humans. Diabetes Technology & Therapeutics 6:378-386. |
| Godsland et al, 2001. Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels. Clinical Science 101:1-9. |
| Gouda et al., Jul. 4, 2003. Thermal inactivation of glucose oxidase. The Journal of Biological Chemistry, 278(27):24324-24333. |
| Gough et al. 2000. Immobilized glucose oxidase in implantable glucose sensor technology. Diabetes Technology & Therapeutics 2(3):377-380. |
| Gough et al. 2003. Frequency characterization of blood glucose dynamics. Annals of Biomedical Engineering 31:91-97. |
| Gross et al. 2000. Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technology & Therapeutics, 2(Suppl 1):S19-26. |
| Gross et al, 2000. Performance evaluation of the MiniMed® continuous glucose monitoring system during patient home use, Diabetes Technology & Therapeutics 2(1):49-56. |
| Guerci et al., 2003. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care, 26:582-589. |
| Hall et al. 1998: Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part I: An adsorption-controlled mechanism. Electrochimica Acta, 43(5-6):579-588. |
| Hall et al. 1998: Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part II: Effect of potential. Electrochimica Acta 43(14-15):2015-2024. |
| Hall et al. 1999. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part III: Effect of temperature. Electrochimica Acta, 44:2455-2462. |
| Hall et al. 1999. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part IV: Phosphate buffer dependence. Electrochimica Acta, 44:4573-4582. |
| Hall et al. 2000. Electrochemical oxidation of hydrogen peroxide at platinum electrodes. Part V: Inhibition by chloride. Electrochimica Acta, 45:3573-3579. |
| Hamilton Syringe Selection Guide. 2006. Syringe Selection, www.hamiltoncompany.com. |
| Hashiguchi et al. (1994). Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method: Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients. Diabetes Care 17(5)387-396. |
| Heller, A. 1992. Electrical Connection of Enzyme Redox Centers to Electrodes, J, Phys. Chem. 96:3579-3587. |
| Heller, A. 1999, Implanted electrochemical glucose sensors for the management of diabetes. Annu Rev Biomed Eng 1:153-175. |
| Heller, A. 2003. Plugging metal connectors into enzymes. Nature Biotechnology 21:631-2. |
| Hicks, 1985, In Situ Monitoring. Clinical Chemistry 31(12):1931-1935. |
| Hitchman, M. L.. 1978: Measurement of Dissolved Oxygen. In Elving et al, (Eds.). . New York: John Wiley & Sons. Chemical Analysis, vol. 49, Chap. 3, pp. 34-49, 59-123. |
| Hoel, Paul G. 1976. Elementary Statistics, Fourth Edition. John Wiley & Sons, Inc.. pp. 113-114. |
| Hrapovic et al. 2003. Picoamperometric detection of glucose at ultrasmall platinum-based biosensors: preparation and characterization. Analytical Chemistry 75:3308-3315. |
| http:--www.merriam-webster.com-dictionary, definition for “aberrant,” Aug. 19, 2008, p. 1. |
| Hu, et al. 1993. A needle-type enzyme-based lactate sensor for in vivo monitoring. Analytica Chimica Acta, 281:503-511. |
| Huang et al. Aug. 1975. Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Anodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum Electrode. U.S. Department of Commerce—NTIS, pp. 1-116. |
| Huang et al., Sep. 1997, A 0.5mW Passive Telemetry IC for Biomedical Applications, Proceedings of the 23rd European Solid-State Circuits Conference (ESSCIRC '97), pp. 172-175, Southampton, UK. |
| Hunter et al. Mar. 31, 2000. Minimally Invasive Glucose Sensor and Insulin Delivery System. MIT Home Automation and Healthcare Consortium. Progress Report No. 2-5, 17 pages. |
| Ishikawa et al. 1998. Initial evaluation of a 290-mm diameter subcutaneous glucose sensor: Glucose monitoring with a biocompatible, flexible-wire, enzyme-based amperometric microsensor in diabetic and nondiabetic humans. Journal of Diabetes and Its Complications, 12:295-301. |
| Jablecki et al. 2000. Simulations of the frequency response of implantable glucose sensors. Analytical Chemistry 72:1853-1859. |
| Jaffari et al. 1995. Recent advances in arnperometric glucose biosensors for in vivo monitoring. Physiol. Meas. 16: 1-15. |
| Jensen et al. 1997, Fast wave forms for pulsed electrochemical detection of glucose by incorporation of reductive desorption of oxidation products. Analytical Chemistry 69(9): 1776-1781. |
| Jeutter, D. C. 1982. A transcutaneous implanted battery recharging and biotelemeter power switching system. IEEE Transactions on Biomedical Engineering 29:314-321. |
| Jobst et al., 1996. Thin-Film Microbiosensors for Glucose-Lactate Monitoring. Analytical Chemistry 8(18): 3173-3179. |
| Johnson et al. 1992. In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue. Biosensors & Bioelectronics, 7:709-714. |
| Johnson, 1991. Reproducible eiectrodeposition of biomolecules for the fabrication of miniature electroenzymatic biosensors. Sensors& Actuators B 5:85-89. |
| Jovanovic, L. 2000. The role of continuous glucose monitoring in gestational diabetes mellitus: Diabetes Technology & Therapeutics, 2(Suppl 1):S67-71. |
| Kacaniklic et al. May-Jun. 1994. Amperometric Biosensors for Detection of L- and D-Amino Acids Based on Coimmoblized Peroxidase and L- and D-Amino Acid Oxidases in Carbon Paste Electrodes. Electroanalysis, 6(5-6): 381-390. |
| Kamath et al. Nov. 13-15, 2008. Calibration of a continuous glucose monitor: effect of glucose rate of change, Eighth Annual Diabetes Technology Meeting, p. A88. |
| Kang et al. 2003. In vitro and short-term in vivo characteristics of a Kel-F thin film modified glucose sensor. Anal Science 19:1481-1486. |
| Kaufman et al. 2001, A pilot study of the continuous glucose monitoring system, Diabetes Care 24(12):2030-2034. |
| Kaufman. 2000. Role of the continuous glucose monitoring system in pediatric patients. Diabetes Technology & Therapeutics 2(1):S-49-S-52. |
| Kawagoe et al, 1991. Enzyme-modified organic conducting salt microelectrode. Analytical Chemistry 63:2961-2965. |
| Keedy et al. 1991. Determination of urate in undiluted whole blood by enzyme electrode. Biosensors & Bioelectronics 6: 491-499. |
| Kerner et al. 1988. A potentially implantable enzyme electrode for amperometric measurement of glucose, Horm Metab Res Suppl. 20:8-13. |
| Kerner et al. 1993. The function of a hydrogen peroxide-detecting electroenzymatic glucose electrode is markedly impaired in human sub-cutaneous tissue and plasma. Biosensors & Bioelectronics 8:473-482. |
| Klueh et al. 2003. Use of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Implantable Sensor Function in Vivo. Biosensor Function and Vegf-Gene Transfer, pp. 1072-1086. |
| Ko, Wen H. 1985. Implantable Sensors for Closed-Loop Prosthetic Systems, Future Pub. Co., Inc., Mt. Kisco, NY, Chapter 15:197-210. |
| Kondo et al. 1982. A miniature glucose sensor, implantable in the blood stream. Diabetes Care. 5(3):218-221. |
| Koschinsky et al. 1988. New approach to technical and clinical evaluation of devices for self-monitoring of blood glucose. Diabetes Care 11(8): 619-619. |
| Koschinsky et al. 2001. Sensors for glucose monitoring: Technical and clinical aspects. Diabetes Metab. Res. Rev. 17:113-123. |
| Kost et al. 1985. Glucose-sensitive membranes containing glucose oxidase: activity, swelling, and permeability studies. Journal of Biomedical Materials Research 19:1117-1133. |
| Koudelka et al. 1989. In vivo response of microfabricated glucose sensors to glycemia changes in normal rats. Biomed Biochim Acta 48(11-12):953-956. |
| Koudelka et al. 1991. In-vivo behaviour of hypodermically implanted microfabricated glucose sensors. Biosensors & Bioelectronics 6:31-36. |
| Kovatchev et al. Aug. 2004 Evaluating the accuracy of continuous glucose-monitoring sensors, continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data, Diabetes Care 27(8): 1922-1928. |
| Kraver et al. 2001. A mixed-signal sensor interface microinstrument. Sensors & Actuators A 91:266-277. |
| Kruger et al. 2000, Psychological motivation and patient education: A role for continuous glucose monitoring. Diabetes Technology & Therapeutics 2(Suppl 1):S93-97. |
| Kulys et al., 1994, Carbon-paste biosensors array for long-term glucose measurement. Biosensors & Bioelectronics, 9:491-500. |
| Kunjan et al. Mar. 2008, Automated blood sampling and glucose sensing in critical care settings. Journal of Diabetes Science and Technology 2(3):194-200. |
| Kurtz et al. 2005. Recommendations for blood pressure measurement in humans and experimental animals, Part 2: Blood pressure measurement in experimental animals, A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45:299-310. |
| Ladd et al., Structure Determination by X-ray Crystallography, 3rd ed. Plenum, 1996, Ch. 1, pp. xxi-xxiv and 1-58. |
| Lehmann et al. May 1994. Retrospective validation of a physiological model of glucose-insulin interaction in type 1 diabetes mellitus. Med. Eng, Phys. 16:193-202. |
| Lerner et al. 1984. An implantable electrochemical glucose sensor. Ann. N. Y. Acad. Sci, 428:263-278. |
| Lewandowski et al. 1988. Evaluation of a miniature blood glucose sensor. Trans Am Soc Artif Intern Organs 34:255-258. |
| Leypoldt et al. 1984. Model of a two-substrate enzyme electrode for glucose. Analytical Chemistry 56:2896-2904. |
| Linke et al. 1994. Amperometric biosensor for in vivo glucose sensing based an glucose oxidase immobilized in a redox hydrogel. Biosensors & Bioelectronics 9:151-158. |
| Lowe, 1984. Biosensors. Trends in Biotechnology 2(3):59-65. |
| Luong et al. 2004, Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane Towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer. Electronanalysis 16(1-2): 132-139. |
| Lyandres et al. (2008). Progress toward an in vivo surface-enhanced raman spectroscopy glucose sensor. Diabetes Technology & Therapeutics, 10(4): 257-265. |
| Maiden et al. 1992. Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors Analytical Chemistry 64:2889-2896. |
| Makale et al. 2003. Tissue window chamber system for validation of implanted oxygen sensors. Am. J. Physiol. Heart Circ. Physiol. 284:H2288-2294. |
| Malin et al. 1999, Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy. Clinical Chemistry 45:9, 1651-1658. |
| Maran et al. 2002. Continuous subcutaneous glucose monitoring in diabetic patients: A multicenter analysis. Diabetes Care 25(2):347-352. |
| March, W. F. 2002. Dealing with the delay. Diabetes Technology & Therapeutics 4(1):49-50. |
| Marena et al. 1993. The artificial endocrine pancreas in clinical practice and research, Panminerva Medica 35(2): 67-74. |
| Mascini et al. 1989. Glucose electrochemical probe with extended linearity for whole blood. J Pharm Biomed Anal 7(12): 1507-1512. |
| Mastrototaro et al. 1991. An electroenzyrnatic glucose sensor fabricated on a flexible substrate. Sensors & Actuators B 5:139-44. |
| Mastrototaro et al. 2003. Reproducibility of the continuous glucose monitoring system matches previous reports and the intended use of the product. Diabetes Care 26:256; author reply p. 257. |
| Mastrototaro, J. J. 2000. The MiniMed continuous glucose monitoring system, Diabetes Technology & Therapeuticsr 2(Suppl 1 ):S13-8. |
| Matsumoto et al. 1998. A micro-planar amperometric glucose sensor unsusceptible to interference species. Sensors & Actuators B 49:68-72. |
| Matthews et al. 1988. An amperometric needle-type glucose sensor testing in rats and man. Diabetic Medicine 5:248-252. |
| Mazze et al. 2008. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technology & Therapeutics 10:149-159. |
| McCartney et al. 2001. Near-infrared fluorescence lifetime assay for serum glucose based on allophycocyanin-labeled concanavalin A. Analytical Biochemistry 292:216-221. |
| McGrath et al. 1995. The use of differential measurements with a glucose biosensor for interference compensation during glucose determinations by flow injection analysis, Biosenors & Bioelectronics 10:937-943. |
| McKean et al. Jul. 7, 1988. A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors. Transactions on Biomedical Engineering 35:526-532. |
| Memoli et al. 2002. A comparison between different immobilised glucoseoxidase-based electrodes. J Pharm Biomed Anal 29:1045-1052. |
| Merriam-Webster Online Dictionary. Jan. 11, 2010. Definition of “acceleration”. http:--www.merriam-webster.com-dictionary-Acceleration. |
| Merriam-Webster Online Dictionary. Jan. 11, 2010. Definition of “system”. http:--www.merriam-webster.com-dictionary-System. |
| Merriam-Webster Online Dictionary. Apr. 23, 2007. Definition of “nominal”. http:--www.merriam-webster.com-dictionary-nominal. |
| Meyerhoff et al. 1992. On line continuous monitoring of subcutaneous tissue glucose in men by combining portable glucosensor with microdialysis. Diabetologia 35:1087-1092. |
| Moatti-Sirat et al. 1992. Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor. Biosensors & Bloelectronics 7:345-352. |
| Moatti-Sirat et al. 1992. Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat subcutaneous tissue. Diabetologia 35:224-230. |
| Moatti-Sirat et al. Jun. 1994. Reduction of acetaminophen interference in glucose sensors by a composite Nafion membrane: demonstration in rats and man. Diabetologia 37(6):610-616. |
| Morff et al. 1990. Microfabrication of reproducible, economical, electroenzymatic glucose sensors, Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 12(2):0483-0484. |
| Mosbach et at 1975. Determination of heat changes in the proximity of immobilized enzymes with an enzyme thermistor and its use for the assay of metabolites, Biochimica Biophysica Acta. 403:256-265. |
| Motonaka et at 1993. Determination of cholesterol and cholesterol ester with novel enzyme microsensors. Analytical Chemistry 65:3258-3261. |
| Moussy et al. 1993. Performance of subcutaneously implanted needle-type glucose sensors employing a novel trilayer coating. Analytical Chemistry 85:2072-2077. |
| Moussy, Francis, Nov. 2002, Implantable Glucose Sensor: Progress and Problems, Sensors, 1:270-273. |
| Muslu. 1991. Trickling filter performance. Applied Biochem. Biotech. 37:211-224. |
| Nafion® 117 Solution Product Description, Product No. 70160, Sigma-Aldrich Corp., St. Louis, Mo. Downloaded from https:--www.signaaldrich.com-cgi- bin-hsrun-Suite7-Suite-HAHTpage-Suite.HsExternal Prod . . . on Apr. 7, 2005. |
| Ohara et al. 1994, “Wired” enzyme electrodes for amperometric determination of glucose or lactate in the presence of interfering substances. Analytical Chemistry 66:2451-2457. |
| Ohara, et al. Dec. 1993. Glucose electrodes based on cross-linked bis(2,2′-bipyridine)chloroosmium(+-2+) complexed poly(l-vinylimidazole) films. Analytical Chemistry, 65:3512-3517. |
| Okuda et al. 1971. Mutarotase effect on micro determinations of D-glucose and its anomers with (3-D-glucose oxidase. Analytical Biochemistry 43:312-315. |
| Oxford English Dictionary Online. Jan. 11, 2010. Definition of “impending”. http:--www.askoxford.com-results-?view=dev dict&field-12668446 impending&branch=. |
| Palmisano et al. 2000. Simultaneous monitoring of glucose and lactate by an interference and crosstalk free dual electrode amperometric biosensor based on electropolymerized thin films. Biosensors & Bioelectronics 15:531-539. |
| Patel et al. 2003 Amperometric glucose sensors based on ferrocene containing polymeric electron transfer systems—a preliminary report. Biosensors & Bioelectronics 18:1073-6. |
| Peacock et al. 2008. Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med., 358: 2117-2126. |
| Pfeiffer et al. 1992. On line continuous monitoring of subcutaneous tissue glucose is feasible by combining portable glucosensor with microdialysis. Horm. Metab. Res. 25:121-124. |
| Pfeiffer, E.F. 1990. The glucose sensor: the missing link in diabetes therapy. Horm Metab Res Suppl. 24:154-164. |
| Pichert et al. 2000, Issues for the coming age of continuous glucose monitoring, Diabetes Educator 26(6):969-980. |
| Pickup et al. 1987-88, Implantable glucose sensors: choosing the appropriate sensing strategy, Biosensors, 3:335-346. |
| Pickup et al. 1989. In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer. Diabetologia, 32:213-217. |
| Pickup et al. 1989. Potentially-implantable, amperornetric glucose sensors with mediated electron transfer: improving the operating stability, Biosensors 4:109-119. |
| Pinner et al. Oct. 1959. Cross-linking of cellulose acetate by ionizing radiation. Nature 184: 1303-1304. |
| Pishko et al. 1991. Amperometric glucose microelectrodes prepared through immobilization of glucose oxidase in redox hydrogels. Analytical Chemistry 63:2268-72. |
| Pitzer et al. 2001, Detection of hypoglycemia with the GlucoWatch biographer. Diabetes Care 24(5):881-885. |
| Poitout et al. 1991. In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor, ASAIO Transactions 37:M298-M300. |
| Poitout et al. 1993. A glucose monitoring system for on line estimation in man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue and a wearable control unit. Diabetologia 36:658-663. |
| Poitout et al. 1994. Development of a glucose sensor for glucose monitoring in man: the disposable implant concept. Clinical Materials 15:241-246. |
| Postlethwaite et al. 1996. Interdigitated array electrode as an alternative to the rotated ring-disk electrode for determination of the reaction products of dioxygen reduction. Analytical Chemistry 68:2951-2958. |
| Prabhu et al. 1981. Electrochemical studies of hydrogen peroxide at a platinum disc electrode. Electrochimica Acta 26(6):725-729. |
| Quinn et al. 1995. Kinetics of glucose delivery to subcutaneous tissue in rats measured with 0.3-mm amperometric microsensors. The American Physiological Society E155-E161. |
| Quinn et al. 1997. Biocompatible, glucose-permeable hydrogel for in situ coating of implantable biosensors, Biomaterials 18:1665-1670. |
| Rabahetal., 1991. Electrochemical wear of graphite anodes during electrolysis of brine. Carbon 29(2):165-171. |
| Reach et al. 1986. A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors. Biosensors 2:211-220. |
| Reach et al. 1992. Can continuous glucose monitoring be used for the treatment of diabetes? Analytical Chemistry 64(5):381-386. |
| Reach, G. 2001. Which threshold to detect hypoglycemia? Value of receiver-operator curve analysis to find a compromise between sensitivity and specificity. Diabetes Care 24(5):803-804. |
| Reach, Gerard. 2001. Letters to the Editor Re: Diabetes Technology & Therapeutics, 2000;2:49-56. Diabetes Technology & Therapeutics 3(1): 129-130. |
| Rebrin et al. 1989. Automated feedback control of subcutaneous glucose concentration in diabetic dogs. Diabetologia 32:573-76 (1989). |
| Rebrin et al. 1992. Subcutaneous glucose monitoring by means of electrochemical sensors: fiction or reality? J. Biomedical Engineering 14:33-40. |
| Reusch. 2004, Chemical Reactivity. Organometallic Compounds. Virtual Textbook of Organic Chem, pp. 1-16, http:--www.cem.msu.edu-˜reusch-VirtualText-orgmetal.htm. |
| Rhodes et al. 1994. Prediction of pocket-portable and implantable glucose enzyme electrode performance from combined species permeability and digital simulation analysis. Analytical Chemistry 66(9): 1520-1529. |
| Rigla et al. 2008. Real-time continuous glucose monitoring together with telemedical assistance improves glycemic control and glucose stability in pump-treated patients. Diabetes Technology & Therapeutics, 10(3): 194-199. |
| Rivers et al. 2001. Central venous oxygen saturation monitoring in the critically ill patient. Current Opinion in Critical Care, 7:204-211. |
| Sakakida et al. 1992. Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations. Artif. Organs Today 2(2): 145-158. |
| Sakakida et al. 1993. Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane. Sensors & Actuators B 13-14:319-322. |
| Salardi et al. 2002. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA1c in pediatric type 1 diabetic patients. Diabetes Care 25(10): 1940-1844. |
| Samuels, M.P. 2004. The effects of flight and altitude. Arch Dis Child. 89: 448-455. |
| San Diego Plastics, Inc. 2009. Polyethylene Data Sheet, http:--www.sdplastics.com-polyeth.html. |
| Sansen et al. 1985. Glucose sensor with telemetry system., in Ko, W. H. (Ed.). Implantable Sensors for Closed Loop Prosthetic Systems. Chap. 12, pp. 167.175, Mount Kisco, NY: Futura Publishing Co. |
| Sansen et al. 1990. A smart sensor for the voltammetric measurement of oxygen or glucose concentrations. Sensors & Actuators B 1:298-302. |
| Schmidt et al. 1993, Glucose concentration in subcutaneous extracellular space. Diabetes Care 16(5):695-700. |
| Schmidtke et al. Jan. 1998. Measurement and modeling of the transient difference between blood and subcutaneous glucose concentrations in the rat after injection of insulin. PNAS USA 95: 294-299. |
| Schmidtke et al. May 1998. Accuracy of the one-point in vivo calibration of “wired” glucose oxidase electrodes implanted in jugular veins of rats in periods of rapid rise and decline of the glucose concentration. Analytical Chemistry 70(10): 2149-2155. |
| Schoemaker et al. 2003. The SCGM1 system: Subcutaneous continuous glucose monitoring based on microdialysis technique. Diabetes Technology & Therapeutics 5(4):599-608. |
| Schoonen et al. 1990. Development of a potentially wearable glucose sensor for patients with diabetes mellitus: design and in-vitro evaluation. Biosensors & Bioelectronics 5:37-46. |
| Service et al. 1970. Mean amplitude of glycemic excursions, a measure of diabetic instability, Diabetes, 19: 644-655. |
| Service et al. 1987. Measurements of glucose control. Diabetes Care, 10: 225-237. |
| Service, R. F. 2002. Can sensors make a home in the body? Science 297:962-3. |
| Sharkawy et al. 1997. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J Biomed Mater Res. 37:401-412. |
| Shaw et al. 1991. In vitro testing of a simply constructed, highly state glucose sensor suitable for implantation in diabetic patients. Biosensors & Bioelectronics 6:401-406. |
| Shichiri et al. 1982. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 2:1129-1131. |
| Shichiri et al., Needle Type Glucose Sensor for Wearable Artificial Endocrine Pancreas, in Implantable Sensors for Closed-Loop Prosthetic Systems by Ko (Ed), Chapter 15, pp. 197-210. |
| Shichiri, et al. 1983. Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas. Diabetologia 24:179-184. |
| Shults et al. 1994. A telemetry-instrumentation system for monitoring multiple subcutaneously implanted glucose sensors. IEEE Transactions on Biomedical Engineering 41(10):937-942. |
| Skyler, J. S. 2000. The economic burden of diabetes and the benefits of improved glycemic control: The potential role of a continuous glucose monitoring system. Diabetes Technology & Therapeutics 2 Suppl 1:S7-12. |
| Slater-Maclean et al. 2008. Accuracy of glycemic measurements in the critically ill. Diabetes Technology & Therapeutics 10:169-177. |
| Sokol et al. 1980. Immobilized-enzyme rate-determination method for glucose analysis. Clinical Chemistry. 26(1 ):89-92. |
| Sriyudthsak et al. 1996. Enzyme-epoxy membrane based glucose analyzing system and medical applications. Biosensors & Bioelectronics 11:735-742. |
| Steil et al. 2003. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technology & Therapeutics 5(1 ):27-31. |
| Stern et al., 1957. Electrochemical polarization: 1. A theoretical analysis of the shape of polarization curves. Journal of the Electrochemical Society, 104(1 ):56-63. |
| Sumino T. et al. 1998. Preliminary study of continuous glucose monitoring with a microdialysis technique. Proceedings of the IEEE. 20(4):1775-1778. |
| Takegami et al. 1992. Pervaporation of ethanol water mixtures using novel hydrophobic membranes containing polydimethylsiloxane. Journal of Membrane Science, 75: 93-105. |
| Tanenberg et al. 2000. Continuous glucose monitoring system: A new approach to the diagnosis of diabetic gastroparesis. Diabetes Technology & Therapeutics, 2(Suppl 1):S73-80. |
| Tatsuma et al. 1991. Oxidase-peroxidase bilayer-modified electrodes as sensors for lactate, pyruvate, cholesterol and uric acid. Analytica Chimica Acta, 242:85-89. |
| Thome et al. 1995. Abstract: Can the decrease in subcutaneous glucose concentration precede the decrease in blood glucose level? Proposition for a push-pull kinetics hypothesis. Horm. Metab. Res. 27:53. |
| Thome-Duret et al. 1996. Modification of the sensitivity of glucose sensor implanted into subcutaneous tissue. Diabetes Metabolism, 22:174-178. |
| Thome-Duret et al. 1996. Use of a subcutaneous glucose sensor to detect decreases in glucose concentration prior to observation in blood. Analytical Chemistry 68:3822-3826. |
| Thome-Duret et al. 1998. Continuous glucose monitoring in the free-moving rat. Metabolism, 47:799-803. |
| Thompson et al. 1986. In Vivo Probes: Problems and Perspectives, Department of Chemistry, University of Toronto, Canada, pp. 255-261, 1986. |
| Tierney et al. 2000. Effect of acetaminophen on the accuracy of glucose measurements obtained with the GlucoWatch biographer. Diabetes Technology & Therapeutics 2(2): 199-207. |
| Tierney et al. 2000. The GlucoWatch® biographer: A frequent, automatic and noninvasive glucose monitor. Ann. Med. 32:632-641. |
| Torjman et al. Mar. 2008. Glucose monitoring in acute care: technologies on the horizon. Journal of Diabetes Science and Technology, 2(2): 178-181. |
| Trecroci, D. 2002. A Glimpse into the Future-Continuous Monitoring of Glucose with a Microfiber, Diabetes Interview 42-43. |
| Tse and Gough. 1987. Time-Dependent Inactivation of Immobilized Glucose Oxidase and Catalase. Biotechnology & Bioengineering. 29:705-713. |
| Turner and Pickup, 1985. Diabetes mellitus: biosensors for research and management. Biosensors 1:85-115 (1985). |
| Turner et al. 1984. Carbon Monoxide: Acceptor Oxidoreductase from Pseudomonas Thermocarboxydovorans Strain C2 and its use in a Carbon Monoxide Sensor, Analytica Chimica Acta, 163: 161-174. |
| Unger et al. 2004. Glucose control in the hospitalized patient. Emergency Medicine 36(9):12-18. |
| Updike et al. 1967. The enzyme electrode. Nature 214:986-988. |
| Updike et al. 1988. Laboratory Evaluation of New Reusable Blood Glucose Sensor. Diabetes Care 11:801-807. |
| Updike et al. 1994. Enzymatic glucose sensor: improved long-term performance in vitro and in vivo. ASAIO Journal, 40(2): 157-163. |
| Updike et al. 1997. Principles of long-term fully implanted sensors with emphasis on radiotelemetric monitoring of blood glucose form inside a subcutaneous foreign body capsule (FBC). Fraser, D.M. (Ed.), Biosensors in the Body. New York. John Wiley & Sons Ltd., pp. 117-137. |
| Updike et al. 2000. A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration, Diabetes Care 23(2):208-214. |
| Utah Medical Products Inc., Blood Pressure Transducers product specifications, 6 pp. 2003-2006, 2003. |
| Vadgama, P. Nov. 1981. Enzyme electrodes as practical biosenscrs. Journal of Medical Engineering & Technology 5(6):293-298. |
| Vadgama, 1988. Diffusion limited enzyme electrodes. NATO ASI Series: Series C, Math and Phys. Sci. 226:359-377. |
| Van den Berghe 2004. Tight blood glucose control with insulin in “real-life” intensive care. Mayo Clinic Proceedings 79(8):977-978. |
| Velho et al. 1989, In vitro and in vivo stability of electrode potentials in needle-type glucose sensors. Influence of needle material. Diabetes 38:164-171. |
| Velho et al. 1989. Strategies for calibrating a subcutaneous glucose sensor. Biomedica Biochimica Acta 48(11-12): 957-964. |
| Von Woedtke et al. 1989. In situ calibration of implanted electrochemical glucose sensors. Biomedica Biochimica Acta 48(11-12):943-952. |
| Wagner et al. 1998. Continuous amperometric monitoring of glucose in a brittle diabetic chimpanzee with a miniature subcutaneous electrode. PNAS USA 95:6379-6382. |
| Wang et al. 1994. Highly Selective Membrane-Free, Mediator-Free Glucose Biosensor, Analytical Chemistry 66:3600-3603. |
| Wang et al. 1997 . Improved ruggedness for membrane-based amperometric sensors using a pulsed amperometric method. Analytical Chemistry 69:4482-4489. |
| Ward et al. 2000. Rise in background current overtime in a subcutaneous glucose sensor in the rabbit: Relevance to calibration and accuracy. Biosensors & Bioelectronics, 15:53-61. |
| Ward et al. 2000. Understanding Spontaneous Output Fluctuations of an Amperornetric Glucose Sensor: Effect of Inhalation Anesthesia and use of a Nonenzyme Containing Electrode. ASAIO Journal 46:540-546. |
| Ward et al. 2002. A new amperometric glucose microsensor: In vitro and short-term in vivo evaluation. Biosensors & Bioelectronics, 17:181-189. |
| Ward et al. 2004. A wire-based dual-analyte sensor for Glucose and Lactate: In Vitro and In Vivo Evaluation, Diabetes Technology Therapeutics 6(3): 389-401. |
| Wientjes, K. J. C. 2000 Development of a glucose sensor for diabetic patients (Ph.D. Thesis). |
| Wikipedia 2006, “Intravenous therapy,” http:--en.wikipedia.org-wiki-Intravenous_therapy, Aug. 15, 2006, 6 pp. |
| Wiley Electrical and Electronics Engineering Dictionary. 2004, John Wiley & Sons, Inc. pp. 141, 142; 548; 549. |
| Wilkins et al. 1988. The coated wire electrode glucose sensor. Horm Metab Res Suppl., 20:50-55. |
| Wilkins et al. 1995. Integrated Implantable device for long-term glucose monitoring. Biosensors & Bioelectronics 10:485-494. |
| Wilkins et al. 1996. Glucose monitoring: state of the art and future possibilities. Med Eng Phys 18:273-288. |
| Wilson et al. 1992. Progress toward the development of an implantable sensor for glucose. Clinical Chemistry 38(9):1613-1617. |
| Wilson et al. 2000. Enzyme-based biosensors for in vivo measurements. Chemistry Review 100:2693-2704. |
| Wood, W. et al. Mar. 1990. Hermetic Sealing with Epoxy. Mechanical Engineering 1-3. |
| Woodward. 1982. How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensor. Diabetes Care 5:278-281. |
| Worsley et al. Mar. 2008. Measurement of glucose in blood with a phenylboronic acid optical sensor, Journal of Diabetes Science and Technology, 2(2):213-220. |
| Wright et al. 1999. Bioelectrochemical dehalogenations via direct electrochemistry of poly(ethylene oxide)-modified myoglobin. Electrochemistry Communications 1: 603-611. |
| Wu et al. 1999. In situ electrochemical oxygen generation with an immunoisolation device. Annals New York Academy of Sciences, pp. 105-125. |
| Yamasaki et al. 1989. Direct measurement of whole blood glucose by a needle-type sensor. Clinica Chimica Acta. 93:93-98. |
| Yamasaki, Yoshimitsu. Sep. 1984. The development of a needle type glucose sensor for wearable artificial endocrine pancreas. Medical Journal of Osaka University 35(1-2):25-34. |
| Yang et al (1996). A glucose biosensor based on an oxygen electrode: In-vitro performances in a model buffer solution and in blood plasma. Biomedical Instrumentation & Technology 30:55-61. |
| Yang et al. 1998. Development of needle-type glucose sensor with high selectivity. Science & Actuators B 46:249-256. |
| Yang et al. 2004. A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate-Nafion Composite Membranes. Journal of Membrane Science 237:145-161. |
| Ye et al. 1993. High Current Density ‘Wired’ Quinoprotein Glucose Dehydrogenase Electrode. Analytical Chemistry 65:238-241. |
| Zamzow et al. 1990. Development and evaluation of a wearable blood glucose monitor. ASAIO Transactions; 36(3): pp. M588-M591. |
| Zethelius et al. 2008. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med., 358: 2107-2116. |
| Zhang et al (1993). Electrochemical oxidation of H202 on Pt and Pt + Ir electrodes in physiological buffer and its applicability to H202-based biosensors. J. Electroanalytical Chemistry 345:253-271. |
| Zhang et al. 1993. In vitro and in vivo evaluation of oxygen effects on a glucose oxidase based implantable glucose sensor, Analytics Chimica Acta, 281:513-520. |
| Zhang et al. 1994. Elimination of the acetaminophen interference in an implantable glucose sensor. Analytical Chemistry 66(7): 1183-1188. |
| Zhu et al. (1994). Fabrication and characterization of glucose sensors based on a microarray H202 electrode. Biosensors & Bioelectronics 9: 295-300. |
| Zhu et al. 2002. Planar amperometric glucose sensor based on glucose oxidase immobilized by chitosan film on Prussian blue layer. Sensors 2:127-136. |
| EP App. No. 05771643.3, filed Dec. 13, 2007: EPO Communication dated Aug. 19, 2009. |
| EP App. No. 05771646.6, filed Jul. 13, 2005: EPO Communication dated Aug. 19, 2009. |
| EP App. No. 05771646.6, filed Jul. 13, 2005: EPO Communication dated Jun. 2, 2010. |
| EP App. No. 05771646.6, filed Jul. 13, 2005: EPO Communication dated Aug. 17, 2011. |
| EP App. No. 06718980.3, filed Jan. 17, 2006: EPO Extended Search Report dated Mar. 9, 2010. |
| EP App. No. 06736006.5, filed Feb. 22, 2006: EPO Communication dated Jul. 30, 2010. |
| EP App. No. 06773682.7, filed Jun. 20, 2006 : EPO Search Report dated Nov. 16, 2009. |
| EP App. No. 06773682.7, filed Jun. 20, 2006: EPO Communication dated Apr. 5, 2011. |
| EP App. No. 10195447.7, filed Jul. 13, 2005EPO Search Report dated Apr. 24, 2011. |
| EP App. No, 10195483.2, filed Jul. 13, 2005: EPO Search Report dated Apr. 5, 2011. |
| EP App. No. 10195496.4, filed Jul. 13, 2005: EPO Search Report dated Apr. 1, 2011. |
| EP App. No. 10195504.5, filed Jul. 13, 2005: EPO Extended Search Report dated May 5, 2011. |
| EP App. No. 10195509.4, filed Jul. 13, 2005: EPO Extended Search Report dated Apr. 12, 2011. |
| EP App. No. 10195511.0, filed Jul. 13, 2005: EPO Communication dated May 12, 2011. |
| EP App. No. 10195514.4, filed Jul. 13, 2005: EPO Search Report dated Apr. 21, 2011. |
| EP App. No. 10195517.7, filed Jul. 13, 2005: EPO Search Report dated Apr. 7, 2011. |
| EP App. No. 10195518.5, filed Jul. 13, 2005: EPO Communication dated Apr. 28, 2011. |
| EP App. No. 10195518.5, filed Jul. 13, 2005: EPO Extended Search Report dated Aug. 2, 2011. |
| EP App. No. 10195518.5, filed Jul. 13, 2005: EPO Extended Search Report dated Aug. 10, 2011. |
| ZZZ JP App. No. 2007-521636, filed Jul. 13, 2005: JIPO Communication dated Mar. 1, 2011. |
| PCT/US02/023903 filed Jul. 26, 2002: International Preliminary Report on Patentability Apr. 18, 2005. |
| PCT/US02/023903 filed Jul. 26, 2002: International Search Report dated Feb. 27, 2003. |
| PCT/US02/023903, filed Jul. 26, 2002: Written Opinion dated Nov. 15, 2004. |
| PCT/US04/023455 filed Jul. 21, 2004: International Preliminary Report on Patentability dated Jan. 23, 2006. |
| PCT/US04/023455 filed Jul. 21, 2004: International Search Report and Written Opinion dated Dec. 23, 2004. |
| PCT/US04/040476, filed Dec. 3, 2004: International Preliminary Report on Patentability dated Dec. 21, 2006. |
| PCT/US04/040476, filed Dec. 3, 2004: International Search Report and Written Opinion dated Nov. 16, 2006. |
| PCT/US05/024994 filed Jul. 13, 2005: International Preliminary Report on Patentability dated Jan. 25, 2007. |
| PCT/US05/024994 filed Jul. 13, 2005: International Search Report and Written Opinion dated Nov. 13, 2005. |
| PCT/US06/001998 filed Jan. 17, 2006; International Search Report and Written Opinion dated Jul. 25, 2006. |
| PCT/US06/006574 filed Feb. 22, 2006: International Preliminary Report on Patentability and Written Opinion dated Aug. 26, 2008. |
| PCT/US06/006574 filed Feb. 22, 2006: International Search Report dated Aug. 4, 2006. |
| PCT/US06/024132 filed Jun. 20, 2006: International Search Report and Written Opinion dated Jul. 20, 2007. |
| PCT/US06/024132, filed Jun. 20, 2006: International Preliminary Report on Patentability dated Dec. 24, 2007. |
| PCT/US06/031496, filed Aug. 10, 2006: International Preliminary Report on Patentability dated Nov. 27, 2008. |
| PCT/US06/031496, filed Aug. 10, 2006: International Search Report and Written Opinion dated Sep. 20, 2007. |
| PCT/US06/038820 filed Oct. 4, 2006: International Search Report and Written Opinion dated Jun. 20, 2007. |
| PCT/US07/005422, filed Mar. 1, 2007: International Preliminary Report on Patentability dated Sep. 1, 2009. |
| PCT/US07/005422, filed Mar. 1, 2007: International Search Report and Written Opinion dated Mar. 1, 2007. |
| PCT/US08/058158, filed Mar. 25, 2008: International Preliminary Report on Patentability dated Sep. 29, 2009. |
| PCT/US08/058158, filed Mar. 25, 2008: International Search Report and Written Opinion dated Aug. 8, 2008. |
| PCT/US2005/024993, filed Jul. 13, 2005: International Preliminary Report on Patentability dated Jan. 16, 2007. |
| PCT/US2005/024993, filed Jul. 13, 2005: International Search Report and Written Opinion dated Nov. 4, 2005. |
| ZZZ U.S. Reexamination Control No. 90/011086, filed Jul. 8, 2010, re Ex Parte Reexamination of U.S. Pat. No. 7,310,544: Substantive Electronic File History; including PTO Office Actions and Applicant and Third Party Submissions dated dated Jul. 8, 2010, Jul. 28, 2010, Aug. 9, 2010, Nov. 8, 2010, Jan. 4, 2011, and Apr. 5, 2011. |
| ZZZ U.S. Reexamination Control No. 90/011351, filed Nov. 22, 2010, re Ex Parte Reexamination of U.S. Pat. No. 7,497,827: Electronic File containing Office Action dated Dec. 17, 2010 and May 11, 2011, and Applicant Responses filed Feb. 17, 2011, Jul. 11, 2011 and Aug. 10, 2011. |
| U.S. Appl. No. 10/896,637, filed Jul. 21, 2004: Office Action dated Mar. 5, 2009. |
| U.S. Appl. No. 10/896,637, filed Jul. 21, 2004: Office Action dated Oct. 8, 2008. |
| U.S. Appl. No. 10/896,637, filed Jul. 21, 2004: Office Action dated Jul. 20, 2009. |
| U.S. Appl. No. 11/077,759, filed Mar. 10, 2005: Office Action dated May 17, 2007. |
| U.S. Appl. No. 11/021,046, filed Dec. 22, 2004: Office Action dated Aug. 19, 2009. |
| U.S. Appl. No. 11/021,046, filed Dec. 22, 2004: Office Action dated Jun. 23, 2008. |
| U.S. Appl. No. 11/021,046, filed Dec. 22, 2004: Office Action dated Dec. 25, 2007. |
| U.S. Appl. No. 11/021,162, filed Dec. 22, 2004: Office Action dated Jun. 19, 2008. |
| U.S. Appl. No. 11/034,343, filed Jan. 11, 2005: Office Action dated Nov. 1, 2007. |
| U.S. Appl. No. 11/034,343, filed Jan. 11, 2005: Office Action dated Jul. 10, 2008. |
| U.S. Appl. No. 11/034,343, filed Jan. 11, 2005: Office Action dated Dec. 30, 2008. |
| U.S. Appl. No. 11/077,643, filed Mar. 10, 2005 (now U.S. Pat. No. 7,654,956 on Feb. 2, 2010): Electronic File History including Office Actions dated Apr. 21, 2008, Oct. 1, 2008, Mar. 11, 2009 and Oct. 16, 2009, and Applicant Responses filed Oct. 21, 2005, Oct. 25, 2007, Jul. 15, 2008, Dec. 17, 2008, and May 27, 2009. |
| U.S. Appl. No. 11/077,693 (now U.S. Pat. No. 7,713,574 on May 11, 2010): Electronic File History, including Office Actions dated Jun. 27, 2008, Dec. 26, 2008, Jun. 10, 2009, Sep. 4, 2009 and Jan. 26, 2010, and Applicant Responses filed Oct. 20, 2005, Sep. 18, 2008, Mar. 25, 2009, Jun. 23, 2009, Nov. 4, 2009, Nov. 10, 2009, Feb. 12, 2010 and Mar. 9, 2010. |
| U.S. Appl. No. 11/077,713, filed Mar. 10, 2005: Electronic File History through Aug. 1, 2011, including Office Actions dated Mar. 10, 2008, May 5, 2008, Feb. 10, 2009, Sep. 2, 2009, Jan. 28, 2011 and Jul. 8, 2011, and Applicant Responses filed Oct. 20, 2005, Oct. 10, 2007, Mar. 13, 2008, Sep. 5, 2008,Nov. 4, 2008, May 11, 2009, Nov. 3, 2009, Jan. 20, 2010, Mar. 17, 2010, Jun. 24, 2010, Sep. 24, 2010 and Apr. 25, 2011. |
| U.S. Appl. No. 11/077,714, filed Mar. 10, 2005: Electronic File History, including Office Actions dated Oct. 11, 2006, Apr. 10, 2007, Jul. 27, 2007,Jan. 10, 2008, Sep. 16, 2008, Apr. 16, 2009, Dec. 31, 2009, Jan. 27, 2010, and Sep. 7, 2010, and Applicant Responses filed Jan. 8, 2007, May 7, 2007, Oct. 5, 2007, Jan. 22, 2008, Apr. 30, 2008, May 28, 2008, Dec. 15, 2008, Jan. 22, 2009, Jul. 3, 2009, Oct. 5, 2009, Jan. 13, 2010, and Jun. 2, 2010. |
| U.S. Appl. No. 11/077,715, filed Mar. 10, 2005 (now U.S. Pat. No. 7,497,827 on Mar. 3, 2009): Electronic File History, including Office Actions dated Oct. 31, 2006, Apr. 10, 2007, Jul. 26, 2007, Jan. 28, 2008, May 12, 2008 and Nov. 12, 2008, and Applicant Responses filed Oct. 21, 2005, Jan. 8, 2007, May 3, 2007, Aug. 16, 2007, Nov. 6, 2007, Feb. 13, 2008, Aug. 11, 2008, Nov. 24, 2008 and Dec. 16, 2008. |
| U.S. Appl. No. 11/077,739, filed Mar. 10, 2005: Electronic File History through Oct. 11, 2011, including Office Actions dated Feb. 4, 2009, Jul. 29, 2009, Dec. 19, 2009 and Mar. 1, 2010, and Applicant Responses filed Oct. 20, 2005, Oct. 11, 2007, Dec. 4, 2007, Apr. 15, 2009, Oct. 7, 2009, Jan. 14, 2010 and May 14, 2010. |
| U.S. Appl. No. 11/077,740, filed Mar. 10, 2005: Electronic File History through Oct. 11, 2011, including Office Actions dated Jun. 1, 2007, Nov. 1, 2007, Jan. 4, 2008, Feb. 7, 2008, Jul. 25, 2008, Apr. 28, 2009, Nov. 23, 2010, Feb. 15, 2011, Jun. 15, 2011 and Mar. 1, 2010, and Applicant Responses filed Oct. 24, 2005, Aug. 21, 2007, Feb. 7, 2008, Mar. 6, 2008, Sep. 16, 2006, Jul. 28, 2009, Jan. 14, 2010, Jan. 24, 2011, Mar. 23, 2011 and Aug. 19, 2011. |
| U.S. Appl. No. 11/077,759, filed Mar. 10, 2005: Office Action dated Jul. 10, 2008. |
| U.S. Appl. No. 11/077,759, filed Mar. 10, 2005: Office Action dated May 26, 2009. |
| U.S. Appl. No. 11/077,759, filed Mar. 10, 2005: Office Action dated Mar. 31, 2008. |
| U.S. Appl. No. 11/077,63, filed Mar. 10, 2005 (now U.S. Pat. No. 7,310,544 on Dec. 18, 2007): Electronic File History including Office Actions dated Jan. 30, 2006, Jan. 30, 2007 and Sep. 4, 2007, and Applicant Response filed Apr. 17, 2007. |
| U.S. Appl. No. 11/077,765, filed Mar. 10, 2005: Electronic File History through Oct. 11, 2011, including Office Actions dated Oct. 24, 2007, Dec. 31, 2007, May 16, 2008, Sep. 19, 2008, Jan. 23, 2009, Jul. 9, 2009 and Feb. 3, 2010, and Applicant Responses filed Oct. 20, 2005, Oct. 5, 2007, Nov. 14, 2007, Feb. 12, 2008, Jun. 11, 2008, Nov. 18, 2008, Mar. 5, 2009, Oct. 5, 2009 and Feb. 10, 2010. |
| U.S. Appl. No. 11/078,072, filed Mar. 10, 2005: Electronic File History through Mar. 22, 2011, including Office Actions dated Jan. 22, 2009, Sep. 2, 2009, Jun. 10, 2010, Sep. 3, 2010 and Feb. 3, 2011, and Applicant Responses filed Oct. 20, 2005, Oct. 25, 2007, Apr. 29, 2008, Jun. 22, 2009, Dec. 2, 2009, May 21, 2010, Jun. 23, 2010, Nov. 16, 2010, and Mar. 22, 2011. |
| U.S. Appl. No. 11/078,232, filed Mar. 10, 2005: Electronic File History through May 3, 2011, including Office Actions dated Mar. 10, 2008, Nov. 12, 2008, Mar. 5, 2009, Jul. 21, 2009, Jan. 5, 2010 and Apr. 27, 2010, and Applicant Responses filed Oct. 5, 2007, Mar. 17, 2008, Apr. 8, 2008, Feb. 11, 2009, Apr. 16, 2009, Oct. 20, 2009, Jan. 26, 2010 and Jun. 3, 2010. |
| U.S. Appl. No. 11/157,365, filed Jun. 21, 2005: Office Action dated Jan. 7, 2009. |
| U.S. Appl. No. 11/157,365, filed Jun. 21, 2005: Office Action dated Jul. 21, 2009. |
| U.S. Appl. No. 11/157,365, filed Jun. 21, 2005: Office Action dated Jun. 26, 2008. |
| U.S. Appl. No. 11/157,365, filed Jun. 21, 2005_: Office Action dated Jan. 21, 2010. |
| U.S. Appl. No. 11/157,746, filed Jun. 21, 2005: Office Action dated May 1, 2008. |
| U.S. Appl. No. 11/157,746, filed Jun. 21, 2005: Office Action dated Jan. 3, 2008. |
| U.S. Appl. No. 11/333,837, filed Jan. 17, 2006: Office Action dated Apr. 2, 2010. |
| U.S. Appl. No. 11/333,837, filed Jan. 17, 2006: Office Action dated Jul. 2, 2010. |
| U.S. Appl. No. 11/333,837, filed Jan. 17, 2006: Office Action dated Nov. 28, 2008. |
| U.S. Appl. No. 11/333,837, filed Jan. 17, 2006: Office Action dated Jun. 29, 2009. |
| U.S. Appl. No. 11/360,250, filed Feb. 22, 2006: Office Action dated Mar. 5, 2010. |
| U.S. Appl. No. 11/360,250, filed Feb. 22, 2006: Office Action dated Jun. 15, 2009. |
| U.S. Appl. No. 11/360,250, filed Feb. 22, 2006: Office Action dated Nov. 28, 2008. |
| U.S. Appl. No. 11/360,250, filed Feb. 22, 2006: Office Action dated Sep. 28, 2010. |
| U.S. Appl. No. 11/360,252, filed Feb. 22, 2006: Office Action dated Jul. 23, 2009. |
| U.S. Appl. No. 11/360,252, filed Feb. 22, 2006: Office Action dated Jun. 30, 2008. |
| U.S. Appl. No. 11/360,262, filed Feb. 22, 2006: Electronic File History through Nov. 16, 2010, including Office Actions dated Jun. 22, 2009 and Apr. 14, 2010, and Applicant Responses filed Oct. 22, 209 and May 19, 2010. |
| U.S. Appl. No. 11/360,299, filed Feb. 22, 2006: Electronic File History through Nov. 17, 2010, including Office Actions dated Aug. 21, 2009, Jan. 22, 2010 and May 12, 2010, and Applicant Responses filed Nov. 9, 2009, Jan. 29, 2010, Jul. 12, 2010 and Jul. 28, 2010. |
| U.S. Appl. No. 11/360,819, filed Feb. 22, 2006: Office Action dated Apr. 7, 2010. |
| U.S. Appl. No. 11/360,819, filed Feb. 11, 2006: Office Action dated Sep. 2, 2010. |
| U.S. Appl. No. 11/360819, filed Feb. 22, 2006: Office Action dated Aug. 11, 2008. |
| U.S. Appl. No. 11/360,819, filed Feb. 22, 2006: Office Action dated Dec. 25, 2008. |
| U.S. Appl. No. 11/360,819, filed Feb. 22, 2006: Office Action dated Oct. 29, 2009. |
| U.S. Appl. No. 11/439,630, filed May 23, 2006: Electronic File History through Nov. 17, 2010, including Office Actions dated Jul. 28, 2008, Sep. 18, 2008, Feb. 23, 2009. Sep. 2, 2009 and Jan. 22, 2010, and Applicant Responses filed Dec. 3, 2007, Aug. 12, 2008, Nov. 14, 2008, Jun. 23, 2009, Nov. 9, 2009 and Jun. 4, 2010. |
| U.S. Appl. No. 11/543,539, filed Oct. 4, 2006: Office Action dated Dec. 12, 2007. |
| U.S. Appl. No. 11/543,539, filed Oct. 4, 2006: Office Action dated May 23, 2007. |
| U.S. Appl. No. 11/543,683, filed Oct. 4, 2006: Office Action dated Dec. 12, 2007. |
| U.S. Appl. No. 11/543,683, filed Oct. 4, 2006: Office Action dated May 18, 2007. |
| U.S. Appl. No. 11/543,707, filed Oct. 4, 2006: Office Action dated Dec. 12, 2007. |
| U.S. Appl. No. 11/543,707, filed Oct. 4, 2006: Office Action dated May 18, 2007. |
| U.S. Appl. No. 11/543,734, filed Oct. 4, 2006: Office Action dated Jun. 5, 2007. |
| U.S. Appl. No. 11/543,734, filed Oct. 4, 2006: Office Action dated Dec. 17, 2007. |
| U.S. Appl. No. 11/692,154, filed Mar. 27, 2007: Office Action dated Jul. 8, 2009. |
| U.S. Appl. No. 11/692,154, filed Mar. 27, 2007: Office Action dated Jan. 22, 2009. |
| U.S. Appl. No. 11/925,603, filed Oct. 26, 2007: Electronic File History through Oct. 13, 2011, including Office Action dated Sep. 28, 2011 and Applicant Response filed Oct. 4, 2011. |
| U.S. Appl. No. 11/021,046, filed Dec. 22, 2004: Office Action dated Feb. 4, 2009. |
| U.S. Appl. No. 12/055,098, filed Mar. 25, 2008: Office Action dated Oct. 5, 2010. |
| U.S. Appl. No. 12/101,790, filed Apr. 11, 2008 (now U.S. Pat. No. 7,949,381 on May 24, 2011: Electronic File History, including Office Actions dated Sep. 24, 2010, Mar. 18, 2011 and Apr. 12, 2011, and Applicant Responses filed Dec. 22, 2010 and Mar. 25, 2011. |
| U.S. Appl. No. 12/111,062, filed Apr. 28, 2008: Office Action dated Mar. 3, 2010. |
| U.S. Appl. No. 12/113,508, filed May 1, 2008: Office Action dated Feb. 23, 2010. |
| U.S. Appl. No. 12/113,724, filed May 1, 2008: Office Action dated Jun. 24, 2010. |
| U.S. Appl. No. 12/137,396, filed Jun. 11, 2008: Office Action dated Jun. 21, 2010. |
| U.S. Appl. No. 12/139,305, filed Jun. 13, 2008; Office Action dated Jan. 13, 2010. |
| U.S. Appl. No. 12/264,160, filed Nov. 3, 2008: Office Action dated Jun. 3, 2010. |
| U.S. Appl. No. 12/729,058, filed Mar. 22, 2010: Electronic File History through Jun. 16, 2011, including Office Actions dated Oct. 1, 2010, Mar. 17, 2011 and Apr. 29, 2011, and Applicant Responses filed Dec. 22, 2010 and Apr. 12, 2011. |
| U.S. Appl. No. 11/360,250, filed Feb. 22, 2006: Office Action dated Nov. 20, 2009. |
| File History of U.S. Appl. No. 15/201,313, filed Jul. 1, 2016, 800 pages. |
| “Raya Systems Pioneers Healthy Video Games,” PlayRight, Nov. 1993, pp. 14-15. |
| Adilman, et al., “Videogames: Knowing the Score, Creative Computing,” Dec. 1983, Dialog: File 148; IAC Trade & Industry Database, vol. 9, p. 224(5) (9 pages). |
| Alberts B., et al., “Molecular Biology of the Cell,” 3rd edition, 1994, p. G19 (3 pages). |
| Amato, et al., “Experience with the Polytetrafluoroethylene Surgical Membrane for Pericardial Closure in Operations for Congenital Cardiac Defects,” Journal of Thoracic and Cardiovascular Surgery, 1989, vol. 97, pp. 929-934. |
| Amer M.M.B., “An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity,” Journal of Medical Engineering & Technology, vol. 26 (5), Sep./Oct. 2002, pp. 208-213. |
| Asberg P., et al., “Hydrogels of a Conducting Conjugated Polymer as 3-D Enzyme Electrode,” Biosensors Bioelectronics, 2003, vol. 19, pp. 199-207. |
| Asker.Co.JP, “What is durometer?,” /Product/, Kobunshi Keiki Co., Ltd. retrieved from http://www.asker.co.jp/en/products/durometer/analog/about/index.html on May 9, 2018, 2 pages. |
| Assolant-Vinet C.H., et al., “New Immoblized Enzyme Membranes for Tailor-Made Biosensors”, Analytical Letters, 1986, vol. 19(7&8), pp. 875-885. |
| ASTM International, Inc., “ASTM, Designation: D2240-05, Standard Test Method for Rubber Property-Durometer Hardness,” 2005, 13 pages. |
| Baker D.A., et al., “Dynamic Concentration Challenges for Biosensor Characterization,” Biosensors & Bioelectronics, vol. 8, 1993, pp. 433-441. |
| Baker D.A., et al., “Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors,” Analytical Chemistry, vol. 68 (8), Apr. 15, 1996, pp. 1292-1297. |
| Bard A.J., et al., “Electrochemical Methods,” Fundamentals and Applications, John Wiley & Sons, New York, 1980, pp. 173-175. |
| Bardeletti G., et al., “A Reliable L-Lactate Electrode with a New Membrane for Enzyme Immobilization for Amperometric Assay of Lactate,” Analytica Chemica Acta, vol. 187, 1986, pp. 47-54. |
| Bertrand C., et al., “Multipurpose Electrode with Different Enzyme Systems Bound to Collagen Films,” Analytica Chemica Acta, 1981, vol. 126, pp. 23-34. |
| Bindra D.S., et al., “Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode,” Analytical Chemistry, vol. 61 (22), Nov. 15, 1989, pp. 2566-2570. |
| Bland J.M., et al., “Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement,” The Lancet, Feb. 8, 1986, pp. 307-310. |
| Bolinder J., et al., “Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients,” Rapid Communication, Diabetologia, vol. 35, 1992, pp. 1177-1180. |
| Bolinder J., et al., “Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue during Ordinary Life Conditions,” Diabetes Care, vol. 20 (1), Jan. 1997, pp. 64-70. |
| Bott A.W., “A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry,” Current Separations, vol. 16 (1), 1997, pp. 23-26. |
| Bott A.W., “Electrochemical Methods for the Determination of Glucose,” Current Separations, vol. 17 (1), 1998, pp. 25-31. |
| Brauker J H., et al., “Neovascularization of Synthetic Membranes Directed by Membrane Microarchitecture,” Journal of Biomedical Material Research, 1995, vol. 29, pp. 1517-1524. |
| Brauker J., “Unraveling Mysteries at the Biointerface: Molecular Mediator of Inhibition of Blood Vessel Formation in the Foreign Body Capsule Revealed,” SurFACTS in Biomaterials, vol. 6 (3), 2001, 2 pages. |
| Brauker, et al., “Sustained Expression of High Levels of Human Factor IX from Human Cells Implanted within an Immunoisolation Device into Athymic Rodents,” Human Gene Therapy, Apr. 10, 1998, vol. 9, pp. 879-888. |
| Bremer T., et al., “Is Blood Glucose Predictable from Previous Values? A Solicitation for Data,” Perspectives in Diabetes, vol. 48, Mar. 1999, pp. 445-451. |
| Brunner G.A., et al., “Validation of Home Blood Glucose Meters with Respect to Clinical and Analytical Approaches,” Diabetes Care, vol. 21(4), Apr. 1998, pp. 585-590. |
| Brunstein E., et al., “Preparation and Validation of Implantable Electrodes for the Measurement of Oxygen and Glucose,” Biomed Biochim. Acta, vol. 48 (11/12), 1989, pp. 911-917. |
| Cameron T., et al., “Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs,” IEEE Transactions on Biomedical Engineering, vol. 44 (9), Sep. 1997, pp. 781-790. |
| Chatterjee G., et al., “Poly(ether urethane) and Poly(ether urethane urea) Membranes with High H2S/CH4 Selectivity,” Journal of Membrane Science, vol. 135, 1997, pp. 99-106. |
| Chen C., et al., “A Noninterference Polypyrrole Glucose Biosensor,” Biosensors and Bioelectronics, vol. 22, 2006, pp. 639-643. |
| Chen T., et al., “Defining the Period of Recovery of the Glucose Concentration after its Local Perturbation by the Implantation of a Miniature Sensor,” Clinical Chemistry and Laboratory Medicine, vol. 40 (8), 2002, pp. 786-789. |
| Chia C.W., et al., “Glucose Sensors: Toward Closed Loop Insulin Delivery,” Endocrinology and Metabolism Clinics of North America, vol. 33, 2004, pp. 175-195. |
| Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method,” Biosensors and Bioelectronics, vol. 17 (8), 2002, pp. 647-654. |
| Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current,” Biosensors and Bioelectronics, vol. 17, 2002, pp. 641-646. |
| Clarke W.L., et al., “Evaluating Clinical Accuracy of Systems for Self Monitoring of Blood Glucose,” Technical Articles, Diabetes Care, vol. 10 (5), Sep.-Oct. 1987, pp. 622-628. |
| Clarke W.L., et al., “Evaluating the Clinical Accuracy of Two Continuous Glucose Sensors Using Continuous Glucose-Error Grid Analysis,” Emerging Treatment and Technologies, Diabetes Care, vol. 28(10), Oct. 2005, pp. 2412-2417. |
| Copeland J.G., et al., “Synthetic Membrane Neo-Pericardium Facilitates Total Artificial Heart Explanation,” The Journal of Heart Lung Transplantation, vol. 20(6), Jun. 2001, pp. 654-656. |
| Coulet P.R., “Polymeric Membranes and Coupled Enzymes in the Design of Biosensors,” Journal of Membrane Science, 1992, vol. 68, pp. 217-228. |
| Coulet P.R., et al., “Enzymes Immobilized on Collagen Membranes: A Tool for Fundamental Research and Enzyme Engineering,” Journal of Chromatography, vol. 215, 1981, pp. 65-72. |
| Csoregi E., et al., “Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers,” Electroanalysis, vol. 6, 1994, pp. 925-933. |
| Currie J.F., et al., “Novel Non-Intrusive Trans-Dermal Remote Wireless Micro-Fluidic Monitoring System Applied to Continuous Glucose and Lactate Assays for Casualty Care and Combat Readiness Assessment,” RTO HFM Symposium, RTO-MP-HFM-109, Aug. 16-18, 2004, pp. 24-1-24-18. |
| Dai W.S., et al., “Hydrogel Membranes with Mesh Size Asymmetry based on the Gradient Crosslinking of Poly(Vinyl Alcohol),” Journal of Membrane Science, 1999, vol. 156, pp. 67-79. |
| D'Arrigo, et al., “Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production,” Proceedings of SPIE, 2003, vol. 4982, pp. 178-184. |
| Dassau E., et al., “Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring,” Emerging Treatment and Technologies, Diabetes Care, vol. 33 (6), Jun. 2010, pp. 1249-1254. |
| Declaration presented during Opposition proceedings EP2407094, Pace L., Nov. 13, 2015. 6 pages. |
| Declaration presented during Opposition proceedings EP2407094, Schoonmaker R., Dec. 14, 2015, 10 pages. |
| Definition of plunger: https://www.merriam-webster.com/dictionary/plunger,dated Nov. 7, 2016, 2 pages. |
| Deutsch T., et al., “Time Series Analysis and Control of Blood Glucose Levels in Diabetic Patients,” Computer Methods and Programs in Biomedicine, Elsevier Scientific Publishers, vol. 41, 1994, pp. 167-182. |
| Dobson, et al.,“1-Butyrul-Glycerol: A Novel Angiogenesis Factor Secreted by Differentiating Adipocytes,” Cell, Apr. 20, 1990, vol. 61 (2), pp. 223-230. |
| English D., et al., “Platelet-Released Phospholipids Link Haemostasis and Angiogenesis,” Cardiovascular Research, 2001, vol. 49, pp. 588-599. |
| European Electronic File History for EP Application No. 10195447.7, filed Jul. 13, 2005—withdrawn, 200 pages. |
| European Electronic File History for EP Application No. 10195504.5, filed Jul. 13, 2005—withdrawn, 186 pages. |
| European Electronic File History for EP Application No. 11182615.2, filed Feb. 22, 2006, 344 pages. |
| European Electronic File History for EP Application No. 11182630.1, filed Sep. 23, 2011, 336 pages. |
| European Electronic File History for EP Application No. 14184330.0, filed Sep. 10, 2014, 377 pages. |
| European Electronic File History for EP Application No. 17198022.0, filed Oct. 24, 2017, 339 pages. |
| European Electronic File History for EP Patent Application No. 06773682.7 filed Jun. 20, 2006, 1697 pages. |
| European Electronic File History for EP Patent No. 1804650 (05771643.3) granted Mar. 14, 2012, 3733 pages. |
| European Electronic File History for EP Patent No. 1855588 (06748336.2), granted Nov. 21, 2007, 862 pages. |
| European Electronic File History for EP Patent No. 1986543 (06736006.5) granted Dec. 13, 2011, 1895 pages. |
| European Electronic File History for EP Patent No. 2322094 (10195496.4) granted Mar. 5, 2014, 1778 pages. |
| European Electronic File History for EP Patent No. 2327362 (10195517.7) granted Nov. 13, 2013, 423 pages. |
| European Electronic File History for EP Patent No. 2327984 (10195521.9) granted Feb. 25, 2015, 394 pages. |
| European Electronic File History for EP Patent No. 2329770 (10195509.4) granted Sep. 10, 2014, 1274 pages. |
| European Electronic File History for EP Patent No. 2332466 (10195483.2) granted Apr. 9, 2014, 484 pages. |
| European Electronic File History for EP Patent No. 2335582 (10195511.0) granted Sep. 10, 2014, 608 pages. |
| European Electronic File History for EP Patent No. 2335583 (10195520.1) granted Mar. 18, 2015, 677 pages. |
| European Electronic File History for EP Patent No. 2335584 (10195519.3) granted Jun. 17, 2015, 796 pages. |
| European Electronic File History for EP Patent No. 2335585 (10195508.6) granted Sep. 7, 2016, 722 pages. |
| European Electronic File History for EP Patent No. 2335586 (10195514.4) granted Feb. 19, 2014, 526 pages. |
| European Electronic File History for EP Patent No. 2335587 (10195518.5) granted Feb. 19, 2014, 1314 pages. |
| European Electronic File History for EP Patent No. 2407094 (11182622.8) granted Oct. 22, 2014, 2417 pages. |
| European Electronic File History for EP Patent No. 2499969 (12151826.0) granted Jun. 4, 2014, 814 pages. |
| European Electronic File History for EP Patent No. 2517623 (12151823.7) granted Mar. 2, 2016, 864 pages. |
| European Electronic File History for EP Patent No. 2532302 (12151819.5) granted Nov. 18, 2015, 845 pages. |
| European Electronic File History for EP Patent No. 2532305 (12171365.5) granted Aug. 13, 2014, 504 pages. |
| European Electronic File History for EP Patent No. 2561807 (12193934.2) granted Oct. 5, 2016, revoked Jan. 31, 2019, 2496 pages. |
| European Electronic File History for EP Patent No. 2596747 (13156245.6) granted Oct. 25, 2017, 1091 pages. |
| European Electronic File History for EP Publication No. 3001952 (15195173.8), published Apr. 16, 2016, 237 pages. |
| European Electronic File History for EP Publication No. 3111832 (16179208.0), published Jan. 4, 2017—pending, 191 pages. |
| Extended European Search Report for Application No. 98908875.2 dated Apr. 29, 2004, 5 pages. |
| Fabietti P.G., et al., “Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes,” Diabetes Technology & Therapeutics, vol. 9 (4), 2007, pp. 327-338. |
| Farlex, Inc, Definition of term “elastomeric”, Free Dictionary, Copyright 2008, retrieved from http://www.thefreedictionary.com/elastomeric, 3 pages. |
| Farlex, Inc., “Statistical Distribution—Definition of Statistical Distribution by the Free Dictionary-Thesaurus,” 2003-2016, 2 pages. |
| File History of U.S. Appl. No. 09/334,996, filed Jun. 17, 1999, 36 pages. |
| File History of U.S. Appl. No. 09/447,227, filed Nov. 22, 1999, 1184 pages. |
| File History of U.S. Appl. No. 09/489,588, filed Jan. 21, 2000, 412 pages. |
| File History of U.S. Appl. No. 09/636,369, filed Aug. 11, 2000, 91 pages. |
| File History of U.S. Appl. No. 09/916,711, filed Jul. 27, 2001, 400 pages. |
| File History of U.S. Appl. No. 09/916,858, filed Jul. 27, 2001, 243 pages. |
| File History of U.S. Appl. No. 10/153,356, filed May 22, 2002, 326 pages. |
| File History of U.S. Appl. No. 10/632,537, filed Aug. 1, 2003, 211 pages. |
| File History of U.S. Appl. No. 10/633,329, filed Aug. 1, 2003, 711 pages. |
| File History of U.S. Appl. No. 10/633,367, filed Aug. 1, 2003, 432 pages. |
| File History of U.S. Appl. No. 10/633,404, filed Aug. 1, 2003, 270 pages. |
| File History of U.S. Appl. No. 10/646,333, filed Aug. 22, 2003, 303 pages. |
| File History of U.S. Appl. No. 10/647,065, filed Aug. 22, 2003, 203 pages. |
| File History of U.S. Appl. No. 10/648,849, filed Aug. 22, 2003, 803 pages. |
| File History of U.S. Appl. No. 10/695,636, filed Oct. 28, 2003, 194 pages. |
| File History of U.S. Appl. No. 10/789,359, filed Feb. 26, 2004, 361 pages. |
| File History of U.S. Appl. No. 10/838,658, filed May 3, 2004, 748 pages. |
| File History of U.S. Appl. No. 10/838,909, filed May 3, 2004, 356 pages. |
| File History of U.S. Appl. No. 10/838,912, filed May 3, 2004, 1288 pages. |
| File History of U.S. Appl. No. 10/842,716, filed May 10, 2004, 670 pages. |
| File History of U.S. Appl. No. 10/846,150, filed May 14, 2004, 382 pages. |
| File History of U.S. Appl. No. 10/885,476, filed Jul. 6, 2004, 226 pages. |
| File History of U.S. Appl. No. 10/896,637, filed Jul. 21, 2004, 295 pages. |
| File History of U.S. Appl. No. 10/896,639, filed Jul. 21, 2004, 337 pages. |
| File History of U.S. Appl. No. 10/896,772, filed Jul. 21, 2004, 210 pages. |
| File History of U.S. Appl. No. 10/897,312, filed Jul. 21, 2004, 238 pages. |
| File History of U.S. Appl. No. 10/897,377, filed Jul. 21, 2004, 178 pages. |
| File History of U.S. Appl. No. 11/039,269, filed Jan. 19, 2005, 209 pages. |
| File History of U.S. Appl. No. 11/077,883, filed Mar. 10, 2005, 1159 pages. |
| File History of U.S. Appl. No. 11/078,230, filed Mar. 10, 2005, 535 pages. |
| File History of U.S. Appl. No. 11/157,365, filed Jun. 21, 2005, 977 pages. |
| File History of U.S. Appl. No. 11/157,746, filed Jun. 21, 2005, 603 pages. |
| File History of U.S. Appl. No. 11/158,227, filed Jul. 21, 2004, 474 pages. |
| File History of U.S. Appl. No. 11/201,445, filed Jul. 21, 2004, 120 pages. |
| File History of U.S. Appl. No. 11/280,102, filed Nov. 16, 2005, 109 pages. |
| File History of U.S. Appl. No. 11/280,672, filed Nov. 16, 2005, 572 pages. |
| File History of U.S. Appl. No. 11/333,837, filed Jan. 17, 2006, 672 pages. |
| File History of U.S. Appl. No. 11/334,107, filed Jan. 17, 2006. |
| File History of U.S. Appl. No. 11/335,879, filed Jan. 18, 2006, 499 pages. |
| File History of U.S. Appl. No. 11/360,819, filed Feb. 22, 2006, 778 pages. |
| File History of U.S. Appl. No. 11/373,628, filed Mar. 9, 2006, 532 pages. |
| File History of U.S. Appl. No. 11/411,656, filed Apr. 26, 2006, 285 pages. |
| File History of U.S. Appl. No. 11/415,593, filed May 2, 2006, 160 pages. |
| File History of U.S. Appl. No. 11/415,999, filed May 2, 2006, 154 pages. |
| File History of U.S. Appl. No. 11/416,375, filed May 2, 2006, 153 pages. |
| File History of U.S. Appl. No. 11/439,559, filed May 23, 2006, 155 pages. |
| File History of U.S. Appl. No. 11/439,800, filed May 23, 2006, 157 pages. |
| File History of U.S. Appl. No. 11/445,792, filed Jun. 1, 2006, 811 pages. |
| File History of U.S. Appl. No. 11/503,367, filed Aug. 10, 2006, 1169 pages. |
| File History of U.S. Appl. No. 11/618,706, filed Dec. 29, 2006, 288 pages. |
| File History of U.S. Appl. No. 11/681,145, filed Mar. 1, 2007, 684 pages. |
| File History of U.S. Appl. No. 11/690,752, filed Mar. 23, 2007, 528 pages. |
| File History of U.S. Appl. No. 11/695,607, filed Mar. 4, 2007, 615 pages. |
| File History of U.S. Appl. No. 11/734,178, filed Apr. 11, 2007, 512 pages. |
| File History of U.S. Appl. No. 11/734,184, filed Apr. 11, 2007, 531 pages. |
| File History of U.S. Appl. No. 11/734,203, filed Apr. 11, 2007, 606 pages. |
| File History of U.S. Appl. No. 11/742,546, filed Apr. 30, 2007, 348 pages. |
| File History of U.S. Appl. No. 11/766,747, filed Jun. 21, 2007, 789 pages. |
| File History of U.S. Appl. No. 11/797,520, filed May 3, 2007, 406 pages. |
| File History of U.S. Appl. No. 11/797,521, filed May 3, 2007, 374 pages. |
| File History of U.S. Appl. No. 11/842,139, filed Aug. 21, 2007. |
| File History of U.S. Appl. No. 11/842,142, filed Aug. 21, 2007. |
| File History of U.S. Appl. No. 11/842,143, filed Aug. 21, 2007, 235 pages. |
| File History of U.S. Appl. No. 11/842,146, filed Aug. 20, 2007. |
| File History of U.S. Appl. No. 11/842,148, filed Aug. 21, 2007. |
| File History of U.S. Appl. No. 11/842,149, filed Aug. 21, 2007, 256 pages. |
| File History of U.S. Appl. No. 11/842,151, filed Aug. 21, 2007, 252 pages. |
| File History of U.S. Appl. No. 11/842,154, filed Aug. 21, 2007. |
| File History of U.S. Appl. No. 11/842,157, filed Aug. 21, 2007, 167 pages. |
| File History of U.S. Appl. No. 11/928,968, filed Oct. 30, 2007, 741 pages. |
| File History of U.S. Appl. No. 12/101,806, filed Apr. 11, 2008, 611 pages. |
| File History of U.S. Appl. No. 12/101,810, filed Apr. 11, 2008, 569 pages. |
| File History of U.S. Appl. No. 12/137,396, filed Jun. 11, 2008, 278 pages. |
| File History of U.S. Appl. No. 12/175,391, filed Jul. 17, 2008, 564 pages. |
| File History of U.S. Appl. No. 12/245,618, filed Oct. 3, 2008, 214 pages. |
| File History of U.S. Appl. No. 12/250,918, filed Oct. 14, 2008, 333 pages. |
| File History of U.S. Appl. No. 12/273,359, filed Nov. 18, 2008, 312 pages. |
| File History of U.S. Appl. No. 12/329,496, filed Dec. 5, 2008, 438 pages. |
| File History of U.S. Appl. No. 12/353,870, filed Jan. 14, 2009, 425 pages. |
| File History of U.S. Appl. No. 12/359,207, filed Jan. 23, 2009, 546 pages. |
| File History of U.S. Appl. No. 12/364,786, filed Feb. 3, 2009, 1230 pages. |
| File History of U.S. Appl. No. 12/391,148, filed Feb. 23, 2009, 484 pages. |
| File History of U.S. Appl. No. 12/393,887, filed Feb. 26, 2009, 502 pages. |
| File History of U.S. Appl. No. 12/405,883, filed Mar. 17, 2009, 215 pages. |
| File History of U.S. Appl. No. 12/437,436, filed May 7, 2009, 524 pages. |
| File History of U.S. Appl. No. 12/537,245, filed Aug. 6, 2009, 107 pages. |
| File History of U.S. Appl. No. 12/610,866, filed Nov. 2, 2009, 682 pages. |
| File History of U.S. Appl. No. 12/683,724, filed Jan. 7, 2010, 497 pages. |
| File History of U.S. Appl. No. 12/683,755, filed Jan. 7, 2010, 694 pages. |
| File History of U.S. Appl. No. 12/728,032, filed Mar. 19, 2010, 819 pages. |
| File History of U.S. Appl. No. 12/728,060, filed Mar. 19, 2010, 323 pages. |
| File History of U.S. Appl. No. 12/728,061, filed Mar. 19, 2010, 437 pages. |
| File History of U.S. Appl. No. 12/728,082, filed Mar. 19, 2010, 802 pages. |
| File History of U.S. Appl. No. 12/729,035, filed Mar. 22, 2010, 466 pages. |
| File History of U.S. Appl. No. 12/729,048, filed Mar. 22, 2010, 488 pages. |
| File History of U.S. Appl. No. 12/730,072, filed Mar. 23, 2010, 278 pages. |
| File History of U.S. Appl. No. 12/748,154, filed Mar. 26, 2010, 419 pages. |
| File History of U.S. Appl. No. 12/749,139, filed Mar. 29, 2010, 489 pages. |
| File History of U.S. Appl. No. 12/749,981, filed Mar. 30, 2010, 662 pages. |
| File History of U.S. Appl. No. 12/775,315, filed May 6, 2010, 447 pages. |
| File History of U.S. Appl. No. 12/780,606, filed May 14, 2010, 372 pages. |
| File History of U.S. Appl. No. 12/780,723, filed May 14, 2010, 519pages. |
| File History of U.S. Appl. No. 12/780,725, filed May 14, 2010, 415 pages. |
| File History of U.S. Appl. No. 12/780,739, filed May 14, 2010, 346 pages. |
| File History of U.S. Appl. No. 12/780,759, filed May 14, 2010, 348 pages. |
| File History of U.S. Appl. No. 12/853,235, filed Aug. 9, 2010, 374 pages. |
| File History of U.S. Appl. No. 13/077,884, filed Mar. 31, 2011, 635 pages. |
| File History of U.S. Appl. No. 13/086,160, filed Apr. 13, 2011, 967 pages. |
| File History of U.S. Appl. No. 13/116,871, filed May 26, 2011, 475 pages. |
| File History of U.S. Appl. No. 13/157,031, filed Jun. 9, 2011, 514 pages. |
| File History of U.S. Appl. No. 13/172,640, filed Jun. 29, 2011, 436 pages. |
| File History of U.S. Appl. No. 13/361,820, filed Jan. 30, 2012, 383 pages. |
| File History of U.S. Appl. No. 13/415,721, filed Mar. 8, 2012, 473 pages. |
| File History of U.S. Appl. No. 13/547,952, filed Jul. 12, 2012, 539 pages. |
| File History of U.S. Appl. No. 13/548,627, filed Jul. 13, 2012, 361 pages. |
| File History of U.S. Appl. No. 13/549,313, filed Jul. 13, 2012, 354 pages. |
| File History of U.S. Appl. No. 13/607,162, filed Sep. 7, 2012, 420 pages. |
| File History of U.S. Appl. No. 13/620,574, filed Sep. 14, 2012, 318 pages. |
| File History of U.S. Appl. No. 13/893,237, filed May 13, 2013, 569 pages. |
| File History of U.S. Appl. No. 13/903,609, filed May 28, 2013, 401 pages. |
| File History of U.S. Appl. No. 13/909,962, filed Jun. 4, 2013, 723 pages. |
| File History of U.S. Appl. No. 13/938,103, filed Jul. 9, 2013, 393 pages. |
| File History of U.S. Appl. No. 14/144,523, filed Dec. 30, 2013, 405 pages. |
| File History of U.S. Appl. No. 14/283,153, filed May 20, 2014, 568 pages. |
| File History of U.S. Appl. No. 14/293,298, filed Jun. 2, 2014, 565 pages. |
| File History of U.S. Appl. No. 14/296,735, filed Jun. 5, 2014, 637 pages. |
| File History of U.S. Appl. No. 14/552,398, filed Nov. 24, 2014, 422 pages. |
| File History of U.S. Appl. No. 14/590,483, filed Jan. 6, 2015, 556 pages. |
| File History of U.S. Appl. No. 14/743,777, filed Jun. 18, 2015, 392 pages. |
| File History of U.S. Appl. No. 14/860,602, filed Sep. 21, 2015, 429 pages. |
| File History of U.S. Appl. No. 14/923,350, filed Oct. 26, 2015, 476 pages. |
| File History of U.S. Appl. No. 14/924,030, filed ct. 27, 2015, 403 pages. |
| File History of U.S. Appl. No. 15/065,623, filed Mar. 9, 2016, 401 pages. |
| File History of U.S. Appl. No. 15/470,766, filed Mar. 27, 2017, 336 pages. |
| File History of U.S. Appl. No. 15/686,650, filed Aug. 25, 2017, 296 pages. |
| File History of U.S. Appl. No. 15/719,298, filed Sep. 28, 2017, 258 pages. |
| File History of U.S. Appl. No. 15/787,595, filed Oct. 18, 2017, 230 pages. |
| File History of U.S. Appl. No. 15/797,986, filed Oct. 30, 2017, 342 pages. |
| File History of U.S. Appl. No. 15/798,097, filed Oct. 30, 2017, 323 pages. |
| File History of U.S. Appl. No. 15/877,311, filed Jan. 22, 2018, 208 pages. |
| File History of U.S. Appl. No. 15/891,201, filed Feb. 7, 2018, 364 pages. |
| File History of U.S. Appl. No. 15/967,338, filed Apr. 30, 2018, 191 pages. |
| File History of U.S. Appl. No. 16/017,668, filed Jun. 25, 2018, 308 pages. |
| File History of U.S. Appl. No. 16/133,469, filed Sep. 17, 2018, 178 pages. |
| File History of U.S. Appl. No. 16/137,411, filed Sep. 20, 2018, 174 pages. |
| File History of U.S. Appl. No. 16/179,662, filed Nov. 2, 2018, 272 pages. |
| File History of U.S. Appl. No. 16/181,678, filed Nov. 6, 2018, 155 pages. |
| File History of U.S. Appl. No. 60/362,899, filed Mar. 8, 2002, 67 pages. |
| File History of U.S. Appl. No. 60/527,892, filed Dec. 8, 2003, 25 pages. |
| File History of U.S. Appl. No. 60/528,382, filed Dec. 9, 2003, 182 pages. |
| File History of U.S. Appl. No. 60/587,787, filed Jul. 13, 2004, 70 pages. |
| File History of U.S. Appl. No. 60/587,800, filed Jul. 13, 2004, 29 pages. |
| File History of U.S. Appl. No. 60/614,683, filed Sep. 30, 2004, 465 pages. |
| File History of U.S. Appl. No. 60/614,764, filed Sep. 30, 2004, 657 pages. |
| File History of U.S. Appl. No. 60/660,743, filed Mar. 10, 2005, 104 pages. |
| File History of U.S. Appl. No. 90/011,663, filed Apr. 29, 2011, 306 pages. |
| File History of U.S. Appl. No. 90/011,887, filed Oct. 7, 2011, 769 pages. |
| File History of U.S. Appl. No. 90/012,558, filed Sep. 13, 2012, 294 pages. |
| File History of U.S. Appl. No. 95/001,038, filed Apr. 17, 2008, 1332 pages. |
| File History of U.S. Appl. No. 95/001,039, filed Apr. 17, 2008, 1409 pages. |
| File History of U.S. Appl. No. 95/002,333, filed Sep. 14, 2012, 556 pages. |
| File History of U.S. Appl. No. 11/334,876, filed Jan. 18, 2006, 751 pages. |
| File History of U.S. Appl. No. 11/360,250, filed Feb. 22, 2006, 950 pages. |
| File History of U.S. Appl. No. 11/360,252, filed Feb. 22, 2006, 594 pages. |
| File History of U.S. Appl. No. 90/011,333, filed Nov. 15, 2010, 315 pages. |
| File History of U.S. Appl. No. 90/011,720, filed Nov. 15, 2010, 361 pages. |
| Freiberger P., “Video Game Takes on Diabetes Superhero ‘Captain Novolin’ Offers Treatment Tips,” Fourth Edition, Jun. 26, 1992, Business Section, 2 pages. |
| Gao S., et al., “Determination of Interfacial Parameters of Cellulose Acetate Membrane Materials by HPLC,” Journal of Liquid Chromatography, 1989, vol. 12(11), pp. 2083-2092. |
| Garg S.K., et al., “Correlation of Fingerstick Blood Glucose Measurements With GlucoWatch Biographer Glucose Results in Young Subjects With Type 1 Diabetes,” Emerging Treatments and Technologies, Diabetes Care, vol. 22 (10), Oct. 1999, pp. 1708-1714. |
| Geller R.I., et al., “Use of an Immunoisolation Device for Cell Transplantation and Tumor Immunotherapy,” Annals of the New York Academy of Science, 1997, vol. 831, pp. 438-451. |
| Gerritsen M., et al., “Influence of Inflammatory Cells and Serum on the Performance of Implantable Glucose Sensors,” Journal of Biomedical Material Research, 2001, vol. 54, pp. 69-75. |
| Gore Preclude®, Pericardial Membrane Brochure, Jun. 2009. W.L. Gore & Associates Inc., Flagstaff, AZ 86004. |
| Gore Preclude®, Pericardial Membrane Brochure, Nov. 2001, W.L. Gore & Associates Inc., Flagstaff, AZ-86004, 4 pages. |
| Gough D.A., “The implantable Glucose Sensor: An Example of Bioengineering Design,” Introduction to Bioengineering, 2001, Chapter 3, pp. 57-66. |
| Gregg B A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Anal Chem, 1990, vol. 62, pp. 258-263. |
| Guerra S., et al., “Enhancing the Accuracy of Subcutaneous Glucose Sensors: A Real-Time Deconvolution-Based Approach,” IEEE Transactions on Biomedical Engineering, vol. 59(6), Jun. 2012, pp. 1658-1669. |
| Guo M., et al., “Modification of Cellulose Acetate Ultrafiltration Membrane by Gamma Ray Radiation,” Shuichuli Jishi Bianji Weiyuanhui, 1998, vol. 23(6), pp. 315-318. (Abstract only). |
| Halvorsen C., et al., “Vasodilation of Rat Retinal Microvessels Induced by Monobutyrin,” Journal of Clinical Investigation, Dec. 1993, vol. 92, pp. 2872-2876. |
| Harada, et al., “Long-Term Results of the Clinical Use of an Expanded Polytetrafluoroethylene Surgical Membrane as a Pericardial Substitute,” Journal of Thoracic and Cardiovascular Surgery, 1988, vol. 96(5), pp. 811-815. |
| Harrison, et al., “Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniaturized Integrated Potentiostat for Glucose Analysis in Whole Blood,” Analytical Chemistry, 1988, vol. 60, pp. 2002-2007. |
| Heise T., et al., “Hypoglycemia warning signal and glucose sensors: Requirements and concepts,” Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 563-571. |
| Heller A., “Electrical Wiring of Redox Enzymes,” Ace. Chem. Res., vol. 23, 1990, pp. 128-134. |
| Heller, et al., “In vivo Glucose Monitoring with Miniature “Wired” Glucose Oxidase Electrodes,” Analytical Sciences, 2001, vol. 17 Supplement, pp. i297-i300. |
| Heydron W H., et al., “A New Look at Pericardial Substitutes”, Journal of Thoracic and Cardiovascular Surgery, 1987, vol. 94(2), pp. 291-296. |
| International Preliminary Report on Patentability for Application No. PCT/US2005/014696 dated Nov. 7, 2006, 6 pages. |
| International Preliminary Report on Patentability for Application No. PCT/US2006/008616 dated Mar. 3, 2009, 7 pages. |
| International Search Report and Written Opinion for Application No. PCT/US2005/014696 dated Jun. 29, 2006, 8 pages. |
| International Search Report and Written Opinion for Application No. PCT/US2006/008616 dated Mar. 13, 2008, 9 pages. |
| International Search Report and Written Opinion for Application No. PCT/US2006/019889 dated Feb. 20, 2007, 6 pages. |
| International Search Report for Application No. PCT/US2001/023850 dated Jan. 16, 2002, 3 pages. |
| International Search Report for Application No. PCT/US2003/015816 dated Sep. 22, 2003, 4 pages. |
| Jaremko J., et al., “Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes,” Diabetes Care, vol. 21 (3), Mar. 1998, pp. 444-450. |
| Jeong R.A., et al., “In Vivo Calibration of the Subcutaneous Amperometric Glucose Sensors Using a Non-Enzyme Electrode,” Biosensors and Bioelectronics, Elsevier, vol. 19, 2003, pp. 313-319. |
| Jeutter D.C., et al., “Design of a Radio-Linked Implantable Cochlear Prosthesis Using Surface Acoustic Wave Devices,” IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, vol. 40 (5), Sep. 1993, pp. 469-477. |
| Johnson R C., et al., “Abstract: Neovascularization of Cell Transplantation Devices: Role of Membrane Architecture and Encapsulated Tissue,” Abstracts of Papers, American Chemical Society, Sep. 7-11, 1997, 214th ACS National Meeting, Part 2, 305-PMSE, 2 pages. |
| Joung G.B., et al., “An Energy Transmission System for an Artificial Heart Using Leakage Inductance Compensation of Transcutaneous Transformer,” IEEE Transactions on Power Electronics, vol. 13 (6), Nov. 1998, pp. 1013-1022. |
| Kamath, et al., “Analysis of Time Lags and Other Sources of Error of the DexCom Seven Continuous Glucose Monitor,” Diabetics Technology and Therapeutic, Nov. 2009, vol. 11, No. 11, pp. 689-695. |
| Kargol M., et al., “Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes,” Biophysical Chemistry, 2001, vol. 91, pp. 263-271. |
| Karube I., et al., “Microbiosensors for Acetylcholine and Glucose,” Biosensors & Bioelectronics, 1993, vol. 8, pp. 219-228. |
| Kerner W., “Implantable Glucose Sensors: Present Status and Future Developments,” Experimental and Clinical Endocrinol Diabetes, vol. 109 (2), 2001, pp. S341-S346. |
| Kidd K R., et al., “Angiogenesis and Neovascularization Associated with Extracellular Matrix Modified Porous Implants,” Journal of Biomedical Materials Research, 2001, vol. 59(2), pp. 366-377. |
| Kiechle F.L., “The Impact of Continuous Glucose Monitoring on Hospital Point-of-Care Testing Programs,” Diabetes Technology and Therapeutics, vol. 3 (4), 2001, pp. 647-650. |
| Klueh U., et al., “Inflammation and Glucose Sensors: Use of Dexamethasone to Extend Glucose Sensor Function and Life Span in Vivo,” Journal of Diabetes Science and Technology, vol. 1 (4), Jul. 2007, pp. 496-504. |
| Krouwer J.S., “Setting Performance Goals and Evaluating Total Analytical Error for Diagnostic Assays,” Clinical Chemistry, vol. 48 (6), 2002, pp. 919-927. |
| Kugler J D., et al., “A New Steroid-Eluting Epicardial Lead: Experience with Atrial and Ventricular Implantation in the Immature Swine,” PACE, Aug. 1990, vol. 13, pp. 976-981. |
| Kunzler J F., et al., “Contact Lens Materials,” Chemistry & Industry, Aug. 21, 1995, pp. 651-655. |
| Kunzler J., et al.,“Hydrogels based on Hydrophilic Side Chain Siloxanes,” Poly Mat Sci and Eng, 1993, vol. 69, pp. 226-227. |
| Kurnik R.T., et al., “Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System,” Sensors and Actuators B, vol. 60, 1999, pp. 19-26. |
| Lacourse W.R., et al., “Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry,” Analytical Chemistry, vol. 65, 1993, pp. 50-52. |
| Lee E., et al., “Effects of Pore Size, Void Volume, and Pore Connectivity on Tissue Responses to Porous Silicone Implants,” Society for Biomaterials, 25th Annual Meeting, 1999, p. 171. |
| Leprince P., et al., “Expanded Polytetrafluoroethylene Membranes to Wrap Surfaces of Circulatory Support Devices in Patients Undergoing Bridge to Heart Transplantation,” European Journal of Cardiothoracic Surgery, 2001, vol. 19, pp. 302-306. |
| Loebe M., et al., “Use of Polytetrafluoroethylene Surgical Membranes as a Pericardial Substitute,” PTFE Membrane in Correction of Congenital Heart Defects, Texas Heart Institute Journal, 1993, vol. 20, No. 3, pp. 213-217. |
| Loffler P., et al., “Separation and Determination of Traces of Ammonia in Air by Means of Chromatomembrane Cells,” Fresenius Journal of Analytical Chemistry, 1995, vol. 352, pp. 613-614. |
| Lohn A., et al., “A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements,” Chemometrics and Intelligent Laboratory Systems, vol. 46, 1999, pp. 57-66. |
| Lyman D J., “Polyurethanes. I. The Solution Polymerization of Diisocyanates with Ethylene Glycol,” Journal of Polymer Science, 1960, vol. XLV, pp. 45-49. |
| Lynch S.M., et al., “Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study,” Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, 2001, pp. 79-80. |
| Lynn P.A., “Recursive Digital Filters for Biological Signals,” Med. & Biol. Engineering, vol. 9, 1971, pp. 37-43. |
| Madaras M B., et al., “Microfabricated Amperometric Creatine and Creatinine Biosensors,” Analytica Chimica Acta, 1996, vol. 319, pp. 335-345. |
| Mancy K.H., et al., “A Galvanic Cell Oxygen Analyzer,” Journal of Electroanalytical Chemistry, vol. 4, 1962, pp. 65-92. |
| Martin R.F., “General Deming Regression for Estimating Systematic Bias and its Confidence Interval in Method-Comparison Studies,” Clinical Chemistry, vol. 46 (1), 2000, pp. 100-104. |
| Mathivanar R., et al., “In Vivo Elution Rate of Drug Eluting Ceramic Leads with a Reduced Dose of Dexamethasone Sodium Phosphate,” PACE, vol. 13, Part II, Dec. 1990, pp. 1883-1886. |
| Matsuki H., “Energy Transfer System Utilizing Amorphous Wires for Implantable Medical Devices,” IEEE Transactions on Magnetics, vol. 31 (2), 1994, pp. 1276-1282. |
| Mazzola F., et al., “Video Diabetes: A Teaching Tool for Children with Insulin-Dependent Diabetes,” IEEE, Proceedings 7th Annual Symposium on Computer Applications in Medical Care, Oct. 1983, 1 page Abstract. |
| Metzger M., et al., “Reproducibility of Glucose Measurements using the Glucose Sensor,” Diabetes Care, vol. 25 (6), Jul. 2002, pp. 1185-1191. |
| Mid-West Innovators, Inc., “Durometer Product Description,” 2014, 1 page. |
| Miller J.A., et al., “Development of an Autotuned Transcutaneous Energy Transfer System,” ASAIO Journal, vol. 39, 1993, pp. M706-M710. |
| Miller K.M., et al., “Generation of IL-1 like Activity in Response to Biomedical Polymer Implants: a Comparison of in Vitro and in Vivo Models,” Journal of Biomedical Materials Research, vol. 23(9), 1989, pp. 1007-1026. |
| Miller K.M., et al., “Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers,” Journal of Biomedical Materials Research, vol. 22 (8), 1988, pp. 713-731. |
| Miller K.M., et al., “In Vitro Stimulation of Fibroblast Activity by Factors Generated from Human Monocytes Activated by Biomedical Polymers,” Journal of Biomedical Materials Research, vol. 23(8), 1989, pp. 911-930. |
| Minale C., et al., “Clinical Experience with Expanded Polytetrafluoroethylene Gore-Tex Surgical Membrane for Pericardial Closer: A Study of 110 Cases,” Journal of Cardiac Surgery, vol. 3, Sep. 1988, pp. 193-201. |
| Mond H.G., et al., “The Electrode-Tissue Interface: The Revolutionary Role of Steroid Elution,” PACE, vol. 15, Jan. 1992, pp. 95-107. |
| Monsod T.P., et al., “Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia and Hyperinsulinemia? ,”Diabetes Care, vol. 25 (5), 2002, pp. 889-893. |
| Moussy F., et al., “A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs,” International Journals of Artificial Organs, vol. 17 (2), 1994, pp. 88-94. |
| Moussy F., et al., “Biomaterials community examines biosensor biocompatibility,” Diabetes Technology & Therapeutics, vol. 2(3), 2000, pp. 473-477. |
| Mowery K.A., et al., “Preparation and Characterization by Hydrophobic Polymeric Films that are Thromboresistant via Nitric Oxide Release,” Biomaterials, 2000, pp. 9-21. |
| Murphy S.M., et al., “Polymer Membranes in Clinical Sensor Applications, II. The Design and Fabrication of Permselective Hydrogels for Electrochemical Devices,” Biomaterials, 1992, vol. 13 (14), pp. 979-990. |
| Myler S., et al., “Ultra-Thin-Polysiloxane-Film-Composite Membranes for the Optimisation of Amperometric Oxidase Enzyme Electrodes,” Biosensors & Bioelectronics, vol. 17, 2002, pp. 35-43. |
| Nakayama Y., et al., “Surface Fixation of Hydrogels: Heparin and Glucose Oxidase Hydrogelated Surfaces” ASAIO Journal, 1992, pp. M421-M424. |
| Nam Y.S., et al., “A Novel Fabrication Method of Macroporous Biodegradable Polymer Scaffolds Using Gas Foaming Salt as a Porogen Additive,” J Biomed Mater Res, 2000, vol. 53, pp. 1-7. |
| Neuburger G.G., et al., “Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform,” Anal. Chem., vol. 59, 1987, pp. 150-154. |
| Nintendo Healthcare, Wired, Dec. 1993, 1 page. |
| Novo Nordisk Pharmaceuticals Inc., “Diabetes Educational Video Game Recognized by Software Publishers Association,” Press Release, Mar. 14, 1994, 4 pages. |
| Office Action for European Application No. 10193214.3 dated May 2, 2013 and Applicant Response filed Aug. 28, 2013, 12 pages. |
| Office Action for U.S. Appl. No. 08/811,473, dated Dec. 7, 1998, 5 pages. |
| Office Action for U.S. Appl. No. 09/916,386, dated Apr. 9, 2003, 8 pages. |
| Office Action for U.S. Appl. No. 10/657,843, dated Sep. 21, 2004, 8 pages. |
| Office Action for U.S. Appl. No. 10/768,889, dated Feb. 4, 2009, 9 pages. |
| Office Action for U.S. Appl. No. 10/991,966, dated Jul. 22, 2008, 12 pages. |
| Office Action for U.S. Appl. No. 10/991,966, dated Nov. 28, 2007, 13 pages. |
| Office Action for U.S. Appl. No. 11/007,635, dated Jan. 27, 2006, 9 pages. |
| Office Action for U.S. Appl. No. 11/007,920, dated Jun. 24, 2008, 10 pages. |
| Office Action for U.S. Appl. No. 11/034,344, dated Jan. 15, 2008, 5 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated Feb. 2, 2010, 18 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated Jan. 5, 2009, 13 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated Jun. 7, 2010, 18 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated Jun. 17, 2008, 11 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated May 19, 2009, 14 pages. |
| Office Action for U.S. Appl. No. 11/038,340, dated Nov. 9, 2009, 16 pages. |
| Office Action for U.S. Appl. No. 11/055,779, dated May 23, 2007, 13 pages. |
| Office Action for U.S. Appl. No. 11/055,779, dated Oct. 24, 2007, 15 pages. |
| Office Action for U.S. Appl. No. 11/415,631, dated Mar. 4, 2010, 6 pages. |
| Office Action for U.S. Appl. No. 11/416,058, dated Mar. 5, 2010, 6 pages. |
| Office Action for U.S. Appl. No. 11/416,346, dated Mar. 4, 2010, 7 pages. |
| Office Action for U.S. Appl. No. 11/416,734, dated May 17, 2010, 10 pages. |
| Office Action for U.S. Appl. No. 11/416,734, dated Oct. 14, 2009, 11 pages. |
| Office Action for U.S. Appl. No. 11/416,825, dated Oct. 22, 2009, 11 pages. |
| Office Action for U.S. Appl. No. 11/546,157, dated Feb. 26, 2010, 6 pages. |
| Office Action for U.S. Appl. No. 11/691,424, dated Dec. 8, 2009, 10 pages. |
| Office Action for U.S. Appl. No. 11/691,424, dated Jun. 11, 2009, 21 pages. |
| Office Action for U.S. Appl. No. 11/691,424, dated Nov. 12, 2009, 18 pages. |
| Office Action for U.S. Appl. No. 11/691,424, dated Sep. 25, 2008, 15 pages. |
| Office Action for U.S. Appl. No. 11/691,432, dated Feb. 18, 2010, 11 pages. |
| Office Action for U.S. Appl. No. 11/691,432, dated Jun. 10, 2009, 17 pages. |
| Office Action for U.S. Appl. No. 11/691,432, dated Nov. 30, 2009, 15 pages. |
| Office Action for U.S. Appl. No. 11/691,432, dated Sep. 19, 2008, 11 pages. |
| Office Action for U.S. Appl. No. 11/691,466, dated Oct. 3, 2008, 15 pages. |
| Office Action for U.S. Appl. No. 12/037,812, dated Apr. 1, 2009, 5 pages. |
| Office Action for U.S. Appl. No. 12/037,812, dated Jul. 24, 2009, 6 pages. |
| Office Action for U.S. Appl. No. 12/037,812, dated Sep. 29, 2008, 7 pages. |
| Office Action for U.S. Appl. No. 12/037,830, dated Aug. 7, 2009, 7 pages. |
| Office Action for U.S. Appl. No. 12/037,830, dated Feb. 23, 2010, 7 pages. |
| Office Action for U.S. Appl. No. 12/037,830, dated Feb. 26, 2009, 7 pages. |
| Office Action for U.S. Appl. No. 12/037,830, dated Sep. 29, 2008, 6 pages. |
| Office Action for U.S. Appl. No. 12/052,489, dated Aug. 25, 2010, 12 pages. |
| Office Action for U.S. Appl. No. 12/098,359, dated Jul. 7, 2010, 18 pages. |
| Office Action for U.S. Appl. No. 12/102,654, dated Jul. 30, 2009, 9 pages. |
| Office Action for U.S. Appl. No. 12/102,654, dated Mar. 10, 2010, 6 pages. |
| Office Action for U.S. Appl. No. 12/102,729, dated Jul. 7, 2009, 7 pages. |
| Office Action for U.S. Appl. No. 12/102,745, dated Dec. 23, 2008, 4 pages. |
| Office Action for U.S. Appl. No. 12/133,738, dated Sep. 10, 2010, 11 pages. |
| Office Action for U.S. Appl. No. 12/133,761, dated Sep. 7, 2010, 11 pages. |
| Office Action for U.S. Appl. No. 12/182,073, dated Jun. 28, 2010, 20 pages. |
| Office Action for U.S. Appl. No. 12/182,083, dated Jun. 24, 2010, 8 pages. |
| Office Action for U.S. Appl. No. 12/536,852, dated Jun. 25, 2010, 8 pages. |
| Office Action for U.S. Appl. No. 12/536,852, dated Oct. 18, 2010, 10 pages. |
| Office Action for U.S. Appl. No. 12/619,502, dated Sep. 7, 2010, 6 pages. |
| Office Action for U.S. Appl. No. 12/829,337, dateded Oct. 5, 2012, 10 pages. |
| Office Action from European Patent Application No. 05856669.6, dated Aug. 4, 2011, 7 pages. |
| Office Action from European Patent Application No. 05856669.6, dated Jun. 7, 2010, 5 pages. |
| Office Action from European Patent Application No. 05856669.6, dated Nov. 8, 2010, 6 pages. |
| Office Action from Japanese Patent Application No. 2011-121598 dated Oct. 18, 2011, 9 pages. |
| Office Action from Japanese Patent Application No. 2012-006893 dated May 22, 2012, 4 pages. |
| Office Action from Japanese Patent Application No. 2012-169323 dated Oct. 16, 2012, 4 pages. |
| Office Action from Japanese Patent Application No. 2013-000959 dated Jan. 31, 2014, 6 pages. |
| Panetti T.S., “Differential Effects of Sphingosine 1-Phosphate and Lysophosphatidic Acid on Endothelial Cells,” Biochimica et Biophysica Acta, vol. 1582, 2002, pp. 190-196. |
| Panteleon A.E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration,” Diabetes Technology & Therapeutics, vol. 5 (3), 2003, pp. 401-410. |
| Paramount Pds., “Durometer Made Easy (R) / Durometer Hardness Scales—General Reference Guide,” Paramount Industries Inc., 2008, 1 page. |
| Park I.B., et al., “Gas Separation Properties of Polysiloxane/Polyether Mixed Soft Segment Urethane Urea Membranes,” Journal of Membrane science, vol. 204, 2002, pp. 257-269. |
| Parker R.S., et al., “A Model-Based Algorithm for Blood Glucose Control in Type I Diabetic Patients,” IEEE Trans Biomed Engg (BME), vol. 46(2), 1999, pp. 148-157. |
| Pegoraro M., et al., “Gas Transport Properties of Siloxane Polyurethanes,” Journal of Applied Polymer Science, vol. 57, 1995, pp. 421-429. |
| Peguin S., et al., “Pyruvate Oxidase and Oxaloacetate Decarbozylase Enzyme Electrodes—Simultaneous Determination of Transaminases with a Two-electrode-based Analyzer,” Analytica Chimica Acta, vol. 222, 1989, pp. 83-93. |
| Phillips R.E., et al., “Biomedical Applications of Polyurethanes: Implications of Failure Mechanisms,” Journal of Biomedical application, vol. 3, Oct. 1988, pp. 206-227. |
| Phillips R.P., “A High Capacity Transcutaneous Energy Transmission System,” ASIAO Journal, vol. 41, 1995, pp. M259-M262. |
| Pickup J.C., et al., “Developing Glucose Sensors for In Vivo Use,” Elsevier Science Publishers Ltd (UK), TIBTECH, vol. 11, 1993, pp. 285-291. |
| Pickup J.C., et al., “Progress Towards in Vivo Glucose Sensing with a Ferrocene-Mediated Amperometric Enzyme Electrode,” Horm Metab Res Suppl, vol. 20, 1988, pp. 34-36. |
| Pickup J.C., et al., “Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man,” Acta Diabetol, vol. 30, 1993, pp. 143-148. |
| Pineda L.M., et al., “Bone Regeneration with Resorbable Polymeric Membranes. III. Effect of Poly(L-lactide) Membrane Pore Size on the Bone Healing Process in Large Defects,” Journal of Biomedical Materials Research, vol. 31, 1996, pp. 385-394. |
| Poirier J.Y., et al., “Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters,” Diabetes Care, vol. 21 (11), Nov. 1998, pp. 1919-1924. |
| Preliminary Amendment for U.S Appl. No. 12/052,489, filed Mar. 20, 2008, 8 pages. |
| Radovsky A.N., et al., “Effects of Dexamethasone Elution on Tissue Reaction Around Stimulating Electrodes of Endocardial Pacing Leads in Dogs,” American Heart Journal, vol. 117 (6), Jun. 1989, pp. 1288-1298. |
| Rafael E., “Cell Transplantation and Immunoisolation: Studies on a Macroencapsulation Device,” Departments of Transplantation Surgery and Pathology, Karolinska Institutet, Huddinge Hospital, Stockholm, Sweden, 1999, pp. 1-82. |
| Ratner B.D., “Reducing Capsular Thickness and Enhancing Angiogenesis around Implant Drug Release Systems,” Journal of Controlled Release, vol. 78, 2002, pp. 211-218. |
| Rawlings R.A., et al., “Translating Glucose Variability Metrics into the Clinic via Continuous Glucose Monitoring: A Graphical User Interface for Diabetes Evaluation (CGM-Guide),” Diabetes Technology & Therapeutics, vol. 13 (12), 2011, pp. 1241-1248. |
| Rebrin K., et al., “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring,” The American Physiological Society, vol. 277, 1999, pp. E561-E571. |
| Revuelta J.M., et al., “Expanded Polytetrafluoroethylene Surgical Membrane for Pericardial Closure,” The Journal of Thoracic and cardiovascular Surgery, vol. 89 (3), Mar. 1985, pp. 451-455. |
| Rinken T., et al., “Calibration of Glucose Biosensors by Using Pre-Steady State Kinetic Data,” Biosensors & Bioelectronics, vol. 13, 1998, pp. 801-807. |
| Sachlos E., et al., “Making Tissue Engineering Scaffolds Work Review on the Application of Sold Freeform Fabrication Technology to the Production of Tissue Engineering Scaffolds,” European Cells and Materials, vol. 5, 2003, pp. 29-40. |
| Sanders E., et al., “Fibrous Encapsulation of Single Polymer Microfibers Depends on their Vertical Dimension in Subcutaneous Tissue Polymer Microfibers,” Journal of Biomedical Material Research, vol. 67A, 2003, pp. 1181-1187. |
| Schaffar B.P.H., “Thick Film Biosensors for Metabolites in Undiluted Whole Blood and Plasma Samples,” Analytical Bioanalytical Chemistry, Dec. 2001, vol. 372, pp. 254-260. |
| Schmidt F.J., et al., “Calibration of a Wearable Glucose Sensor,” The International Journal of Artificial Organs, vol. 15 (1), 1992, pp. 55-61. |
| Schuler, et al., “Modified Gas-Permeable Silicone Rubber Membranes for Covalent Immobilisation of Enzymes and their Use in Biosensor Development,” Analyst, 1999, vol. 124, pp. 1181-1184. |
| Selam J.L., “Management of Diabetes with Glucose Sensors and Implantable Insulin Pumps,” From the Dream of the 60s to the Realities of the 90s, ASAIO Journal 1997, vol. 43, pp. 137-141. |
| Shichiri M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor,” Diabetes Nutrition & Metabolism, vol. 2 (4), 1989, pp. 309-313. |
| Shichiri M., et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9 (3), May-Jun. 1986, pp. 298-301. |
| Sieminski, et al., “Biomaterial-Microvasculature Interactions,” Biomaterials, 2000, vol. 21, pp. 2233-2241. |
| Sigma-Aldrich Corp., “Cellulose Acetate,” Product Description, Product No. 419028, St. Louis, MO, 2005, 1 page. |
| Smith B., et al., “An Externally Powered, Multichannel, Implantable Stimulator-Telemeter for Control of Paralyzed Muscle,” IEEE Transactions on Biomedical Engineering, vol. 45 (4), Apr. 1998, pp. 463-475. |
| Smith, “The Scientist and Engineer's Guide to Digital Signal Processing,” California Technical Publishing, 1997-2007, retrieved from http://www.dspguide.com/ch19.htm on Jan. 1, 2009, 2 Pages. |
| Smith, et al.,“A Comparison of Islet Transplantation and Subcutaneous Insulin Injections for the Treatment of Diabetes Mellitus,” Computers in Biology and Medicine, 1991, vol. 21 (6), pp. 417-427. |
| Smooth-On, “Durometer Shore Hardness Scale,” downloaded from https://www.smooth-on.com/page/durometer-shore-hardness-scale/ on May 19, 2016, 1 page. |
| Sokolov S., et al., “Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor,” Medical Engineering & Physics, vol. 17 (6), 1995, pp. 471-476. |
| Sparacino G., et al., “Continuous Glucose Monitoring Time Series and Hypo-Hyperglycemia Prevention: Requirements, Methods, Open Problems,” Current Diabetes Reviews, vol. 4 (3), 2008, pp. 181-192. |
| Sproule B.A., et al., “Fuzzy Pharmacology: Theory and Applications,” Trends in Pharmacological Sciences, vol. 23 (9), Sep. 2002, pp. 412-417. |
| Sternberg F., et al., “Does Fall in Tissue Glucose Precede Fall in Blood Glucose?,” Diabetologia, vol. 39, 1996, pp. 609-612. |
| Sternberg R., et al., “Study and Development of Multilayer Needle-type Enzyme Based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40. |
| Sternberg, et al., “Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development,” Anal Chem, Dec. 1988, vol. 60(24), pp. 2781-2786. |
| Stokes, “Polyether Polyurethanes: Biostable or Not,” Journal of Biomaterials Applications, Oct. 1988, vol. 3, pp. 228-259. |
| Street J.O., et al., “A Note on Computing Robust Regression Estimates Via Iteratively Reweighted Least Squares,” The American Statistician, vol. 42 (2), May 1988, pp. 152-154. |
| Street, et al., “Islet Graft Assessment in the Edmonton Protocol: Implications for Predicting Long-Term Clinical Outcome,” Diabetes, 2004, vol. 53, pp. 3107-3114. |
| Suh, et al., “Behavior of Fibroblasts on a Porous Hyaluronic Acid Incorporated Collagen Matrix,” Yonsei Medical Journal, 2002, vol. 43 (2), pp. 193-202. |
| Takatsu, et al., “Solid State Biosensors Using Thin-Film Electrodes,” Sensors and Actuators, 1997, vol. 11, pp. 309-317. |
| Tamura T., et al., “Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method—A Numerical Analysis,” Frontiers of Medical & Biological Engineering, vol. 10 (2), 2000, pp. 147-156. |
| Tang, et al., “Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials,” J.Exp.Med, 1993, vol. 178, pp. 2147-2156. |
| Tang, et al., “Inflammatory Responses to Biomaterials,” Am J Clin Pathol, 1995, vol. 103, pp. 466-471. |
| Tang, et al., “Mast Cells Mediate Acute Inflammatory Responses to Implanted Biomaterials,” Proceedings of the National Academy of Sciences of the USA, 1998, vol. 95, pp. 8841-8846. |
| Tang, et al., “Molecular Determinants of Acute Inflammatory Responses to Biomaterials,” J Clin Invest, 1996, vol. 97, pp. 1329-1334. |
| Taub M.B., et al., “Numerical Simulation of the Effect of Rate of Change of Glucose on Measurement Error of Continuous Glucose Monitors,” Journal of Diabetes Science and Technology, vol. 1 (5), Sep. 2007, pp. 685-694. |
| Thijssen P.C.,“A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 2,Optimal Designs, Analytica chimica Acta, vol. 162, 1984, pp. 253-262. |
| Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 1,Theory and Simulations, Analytica chimica Acta, 1984, vol. 156, pp. 87-101. |
| Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 3,Variance Reduction ,Analytica chimica Acta, 1985, vol. 173, pp. 265-272. |
| Thijssen, et al., “A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems,” Part 4,Flow Injection Analysis, Analytica chimica Acta, 1985, vol. 174, pp. 27-40. |
| Tibell, et al., “Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year after Transplantation in Nonimmunosuppressed Humans,” Cell Transplantation, 2001, vol. 10, pp. 591-599. |
| Tilbury J.B., et al., “Receiver Operating Characteristic Analysis for Intelligent Medical Systems—A New Approach for Finding Confidence Intervals,” IEEE Transactions on Biomedical Engineering, vol. 47 (7), Jul. 2000, pp. 952-963. |
| Trajanoski Z., et al., “Neural Predictive Controller for Insulin Delivery Using the Subcutaneous Route,” IEEE Transactions on Biomedical Engineering, vol. 45(9), 1998, pp. 1122-1134. |
| Turner A.P.F., “Amperometric Biosensor based on Mediator-Modified Electrodes,” Methods in Enzymology, 1988, vol. 137, pp. 90-103. |
| Updike S.J., et al., “Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector,” Journal of Laboratory and Clinical Medicine, vol. 93(4), 1979, pp. 518-527. |
| Updike S.J., et al., “Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions,” Diabetes Care, vol. 5 (3), May-Jun. 1982, pp. 207-212. |
| Valdes T.I., et al., “In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme used for an Implantable Glucose Biosensor,” Diabetes Technology & Therapeutics, vol. 2 (3), 2000, pp. 367-376. |
| Vig, et al., “A Review of Sensor Sensitivity and Stability,” IEEE/EIA International Frequency Control Symposium and Exhibition, 2000, pp. 30-33. |
| Wade L.G., “Reactions of Aromatic Compounds,” Organic Chemistry, Chapter 17, 5th edition, 2003, pp. 762-763. |
| Wang J., “Electrochemical Glucose Biosensors,” American Chemical Society, Chemical Reviews, Published on Web Dec. 23, 2007, pp. 1-12. |
| Ward W.K., et al., “Assessment of Chronically Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses,” ASAIO Journal, 1999, vol. 45 (6), pp. 555-561. |
| Wolpert H., “Establishing a Continuous Glucose Monitoring Program,” Journal of Diabetes Science and Technology, Mar. 2008, vol. 2 (2), pp. 307-310. |
| Yang S., et al., “Glucose Biosensors with Enzyme Entrapped in Polymer Coating,” Biomedical Instrument and Technology, Mar./Apr. 1995, vol. 29 (2), pp. 125-133. |
| Yang X., et al., “Polyelectrolyte and Molecular Host Ion Self-Assembly to Multilayer Thin Films: An Approach to Thin Film Chemical Sensors,” Sensors and Actuators B, vol. 45, 1997, pp. 87-92. |
| Zavalkoff S.R., et al., “Evaluation of Conventional Blood Glucose Monitoring as an Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor,” Diabetes Care, vol. 25(9), 2002, pp. 1603-1606. |
| Ziaie, et al., “A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation,” IEEE Transactions on Biomedical Engineering, 1997, vol. 44(10), pp. 909-920. |
| Number | Date | Country | |
|---|---|---|---|
| 20140142405 A1 | May 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60614764 | Sep 2004 | US | |
| 60614683 | Sep 2004 | US | |
| 60587800 | Jul 2004 | US | |
| 60587787 | Jul 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13077884 | Mar 2011 | US |
| Child | 14163346 | US | |
| Parent | 11077883 | Mar 2005 | US |
| Child | 13077884 | US |
